



Rhode Island Cancer Registry  
*aut viam inveniam aut faciam*

# *Reporting Manual*

## Instructions for Health Care Facilities

### 2021

Rhode Island Cancer Registry  
405 Promenade Street, Suite C  
Providence, RI 02908  
Phone: (401) 443-2803 Fax: (401) 533-9238  
<http://www.hari.org/ricr.html>

This publication was prepared by:

Nancy Lebrun, BS, CTR  
Director, CIS; Education & Training Coordinator

Lisa Garcia, CPEHR  
Quality Assurance Coordinator

~~Nicole James, AS, CTR~~ Nikki Lobo  
Data Quality Coordinator

Stephanie Rego, BS  
Systems Administrator

Published **February 2021**  
Revised

Formatted: Indent: Left: 0", Hanging: 0.5"

Formatted: Tab stops: 0.5", Left

Formatted: Font: Bold

Formatted: Space After: 0 pt

Formatted: Font: Bold

# Table of Contents

## [Summary of 2021 Changes](#)

### [Section 1: Introduction](#)

Mission Statement

Program Statement

History of the Registry

Services

Contact Information

### [Section 2: Rhode Island Regulations & Confidentiality](#)

Cancer Reporting Laws

State Registry Disclosure

HIPAA

Data Requests

### [Section 3: Determining Case Reportability](#)

State Reporting Rules: Hospital, Laboratory, and Radiation Facilities

Case Ascertainment (Casefinding)

Ambiguous Terminology (Casefinding)

Ambiguous Terminology (Diagnosis)

Case Reportability: Hematopoietic and Lymphoid Neoplasms

Reportable List for RICR

Cases That Must Be Reported

### [Section 4: Reporting Requirements](#)

Reporting Frequency

Required Data Items

Residency Rules

RI Specific Reporting Requirement

Modified Record Reporting

Edits

## [Section 5: Text Requirements](#)

## [Section 6: Instructions for Electronic Submission](#)

Secured Data Transmission

## [Section 7: Quality Control](#)

Data Submission Standards for NPCR

Data Submission Standards for NAACCR

Field Code Changed

## [Appendices](#)

[Appendix A: Rhode Island State Cancer Reporting Law](#)

[Appendix B: Confidentiality of Health Care Communications and Information Act](#)

[Appendix C: Rhode Island Cancer Registry Confidentiality Pledge](#)

[Appendix D: ICD-10 Casefinding List](#)

[Appendix E: RICR Standard for Inclusion and Reportability/RICR Reportable List](#)

[Appendix F: NAACCR Required Data Items](#)

[Appendix G: Approved Abstracting Abbreviations List](#)

[Appendix H: Effective Dates for Cancer Registry Standard References](#)

[Appendix I: References for Tumor Registrars or Tumor Reporting Personnel](#)

[Appendix J: Acronyms of Cancer Organizations for the United States](#)

## Summary of 2021 Changes

The following describes the changes to required data items and coding instructions effective for cases diagnosed 1/1/2021 and after. Only the requirements for submission to the RICR are described. There were no changes for 2019-2020. Additional changes required for CoC Accredited Cancer Programs can be found in the STORE: <https://www.facs.org/quality-programs/cancer/ncdb/call-for-data>

### COVID-19 Documentation

- Capturing the ICD-10-CM U codes for COVID-19 in the Secondary Diagnoses data items is required.
- Collecting the four SARSCoV2 data items is required.
- Documentation of COVID-19 and treatment delays in the text is required. **Make sure any text related to COVID-19 specifically includes the word "COVID-19"**. The standard use of the word "COVID-19" in the text will allow cases to be identified and isolated for further evaluation. Below is the CCR's guidance on how to standardize this documentation in the text.

Lab Text	Date and results of COVID-19 and antibody testing (both positive and negative)
Treatment Text	If treatment is delayed, modified, or not given due to COVID-19, add the detail to the corresponding treatment text field
Remarks Text	Record COVID-19 related ICD-10 codes specified in the medical record

### NCDB COVID-related Data Items

COVID-related data items have been added to evaluate the impact of SARSCoV2 diagnosis on cancer patients. The first three data items denote patient status for the SARSCoV2 virus, and the fourth item denotes any treatment effects from hospital services disruptions related to the COVID19 pandemic.

NCDB\_SARSCoV2\_Test [3943]  
NCDB\_SARSCoV2\_Pos\_Date [3945]  
NCDB\_SARSCoV2\_Pos [3944]  
NCDB\_COVID19\_Tx\_Impact [3946]

### Secondary Diagnoses 1-10

U codes have been added as eligible codes to capture COVID-19 diagnoses. U07.1 is used for confirmed COVID-19 cases. This includes a confirmed diagnosis of the 2019 novel coronavirus disease (COVID-19) as documented by the provider, documentation of a positive COVID-19 test result, or a presumptive positive COVID-19 test result. This is an exception to the hospital inpatient guideline Section II, H. In this context, "confirmation" does not require documentation of the type of test performed; the provider's documentation that the individual has COVID-19 is sufficient.

Presumptive positive COVID-19 test results are coded as confirmed. A presumptive positive test result means an individual has tested positive for the virus at a local or state level, but it has not yet been confirmed by the Centers for Disease Control and Prevention (CDC). CDC confirmation of local and state tests for COVID-19 is no longer required.

U07.1 is not used if the provider documents "suspected," "possible," "probable," or "inconclusive" COVID19.

### **ICD-O-3 Histology Revisions**

The RICR follows the reportability indicators in the official ICD-O references unless otherwise specified in the RICRRM. Using the ICD-O references on the NAACCR and SEER websites jointly with the RICRRM is required to accurately determine which conditions are reportable and the code for that condition.

<https://www.naaccr.org/icdo3/>

Beginning with cases diagnosed January 1, 2021, the ICD-O-3.2 is the preferred morphology coding reference manual. The following manuals must be used jointly to accurately determine case reportability (based on behavior code) and the final histology and behavior code for each case. It is recommended that these websites be bookmarked and used when abstracting each case.

ICD-O-3.2 (second revision morphology):

[http://www.iacr.com.fr/index.php?option=com\\_content&view=category&layout=blog&id=100&Itemid=577%20o](http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577%20o)

Also available on the NAACCR website: <https://www.naaccr.org/icdo3/>

2021 ICD-O Histology and Behavior Code Update Tables: <https://www.naaccr.org/icdo3/>

Changes are provided in 5 different tables based on the type of change. Plus 2 combination tables that list all changes in numerical (Table 6) and alphabetical (Table 7) order.

**This also results in a change to reportability for some conditions.**

SEER Solid Tumor Coding Rules: <https://seer.cancer.gov/tools/solidtumor/>

SEER Hematopoietic and Lymphoid Neoplasm Database: <https://seer.cancer.gov/tools/heme/>

#### **How to use these references jointly to determine if the case is reportable:**

Review the ICD-O-3.2 Excel document. Search for the term (or key letters from the term). Find the code that best matches the term. 2021 ICD O 3.2 Coding Table Excel.

For pre-2021 diagnoses, also check the 2021 ICD-O-3.2 Update Table (6 or 7) to confirm the code and behavior for pre-2021 diagnoses.

Table 6 (changes listed in numerical order): 2021 ICD O 3.2 Numeric Table

Table 7 (changes listed in alphabetical order): 2021 ICD O 3.2 Coding Table

If not in the ICD O 3.2, check SEER SING to see if the question has already been asked.

If not, submit a question to Ask a SEER Registrar.

#### **How to use these references jointly to determine the histology code and behavior:**

Review the SEER Hematopoietic/Lymphoid Database or the SEER Solid Tumor Rules (MP/H) FIRST – whichever is appropriate based on site and histology.

If the SEER Heme Database or Solid Tumor Rules do not provide the coding instruction, review the ICD-O-3.2 Excel document. Search for the term (or key letters from the term). Find the code that best matches the term. 2021 ICD O 3.2 Coding Table Excel.

For pre-2021 diagnoses, also check the 2021 ICD-O-3.2 Update Table (6 or 7) to confirm the code and behavior for pre-2021 diagnoses.

Table 6 (changes listed in numerical order): 2021 ICD O 3.2 Numeric Table

Table 7 (changes listed in alphabetical order): 2021 ICD O 3.2 Coding Table

If not in the ICD O 3.2, check SEER SING to see if the question has already been asked.

If not, submit a question to Ask a SEER Registrar.

### Changes in Reportability

Beginning with cases diagnosed January 1, 2021, ICD-O-3.2 is the preferred morphology coding reference manual. The ICD-O-3.2 must be used jointly with the 2021 ICD-O Histology and Behavior Code Update tables, Hematopoietic and Lymphoid Neoplasm Database, and Solid Tumor (MP/H) rules to determine reportability as well as the final ICD-O code. A few of the major changes are listed below. **You must refer to the 2021 ICD-O Histology and Behavior Code Update tables for a complete list of changes.** <https://www.naaccr.org/icdo3/>

#### Now Reportable as of 1/1/2021 (not reportable prior to 2021)

Early or evolving melanoma in situ (8720/2) and early or evolving melanoma (8720/3) is now reportable. Previously only reportable if stated to be a Clarks Level 1.

Most GIST tumors (8936/3) are now behavior code 3. GIST with a Behavior Code of 1 is not reportable. GIST with a Behavior Code of 3 is reportable. The Date of Initial Diagnosis is the earliest date the GIST is found malignant, noted to have multiple foci, metastasis of positive lymph nodes.

Nearly all neuroendocrine tumors are now behavior code 3.

Nearly all thymomas (8580/3-8585/3) are now behavior code 3. Previously thymomas were only reportable if stated to be malignant. Now they are not reportable only if specifically stated to be benign. The exceptions are: Microscopic thymoma or thymoma, benign (8580/0); Micronodular thymoma with lymphoid stroma (8580/1); Ectopic hamartomatous thymoma (8587/0)

Lymphomatoid granulomatosis: Grades have been introduced. Grade 3 now has a behavior of 3 (9766/3) and is reportable. Grades 1 and 2 still have a behavior of 1 (9766/1) and are not reportable.

8380/2 Endometrioid intraepithelial neoplasia (C54.1) is now reportable.

#### No longer Reportable (behavior change to 1) for cases diagnosed 1/1/2021 and after.

ICD-O Code	Term/Site	Comments
8832/1	Dermatofibrosarcoma protuberans, NOS (C44. _) Dermatofibrosarcoma, NOS (C44. _)	Change from /3
8833/1	Pigmented dermatofibrosarcoma protuberans (C44. _) Bednar tumor (C44. _)	Change from /3
9080/1	Immature teratoma of the lung (C34. _) Immature teratoma of thymus (C37.9) Immature teratoma of thyroid (C73.9)	Change from behavior /3 for the histology/site combination will make these terms non-reportable
9709/1	Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. _)	Change from /3
9718/1	Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. _) Lymphoid papulosis (C44. _)	Change for /3
9725/1	Hydroa vacciniforme-like lymphoproliferative disorder	Change from /3.

9751/1	Langerhans cell histiocytosis, NOS Langerhans cell histiocytosis, monostotic Langerhans cell histiocytosis, polystotic	Change from /3
9971/1	Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD)	Change from /3
8335/1	Follicular tumor of uncertain malignant potential (C73.0) Preferred term Follicular carcinoma, encapsulated (C73.9)	Change from /3
8343/1	Non-invasive EFVPTC; Non-invasive encapsulated follicular variant of papillary thyroid carcinoma EFVPTC (C73.9)	Change from /2
8349/1	Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); Non-invasive FTP (C73.9)	Change from /2

**\*\*Please refer to the ICD-O-3 Implementation Guidelines for all changes:**

<https://www.naaccr.org/icdo3/>

#### ***Solid Tumor Rules***

The Cutaneous Melanoma Solid Tumor Rules have been revised for 2021. Use the 2021 Solid Tumor Cutaneous Melanoma rules to determine the number of primaries to abstract and the histology to code for cases diagnosed 1/1/2021 forward.

Download the rules for 2021 at: <https://seer.cancer.gov/tools/solidtumor/>

The Other Sites rules are currently being revised. Continue to use the 2007 Other Sites MP/H rules for cases diagnosed in 2007-2021.

Minor updates to other site-specific rules:

New histologies, codes, and terms from ICD-O-3.2 and the 2021 ICD-O Update added to tables

Corrections to histology tables o Additional H rules to enforce correct histology coding

Clarification of coding histology prior to neo-adjuvant therapy

Clarification to Malignant and Benign CNS Terms & Definitions: WHO Grade II and behavior

#### ***AJCC Editions and Versions***

The AJCC has started rolling out updates to site chapters on a site-by-site basis. The first release was for Cervix Uteri. Cervix Uteri, version 9 becomes effective on January 1, 2021 and replaces the 8th Edition Cervix Uteri cancer site content. All other disease sites in the 8th Edition Cancer Staging Manual remain current for 2021. As warranted by medical practice, additional disease sites will be updated in the future, as necessary. There will no longer be a single edition or version number applicable to every disease site for the diagnosis year. This marks the start of the all-digital format for Version 9 of the AJCC Cancer Staging System and can be downloaded from Amazon Kindle. No printed option is being offered at this time. <https://www.facs.org/quality-programs/cancer/news/ajcc-kindle-092420>

Additional updates to the AJCC Cancer Staging Manual are always available at:

<https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx>

#### ***New Data Items Required to be Collected for Cases Diagnosed 1/1/2021 and After***

## **Schema Discriminator 2**

Schema Discriminator 2 [3927] is now required for C473, C475, C493-C495 with respect to Soft Tissue Abdomen and Thoracic or Soft Tissue Trunk and Extremities. These sites can be an external structure or internal viscera, and correct classification within a schema depends on this distinction. For those cases diagnosed in 2018-2020, the value '8' should be assigned to indicate the distinction was not captured and these cases will remain in Soft Tissue Abdomen and Thoracic.

## **Name–Birth Surname**

Name–Birth Surname [2232] replaces Name—Maiden [2390]. This data item provides a gender-neutral data item name to record the last name (surname) of patients at birth, regardless of gender or marital status. Allowable values remain the same.

## **Grade**

A new Grade Post Therapy Clin (yc) [1068] data item has been added. Grade Post Therapy [3845] was renamed to Grade Post Therapy Path (yp) for clarity.

The Grade fields for Lacrimal Gland have had Codes A-D removed, and Code 4 has been added. Since Code 1 and Code A both meant Well Differentiated (and similarly for codes 2 and B and codes 3 and C), it was decided to streamline the available codes. Code 4 was added to capture the Undifferentiated, anaplastic cases.

The Grade fields for Lymphoma Ocular Adnexa have been modified.

Code 3 is now G3, more than 15 centroblasts per 10 HPF but with admixed centrocytes. Cases that used to have Code 4 should be changed to Code 3.

Code 4 is now G4, more than 15 centroblasts per 10 HPF but without centrocytes.

Code 5 has been removed. Cases that used to have Code 5 should be changed to Code 4.

Code L was removed. Low Grade (1 or 2) was determined to be a variation of Unknown, so cases that used to have L should be changed to Code 9.

## **yc Data Items**

A new grade data item, Grade Post Therapy Clin (yc), has been added. Note: The AJCC Post Therapy Clin (yc) and AJCC Post Therapy Path (yp) data items are not included in the RICRRM. These data items are required by CoC Facilities only. The new AJCC Post Therapy Clin (yc) staging will be used for cases receiving neoadjuvant therapy with the planned surgery cancelled for various reasons. These data items have the same valid value lists as the corresponding AJCC Post Therapy Path (yp) data items for each site. Refer to the STORE for coding instructions.

## **Data Items Changes**

### **Radiation Treatment Modality**

When the data item Phase I Radiation Treatment Modality [1506] was implemented in 2018 (v18) a code indicating radiation was given but type of radiation unknown was not included. Currently patients that receive radiation, but the modality is not known, are assigned a code 99. Code 99 is also used when it is unknown if radiation is given. This makes it difficult to distinguish patients that did receive radiation from those where it is unknown if radiation was given. Code 98 has been added to the data item Phase I Radiation Treatment Modality for cases where it is known radiation was given, but modality is unknown. Code 99 is only used when it is unknown if radiation was given. The new code and changed code may be used for all cases abstracted after the v21 implementation regardless of diagnosis year.



## SSDIs

Visceral and Parietal Pleural Invasion [3937], used in the Lung schema, has been modified. Codes 1, 2 and 3 are being removed and code 5 has been added. Codes 1 (PL1) and 2 (PL2) are now collapsed into Code 4 (PL1 or PL2) as they are treated similarly clinically. Code 3 has been moved to Code 5.

## Name Changes

Grade Post Therapy [3845] = Grade Post Therapy Path (yp)

Schema ID 00470 (Melanoma Skin) SSDI: LDH Pretreatment Level [3869] = LDH Level

Schema ID 00470 (Melanoma Skin) SSDI: LDH Pretreatment Lab Value [3932] = LDH Lab Value

## Summary of Staging Requirements by Year of Diagnosis

Below is a summary of the staging requirements based on the year of diagnosis:

2004-2014	Collaborative Stage, CS SSFs (SSFs cannot be blank)
2015	Collaborative Stage, SS2000, AJCC TNM 7th Edition, CS SSFs (SSFs cannot be blank)
2016-2017	SS2000, AJCC TNM 7th Edition, CS SSFs (designated SSFs only cannot be blank)
2018-present	SS2018, AJCC TNM 8th Edition (with chapter revisions), SSDIs

Important: Assigning Summary Stage and AJCC Stage (all editions) is required for ALL cases. This includes non-analytic cases. If the Summary Stage or any component of the AJCC Stage AT DIAGNOSIS is known, then record in the appropriate data items. If the Summary Stage or any component of the AJCC Stage AT DIAGNOSIS is NOT known, then record the appropriate value for unknown.

Each component of the AJCC stage is important. **Even if complete AJCC TNM information is not available in the record, any piece of staging information should be collected and reported.** For example, if information to assign the T is available but no information is available on N, the T data item should be completed. Leave the N blank and document the reasoning for the TNM categories assigned in the text.

## Section 1: Introduction

### Mission Statement

The primary purpose of the Rhode Island Cancer Registry (RICR) is to collect timely, complete, and accurate data from reporting sources to ensure an accurate, continuing, and systemic foundation of state-specific cancer data. Reporting sources include all hospitals, clinical laboratories, and other treatment facilities that diagnose and/or treat cancer in the state of Rhode Island. Accurate data helps to prepare and publish technical and statistical reports and publications related to the cancer burden among Rhode Islanders.

### Program Statement

The goal of the RICR is to gather comprehensive, timely, and accurate data on the incidences of cancer among Rhode Island residents.

Accurate data also aids in the development of queries and analyzes the cancer registry data to provide epidemiological reports for the Rhode Island Department of Health's Comprehensive Cancer Control, Women's Cancer Screening, and Colorectal Cancer Programs, as well as the media, health care systems, consumers, and responses to all requests for Rhode Island cancer data.

### History of the Registry

The RICR has collected cancer case reports since October 1986. Since 1995, this effort has been supported in part by the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC), a federally mandated program that supports population-based cancer surveillance systems.

The Registry receives data from hospitals, pathology laboratories, and radiation centers throughout the state of Rhode Island. The number of facilities can increase each year with the opening of new facilities and the Registry develops new relationships. As a result of this and state population growth, the number of reportable cancer cases can also increase.

### Services Provided

The RICR provides the following services:

- Case processing and quality control activities on cases abstracted by hospitals and out-patient facilities
- Acceptance and processing of reports from pathology laboratories
- Abstraction of pathology reports from facilities that do not submit electronically
- Execution of data exchange agreements with other states
- Implementation of training activities for cancer registrars in the state
- Contribution of statistical cancer data for researchers, prevention programs, medical professionals, and community partners

Contact and Location Information

Rhode Island Central Cancer Registry

405 Promenade Street, Suite C

Providence, RI 02908

Telephone: (401) 443-2803 ext. 516

Fax: (401) 533-9328

Web Site: <http://www.hari.org/ricr.html>

Rhode Island Department of Health

3 Capitol Hill

Providence, RI 02908

Telephone: (401) 222-4577

Fax: (401) 222-1442

Website: <https://health.ri.gov/cancer/>

## Section 2: Rhode Island Regulations & Confidentiality

### Cancer Reporting Laws

Pursuant to the authority conferred under R.I. Gen. Laws §§ [23-1-18\(2\)](#), [23-8-1](#), and [23-12-4](#), Rhode Island Cancer Registry rules and regulations establish a unified procedure for the reporting of cancer to the Rhode Island Cancer Registry.

To comply with the rules and regulations, each health care facility and/or health care provider shall submit a set of available information on reportable cases within thirty (30) to forty-five (45) days from the date of a case first seen by a provider (including but not limited to: patient demographic information, date of diagnosis, primary site, histology, behavior, tumor identifier, tumor sequence number, and facility/provider information), as defined in § 2.2 of the Regulations, and specified by the Rhode Island Cancer Registry.

Within one hundred eighty (180) days from the date of a reportable case first seen by a provider as defined in § 2.2 of the Regulations Part, a health care facility and/or health care provider shall complete and report all required information, as specified by the Rhode Island Cancer Registry.

Modified abstracts are to be submitted yearly. Please see [Section 4](#) for more information.

For a detailed description of the Rhode Island State Regulation for the Cancer Registry, please see [Appendix A](#) or visit: <https://rules.sos.ri.gov/regulations/part/216-10-10-2>.

### State Registry Disclosure

RICR shall maintain comprehensive records of all reported cancer cases submitted pursuant to the provisions of the Acts and the Rules and Regulations (216-RICR-10-10-2). Such reports shall be confidential in accordance with R.I. Gen. Laws Chapter [5-37.3](#) (Confidentiality of Health Care Communications and Information Act: [Appendix B](#)) and subject to the restrictions on release incorporated therein.

RICR shall employ the highest data protection available while conducting data releases to or mutual data exchanges with CDC NPCR, NAACCR, other central cancer registries, reporting facilities and other data users, pursuant to reciprocal contracts for said purpose.

RICR employees must sign the confidentiality policy document. This will be kept in the employee's folder. All computerized data exchanged between RICR and reporting hospitals are uploaded to a secure encrypted, password-protected website. RICR staff shall sign confidentiality pledges when required by reporting facilities while conducting RICR business. See [Appendix C](#) for the RICR Confidentiality Pledge.

### Health Insurance Portability and Accountability Act of 1996 (HIPAA)

The HIPAA Privacy Rule addresses the concerns for patient privacy and data confidentiality that arise with the collection and transmission of electronic health information. HIPAA recognizes the legitimate need for public health authorities to have access to personal health information (PHI) for the purposes of health surveillance. It authorizes the disclosure of such information without patient authorization as required by state and local public health laws, including reporting of cancer surveillance data to central cancer registries. The Privacy Rule, however, does require reporting sources to document disclosure of information to the central registries.

The Privacy Rule also distinguishes between public health practice (Public Health surveillance, disease control, or program evaluation) and activities which may develop into an ongoing research study and are, therefore, subject to research disclosure provisions.

Further information on the HIPAA Privacy Rule and Public Health is available in a report prepared by the Epidemiology Program Office of the CDC and Published in the MMWR on April 11, 2003. This report is available at: [www.cdc.gov/mmwr/preview/mmwrhtml/m2e411a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/m2e411a1.htm), and is intended to help public health agencies and other understand and interpret their responsibilities under the Privacy Rule.

For more details on HIPAA and Protected Health Information, visit <https://www.cdc.gov/mmwr/preview/mmwrhtml/m2e411a1.htm>

HIPAA also provides for the study of issues related to the adoption of uniform data standards for patient's medical record information and the electronic exchange of such information. NPCR and RICR promotes electronic data submission from reporting facilities and exchange among central registries. RICR incorporates HIPAA standards relating to registries use of electronic data as enabling technologies are realized.

More information about application of data privacy requirements to cancer registries can be found at: <https://www.naaccr.org/confidentiality-issues/>

#### **Data Requests**

If your reporting facility would like to request data, please contact the Director of Cancer Information Systems at HARI.

## Section 3: Determining Case Reportability

### Basic Hospital, Laboratory, and Radiation Rules for Reporting

All eligible cases diagnosed on or after January 1, 1995 must be abstracted and reported to the RICR.

Newly added suspense cases should be submitted to the RICR within thirty (30) to forty-five (45) days of initial diagnosis or treatment at your facility. Completed abstracts should be submitted within one hundred eighty (180) days from the date of a reportable case first seen by a provider, a health care facility and/or health care provider. Modified abstracts from reporting facilities are required to be submitted yearly. Please see section 4 for more information on modified abstract submission.

### Case Ascertainment

Case ascertainment (casefinding) is the system used to identify patients with reportable neoplasms. Casefinding involves thorough, systematic monitoring of records maintained by various departments throughout the hospital. Multiple sources must be used to ensure complete reporting of all cases.

Casefinding sources include, but are not limited to:

- Admission and discharge documents
- Disease indices/discharge diagnosis lists
- Surgery schedules/logs
- Pathology and Cytology reports
- Hematology reports
- Autopsy reports
- Outpatient medical records/logs, including Radiation Oncology and Medical Oncology logs
- Radiology/Nuclear medicine documents
- Billing data

Records from all case finding sources should be screened for reportable diagnoses using the appropriate ICD case finding list. Beginning October 1, 2019, facilities should use the FY2020 ICD-10-CM Casefinding List. The current and previous versions of the ICD case finding list are available at <http://seer.cancer.gov/tools/casefinding/>. The current ICD-10 Casefinding List can be found in [Appendix D](#).

### Ambiguous Terminology for Casefinding for Solid Tumors

#### In Situ and Invasive (Behavior codes /2 and /3)

If any of the reportable **ambiguous terms precede** a word that is **synonymous** with an in situ or invasive tumor (e.g., cancer, carcinoma, malignant neoplasm, etc.), accession the case.

**Example:** The pathology report says: Prostate biopsy with markedly abnormal cells that are typical of adenocarcinoma. Accession the case.

**Negative Example:** The final diagnosis on the outpatient report reads: Rule out pancreatic cancer. Do not accession the case.

#### Discrepancies

Accession the case based on the reportable ambiguous term when there are reportable and non-reportable ambiguous terms in the medical record.

Do **not** accession a case when the original source document used a **non-reportable** ambiguous term and subsequent documents refer to history of cancer.

**Example:** Report from the dermatologist is “possible melanoma.” Patient admitted later for unrelated procedure and physician listed history of melanoma. Give priority to the information from the dermatologist and do not report this case. “Possible” is **not** a reportable ambiguous term. The later information is less reliable in this case.

Accept the reportable term and accession the case when there is a single report in which both reportable and non-reportable terms are used.

**Example:** Abdominal CT reveals a 1 cm liver lesion. “The lesion is consistent with hepatocellular carcinoma” appears in the discussion section of the report. The final diagnosis is “1 cm liver lesion, possibly hepatocellular carcinoma.” Accession the case. “Consistent with” is a reportable ambiguous term. Accept “consistent with” over the non-reportable term “possibly.”

Do **not** accession a case based **ONLY** on **suspicious** cytology

**Note:** “Suspicious cytology” means any cytology report diagnosis that uses an ambiguous term, including ambiguous terms that are listed as reportable on the preceding page.

Follow back on cytology diagnoses using ambiguous terminology is strongly commended.

Cytology refers to the microscopic examination of cells in body fluids obtained from aspirations, washings, scrapings, and smears; usually a function of the pathology department.

**Important:** Accession cases with cytology diagnoses that are **positive** for malignant cells.

Use the reportable ambiguous terms when **screening** diagnoses on pathology reports, operative reports, scans, mammograms, and other diagnostic testing except for tumor markers

Do not accession a case when resection, excision, biopsy, cytology, or physician’s statement proves the ambiguous diagnosis is not reportable

**Example 1:** Mammogram shows calcifications suspicious for intraductal carcinoma. The biopsy of the area surrounding the calcifications is negative for malignancy. Do not accession the case.

**Example 2:** CT report states “mass in the right kidney, highly suspicious for renal cell carcinoma.” A malignant neoplasm cannot be excluded.” Discharged back to the nursing home and no other information is available. Do not accession the case. The suspicious CT finding was biopsied and not proven to be malignant. “Suggestive of” is not a reportable ambiguous term.

**Example 3:** Stereotactic biopsy of the left breast is “focally suspicious for DCIS” and is followed by a negative needle localization excisional biopsy. Do not accession the case. The needle localization excisional biopsy was performed to further evaluate the suspicious stereotactic biopsy finding. The suspicious diagnosis was proven to be false.

**Example 4:** Esophageal biopsy with diagnosis of “focal areas suspicious for adenocarcinoma in situ.” Diagnosis on partial esophagectomy specimen “with foci of high-grade dysplasia; no invasive carcinoma identified.” Do not accession the case. The esophagectomy proved that the suspicious biopsy result was false.

### Benign and borderline primary intracranial and CNS tumors

Use the “Ambiguous terms that are reportable” list [below](#) to identify benign and borderline primary intracranial and CNS tumors that are reportable.

**Neoplasm** and **tumor** are **reportable** terms for brain and CNS because they are listed in ICD-O-3 with behavior codes of /0 and /1.

Accession the case when any of the reportable **ambiguous terms precede** either the word “**tumor**” or the word “**neoplasm**”.

**Example:** The mass on the CT scan is consistent with pituitary tumor. Accession the case.

**Mass and lesion are not reportable terms for brain and CNS because they are not listed in ICD-O-3 with behavior codes of /0 or /1.**

#### Discrepancies

Accession the case based on the reportable ambiguous term when there are reportable and non-reportable ambiguous terms in the medical record.

Do not accession a case when subsequent documents refer to history of tumor and the original source document used a **non-reportable** ambiguous term.

Accept the reportable term and accession the case when there is a single report and one section of a report uses a reportable term such as “apparently” and another section of the same report uses a term that is not on the reportable list.

**Exception:** Do not accession a case based ONLY on ambiguous cytology (the reportable term is preceded by an ambiguous term, i.e., apparently, appears, compatible with, etc.).

Use these terms when **screening** diagnoses on pathology reports, scans, ultrasounds, and other diagnostic testing other than tumor markers.

Do not accession the case when resection, excision, biopsy, cytology, or physician’s statement proves the ambiguous diagnosis is not reportable.

This complete list can be found in the SEER Program Coding and Staging Manual

[https://seer.cancer.gov/manuals/2018/SPCSM\\_2018\\_maindoc.pdf](https://seer.cancer.gov/manuals/2018/SPCSM_2018_maindoc.pdf)

### Ambiguous Terminology at Diagnosis for Solid Tumors

As part of the registry casefinding activities, all diagnostic reports should be reviewed to confirm whether a case is required. If the terminology is ambiguous, use the following guidelines to determine whether a particular case should be included. Words or phrases that appear to be synonyms of these terms do not constitute a diagnosis. For example, “likely” alone does not constitute a diagnosis.

Ambiguous Terms that Constitute a Diagnosis	
Apparent(ly)	Neoplasm* (beginning with 2004 diagnoses and only for C70.0-C72.9, C75.1-C75.3)
Appears	Presumed



Comparable with	Probable
Compatible with	Suspect(ed)
Consistent with	Suspicious (for)
Favors	Tumor* (beginning with 2004 diagnoses and only for C70.0-C72.9, C75.1-C75.3)
Malignant appearing	Typical of
Most likely	

\*additional terms for nonmalignant primary intracranial and central nervous system tumors only

Exception: if the cytology is reported using any of these ambiguous terms and neither a positive biopsy nor a physician's clinical impression supports the cytology findings, do not consider as diagnostic of cancer.

Ambiguous Terminology NOT Considered as Diagnostic of Cancer without additional information

Cannot be ruled out	Questionable
Equivocal	Rule out
Possible	Suggests
Potentially malignant	Worrisome

More specific information pertaining to NAACCR case eligibility and standards for tumor inclusion and reportability can be found at <http://datadictionary.naacr.org/?c=3>

#### Case Reportability for Hematopoietic and Lymphoid Neoplasms

Search the [Heme DB](#) to determine case reportability.

Report all cases with morphology codes **9590-9992** with a /3 behavior.

**Note 1:** In ICD-O, preleukemia is listed as 9989/3 in the numeric list and 9989/1 in the alphabetic list. Change the 9989/1 in the alphabetic list to a 9989/3.

**Note 2:** Report the case and change the behavior code to a /0 or /1 in the rare instances of a benign or borderline hematopoietic neoplasm occurring in the brain and/or CNS diagnosed 1/1/2004 or later.

Report hematopoietic and lymphoid neoplasms with morphology codes **9590-9992** listed in ICD-O as /1 that are **described as malignant** by a physician. Apply the matrix rule and change the behavior code to /3.

**Note:** Do not report in situ (/2) lymphomas.

Report the case when the diagnosis of a hematopoietic neoplasm is preceded by one or more of the **ambiguous terms listed below**:

**This instruction pertains to reportability and casefinding only. See the [Histology Coding Instructions, #3-5](#) for instructions on assigning histology with ambiguous terminology.**

- Apparently
- Appears
- Comparable with
- Compatible with
- Consistent with
- Favor(s)
- Malignant appearing
- Most likely
- Presumed
- Probable
- Suspect(ed)
- Suspicious (for)
- Typical (of)

**Note 1:** Use these terms when screening all reports other than cytology and tumor markers.

**Note 2:** Report cases that use only the words on the list or an equivalent word such as “favored” rather than “favor(s)”. Do not substitute synonyms such as “supposed” for “presumed” or “equal” for “comparable with.” Do not substitute “likely” for “most likely.” See [SEER coding manual](#) - Reportability section.

**Note 3:** Accept the reportable term and report the case when one part of the medical record uses a reportable ambiguous term such as “apparently” and another section of the medical record(s) uses a term that is not on the reportable list.

**Note 4:** Follow back is recommended for diagnoses based on ambiguous terminology to see if the diagnosis has been confirmed or proven to be incorrect (see note 5).

**Note 5:** Do not report the case when biopsy or physician’s statement confirms a non-reportable condition or proves the ambiguous diagnosis is wrong.

**Example:** CT scan shows enlarged lymph nodes suspicious for lymphoma. Subsequent biopsies of the lymph nodes thought to be involved with a neoplasm are negative for malignancy. The pathology is more reliable than the scan; the negative biopsy proves that the ambiguous diagnosis was wrong. Do not report the case.

**Note 6:** Do not report cases diagnosed only by ambiguous cytology (cytology diagnosis preceded by ambiguous term).

**Example:** Parotid ultrasound guided FNA: consistent with non-Hodgkin’s lymphoma. This case was diagnosed based on cytology/fine needle aspiration (FNA) preceded by ambiguous terminology (consistent with). Do not report this case based on ambiguous cytology.

Report the case when the patient is **treated** for a reportable neoplasm.

**Note 1:** Report the case even if the diagnostic tests are inconclusive, equivocal, or negative.

**Note 2:** For treatment information see the National Cancer Institute’s Physicians’ Data Query (PDQ) website at <https://www.cancer.gov/publications/pdq> the [SEER\\*Rx](#) Antineoplastic Drugs Database.

Report the case when there is a **clinical diagnosis** (physician’s statement) of reportable hematopoietic or lymphoid neoplasm.

**Note 1:** The clinical diagnosis may be a final diagnosis found within the medical record or recorded on a scan (CT, MRI for example).

**Note 2:** Report the case even if the diagnostic tests are equivocal. A number of hematopoietic neoplasms are “diagnoses of exclusion” in which the diagnostic tests are equivocal, and the physician makes the clinical diagnosis based on the equivocal tests and the clinical picture. See the [Heme DB](#) for definitive diagnostic methods for the specific neoplasm being abstracted.

Report the case when a reportable diagnosis appears in any text or report described as a **Definitive Diagnostic Method** in the Heme DB.

**Note:** Definitive diagnostic methods differ depending upon the histology. See the [Heme DB](#) for details.

## Reportable List for RICR

Use the following rules to determine reportability:

### *Reference Date*

All eligible cases diagnosed on or after January 1, 1995 must be abstracted and reported to the RICR.

### *Residency*

Rhode Island residents and non-residents must be reported, including residents of foreign countries that are treated in any reporting facility within Rhode Island.

### *Invasive and In Situ Neoplasms*

All in situ or invasive neoplasms with a behavior code of '/2' or '/3' in the most current ICD-O-3 Manual must be reported. CIN III cases diagnosed 1/1/2018 are reportable.

*Exclusions: The following conditions are not required to be reported*

Skin cancers (C44.\_) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110  
PIN III (after 1/1/2011)

The list below are the abstracts reportable by Class of Case.

Class of Case 00-22, 30-32, 34-38, and 43 must be reported by all facilities if the case meets reporting requirements.

Class of Case 34 and 36 would be used for VIN III, VAIN III, and AIN III; will also be used for CIN III (diagnosed 1/1/2018 and later)

New cancer programs should submit class of case 35 and 37 for cases diagnosed 1/1/1995 or later.

Do **not** use class of case 99.

Please see the RICR Standard for Inclusion and Reportability/RICR Reportable List in [Appendix E](#). Please note: the RICR follows NPCR standards for inclusion and reportability – except for CIN III/in situ neoplasm of cervix. **CIN III is reportable to RICR beginning with diagnosis 1/1/2018 and forward.**

Further definition for Cervical Intraepithelial Neoplasia III (CIN III); in situ neoplasm of cervix

Synonyms for in situ carcinoma may include: CIN grade III, confined to epithelium, intraepidermal, intraepithelial, involvement up to but not including the basement membrane, noninfiltrating, noninvasive, no stromal involvement, papillary noninfiltrating. Other synonyms may include: HSIL, HGSIL, high-grade SIL, or high grade squamous intraepithelial neoplasia.

All cases diagnosed as "CIN III", "CIS", or "AIS" are eligible. If a pathologist does not use the CIN terminology and only provides an assessment using the dysplasia scale, then cases listed as "severe dysplasia" or "HSIL" are eligible. Cases diagnosed as LSIL are not eligible. Cases diagnosed as "CIN II" or "CIN II/III" are not eligible unless they are positive for p16, or HSIL is noted.

### *In Utero Diagnoses*

Diagnoses made in utero are reportable if the pregnancy results in a live birth. When a reportable diagnosis is confirmed prior to birth and disease is not evident at birth due to regression, accession the case based on the pre-birth diagnosis.

#### *Cancer Diagnosed on Autopsy*

Cases diagnosed at autopsy and/or dead on arrival (DOA) with a cancer diagnosis must be reported.

#### *Multiple Primaries*

If more than one primary cancer is diagnosed in a patient, based on the 2018 Solid Tumor Rules or Hematopoietic and Lymphoid Neoplasm Coding Manual, a separate report must be submitted for each primary.

Please follow link for coding manuals: SEER Webpage

(<https://seer.cancer.gov/registrars/guidelines.html>) or the STORE Manual ([https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/store\\_manual\\_2021.ashx](https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/store_manual_2021.ashx))

## Section 4: Reporting Requirements

### Reporting Frequency

Between the 5th and 10th of each month, all reporting facilities in RI are expected to upload files on the ShareFile® site of all new case abstracts since the previous submission. Reporting facilities are instructed to follow the appropriate standard setter guidelines, and files must be submitted in the applicable NAACCR format.

### Required Data Items

Initial data submission (within 30-45 days from the first encounter):

Accession Number

Record Type

Last Name

First Name

Middle Name/Initial

Social Security Number

Date of Birth

Sex

Address at DX – No. and Street

Address at DX – Supplement

Address at DX – City

Address at DX – State

Address at DX – Postal Code

County at DX

Current Address – No. and Street

Current City

Current State

Current Postal Code

Birthplace – State and Country

Race 1-5

Spanish/Hispanic Origin

Occupation and Industry

Date of Initial Diagnosis

Age at Diagnosis

Diagnostic Confirmation

Primary Site

Histology

Behavior

Laterality

Height

Weight

Tobacco fields (4)

First Course Treatment information available (biopsy, surgery, chemotherapy, radiation, etc)

\*Fill in as much as possible – including date fields and/or associated flags.

Site Specific Data Items – as available (if applicable)

Reporting Facility  
Sequence Number – Hospital  
Type of Reporting Source  
Date of 1<sup>st</sup> Contact  
Date of Last Contact  
Medical Record Number  
Class of Case  
Primary Payer at Diagnosis  
Casefinding Source  
Physician Information

*Please complete as much information when adding the case to suspense as possible, including text information.*

#### **Complete data submission (within 180 days).**

The RICR is a NPCR state and requires all NPCR data items to be completed. Please see the full list of data items in [Appendix F](#).

Please refer to the STORE Manual for directions on coding data items: [https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/store\\_manual\\_2021.ashx](https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/store_manual_2021.ashx)

#### **Residency Rules**

The patient's address at diagnosis is the patient's place of residence at the time of the original diagnosis. It does not change if the patient moves. If the patient has more than one primary tumor, the address at diagnosis may be different for each primary.

Normally a residence is the home named by the patient. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with the rules of the Census Bureau whenever possible. The registry can resolve residency questions by using the Census Bureau's definition, "the place where he or she lives and sleeps most of the time or the place the person considers to be his or her usual home."

##### *Rules for Persons with Ambiguous Residences*

Persons with More than One Residence (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.

Persons with No Usual Residence (transients, homeless): Use the address the patient was staying when the cancer was diagnosed. This location may be a shelter or diagnosing facility.

Persons Away at School: College students are residents of the school area. Boarding school students below the college level are residents of their parents' homes.

Persons in Institutions: The Census Bureau states, "Persons under formally authorized, supervised care or custody" are residents of the institution. This classification includes the following:

- Incarcerated persons
- Persons in nursing, convalescent, and rest homes
- Persons in homes, schools, hospitals, or wards for the physically disabled, mentally retarded, or

mentally ill.

- Long-term residents of other hospitals, such as Veterans Affairs (VA) hospitals.

Persons in the Armed Forces and on Maritime Ships: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their families. Military personnel may use the installation address or the surrounding community's address. The Census Bureau has detailed residency rules for Navy personnel, Coast Guard, and maritime ships. Refer to Census Bureau publications for the detailed rules.

This information can be found in the 'Overview of Coding Principles' within the STORE Manual:

[https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/store\\_manual\\_2021.ashx](https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/store_manual_2021.ashx)

## RI Specific Reporting Requirements

To ensure proper tumor linkage and data item recognition via the RICR abstract processing software, all data items pertaining to demographic information entered in abstracts should be recorded in **CAPITAL letters**. Data items not recorded in uniform **CAPITAL letters** are at risk of electronic and/or manual disaffirmation or rejection.

### *Address at Diagnosis*

Because cancer registry data is used to analyze cancer trends geographically, the address at diagnosis **must** be recorded accurately. Record the patient's residence when the tumor was first diagnosed. It should be noted the patient's address at diagnosis may be different than the patient's current address. The address should be the residence, not the mailing address. If the patient has multiple tumors, the address at diagnosis may be different for each subsequent primary. If the address is unknown, record UNKNOWN. All cases seen at your facility are required to be reported to the RICR, regardless of residence at diagnosis.

Address at DX-NO & Street should contain the house number and street name, completely spelled out.

Address at DX-Supplemental should contain any apartment numbers, suites, and/or facility names.

Address at DX-City should contain the complete city name with no abbreviations or punctuations.

### Modified Record Reporting

The RICR normally requests all reporting hospitals submit modified record abstracts. Currently, RICR is requesting all reporting facilities to temporarily halt all modified record submissions until further notice. Once a modified reporting schedule has been established, facilities will be contacted directly with instructions for routine submissions.

### Edits

Data received must be of reasonable quality: 5% or less edit failure for currently determined core data items. Each submission will be scanned with edit software using a specific Rhode Island edit set. The Systems Administrator will then review for discrepancies or repetitive edit issues.

The RICR Director will then determine the acceptance of the file. If rejected, the submitting facility will be required to make the required corrections and resubmit within 30 days.



Hospital registries are required to run data through the most current standard setter edit metafiles prior to submission to the Central Registry.

### Instructions for Coding

#### *Patient Identification*

Medical Record Number  
Social Security Number  
Last Name  
First Name  
Middle Name  
Birth Surname  
Address at Diagnosis – Number and Street  
Address at Diagnosis – Supplemental  
Address at Diagnosis – City  
Address at Diagnosis – State  
Address at Diagnosis – Postal Code  
Address at Diagnosis – Country  
County at Diagnosis – Reported  
Birthplace – State  
Birthplace – Country  
Date of Birth  
Date of Birth Flag  
Race 1  
Race 2-5  
Spanish/Hispanic Origin  
Sex  
Text – Usual Occupation  
Text – Usual Industry  
Primary Payer at Diagnosis  
Secondary Diagnosis #1  
Secondary Diagnosis #2-10  
NCDB\_SARSCoV2 – Test  
NCDB\_SARSCoV2 – Pos  
NCDB\_SARSCoV2 – Pos\_Date  
NCDB\_SARSCoV2 – Tx\_Impact  
NPI – Managing Physician  
Managing Physician  
NPI – Following Physician  
Following Physician  
NPI – Primary Surgeon  
Primary Surgeon  
NPI – Physician #3  
Physician #3  
NPI – Physician #4

Physician #4

*RICR State Specific Data Items*

Height

Weight

Tobacco Use (4 data items)

*Cancer Identification*

Sequence Number

Class of Case

Date of First Contact

Date of First Contact Flag

Date of Initial Diagnosis

Estimating Dates

Primary Site

When the medical record does not contain enough information to assign a primary  
Site-specific coding guidelines

Laterality

Paired Organ Sites (Laterality must be coded 1-5 or 9)

Histology

Behavior Code

Grade Data Items

Grade (Effective 1/1/2021)

Grade (Effective 1/1/2018)

Grade Clinical (Effective 1/1/2018)

Grade Post Therapy Clin (yc) (effective 1/1/2021)

Grade Pathological (Effective 1/1/2018)

Grade Post Therapy Path (yp) (Effective 1/1/2018)

Diagnostic Confirmation

Codes for Solid Tumors

Codes for Hematopoietic and Lymphoid Neoplasms

*Stage of Disease at Diagnosis*

Date of Surgical Diagnostic and Staging Procedure

RX Date – DX/STG Proc Flag

Surgical Diagnostic and Staging Procedure

Regional Lymph Nodes Examined

Regional Lymph Nodes Positive

Lymphovascular Invasion (revised for 2018)

Tumor Size Summary (Effective 1/1/2016)

*2018 Stage Data Items*

Summary Stage 2018 (Effective 1/1/2018)

## Section 5: Text Requirement

### General Instructions

The RICR requires the submission of text information to validate coded data items. Text is used for quality control purposes to justify codes for various data items. Text is also used to identify errors, to determine multiple primaries and to resolve discrepancies in data submitted on the same patient by multiple facilities.

All cancer registry software must include specific fields, which have been designed to record text information. These fields are transmitted to the RICR along with the other required data fields when you make your monthly electronic submission. Please refer to the table in [Appendix F](#), Table of Required Data Items, for the maximum number of characters per field. Please refer to [Appendix G](#) for a list of recommended abbreviations. Recording text information should include but not be limited to the following:

Record text to support primary site, laterality, histology, grade, stage, and treatment codes.

Record text to justify any unusual information about the case that could result in potential questions, e.g., record text to support unusual site/histology combinations, such as age/site combinations, gender/site combinations, name/gender combinations, pediatric age.

Record text to clarify modifications or dates on the abstract.

If limited [or no](#) information is available in the medical record about a case, utilize the text field [s](#) to state that limited [or no](#) information was available. ~~in the medical record.~~

Document dates as M/D/[YY](#)YY.

Record text to support MP/H or STR rule used to determine multiple primary/histology.

### Description of the table:

The following table gives the name of each text field, a description of what text should be entered in column 2, and, in the third column, suggestions and examples of text and abbreviations that can be entered.

Text Field	Description of Text to Enter	Suggestions for Text to Enter, and Examples	Field Length
<b>Required Fields for All Reporting Facilities</b>			
<b>Primary Site Title Text</b>	Type in the primary site of the tumor being reported and the laterality (side of the body) if it is a paired site. (some sites are not paired such as the prostate, uterus, esophagus, pancreas, and colon)	<b>Suggestions for text:</b> Location of the primary site of the tumor Available information on tumor laterality (if paired site) <b>Examples:</b> Lung, L lower lobe Prostate Breast, R upper outer quadrant Sigmoid colon Left temporal lobe of brain	<b>100</b>
<b>Histology Title (Morphology)</b>	Review the pathology report and type in the histologic type (adenocarcinoma, squamous cell cancer, etc.), the “behavior” (malignant, in situ, benign), and the grade (differentiation) of the tumor being reported.	<b>Suggestions for text:</b> Histologic type and behavior Information on differentiation from scoring system such as Gleason score, Bloom Richardson score <b>Examples:</b> Adenocarcinoma of transverse colon, invasive, grade III Adenocarcinoma of prostate, Gleason score 5, Grade 2 Melanoma skin right arm, in situ, grade 0 Melanoma skin left leg, in situ, grade not stated	<b>100</b>

<b>Pathology</b>	<p>Review the pathology report and type in the text from cytology and histopathology reports.</p> <p><b>*Must include: Date of Procedure, Facility Name (abbreviation), Pathology Number, Type of Procedure, and Findings.</b></p> <p>Data should verify/validate the coding of the following fields: Date of Diagnosis, Primary Site, Laterality, Histology ICD-O-3, Grade, Collaborative Stage variables, Diagnostic confirmation</p>	<p><b>Suggestions for Text:</b></p> <p>Date(s) of procedure(s)</p> <p>Type of tissue specimen(s)</p> <p>Tumor type and grade (include all modifying adjectives, i.e., predominantly, with features of, with foci of, elements of, etc.)</p> <p>Gross tumor size; Extent of tumor spread; Involvement of resection margins</p> <p>Number of lymph nodes involved and examined</p> <p>Record any additional comments from the pathologist, including differential diagnoses considered and any ruled out or favored</p> <p><b>Examples:</b></p> <p>11/12/2006 colon polyp, 1.2x1.0x0.8 cm. Adenocarcinoma contained within polyp showing invasion of submucosa. Stalk: no evidence of adenocarcinoma or dysplasia.</p>	<b>1000</b>
------------------	---	--	-------------

Text Field	Description of Text to Enter	Suggestions for Text to Enter, and Examples	Field Length
<b>Required Fields for All Reporting Facilities</b>			
<b>Text—Remarks</b>	Type in more information that you have or use if you ran out of room in other text fields. Problematic coding issues can also be discussed in this section.	<b>Suggestions for Text:</b> Overflow of information from any other Text field Justification of over-ride flags Family and personal history of cancer Comorbidities Information on sequence numbers if a person was diagnosed with another cancer out-of-state or before the registry's reference date Place of birth Solid Tumor Rule; Multiple Primary/Histology Rule <b>Example:</b> <b>Patient severely ill; could not undergo further surgery or staging; no treatment planned</b>	<b>1000</b>
<b>Laboratory Text</b>	Text area for information from laboratory examinations other than cytology or histopathology.  <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Type of lab test/tissue specimen(s) Record both positive and negative findings, record positive test results first. Information can include tumor markers, serum and urine electrophoresis, special studies, etc. Date(s) of lab test(s) Tumor markers included, but are not limited to <ul style="list-style-type: none"> <li>○ Breast Cancer: Estrogen Receptor Assay (ERA), Progesterone Receptor Assay (PRA), Her 2/neu.</li> <li>○ Prostate Cancer: Prostatic Specific Antigen (PSA)</li> <li>○ Testicular Cancer: Human Chorionic Gonadotropin (hCG), Alpha Fetoprotein (AFP), Lactate Dehydrogenase (LDH)</li> </ul>	<b>1000</b>

Text Field	Description of Text to Enter	Suggestions for Text to Enter, and Examples	Field Length
<b>Required Fields for All Reporting Facilities</b>			
<b>Operations Text</b>	Text area for manual documentation of all surgical procedures that provide information for staging. Data should verify/validate the coding of the following fields: Date of 1 <sup>st</sup> positive Bx; Date of Diagnosis; Rx Summary—diagnostic-staging procedures; Rx Summary—Surgery at primary site	<b>Suggestions for Text:</b> Dates and descriptions of biopsies and all other surgical procedures from which staging information was derived. Number of lymph nodes removed. Size of tumor removed. Documentation of residual tumor Evidence of invasion of surrounding areas	<b>1000</b>
<b>Physical Examination Text</b>	Text area for the history and physical examination related to the current tumor and the clinical description of the tumor.	<b>Suggestions for Text:</b> Date of physical exam Age, sex, race/ethnicity History that relates to cancer diagnosis Height Weight Tobacco History Family History Any information known prior to patient receiving treatment at your facility.	<b>1000</b>
<b>Scopes Text</b>	Text area for endoscopic examinations that provide information for staging and treatment.  <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date(s) of endoscopic exam(s) Primary site Histology (if given) Tumor location Tumor size Lymph nodes Record positive and negative clinical findings. Record positive result first.	<b>1000</b>

Text Field	Description of Text to Enter	Suggestions for Text to Enter, and Examples	Field Length
<b>Required Fields for All Reporting Facilities</b>			
<b>X-Rays and Scans Text</b>	Text area for all X-rays, scan, and/or other imaging examinations that provide information about staging.  <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date(s) of X-ray/Scan(s) Age, sex, race/ethnicity (when given) Primary site Histology (if given) Tumor location Tumor size Lymph nodes Record positive and negative clinical findings. Record positive results First Distant disease or metastasis	<b>1000</b>
<b>Place of Diagnosis Text</b>	Text area for the facility, physician office, city, state, or county where the diagnosis was made	<b>Suggestions for Text:</b> The complete name of the hospital or the physician office where diagnosis occurred. The initials of a hospital are not adequate. For out-of-state residents and facilities, include the city and the state where the medical facility is located.	<b>60</b>
<b>Staging Text</b>	Text area for staging Information  <b>Please include AJCC Staging information and SEER Summary Staging information</b>	<b>Suggestions for Text:</b> Date(s) of procedure(s), including clinical procedures, that provided information for assigning state. Organs involved by direct extension. Size of tumor Status of margins Number and sites of positive lymph nodes Site(s) of distant metastasis Physician's specialty and comments	<b>1000</b>

Formatted: No bullets or numbering



Text Field	Description of Text to Enter	Suggestions for Text to Enter, and Examples	Field Length
<b>Required Fields for All Reporting Facilities</b>			
<b>Treatment— Biologic Response Modifiers Text</b>	Text area for information regarding the treatment of the tumor being reported with biological response modifiers or immunotherapy <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> When Treatment was given, e.g., at this facility; at another facility. Type of BRM agent, e.g., Interferon, BCG BRM procedures, e.g., bone marrow transplant, stem cell transplant Other treatment information, e.g., treatment cycle incomplete; unknown if BRM was given	<b>1000</b>
<b>Treatment— Chemotherapy Text</b>	Text area for information regarding chemotherapy treatment of the reported tumor. <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date when chemotherapy began Where treatment was given, e.g., name of agent(s) or protocol Other treatment information, e.g., treatment cycle incomplete, unknown if chemotherapy was given	<b>1000</b>
<b>Treatment-- Hormonal Text</b>	Text area for information about hormonal treatment <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date treatment was started Where treatment was given, e.g., at this facility, at another facility Type of hormone or antihormone, e.g., Tamoxifen Type of endocrine surgery or radiation, e.g., orchiectomy Other treatment information, e.g., treatment cycle incomplete; unknown if hormones were given.	<b>1000</b>

Formatted: Font: 4 pt

<b>Treatment— Other Text</b>	Text area for information regarding the treatment of the tumor being reported with treatment that cannot be defined as surgery, radiation, or systemic therapy. This includes experimental treatments and blinded clinical trials. <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date treatment was started Where treatment was given, e.g., at this facility, at another facility Type of other treatment, e.g., blinded clinical trial, hyperthermia Other treatment information, e.g., treatment cycle incomplete; unknown if other treatment was given.	<b>1000</b>
----------------------------------	---	---	-------------

Text Field	Description of Text to Enter	Suggestions for Text to Enter, and Examples	Field Length
<b>Required Fields for All Reporting Facilities</b>			
<b>Treatment – Radiation Text</b>	Text area for information regarding treatment of the tumor being reported with beam radiation. <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date when radiation treatment began Where treatment was given, e.g., at this facility, at another facility Type(s) of beam radiation, e.g., Orthovoltage, Cobalt 60, MV X-rays, Electrons, Mixed modalities Other treatment information, e.g., patient discontinued after 5 treatments; unknown if radiation was given	<b>1000</b>
<b>Treatment—Surgery Text</b>	Text area for information describing all surgical procedures performed as part of treatment. <b>*Must Include Date, Facility Name, and Suggested Text</b>	<b>Suggestions for Text:</b> Date of each procedure Type(s) of surgical procedure(s), including excisional biopsies and surgery to other and distant sites Lymph nodes removed Regional tissues removed Metastatic sites Facility where each procedure was performed. Record positive and negative findings. Record positive findings first	<b>1000</b>

## Section 6: Instructions for Electronic Submission

All reporting facilities in Rhode Island are required to submit data electronically in an approved data format (current NAACCR format).

### Secured Data Transmission

#### Sharefile® Encrypted Cloud Services

(reproduced from: <https://www.sharefile.com/secure-file-sharing>)

All in-state reporting facilities submit their cancer cases via a cloud-based software site and data center called ShareFile.com. Files are secured with encryption protocols and algorithms while in transit and once saved. Datacenters are equipped to protect against data loss. Configurable controls include password settings with individual interfaces to access restricted folders assigned to specific persons.

The RICR will set up your specific folder on Sharefile. Once this is completed, you will receive an email from the Sharefile website with instructions to set up your login information. Your email address will act as your username and you will need to set up a password for your secure folder. Once you are able to log into your folder, you will have the ability to upload by either pressing the green “+” button on the upper right hand side of the folder screen or by using the “drag and drop” feature: files.

Once all the steps are complete for setting up secure connection, you are now able to upload monthly submission files and other pertinent information that contains PHI. The RICR will receive an email stating that something has been uploaded. If the RICR uploads something to your specific folder, you will get an email stating that something has been uploaded.

#### ShareFile Upload Processes

(These steps will be followed after already being logged into Once logged into ShareFile, please choose an option below)

##### Option 1

Drag file from “File Explorer” to the browser and then browser will change screen to “Drop files here” and let go of mouse over browser.

##### Option 2

On the right side, move mouse over to “+” symbol, select “Upload” on the drop-down menu.  
Drag file from “File Explorer” to browser where it says “Drag files here”  
Select “Upload”

##### Option 3

On right hand side, move mouse over to the “+” symbol, select “Upload” on the drop-down menu.  
On that screen select “Browse file” and locate desired file.

Formatted: Font: Not Bold, No underline

Formatted: Font: Not Bold, No underline

## Section 7: Quality Control

To ensure completeness and accuracy of the RICR cancer data, the RICR routinely conducts quality control activities. Quality control activities consist of routine data processing, as well as periodic auditing and monitoring activities. Routine data processing activities consist of deduplication, consolidation, and data editing. Electronic reports, pathology reports and abstracts received and imported into the RICR database undergo extensive data processing routines to ensure accurate data. Periodically, the RICR staff will perform audits and monitor cancer reporting from all reporting facilities. The audits aid in monitoring case reporting completeness and accuracy to deliver only the most pristine information through annual data submissions to NPCR and NAACCR.

### Data Submission Standards for NPCR

All grantees funded by CDC's National Program of Cancer Registries (NPCR) are expected to meet established NPCR standards. One standard requires state central registries to submit de-identified cancer data to CDC. Annually, these data are evaluated for quality, completeness, and timeliness according to the National Data Quality Standard for 23-month data and the Advanced National Data Quality Standard for 12-month data. Data also are evaluated according to the United States Cancer Statistics (USCS) Publication Standard before publication.

NPCR-CSS Data Quality Criteria					
Criteria	NPCR Advanced National Data Quality Standard (12-month)	NPCR National Data Quality Standard (24-month)	USCS Publication Criteria	U.S. County Public Use File Criteria	Measurement Error
Percentage Completeness of Case Ascertainment	>=90%	>=95%	NA	NA	-1.00%
Percentage Missing or Unknown	Age	<=2%	<=3%	<=3%	-0.40%
	Sex	<=2%	<=3%	<=3%	-0.40%
	Race	<=3%	<=5%	<=5%	-0.40%
	County	<=2%	NA	<=3%	-0.40%
Percentage Death Certificate Only (DCO)	NA	<=3%	<=5%	<=5%	-0.40%
Unresolved Duplicates (per 1,000)	<=2	<=1	NA	NA	-0.4
Percentage Passing Edits	>=97%	>=99%	>=97%	>=97%	NA

### Data Submission Standards for NAACCR

In 1997, NAACCR instituted a program that annually reviews member registries for their ability to produce complete, accurate, and timely data. NAACCR annually reviews data from member registries to assure the quality, accuracy, and completeness of cancer incidence data based on pre-determined

objective and independent registry certification criteria. Registry staff receive a report containing the results of registry certification evaluation for the most recent data year.

#### NAACCR Criteria for Certification

Criteria	Certification
Data Years	**Changes yearly
Completeness	90% Silver 95% Gold
% Passing EDITS	97% Silver 100% Gold
Death Clearance Only Cases	<=5% Silver <=3% Gold
Timeliness	**Changes yearly
Duplicate Reports*	<=2/1,000 Silver <=1/1,000 Gold
Missing Data Field Sex, Age, County	<=3% Silver <=2% Gold
Missing Data Field Race	<=5% Silver <=3% Gold

## Appendices

[Appendix A: Rhode Island State Cancer Reporting Law](#)

[Appendix B: Confidentiality of Health Care Communications and Information Act](#)

[Appendix C: Rhode Island Cancer Registry Confidentiality Pledge](#)

[Appendix D: ICD-10 Casefinding List](#)

[Appendix E: RICR Standard for Inclusion and Reportability/RICR Reportable List](#)

[Appendix F: NAACCR Required Data Items](#)

[Appendix G: Approved Abstracting Abbreviations List](#)

[Appendix H: Effective Dates for Cancer Registry Standard References](#)

[Appendix I: References for Tumor Registrars or Tumor Reporting Personnel](#)

[Appendix J: Acronyms of Cancer Organizations for the United States](#)

## Appendix A: Rhode Island Cancer Reporting Law 216-RICR-10-10-2

### **TITLE 216 – DEPARTMENT OF HEALTH**

#### **CHAPTER 10 – PUBLIC HEALTH ADMINISTRATION**

##### **SUBCHAPTER 10 – REGISTRIES**

#### **PART 2 – Rhode Island Cancer Registry**

### **2.1 Authority**

These rules and regulations are promulgated pursuant to the authority conferred under R.I. Gen. Laws §§ 23-1-18(2), 23-8-1, and 23-12-4 for the purpose of establishing a unified procedure for the reporting of cancer to the Rhode Island Cancer Registry.

### **2.2 Definitions**

Whenever used in these Regulations, the following terms shall be construed as follows:

"Acts" refers to R.I. Gen. Laws Chapters 23-1, 23-8, and 23-12.

"Administrator of the Rhode Island Cancer Registry" means the individual within the Department of Health designated by the Director to be responsible for the operation of the Rhode Island Cancer Registry. For the purpose of this Part, this individual may also be referred to as the Registrar.

"Director" means the Director of the Rhode Island Department of Health.

"Health care facility and/or health care provider" means hospitals, freestanding ambulatory surgical centers and radiotherapy facilities, health maintenance organizations, independent clinical laboratories providing histopathology and/or cytology, licensed pursuant to R.I. Gen. Laws Chapters 23-17, 23-16.2 or 27-41 and furthermore includes such other health care facilities not listed above and health care providers (such as physicians, dentists) licensed in accordance with statutory provisions of this state, who may produce a positive test result for, make a diagnosis of, or provide treatment for cancer as defined in § 2.2(A)(5) of this Part, independent of the health care facilities listed above.



"Reportable case" means all incident cancer, benign neoplasm (tumor), or premalignant (precancerous) case specified by the Rhode Island Cancer Registry as follows:

"Benign neoplasm of the brain or central nervous system", a diagnosis of benign or borderline neoplasm, established by a licensed physician, occurring in the brain, meninges, spinal cord, cauda equine, a cranial nerve or nerves, other part of the central nervous system, pituitary gland, pineal gland, craniopharyngeal duct," or other related anatomical sites, by the current amended "International Classification of Diseases for Oncology" (ICD-O) published by the World Health Organization.

"Cancer", a diagnosis of in situ or invasive malignant disease (made microscopically and/or non-microscopically) established by a licensed physician which includes cancers at all sites and all stages of the disease and which are listed in the current amended "International Classification of Diseases for Oncology" (ICD-O), published by the World Health Organization. Excluded are squamous cell and basal cell carcinomas of the skin, but included are all carcinomas (including in situ) of the breast (including lobular carcinoma in situ: LCIS), cervix (also known as squamous intraepithelial neoplasia 3: CIN-3), vagina (including intraepithelial neoplasia 3: VAIN-3), prepuce, clitoris, vulva (including intraepithelial neoplasia 3: VIN-3), labia, penis and scrotum.

"Rhode Island Cancer Registry" means the Central Registry established within the Department of Health by the Director pursuant to R.I. Gen. Laws §§ 23-1-1, 23-1-18(2), 23-8-1 and 23-12-4 as the statewide Registry for the collection and recording of information on reportable cases as defined in § 2.2(A)(5) of this Part for the purpose of understanding the extent and nature of the diseases among the citizens of the state and to apply preventive and control measures.

"This Part" mean all parts of the rules and regulations pertaining to the Rhode Island Cancer Registry (216-RICR-10-10-2).

### **2.3 Administration of the Rhode Island Cancer Registry**

All cases as defined in § 2.2(A)(5) of this Part shall be reportable in accordance with the statutory and regulatory provision herein.

Pursuant to R.I. Gen. Laws § 23-12-4, the Director may enter into a contract with a non-profit organization to be responsible to the Rhode Island Cancer Registry for the collection and recording of all reportable cases as defined in § 2.2(A)(5) of this Part.

A contract entered into with a non-profit organization shall clearly delineate the mutual responsibilities of the parties involved and shall include other terms of agreement such as reimbursement, designation of services to be rendered, confidentiality, disclosure of data, assurance of compliance with the requirements herein, and such other terms of agreement as may be mutually acceptable.

## 2.4 Reporting Requirements

Health care facilities and/or health care providers as defined in § 2.2(A)(4) of this part, shall be responsible to report to the Rhode Island Cancer Registry and the organization and/or agency approved by the Director, each reportable malignant disease indicated by test results, diagnosed and/or confirmed within the health care facility and/or by the health care provider on and after October 1, 1986, each reportable benign neoplasm of the brain or central nervous system indicated by test results, diagnosed and/or confirmed within the health care facility and/or by the health care provider on and after January 1, 1998, and each reportable in-situ carcinomas of the cervix (also known as squamous intraepithelial neoplasia 3: CIN-3) indicated by test results, diagnosed and/or confirmed within the health care facility and/or by the health care provider on and after January 1, 2018, including all histopathology and cytology specimens removed elsewhere but found to be positive for each reportable case upon initial reading or upon consultative reading at the health care facility and/or by the health care provider. Health care facilities and/or health care providers shall report each reportable case treated within the health care facility and/or by the health care provider if that case was diagnosed therein or thereby, or if the treatment therein or thereby is part of the first course of definitive treatment for the case.

Each health care facility and/or health care provider shall electronically submit such data and information on reportable cases and shall meet data element requirements, format, completeness, quality, and timelines prescribed by:

Chapter VII "Record Layout Table" of the "Standards Volume II" of the "Central Cancer Registry Standards" (Version 18, Revised October 12, 2018) published by the North American Association of Central Cancer Registries, incorporated herein by reference, not including any later editions or amendments thereof; and

"Standards for Oncology Registry Entry" (Revised January 1, 2018) published by the Commission on Cancer, incorporated herein by reference, not including any later editions or amendments thereof.

## 2.5 Procedure for Reporting

Each health care facility and/or health care provider shall submit a set of available information on reportable cases within thirty (30) to forty-five (45) days from the date of a case first seen by provider (including but not limited to patient demographic information, date of diagnosis, primary site, histology, behavior, tumor identifier, tumor sequence number, and facility/provider information), as defined in § 2.2 of this Part and specified by the Rhode Island Cancer Registry.

Within one hundred eighty (180) days from the date of a reportable case first seen by provider as defined in § 2.2 of this Part, a health care facility and/or

health care provider shall report complete all required information, as specified by the Rhode Island Cancer Registry. The originating health care facility and/or provider shall retain a duplicate copy of submitted information for a two (2) year period from the date of submission. Said information and data shall be submitted in a manner consistent with § 2.4 of this Part.

## **2.6 Validation of Data**

To ensure the accuracy of the data and the completeness of reporting, the Administrator is authorized to review periodically patients' medical records and all other sources of patient information, including but not limited to, pathology reports or logs, cytology reports or logs, disease indexes, operating room logs, or radiation therapy logs, as may be necessary to substantiate the accuracy of the data and the completeness of reporting. Nothing under the provisions of the Acts and this Part shall be construed to compel any individual to submit to physical examination or medical supervision.

## **2.7 Confidentiality**

The Rhode Island Cancer Registry shall maintain comprehensive records of all reports of reportable cases submitted pursuant to the provisions of the Acts and the rules and regulations herein. Such reports shall be confidential in accordance with R.I. Gen. Laws Chapter 5-37.3 and subject to the restrictions on release incorporated therein. The mutual exchange of cancer related data with neighboring states pursuant to reciprocal contracts for said purpose shall also be subject to the aforementioned statutory provisions on confidentiality.

## **2.8 Ownership and Publication of Data**

All individual records and aggregate data relating to the Rhode Island Cancer Registry are the property of the Rhode Island Department of Health. The use of confidential records by any person shall be subject to the approval of the Director in accordance with applicable federal and state law, rules and regulations regarding confidentiality and public access to data.

## **2.9 Violations/Sanctions**

Failure of any health care facility and/or health care provider to comply with the provisions of the Acts and this Part shall be subject to sanctions and referred to the appropriate licensing and/or disciplinary body.

## **2.10 Exception**

Modification of any individual requirement of this Part may be granted by the Director upon motion of the Rhode Island Cancer Registry or upon request of a

contracting agency and/or organization in a specific case, if the Director finds that the modification to the requirement is not contrary to the purpose of the Rhode Island Cancer Registry nor contrary to the public interest.

A request for modification of a requirement shall require advance written request to the Director and written approval by the Director.

**TITLE 5**  
**Businesses and Professions**  
**CHAPTER 5-37.3**  
**Confidentiality of Health Care Communications and**  
**Information Act**  
**SECTION 5-37.3-4**

**§ 5-37.3-4. Limitations on and permitted disclosures.**

(a)(1) Except as provided in subsection (b) of this section, or as specifically provided by the law, a patient's confidential health care information shall not be released or transferred without the written consent of the patient, or his or her authorized representative, on a consent form meeting the requirements of subsection (d) of this section. A copy of any notice used pursuant to subsection (d) of this section, and of any signed consent shall, upon request, be provided to the patient prior to his or her signing a consent form. Any and all managed care entities and managed care contractors writing policies in the state shall be prohibited from providing any information related to enrollees that is personal in nature and could reasonably lead to identification of an individual and is not essential for the compilation of statistical data related to enrollees, to any international, national, regional, or local medical information database. This provision shall not restrict or prohibit the transfer of information to the department of health to carry out its statutory duties and responsibilities.

(2) Any person who violates the provisions of this section may be liable for actual and punitive damages.

(3) The court may award a reasonable attorney's fee at its discretion to the prevailing party in any civil action under this section.

(4) Any person who knowingly and intentionally violates the provisions of this section shall, upon conviction, be fined not more than five thousand (\$5,000) dollars for each violation, or imprisoned not more than six (6) months for each violation, or both.

(5) Any contract or agreement that purports to waive the provisions of this section shall be declared null and void as against public policy.

(b) No consent for release or transfer of confidential health care information shall be required in the following situations:

(1) To a physician, dentist, or other medical personnel who believes, in good faith, that the information is necessary for diagnosis or treatment of that individual in a medical or dental emergency;

(2) To medical and dental peer review boards, or the board of medical licensure and discipline, or board of examiners in dentistry;

(3) To qualified personnel for the purpose of conducting scientific research, management audits, financial audits, program evaluations, actuarial, insurance underwriting, or similar studies; provided, that personnel shall not identify, directly or indirectly, any individual patient in any report of that research, audit, or evaluation, or otherwise disclose patient identities in any manner;

(4)(i) By a health care provider to appropriate law enforcement personnel, or to a person if the health care provider believes that person, or his or her family, is in danger from a patient; or to appropriate law enforcement personnel if the patient has, or is attempting to obtain, narcotic drugs from the health care provider illegally; or to appropriate law enforcement personnel, or appropriate child protective agencies, if the patient is a minor child or the parent or guardian of said child and/or the health care provider believes, after providing health care services to the patient, that the child is, or has been, physically, psychologically, or sexually abused and neglected as reportable pursuant to § 40-11-3; or to appropriate law enforcement personnel or the division of elderly affairs if the patient is an elder person and the healthcare provider believes, after providing healthcare services to the patient, that the elder person is, or has been, abused, neglected, or exploited as reportable pursuant to § 42-66-8; or to law enforcement personnel in the case of a gunshot wound reportable under § 11-47-48;

(ii) A health care provider may disclose protected health information in response to a law enforcement official's request for such information for the purpose of identifying or locating a suspect, fugitive, material witness, or missing person, provided that the health care provider may disclose only the following information:

(A) Name and address;

(B) Date and place of birth;

(C) Social security number;

(D) ABO blood type and rh factor;

(E) Type of injury;

(F) Date and time of treatment;

(G) Date and time of death, if applicable; and

(H) A description of distinguishing physical characteristics, including height, weight, gender, race, hair and eye color, presence or absence of facial hair (beard or moustache), scars, and tattoos.

(I) Except as permitted by this subsection, the health care provider may not disclose for the purposes of identification or location under this subsection any protected health information related to the patient's DNA or DNA analysis, dental records, or typing, samples, or analysis of body fluids or tissue.

(iii) A health care provider may disclose protected health information in response to a law enforcement official's request for such information about a patient who is, or is suspected to be, a victim of a crime, other than disclosures that are subject to subsection (b)(4)(vii) of this section, if:

(A) The patient agrees to the disclosure; or

(B) The health care provider is unable to obtain the patient's agreement because of incapacity or other emergency circumstances provided that:

(1) The law enforcement official represents that such information is needed to determine whether a violation of law by a person other than the victim has occurred, and such information is not intended to be used against the victim;

(2) The law enforcement official represents that immediate law enforcement activity that depends upon the disclosure would be materially and adversely affected by waiting until the patient is able to agree to the disclosure; and

(3) The disclosure is in the best interests of the patient as determined by the health care provider in the exercise of professional judgment.

(iv) A health care provider may disclose protected health information about a patient who has died to a law enforcement official for the purpose of alerting law enforcement of the death of the patient if the health care provider has a suspicion that such death may have resulted from criminal conduct.

(v) A health care provider may disclose to a law enforcement official protected health information that the health care provider believes in good faith constitutes evidence of criminal conduct that occurred on the premises of the health care provider.

(vi)(A) A health care provider providing emergency health care in response to a medical emergency, other than such emergency on the premises of the covered health care provider, may disclose protected health information to a law enforcement official if such disclosure appears necessary to alert law enforcement to:

(1) The commission and nature of a crime;

(2) The location of such crime or of the victim(s) of such crime; and

(3) The identity, description, and location of the perpetrator of such crime.

(B) If a health care provider believes that the medical emergency described in subsection (b)(4)(vi)(A) of this section is the result of abuse, neglect, or domestic violence of the individual in need of emergency health care, subsection (b)(4)(vi)(A) of this section does not apply and any disclosure to a law enforcement official for law enforcement purposes is subject to subsection (b)(4)(vii) of this section.

(vii)(A) Except for reports permitted by subsection (b)(4)(i) of this section, a health care provider may disclose protected health information about a patient the health care provider reasonably believes to be a victim of abuse, neglect, or domestic violence to law enforcement or a government authority, including a social service or protective services agency, authorized by law to receive reports of such abuse, neglect, or domestic violence:

(1) To the extent the disclosure is required by law and the disclosure complies with, and is limited to, the relevant requirements of such law;

(2) If the patient agrees to the disclosure; or

(3) To the extent the disclosure is expressly authorized by statute or regulation and:

(i) The health care provider, in the exercise of professional judgment, believes the disclosure is necessary to prevent serious harm to the patient or other potential victims; or

(ii) If the patient is unable to agree because of incapacity, a law enforcement or other public official authorized to receive the report represents that the protected health information for which disclosure is sought is not intended to be used against the patient and that an immediate enforcement activity that depends upon the disclosure would be materially and adversely affected by waiting until the patient is able to agree to the disclosure.

(B) A health care provider that makes a disclosure permitted by subsection (b)(4)(vii)(A) of this section must promptly inform the patient that such a report has been, or will be, made, except if:

(1) The health care facility, in the exercise of professional judgment, believes informing the patient would place the individual at risk of serious harm; or

(2) The health care provider would be informing a personal representative, and the health care provider reasonably believes the personal representative is responsible for the abuse, neglect, or other injury, and that informing such person would not be in the best interests of the individual as determined by the covered entity in the exercise of professional judgment.

(viii) The disclosures authorized by this subsection shall be limited to the minimum amount of information necessary to accomplish the intended purpose of the release of information.

(5) Between, or among, qualified personnel and health care providers within the health care system for purposes of coordination of health care services given to the patient and for purposes of education and training within the same health care facility; or

(6) To third party health insurers, including to utilization review agents as provided by § 23-17.12-9 (c)(4), third party administrators licensed pursuant to chapter 20.7 of title 27, and other entities that provide operational support to adjudicate health insurance claims or administer health benefits;

(7) To a malpractice insurance carrier or lawyer if the health care provider has reason to anticipate a medical liability action; or

(8)(i) To the health care provider's own lawyer or medical liability insurance carrier if the patient whose information is at issue brings a medical liability action against a health care provider.

(ii) Disclosure by a health care provider of a patient's health care information that is relevant to a civil action brought by the patient against any person or persons other than that health care provider may occur only under the discovery methods provided by the applicable rules of civil procedure (federal or state). This disclosure shall not be through ex parte contacts and not through informal ex parte contacts with the provider by persons other than the patient or his or her legal representative.

Nothing in this section shall limit the right of a patient, or his or her attorney, to consult with that patient's own physician and to obtain that patient's own health care information;

(9) To public health authorities in order to carry out their functions as described in this title and titles 21 and 23 and rules promulgated under those titles. These functions include, but are not restricted to, investigations into the causes of disease, the control of public health hazards, enforcement of sanitary



laws, investigation of reportable diseases, certification and licensure of health professionals and facilities, review of health care such as that required by the federal government and other governmental agencies;

(10) To the state medical examiner in the event of a fatality that comes under his or her jurisdiction;

(11) In relation to information that is directly related to a current claim for workers' compensation benefits or to any proceeding before the workers' compensation commission or before any court proceeding relating to workers' compensation;

(12) To the attorneys for a health care provider whenever that provider considers that release of information to be necessary in order to receive adequate legal representation;

(13) By a health care provider to appropriate school authorities of disease, health screening, and/or immunization information required by the school; or when a school-age child transfers from one school or school district to another school or school district;

(14) To a law enforcement authority to protect the legal interest of an insurance institution, agent, or insurance-support organization in preventing and prosecuting the perpetration of fraud upon them;

(15) To a grand jury, or to a court of competent jurisdiction, pursuant to a subpoena or subpoena duces tecum when that information is required for the investigation or prosecution of criminal wrongdoing by a health care provider relating to his, her or its provisions of health care services and that information is unavailable from any other source; provided, that any information so obtained, is not admissible in any criminal proceeding against the patient to whom that information pertains;

(16) To the state board of elections pursuant to a subpoena or subpoena duces tecum when that information is required to determine the eligibility of a person to vote by mail ballot and/or the legitimacy of a certification by a physician attesting to a voter's illness or disability;

(17) To certify, pursuant to chapter 20 of title 17, the nature and permanency of a person's illness or disability, the date when that person was last examined and that it would be an undue hardship for the person to vote at the polls so that the person may obtain a mail ballot;

(18) To the central cancer registry;

(19) To the Medicaid fraud control unit of the attorney general's office for the investigation or prosecution of criminal or civil wrongdoing by a health care provider relating to his, her or its provision of health care services to then-Medicaid-eligible recipients or patients, residents, or former patients or residents of long-term residential care facilities; provided, that any information obtained shall not be admissible in any criminal proceeding against the patient to whom that information pertains;

(20) To the state department of children, youth and families pertaining to the disclosure of health care records of children in the custody of the department;

(21) To the foster parent, or parents, pertaining to the disclosure of health care records of children in the custody of the foster parent, or parents; provided, that the foster parent or parents receive appropriate training and have ongoing availability of supervisory assistance in the use of sensitive information that may be the source of distress to these children;

(22) A hospital may release the fact of a patient's admission and a general description of a patient's condition to persons representing themselves as relatives or friends of the patient or as a representative of the news media. The access to confidential health care information to persons in accredited educational programs under appropriate provider supervision shall not be deemed subject to release or transfer of that information under subsection (a) of this section; or

(23) To the workers' compensation fraud prevention unit for purposes of investigation under §§ 42-16.1-12 – 42-16.1-16. The release or transfer of confidential health care information under any of the above exceptions is not the basis for any legal liability, civil or criminal, nor considered a violation of this chapter; or

(24) To a probate court of competent jurisdiction, petitioner, respondent, and/or their attorneys, when the information is contained within a decision-making assessment tool that conforms to the provisions of § 33-15-47.

(c) Third parties receiving, and retaining, a patient's confidential health care information must establish at least the following security procedures:

(1) Limit authorized access to personally identifiable, confidential health care information to persons having a "need to know" that information; additional employees or agents may have access to that information that does not contain information from which an individual can be identified;

(2) Identify an individual, or individuals, who have responsibility for maintaining security procedures for confidential health care information;

(3) Provide a written statement to each employee or agent as to the necessity of maintaining the security and confidentiality of confidential health care information, and of the penalties provided for in this chapter for the unauthorized release, use, or disclosure of this information. The receipt of that statement shall be acknowledged by the employee or agent, who signs and returns the statement to his or her employer or principal, who retains the signed original. The employee or agent shall be furnished with a copy of the signed statement; and

(4) Take no disciplinary or punitive action against any employee or agent solely for bringing evidence of violation of this chapter to the attention of any person.

(d) Consent forms for the release or transfer of confidential health care information shall contain, or in the course of an application or claim for insurance be accompanied by a notice containing, the following information in a clear and conspicuous manner:

(1) A statement of the need for and proposed uses of that information;

(2) A statement that all information is to be released or clearly indicating the extent of the information to be released; and

(3) A statement that the consent for release or transfer of information may be withdrawn at any future time and is subject to revocation, except where an authorization is executed in connection with an application for a life or health insurance policy in which case the authorization expires two (2) years from the issue date of the insurance policy, and when signed in connection with a claim for benefits under any insurance policy, the authorization shall be valid during the pendency of that claim. Any revocation shall be transmitted in writing.

(e) Except as specifically provided by law, an individual's confidential health care information shall not be given, sold, transferred, or in any way relayed to any other person not specified in the consent form or notice meeting the requirements of subsection (d) of this section without first obtaining the individual's additional written consent on a form stating the need for the proposed new use of this information or the need for its transfer to another person.

(f) Nothing contained in this chapter shall be construed to limit the permitted disclosure of confidential health care information and communications described in subsection (b) of this section.

History of Section.

(P.L. 1978, ch. 297, § 1; P.L. 1979, ch. 221, § 1; P.L. 1981, ch. 283, § 1; P.L. 1983, ch. 172, § 20; P.L. 1985, ch. 402, § 6; P.L. 1989, ch. 502, § 1; P.L. 1992, ch. 427, § 1; P.L. 1993, ch. 281, § 1; P.L. 1996, ch. 248, § 2; P.L. 1996, ch. 266, § 2; P.L. 1996, ch. 343, § 1; P.L. 1996, ch. 401, § 1; P.L. 1997, ch. 326, § 5; P.L. 1998, ch. 180, § 1; P.L. 1998, ch. 420, § 1; P.L. 1999, ch. 216, § 1; P.L. 1999, ch. 384, § 1; P.L. 2003, ch. 42, § 1; P.L. 2003, ch. 281, § 1; P.L. 2004, ch. 314, § 1; P.L. 2006, ch. 216, § 1; P.L. 2010, ch. 82, § 1; P.L. 2010, ch. 85, § 1; P.L. 2013, ch. 302, § 1; P.L. 2013, ch. 403, § 1; P.L. 2014, ch. 277, § 1; P.L. 2014, ch. 333, § 1.)

## Appendix C: Rhode Island Cancer Registry Confidentiality Pledge



Teresa Paiva Weed  
President

### HOSPITAL ASSOCIATION OF RHODE CANCER REGISTRY

#### CONFIDENTIALITY PLEDGE

I understand and accept the legal and moral responsibility of maintaining the confidentiality of all data and information collected and processed by Hospital Association of Rhode Island (HARI) cancer registry. I also understand my role in ensuring the right to privacy of persons and institutions cooperating with the cancer registry data collection activities. Furthermore, I understand that the hospitals in the State of Rhode Island have policies that protect the patients' rights to every consideration of their privacy regarding their medical information. I understand that I must not reveal such information, such as another staff member or the original reporting source. I also understand that failure to adhere to this policy may result in disciplinary action up to and including automatic dismissal without further notice.

I have read and understand HARI's confidentiality policy and procedures and pledge to act in accordance with these policies and procedures.

---

Signature

---

Date

## Appendix D: ICD-10 Casefinding List

Effective 10/1/2020-9/30/2021

ICD-10-CM Code Specific	ICD-10-CM Code Definition
<u>C00</u>	<u>Malignant neoplasm of lip</u>
<u>C00.0</u>	<u>Malignant neoplasm of external upper lip</u>
<u>C00.1</u>	<u>Malignant neoplasm of external lower lip</u>
<u>C00.2</u>	<u>Malignant neoplasm of external lip, unspecified</u>
<u>C00.3</u>	<u>Malignant neoplasm of upper lip, inner aspect</u>
<u>C00.4</u>	<u>Malignant neoplasm of lower lip, inner aspect</u>
<u>C00.5</u>	<u>Malignant neoplasm of lip, unspecified, inner aspect</u>
<u>C00.6</u>	<u>Malignant neoplasm of commissure of lip, unspecified</u>
<u>C00.8</u>	<u>Malignant neoplasm of overlapping sites of lip</u>
<u>C00.9</u>	<u>Malignant neoplasm of lip, unspecified</u>
<u>C01</u>	<u>Malignant neoplasm of base of tongue</u>
<u>C02</u>	<u>Malignant neoplasm of other and unspecified parts of tongue</u>
<u>C02.0</u>	<u>Malignant neoplasm of dorsal surface of tongue</u>
<u>C02.1</u>	<u>Malignant neoplasm of border of tongue</u>
<u>C02.2</u>	<u>Malignant neoplasm of ventral surface of tongue</u>
<u>C02.3</u>	<u>Malignant neoplasm of anterior two-thirds of tongue, part unspecified</u>
<u>C02.4</u>	<u>Malignant neoplasm of lingual tonsil</u>
<u>C02.8</u>	<u>Malignant neoplasm of overlapping sites of tongue</u>
<u>C02.9</u>	<u>Malignant neoplasm of tongue, unspecified</u>
<u>C03</u>	<u>Malignant neoplasm of gum</u>
<u>C03.0</u>	<u>Malignant neoplasm of upper gum</u>
<u>C03.1</u>	<u>Malignant neoplasm of lower gum</u>
<u>C03.9</u>	<u>Malignant neoplasm of gum, unspecified</u>
<u>C04</u>	<u>Malignant neoplasm of floor of mouth</u>
<u>C04.0</u>	<u>Malignant neoplasm of anterior floor of mouth</u>
<u>C04.1</u>	<u>Malignant neoplasm of lateral floor of mouth</u>
<u>C04.8</u>	<u>Malignant neoplasm of overlapping sites of floor of mouth</u>
<u>C04.9</u>	<u>Malignant neoplasm of floor of mouth, unspecified</u>
<u>C05</u>	<u>Malignant neoplasm of palate</u>
<u>C05.0</u>	<u>Malignant neoplasm of hard palate</u>
<u>C05.1</u>	<u>Malignant neoplasm of soft palate</u>
<u>C05.2</u>	<u>Malignant neoplasm of uvula</u>
<u>C05.8</u>	<u>Malignant neoplasm of overlapping sites of palate</u>
<u>C05.9</u>	<u>Malignant neoplasm of palate, unspecified</u>
<u>C06</u>	<u>Malignant neoplasm of other and unspecified parts of mouth</u>
<u>C06.0</u>	<u>Malignant neoplasm of cheek mucosa</u>

Formatted: Normal

Formatted: Font: Not Bold

Formatted Table

<a href="#"><u>C06.1</u></a>	<a href="#"><u>Malignant neoplasm of vestibule of mouth</u></a>
<a href="#"><u>C06.2</u></a>	<a href="#"><u>Malignant neoplasm of retromolar area</u></a>
<a href="#"><u>C06.8</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of other and unspecified parts of mouth</u></a>
<a href="#"><u>C06.80</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of unspecified parts of mouth</u></a>
<a href="#"><u>C06.89</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of other parts of mouth</u></a>
<a href="#"><u>C06.9</u></a>	<a href="#"><u>Malignant neoplasm of mouth, unspecified</u></a>
<a href="#"><u>C07</u></a>	<a href="#"><u>Malignant neoplasm of parotid gland</u></a>
<a href="#"><u>C08</u></a>	<a href="#"><u>Malignant neoplasm of other and unspecified major salivary glands</u></a>
<a href="#"><u>C08.0</u></a>	<a href="#"><u>Malignant neoplasm of submandibular gland</u></a>
<a href="#"><u>C08.1</u></a>	<a href="#"><u>Malignant neoplasm of sublingual gland</u></a>
<a href="#"><u>C08.9</u></a>	<a href="#"><u>Malignant neoplasm of major salivary gland, unspecified</u></a>
<a href="#"><u>C09</u></a>	<a href="#"><u>Malignant neoplasm of tonsil</u></a>
<a href="#"><u>C09.0</u></a>	<a href="#"><u>Malignant neoplasm of tonsillar fossa</u></a>
<a href="#"><u>C09.1</u></a>	<a href="#"><u>Malignant neoplasm of tonsillar pillar (anterior) (posterior)</u></a>
<a href="#"><u>C09.8</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of tonsil</u></a>
<a href="#"><u>C09.9</u></a>	<a href="#"><u>Malignant neoplasm of tonsil, unspecified</u></a>
<a href="#"><u>C10</u></a>	<a href="#"><u>Malignant neoplasm of oropharynx</u></a>
<a href="#"><u>C10.0</u></a>	<a href="#"><u>Malignant neoplasm of vallecula</u></a>
<a href="#"><u>C10.1</u></a>	<a href="#"><u>Malignant neoplasm of anterior surface of epiglottis</u></a>
<a href="#"><u>C10.2</u></a>	<a href="#"><u>Malignant neoplasm of lateral wall of oropharynx</u></a>
<a href="#"><u>C10.3</u></a>	<a href="#"><u>Malignant neoplasm of posterior wall of oropharynx</u></a>
<a href="#"><u>C10.4</u></a>	<a href="#"><u>Malignant neoplasm of branchial cleft</u></a>
<a href="#"><u>C10.8</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of oropharynx</u></a>
<a href="#"><u>C10.9</u></a>	<a href="#"><u>Malignant neoplasm of oropharynx, unspecified</u></a>
<a href="#"><u>C11</u></a>	<a href="#"><u>Malignant neoplasm of nasopharynx</u></a>
<a href="#"><u>C11.0</u></a>	<a href="#"><u>Malignant neoplasm of superior wall of nasopharynx</u></a>
<a href="#"><u>C11.1</u></a>	<a href="#"><u>Malignant neoplasm of posterior wall of nasopharynx</u></a>
<a href="#"><u>C11.2</u></a>	<a href="#"><u>Malignant neoplasm of lateral wall of nasopharynx</u></a>
<a href="#"><u>C11.3</u></a>	<a href="#"><u>Malignant neoplasm of anterior wall of nasopharynx</u></a>
<a href="#"><u>C11.8</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of nasopharynx</u></a>
<a href="#"><u>C11.9</u></a>	<a href="#"><u>Malignant neoplasm of nasopharynx, unspecified</u></a>
<a href="#"><u>C12</u></a>	<a href="#"><u>Malignant neoplasm of pyriform sinus</u></a>
<a href="#"><u>C13</u></a>	<a href="#"><u>Malignant neoplasm of hypopharynx</u></a>
<a href="#"><u>C13.0</u></a>	<a href="#"><u>Malignant neoplasm of postcricoid region</u></a>
<a href="#"><u>C13.1</u></a>	<a href="#"><u>Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect</u></a>
<a href="#"><u>C13.2</u></a>	<a href="#"><u>Malignant neoplasm of posterior wall of hypopharynx</u></a>
<a href="#"><u>C13.8</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of hypopharynx</u></a>
<a href="#"><u>C13.9</u></a>	<a href="#"><u>Malignant neoplasm of hypopharynx, unspecified</u></a>
<a href="#"><u>C14</u></a>	<a href="#"><u>Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx</u></a>
<a href="#"><u>C14.0</u></a>	<a href="#"><u>Malignant neoplasm of pharynx, unspecified</u></a>

<a href="#">C14.2</a>	<a href="#">Malignant neoplasm of Waldeyer's ring</a>
<a href="#">C14.8</a>	<a href="#">Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx</a>
<a href="#">C15</a>	<a href="#">Malignant neoplasm of esophagus</a>
<a href="#">C15.3</a>	<a href="#">Malignant neoplasm of upper third of esophagus</a>
<a href="#">C15.4</a>	<a href="#">Malignant neoplasm of middle third of esophagus</a>
<a href="#">C15.5</a>	<a href="#">Malignant neoplasm of lower third of esophagus</a>
<a href="#">C15.8</a>	<a href="#">Malignant neoplasm of overlapping sites of esophagus</a>
<a href="#">C15.9</a>	<a href="#">Malignant neoplasm of esophagus, unspecified</a>
<a href="#">C16</a>	<a href="#">Malignant neoplasm of stomach</a>
<a href="#">C16.0</a>	<a href="#">Malignant neoplasm of cardia</a>
<a href="#">C16.1</a>	<a href="#">Malignant neoplasm of fundus of stomach</a>
<a href="#">C16.2</a>	<a href="#">Malignant neoplasm of body of stomach</a>
<a href="#">C16.3</a>	<a href="#">Malignant neoplasm of pyloric antrum</a>
<a href="#">C16.4</a>	<a href="#">Malignant neoplasm of pylorus</a>
<a href="#">C16.5</a>	<a href="#">Malignant neoplasm of lesser curvature of stomach, unspecified</a>
<a href="#">C16.6</a>	<a href="#">Malignant neoplasm of greater curvature of stomach, unspecified</a>
<a href="#">C16.8</a>	<a href="#">Malignant neoplasm of overlapping sites of stomach</a>
<a href="#">C16.9</a>	<a href="#">Malignant neoplasm of stomach, unspecified</a>
<a href="#">C17</a>	<a href="#">Malignant neoplasm of small intestine</a>
<a href="#">C17.0</a>	<a href="#">Malignant neoplasm of duodenum</a>
<a href="#">C17.1</a>	<a href="#">Malignant neoplasm of jejunum</a>
<a href="#">C17.2</a>	<a href="#">Malignant neoplasm of ileum</a>
<a href="#">C17.3</a>	<a href="#">Meckel's diverticulum, malignant</a>
<a href="#">C17.8</a>	<a href="#">Malignant neoplasm of overlapping sites of small intestine</a>
<a href="#">C17.9</a>	<a href="#">Malignant neoplasm of small intestine, unspecified</a>
<a href="#">C18</a>	<a href="#">Malignant neoplasm of colon</a>
<a href="#">C18.0</a>	<a href="#">Malignant neoplasm of cecum</a>
<a href="#">C18.1</a>	<a href="#">Malignant neoplasm of appendix</a>
<a href="#">C18.2</a>	<a href="#">Malignant neoplasm of ascending colon</a>
<a href="#">C18.3</a>	<a href="#">Malignant neoplasm of hepatic flexure</a>
<a href="#">C18.4</a>	<a href="#">Malignant neoplasm of transverse colon</a>
<a href="#">C18.5</a>	<a href="#">Malignant neoplasm of splenic flexure</a>
<a href="#">C18.6</a>	<a href="#">Malignant neoplasm of descending colon</a>
<a href="#">C18.7</a>	<a href="#">Malignant neoplasm of sigmoid colon</a>
<a href="#">C18.8</a>	<a href="#">Malignant neoplasm of overlapping sites of colon</a>
<a href="#">C18.9</a>	<a href="#">Malignant neoplasm of colon, unspecified</a>
<a href="#">C19</a>	<a href="#">Malignant neoplasm of rectosigmoid junction</a>
<a href="#">C20</a>	<a href="#">Malignant neoplasm of rectum</a>
<a href="#">C21</a>	<a href="#">Malignant neoplasm of anus and anal canal</a>
<a href="#">C21.0</a>	<a href="#">Malignant neoplasm of anus, unspecified</a>
<a href="#">C21.1</a>	<a href="#">Malignant neoplasm of anal canal</a>

<a href="#">C21.2</a>	<a href="#">Malignant neoplasm of cloacogenic zone</a>
<a href="#">C21.8</a>	<a href="#">Malignant neoplasm of overlapping sites of rectum, anus and anal canal</a>
<a href="#">C22</a>	<a href="#">Malignant neoplasm of liver and intrahepatic bile ducts</a>
<a href="#">C22.0</a>	<a href="#">Liver cell carcinoma</a>
<a href="#">C22.1</a>	<a href="#">Intrahepatic bile duct carcinoma</a>
<a href="#">C22.2</a>	<a href="#">Hepatoblastoma</a>
<a href="#">C22.3</a>	<a href="#">Angiosarcoma of liver</a>
<a href="#">C22.4</a>	<a href="#">Other sarcomas of liver</a>
<a href="#">C22.7</a>	<a href="#">Other specified carcinomas of liver</a>
<a href="#">C22.8</a>	<a href="#">Malignant neoplasm of liver, primary, unspecified as to type</a>
<a href="#">C22.9</a>	<a href="#">Malignant neoplasm of liver, not specified as primary or secondary</a>
<a href="#">C23</a>	<a href="#">Malignant neoplasm of gallbladder</a>
<a href="#">C24</a>	<a href="#">Malignant neoplasm of other and unspecified parts of biliary tract</a>
<a href="#">C24.0</a>	<a href="#">Malignant neoplasm of extrahepatic bile duct</a>
<a href="#">C24.1</a>	<a href="#">Malignant neoplasm of ampulla of Vater</a>
<a href="#">C24.8</a>	<a href="#">Malignant neoplasm of overlapping sites of biliary tract</a>
<a href="#">C24.9</a>	<a href="#">Malignant neoplasm of biliary tract, unspecified</a>
<a href="#">C25</a>	<a href="#">Malignant neoplasm of pancreas</a>
<a href="#">C25.0</a>	<a href="#">Malignant neoplasm of head of pancreas</a>
<a href="#">C25.1</a>	<a href="#">Malignant neoplasm of body of pancreas</a>
<a href="#">C25.2</a>	<a href="#">Malignant neoplasm of tail of pancreas</a>
<a href="#">C25.3</a>	<a href="#">Malignant neoplasm of pancreatic duct</a>
<a href="#">C25.4</a>	<a href="#">Malignant neoplasm of endocrine pancreas</a>
<a href="#">C25.7</a>	<a href="#">Malignant neoplasm of other parts of pancreas</a>
<a href="#">C25.8</a>	<a href="#">Malignant neoplasm of overlapping sites of pancreas</a>
<a href="#">C25.9</a>	<a href="#">Malignant neoplasm of pancreas, unspecified</a>
<a href="#">C26</a>	<a href="#">Malignant neoplasm of other and ill-defined digestive organs</a>
<a href="#">C26.0</a>	<a href="#">Malignant neoplasm of intestinal tract, part unspecified</a>
<a href="#">C26.1</a>	<a href="#">Malignant neoplasm of spleen</a>
<a href="#">C26.9</a>	<a href="#">Malignant neoplasm of ill-defined sites within the digestive system</a>
<a href="#">C30</a>	<a href="#">Malignant neoplasm of nasal cavity and middle ear</a>
<a href="#">C30.0</a>	<a href="#">Malignant neoplasm of nasal cavity</a>
<a href="#">C30.1</a>	<a href="#">Malignant neoplasm of middle ear</a>
<a href="#">C31</a>	<a href="#">Malignant neoplasm of accessory sinuses</a>
<a href="#">C31.0</a>	<a href="#">Malignant neoplasm of maxillary sinus</a>
<a href="#">C31.1</a>	<a href="#">Malignant neoplasm of ethmoidal sinus</a>
<a href="#">C31.2</a>	<a href="#">Malignant neoplasm of frontal sinus</a>
<a href="#">C31.3</a>	<a href="#">Malignant neoplasm of sphenoid sinus</a>
<a href="#">C31.8</a>	<a href="#">Malignant neoplasm of overlapping sites of accessory sinuses</a>
<a href="#">C31.9</a>	<a href="#">Malignant neoplasm of accessory sinus, unspecified</a>
<a href="#">C32</a>	<a href="#">Malignant neoplasm of larynx</a>



<a href="#">C32.0</a>	<a href="#">Malignant neoplasm of glottis</a>
<a href="#">C32.1</a>	<a href="#">Malignant neoplasm of supraglottis</a>
<a href="#">C32.2</a>	<a href="#">Malignant neoplasm of subglottis</a>
<a href="#">C32.3</a>	<a href="#">Malignant neoplasm of laryngeal cartilage</a>
<a href="#">C32.8</a>	<a href="#">Malignant neoplasm of overlapping sites of larynx</a>
<a href="#">C32.9</a>	<a href="#">Malignant neoplasm of larynx, unspecified</a>
<a href="#">C33</a>	<a href="#">Malignant neoplasm of trachea</a>
<a href="#">C34</a>	<a href="#">Malignant neoplasm of bronchus and lung</a>
<a href="#">C34.0</a>	<a href="#">Malignant neoplasm of main bronchus</a>
<a href="#">C34.00</a>	<a href="#">Malignant neoplasm of unspecified main bronchus</a>
<a href="#">C34.01</a>	<a href="#">Malignant neoplasm of right main bronchus</a>
<a href="#">C34.02</a>	<a href="#">Malignant neoplasm of left main bronchus</a>
<a href="#">C34.1</a>	<a href="#">Malignant neoplasm of upper lobe, bronchus or lung</a>
<a href="#">C34.10</a>	<a href="#">Malignant neoplasm of upper lobe, unspecified bronchus or lung</a>
<a href="#">C34.11</a>	<a href="#">Malignant neoplasm of upper lobe, right bronchus or lung</a>
<a href="#">C34.12</a>	<a href="#">Malignant neoplasm of upper lobe, left bronchus or lung</a>
<a href="#">C34.2</a>	<a href="#">Malignant neoplasm of middle lobe, bronchus or lung</a>
<a href="#">C34.3</a>	<a href="#">Malignant neoplasm of lower lobe, bronchus or lung</a>
<a href="#">C34.30</a>	<a href="#">Malignant neoplasm of lower lobe, unspecified bronchus or lung</a>
<a href="#">C34.31</a>	<a href="#">Malignant neoplasm of lower lobe, right bronchus or lung</a>
<a href="#">C34.32</a>	<a href="#">Malignant neoplasm of lower lobe, left bronchus or lung</a>
<a href="#">C34.8</a>	<a href="#">Malignant neoplasm of overlapping sites of bronchus and lung</a>
<a href="#">C34.80</a>	<a href="#">Malignant neoplasm of overlapping sites of unspecified bronchus and lung</a>
<a href="#">C34.81</a>	<a href="#">Malignant neoplasm of overlapping sites of right bronchus and lung</a>
<a href="#">C34.82</a>	<a href="#">Malignant neoplasm of overlapping sites of left bronchus and lung</a>
<a href="#">C34.9</a>	<a href="#">Malignant neoplasm of unspecified part of bronchus or lung</a>
<a href="#">C34.90</a>	<a href="#">Malignant neoplasm of unspecified part of unspecified bronchus or lung</a>
<a href="#">C34.91</a>	<a href="#">Malignant neoplasm of unspecified part of right bronchus or lung</a>
<a href="#">C34.92</a>	<a href="#">Malignant neoplasm of unspecified part of left bronchus or lung</a>
<a href="#">C37</a>	<a href="#">Malignant neoplasm of thymus</a>
<a href="#">C38</a>	<a href="#">Malignant neoplasm of heart, mediastinum and pleura</a>
<a href="#">C38.0</a>	<a href="#">Malignant neoplasm of heart</a>
<a href="#">C38.1</a>	<a href="#">Malignant neoplasm of anterior mediastinum</a>
<a href="#">C38.2</a>	<a href="#">Malignant neoplasm of posterior mediastinum</a>
<a href="#">C38.3</a>	<a href="#">Malignant neoplasm of mediastinum, part unspecified</a>
<a href="#">C38.4</a>	<a href="#">Malignant neoplasm of pleura</a>
<a href="#">C38.8</a>	<a href="#">Malignant neoplasm of overlapping sites of heart, mediastinum and pleura</a>
<a href="#">C39</a>	<a href="#">Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs</a>
<a href="#">C39.0</a>	<a href="#">Malignant neoplasm of upper respiratory tract, part unspecified</a>
<a href="#">C39.9</a>	<a href="#">Malignant neoplasm of lower respiratory tract, part unspecified</a>
<a href="#">C40</a>	<a href="#">Malignant neoplasm of bone and articular cartilage of limbs</a>

<a href="#">C40.0</a>	<a href="#">Malignant neoplasm of scapula and long bones of upper limb</a>
<a href="#">C40.00</a>	<a href="#">Malignant neoplasm of scapula and long bones of unspecified upper limb</a>
<a href="#">C40.01</a>	<a href="#">Malignant neoplasm of scapula and long bones of right upper limb</a>
<a href="#">C40.02</a>	<a href="#">Malignant neoplasm of scapula and long bones of left upper limb</a>
<a href="#">C40.1</a>	<a href="#">Malignant neoplasm of short bones of upper limb</a>
<a href="#">C40.10</a>	<a href="#">Malignant neoplasm of short bones of unspecified upper limb</a>
<a href="#">C40.11</a>	<a href="#">Malignant neoplasm of short bones of right upper limb</a>
<a href="#">C40.12</a>	<a href="#">Malignant neoplasm of short bones of left upper limb</a>
<a href="#">C40.2</a>	<a href="#">Malignant neoplasm of long bones of lower limb</a>
<a href="#">C40.20</a>	<a href="#">Malignant neoplasm of long bones of unspecified lower limb</a>
<a href="#">C40.21</a>	<a href="#">Malignant neoplasm of long bones of right lower limb</a>
<a href="#">C40.22</a>	<a href="#">Malignant neoplasm of long bones of left lower limb</a>
<a href="#">C40.3</a>	<a href="#">Malignant neoplasm of short bones of lower limb</a>
<a href="#">C40.30</a>	<a href="#">Malignant neoplasm of short bones of unspecified lower limb</a>
<a href="#">C40.31</a>	<a href="#">Malignant neoplasm of short bones of right lower limb</a>
<a href="#">C40.32</a>	<a href="#">Malignant neoplasm of short bones of left lower limb</a>
<a href="#">C40.8</a>	<a href="#">Malignant neoplasm of overlapping sites of bone and articular cartilage of limb</a>
<a href="#">C40.80</a>	<a href="#">Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb</a>
<a href="#">C40.81</a>	<a href="#">Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb</a>
<a href="#">C40.82</a>	<a href="#">Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb</a>
<a href="#">C40.9</a>	<a href="#">Malignant neoplasm of unspecified bones and articular cartilage of limb</a>
<a href="#">C40.90</a>	<a href="#">Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb</a>
<a href="#">C40.91</a>	<a href="#">Malignant neoplasm of unspecified bones and articular cartilage of right limb</a>
<a href="#">C40.92</a>	<a href="#">Malignant neoplasm of unspecified bones and articular cartilage of left limb</a>
<a href="#">C41</a>	<a href="#">Malignant neoplasm of bone and articular cartilage of other and unspecified sites</a>
<a href="#">C41.0</a>	<a href="#">Malignant neoplasm of bones of skull and face</a>
<a href="#">C41.1</a>	<a href="#">Malignant neoplasm of mandible</a>
<a href="#">C41.2</a>	<a href="#">Malignant neoplasm of vertebral column</a>
<a href="#">C41.3</a>	<a href="#">Malignant neoplasm of ribs, sternum and clavicle</a>
<a href="#">C41.4</a>	<a href="#">Malignant neoplasm of pelvic bones, sacrum and coccyx</a>
<a href="#">C41.9</a>	<a href="#">Malignant neoplasm of bone and articular cartilage, unspecified</a>
<a href="#">C43</a>	<a href="#">Malignant melanoma of skin</a>
<a href="#">C43.0</a>	<a href="#">Malignant melanoma of lip</a>
<a href="#">C43.1</a>	<a href="#">Malignant melanoma of eyelid, including canthus</a>
<a href="#">C43.10</a>	<a href="#">Malignant melanoma of unspecified eyelid, including canthus</a>
<a href="#">C43.11</a>	<a href="#">Malignant melanoma of right eyelid, including canthus</a>
<a href="#">C43.111</a>	<a href="#">Malignant melanoma of right upper eyelid, including canthus</a>

<a href="#">C43.112</a>	<a href="#">Malignant melanoma of right lower eyelid, including canthus</a>
<a href="#">C43.12</a>	<a href="#">Malignant melanoma of left eyelid, including canthus</a>
<a href="#">C43.121</a>	<a href="#">Malignant melanoma of left upper eyelid, including canthus</a>
<a href="#">C43.122</a>	<a href="#">Malignant melanoma of left lower eyelid, including canthus</a>
<a href="#">C43.2</a>	<a href="#">Malignant melanoma of ear and external auricular canal</a>
<a href="#">C43.20</a>	<a href="#">Malignant melanoma of unspecified ear and external auricular canal</a>
<a href="#">C43.21</a>	<a href="#">Malignant melanoma of right ear and external auricular canal</a>
<a href="#">C43.22</a>	<a href="#">Malignant melanoma of left ear and external auricular canal</a>
<a href="#">C43.3</a>	<a href="#">Malignant melanoma of other and unspecified parts of face</a>
<a href="#">C43.30</a>	<a href="#">Malignant melanoma of unspecified part of face</a>
<a href="#">C43.31</a>	<a href="#">Malignant melanoma of nose</a>
<a href="#">C43.39</a>	<a href="#">Malignant melanoma of other parts of face</a>
<a href="#">C43.4</a>	<a href="#">Malignant melanoma of scalp and neck</a>
<a href="#">C43.5</a>	<a href="#">Malignant melanoma of trunk</a>
<a href="#">C43.51</a>	<a href="#">Malignant melanoma of anal skin</a>
<a href="#">C43.52</a>	<a href="#">Malignant melanoma of skin of breast</a>
<a href="#">C43.59</a>	<a href="#">Malignant melanoma of other part of trunk</a>
<a href="#">C43.6</a>	<a href="#">Malignant melanoma of upper limb, including shoulder</a>
<a href="#">C43.60</a>	<a href="#">Malignant melanoma of unspecified upper limb, including shoulder</a>
<a href="#">C43.61</a>	<a href="#">Malignant melanoma of right upper limb, including shoulder</a>
<a href="#">C43.62</a>	<a href="#">Malignant melanoma of left upper limb, including shoulder</a>
<a href="#">C43.7</a>	<a href="#">Malignant melanoma of lower limb, including hip</a>
<a href="#">C43.70</a>	<a href="#">Malignant melanoma of unspecified lower limb, including hip</a>
<a href="#">C43.71</a>	<a href="#">Malignant melanoma of right lower limb, including hip</a>
<a href="#">C43.72</a>	<a href="#">Malignant melanoma of left lower limb, including hip</a>
<a href="#">C43.8</a>	<a href="#">Malignant melanoma of overlapping sites of skin</a>
<a href="#">C43.9</a>	<a href="#">Malignant melanoma of skin, unspecified</a>
<a href="#">C44.00</a>	<a href="#">Unspecified malignant neoplasm of skin of lip</a>
<a href="#">C44.09</a>	<a href="#">Other specified malignant neoplasm of skin of lip</a>
<a href="#">C44.10</a>	<a href="#">Unspecified malignant neoplasm of skin of eyelid, including canthus</a>
<a href="#">C44.101</a>	<a href="#">Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus</a>
<a href="#">C44.102</a>	<a href="#">Unspecified malignant neoplasm of skin of right eyelid, including canthus</a>
<a href="#">C44.1021</a>	<a href="#">Unspecified malignant neoplasm of skin of right upper eyelid, including canthus</a>
<a href="#">C44.1022</a>	<a href="#">Unspecified malignant neoplasm of skin of right lower eyelid, including canthus</a>
<a href="#">C44.109</a>	<a href="#">Unspecified malignant neoplasm of skin of left eyelid, including canthus</a>
<a href="#">C44.1091</a>	<a href="#">Unspecified malignant neoplasm of skin of left upper eyelid, including canthus</a>
<a href="#">C44.1092</a>	<a href="#">Unspecified malignant neoplasm of skin of left lower eyelid, including canthus</a>
<a href="#">C44.13</a>	<a href="#">Sebaceous cell carcinoma of skin of eyelid, including canthus</a>
<a href="#">C44.131</a>	<a href="#">Sebaceous cell carcinoma of skin of unspecified eyelid, including canthus</a>
<a href="#">C44.132</a>	<a href="#">Sebaceous cell carcinoma of skin of right eyelid, including canthus</a>
<a href="#">C44.1321</a>	<a href="#">Sebaceous cell carcinoma of skin of right upper eyelid, including canthus</a>

<a href="#">C44.1322</a>	<a href="#">Sebaceous cell carcinoma of skin of right lower eyelid, including canthus</a>
<a href="#">C44.139</a>	<a href="#">Sebaceous cell carcinoma of skin of left eyelid, including canthus</a>
<a href="#">C44.1391</a>	<a href="#">Sebaceous cell carcinoma of skin of left upper eyelid, including canthus</a>
<a href="#">C44.1392</a>	<a href="#">Sebaceous cell carcinoma of skin of left lower eyelid, including canthus</a>
<a href="#">C44.19</a>	<a href="#">Other specified malignant neoplasm of skin of eyelid, including canthus</a>
<a href="#">C44.191</a>	<a href="#">Other specified malignant neoplasm of skin of unspecified eyelid, including canthus</a>
<a href="#">C44.192</a>	<a href="#">Other specified malignant neoplasm of skin of right eyelid, including canthus</a>
<a href="#">C44.1921</a>	<a href="#">Other specified malignant neoplasm of skin of right upper eyelid, including canthus</a>
<a href="#">C44.1922</a>	<a href="#">Other specified malignant neoplasm of skin of right lower eyelid, including canthus</a>
<a href="#">C44.199</a>	<a href="#">Other specified malignant neoplasm of skin of left eyelid, including canthus</a>
<a href="#">C44.1991</a>	<a href="#">Other specified malignant neoplasm of skin of left upper eyelid, including canthus</a>
<a href="#">C44.1992</a>	<a href="#">Other specified malignant neoplasm of skin of left lower eyelid, including canthus</a>
<a href="#">C44.20</a>	<a href="#">Unspecified malignant neoplasm of skin of ear and external auricular canal</a>
<a href="#">C44.201</a>	<a href="#">Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal</a>
<a href="#">C44.202</a>	<a href="#">Unspecified malignant neoplasm of skin of right ear and external auricular canal</a>
<a href="#">C44.209</a>	<a href="#">Unspecified malignant neoplasm of skin of left ear and external auricular canal</a>
<a href="#">C44.29</a>	<a href="#">Other specified malignant neoplasm of skin of ear and external auricular canal</a>
<a href="#">C44.291</a>	<a href="#">Other specified malignant neoplasm of skin of unspecified ear and external auricular canal</a>
<a href="#">C44.292</a>	<a href="#">Other specified malignant neoplasm of skin of right ear and external auricular canal</a>
<a href="#">C44.299</a>	<a href="#">Other specified malignant neoplasm of skin of left ear and external auricular canal</a>
<a href="#">C44.30</a>	<a href="#">Unspecified malignant neoplasm of skin of other and unspecified parts of face</a>
<a href="#">C44.300</a>	<a href="#">Unspecified malignant neoplasm of skin of unspecified part of face</a>
<a href="#">C44.301</a>	<a href="#">Unspecified malignant neoplasm of skin of nose</a>
<a href="#">C44.309</a>	<a href="#">Unspecified malignant neoplasm of skin of other parts of face</a>
<a href="#">C44.39</a>	<a href="#">Other specified malignant neoplasm of skin of other and unspecified parts of face</a>
<a href="#">C44.390</a>	<a href="#">Other specified malignant neoplasm of skin of unspecified parts of face</a>
<a href="#">C44.391</a>	<a href="#">Other specified malignant neoplasm of skin of nose</a>
<a href="#">C44.399</a>	<a href="#">Other specified malignant neoplasm of skin of other parts of face</a>
<a href="#">C44.40</a>	<a href="#">Unspecified malignant neoplasm of skin of scalp and neck</a>
<a href="#">C44.49</a>	<a href="#">Other specified malignant neoplasm of skin of scalp and neck</a>
<a href="#">C44.50</a>	<a href="#">Unspecified malignant neoplasm of skin of trunk</a>
<a href="#">C44.500</a>	<a href="#">Unspecified malignant neoplasm of anal skin</a>
<a href="#">C44.501</a>	<a href="#">Unspecified malignant neoplasm of skin of breast</a>

<a href="#">C44.509</a>	<a href="#">Unspecified malignant neoplasm of skin of other part of trunk</a>
<a href="#">C44.59</a>	<a href="#">Other specified malignant neoplasm of skin of trunk</a>
<a href="#">C44.590</a>	<a href="#">Other specified malignant neoplasm of anal skin</a>
<a href="#">C44.591</a>	<a href="#">Other specified malignant neoplasm of skin of breast</a>
<a href="#">C44.599</a>	<a href="#">Other specified malignant neoplasm of skin of other part of trunk</a>
<a href="#">C44.60</a>	<a href="#">Unspecified malignant neoplasm of skin of upper limb, including shoulder</a>
<a href="#">C44.601</a>	<a href="#">Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder</a>
<a href="#">C44.602</a>	<a href="#">Unspecified malignant neoplasm of skin of right upper limb, including shoulder</a>
<a href="#">C44.609</a>	<a href="#">Unspecified malignant neoplasm of skin of left upper limb, including shoulder</a>
<a href="#">C44.69</a>	<a href="#">Other specified malignant neoplasm of skin of upper limb, including shoulder</a>
<a href="#">C44.691</a>	<a href="#">Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder</a>
<a href="#">C44.692</a>	<a href="#">Other specified malignant neoplasm of skin of right upper limb, including shoulder</a>
<a href="#">C44.699</a>	<a href="#">Other specified malignant neoplasm of skin of left upper limb, including shoulder</a>
<a href="#">C44.70</a>	<a href="#">Unspecified malignant neoplasm of skin of lower limb, including hip</a>
<a href="#">C44.701</a>	<a href="#">Unspecified malignant neoplasm of skin of unspecified lower limb, including hip</a>
<a href="#">C44.702</a>	<a href="#">Unspecified malignant neoplasm of skin of right lower limb, including hip</a>
<a href="#">C44.709</a>	<a href="#">Unspecified malignant neoplasm of skin of left lower limb, including hip</a>
<a href="#">C44.79</a>	<a href="#">Other specified malignant neoplasm of skin of lower limb, including hip</a>
<a href="#">C44.791</a>	<a href="#">Other specified malignant neoplasm of skin of unspecified lower limb, including hip</a>
<a href="#">C44.792</a>	<a href="#">Other specified malignant neoplasm of skin of right lower limb, including hip</a>
<a href="#">C44.799</a>	<a href="#">Other specified malignant neoplasm of skin of left lower limb, including hip</a>
<a href="#">C44.80</a>	<a href="#">Unspecified malignant neoplasm of overlapping sites of skin</a>
<a href="#">C44.89</a>	<a href="#">Other specified malignant neoplasm of overlapping sites of skin</a>
<a href="#">C44.90</a>	<a href="#">Unspecified malignant neoplasm of skin, unspecified</a>
<a href="#">C44.99</a>	<a href="#">Other specified malignant neoplasm of skin, unspecified</a>
<a href="#">C45</a>	<a href="#">Mesothelioma</a>
<a href="#">C45.0</a>	<a href="#">Mesothelioma of pleura</a>
<a href="#">C45.1</a>	<a href="#">Mesothelioma of peritoneum</a>
<a href="#">C45.2</a>	<a href="#">Mesothelioma of pericardium</a>
<a href="#">C45.7</a>	<a href="#">Mesothelioma of other sites</a>
<a href="#">C45.9</a>	<a href="#">Mesothelioma, unspecified</a>
<a href="#">C46</a>	<a href="#">Kaposi's sarcoma</a>
<a href="#">C46.0</a>	<a href="#">Kaposi's sarcoma of skin</a>
<a href="#">C46.1</a>	<a href="#">Kaposi's sarcoma of soft tissue</a>
<a href="#">C46.2</a>	<a href="#">Kaposi's sarcoma of palate</a>
<a href="#">C46.3</a>	<a href="#">Kaposi's sarcoma of lymph nodes</a>
<a href="#">C46.4</a>	<a href="#">Kaposi's sarcoma of gastrointestinal sites</a>

<a href="#">C46.5</a>	<a href="#">Kaposi's sarcoma of lung</a>
<a href="#">C46.50</a>	<a href="#">Kaposi's sarcoma of unspecified lung</a>
<a href="#">C46.51</a>	<a href="#">Kaposi's sarcoma of right lung</a>
<a href="#">C46.52</a>	<a href="#">Kaposi's sarcoma of left lung</a>
<a href="#">C46.7</a>	<a href="#">Kaposi's sarcoma of other sites</a>
<a href="#">C46.9</a>	<a href="#">Kaposi's sarcoma, unspecified</a>
<a href="#">C47</a>	<a href="#">Malignant neoplasm of peripheral nerves and autonomic nervous system</a>
<a href="#">C47.0</a>	<a href="#">Malignant neoplasm of peripheral nerves of head, face and neck</a>
<a href="#">C47.1</a>	<a href="#">Malignant neoplasm of peripheral nerves of upper limb, including shoulder</a>
<a href="#">C47.10</a>	<a href="#">Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder</a>
<a href="#">C47.11</a>	<a href="#">Malignant neoplasm of peripheral nerves of right upper limb, including shoulder</a>
<a href="#">C47.12</a>	<a href="#">Malignant neoplasm of peripheral nerves of left upper limb, including shoulder</a>
<a href="#">C47.2</a>	<a href="#">Malignant neoplasm of peripheral nerves of lower limb, including hip</a>
<a href="#">C47.20</a>	<a href="#">Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip</a>
<a href="#">C47.21</a>	<a href="#">Malignant neoplasm of peripheral nerves of right lower limb, including hip</a>
<a href="#">C47.22</a>	<a href="#">Malignant neoplasm of peripheral nerves of left lower limb, including hip</a>
<a href="#">C47.3</a>	<a href="#">Malignant neoplasm of peripheral nerves of thorax</a>
<a href="#">C47.4</a>	<a href="#">Malignant neoplasm of peripheral nerves of abdomen</a>
<a href="#">C47.5</a>	<a href="#">Malignant neoplasm of peripheral nerves of pelvis</a>
<a href="#">C47.6</a>	<a href="#">Malignant neoplasm of peripheral nerves of trunk, unspecified</a>
<a href="#">C47.8</a>	<a href="#">Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system</a>
<a href="#">C47.9</a>	<a href="#">Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified</a>
<a href="#">C48</a>	<a href="#">Malignant neoplasm of retroperitoneum and peritoneum</a>
<a href="#">C48.0</a>	<a href="#">Malignant neoplasm of retroperitoneum</a>
<a href="#">C48.1</a>	<a href="#">Malignant neoplasm of specified parts of peritoneum</a>
<a href="#">C48.2</a>	<a href="#">Malignant neoplasm of peritoneum, unspecified</a>
<a href="#">C48.8</a>	<a href="#">Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum</a>
<a href="#">C49</a>	<a href="#">Malignant neoplasm of other connective and soft tissue</a>
<a href="#">C49.0</a>	<a href="#">Malignant neoplasm of connective and soft tissue of head, face and neck</a>
<a href="#">C49.1</a>	<a href="#">Malignant neoplasm of connective and soft tissue of upper limb, including shoulder</a>
<a href="#">C49.10</a>	<a href="#">Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder</a>
<a href="#">C49.11</a>	<a href="#">Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder</a>
<a href="#">C49.12</a>	<a href="#">Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder</a>
<a href="#">C49.2</a>	<a href="#">Malignant neoplasm of connective and soft tissue of lower limb, including hip</a>

<a href="#">C49.20</a>	<a href="#">Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip</a>
<a href="#">C49.21</a>	<a href="#">Malignant neoplasm of connective and soft tissue of right lower limb, including hip</a>
<a href="#">C49.22</a>	<a href="#">Malignant neoplasm of connective and soft tissue of left lower limb, including hip</a>
<a href="#">C49.3</a>	<a href="#">Malignant neoplasm of connective and soft tissue of thorax</a>
<a href="#">C49.4</a>	<a href="#">Malignant neoplasm of connective and soft tissue of abdomen</a>
<a href="#">C49.5</a>	<a href="#">Malignant neoplasm of connective and soft tissue of pelvis</a>
<a href="#">C49.6</a>	<a href="#">Malignant neoplasm of connective and soft tissue of trunk, unspecified</a>
<a href="#">C49.8</a>	<a href="#">Malignant neoplasm of overlapping sites of connective and soft tissue</a>
<a href="#">C49.9</a>	<a href="#">Malignant neoplasm of connective and soft tissue, unspecified</a>
<a href="#">C49.A</a>	<a href="#">Gastrointestinal stromal tumor</a>
<a href="#">C49.A0</a>	<a href="#">Gastrointestinal stromal tumor, unspecified site</a>
<a href="#">C49.A1</a>	<a href="#">Gastrointestinal stromal tumor, of esophagus</a>
<a href="#">C49.A2</a>	<a href="#">Gastrointestinal stromal tumor, of stomach</a>
<a href="#">C49.A3</a>	<a href="#">Gastrointestinal stromal tumor, of small intestine</a>
<a href="#">C49.A4</a>	<a href="#">Gastrointestinal stromal tumor, of large intestine</a>
<a href="#">C49.A5</a>	<a href="#">Gastrointestinal stromal tumor, of rectum</a>
<a href="#">C49.A9</a>	<a href="#">Gastrointestinal stromal tumor, of other sites</a>
<a href="#">C4A</a>	<a href="#">Merkel cell carcinoma</a>
<a href="#">C4A.0</a>	<a href="#">Merkel cell carcinoma of lip</a>
<a href="#">C4A.1</a>	<a href="#">Merkel cell carcinoma of eyelid, including canthus</a>
<a href="#">C4A.10</a>	<a href="#">Merkel cell carcinoma of unspecified eyelid, including canthus</a>
<a href="#">C4A.11</a>	<a href="#">Merkel cell carcinoma of right eyelid, including canthus</a>
<a href="#">C4A.111</a>	<a href="#">Merkel cell carcinoma of right upper eyelid, including canthus</a>
<a href="#">C4A.112</a>	<a href="#">Merkel cell carcinoma of right lower eyelid, including canthus</a>
<a href="#">C4A.12</a>	<a href="#">Merkel cell carcinoma of left eyelid, including canthus</a>
<a href="#">C4A.121</a>	<a href="#">Merkel cell carcinoma of left upper eyelid, including canthus</a>
<a href="#">C4A.122</a>	<a href="#">Merkel cell carcinoma of left lower eyelid, including canthus</a>
<a href="#">C4A.2</a>	<a href="#">Merkel cell carcinoma of ear and external auricular canal</a>
<a href="#">C4A.20</a>	<a href="#">Merkel cell carcinoma of unspecified ear and external auricular canal</a>
<a href="#">C4A.21</a>	<a href="#">Merkel cell carcinoma of right ear and external auricular canal</a>
<a href="#">C4A.22</a>	<a href="#">Merkel cell carcinoma of left ear and external auricular canal</a>
<a href="#">C4A.3</a>	<a href="#">Merkel cell carcinoma of other and unspecified parts of face</a>
<a href="#">C4A.30</a>	<a href="#">Merkel cell carcinoma of unspecified part of face</a>
<a href="#">C4A.31</a>	<a href="#">Merkel cell carcinoma of nose</a>
<a href="#">C4A.39</a>	<a href="#">Merkel cell carcinoma of other parts of face</a>
<a href="#">C4A.4</a>	<a href="#">Merkel cell carcinoma of scalp and neck</a>
<a href="#">C4A.5</a>	<a href="#">Merkel cell carcinoma of trunk</a>
<a href="#">C4A.51</a>	<a href="#">Merkel cell carcinoma of anal skin</a>
<a href="#">C4A.52</a>	<a href="#">Merkel cell carcinoma of skin of breast</a>

<a href="#">C4A.59</a>	<a href="#">Merkel cell carcinoma of other part of trunk</a>
<a href="#">C4A.6</a>	<a href="#">Merkel cell carcinoma of upper limb, including shoulder</a>
<a href="#">C4A.60</a>	<a href="#">Merkel cell carcinoma of unspecified upper limb, including shoulder</a>
<a href="#">C4A.61</a>	<a href="#">Merkel cell carcinoma of right upper limb, including shoulder</a>
<a href="#">C4A.62</a>	<a href="#">Merkel cell carcinoma of left upper limb, including shoulder</a>
<a href="#">C4A.7</a>	<a href="#">Merkel cell carcinoma of lower limb, including hip</a>
<a href="#">C4A.70</a>	<a href="#">Merkel cell carcinoma of unspecified lower limb, including hip</a>
<a href="#">C4A.71</a>	<a href="#">Merkel cell carcinoma of right lower limb, including hip</a>
<a href="#">C4A.72</a>	<a href="#">Merkel cell carcinoma of left lower limb, including hip</a>
<a href="#">C4A.8</a>	<a href="#">Merkel cell carcinoma of overlapping sites</a>
<a href="#">C4A.9</a>	<a href="#">Merkel cell carcinoma, unspecified</a>
<a href="#">C50</a>	<a href="#">Malignant neoplasm of breast</a>
<a href="#">C50.0</a>	<a href="#">Malignant neoplasm of nipple and areola</a>
<a href="#">C50.01</a>	<a href="#">Malignant neoplasm of nipple and areola, female</a>
<a href="#">C50.011</a>	<a href="#">Malignant neoplasm of nipple and areola, right female breast</a>
<a href="#">C50.012</a>	<a href="#">Malignant neoplasm of nipple and areola, left female breast</a>
<a href="#">C50.019</a>	<a href="#">Malignant neoplasm of nipple and areola, unspecified female breast</a>
<a href="#">C50.02</a>	<a href="#">Malignant neoplasm of nipple and areola, male</a>
<a href="#">C50.021</a>	<a href="#">Malignant neoplasm of nipple and areola, right male breast</a>
<a href="#">C50.022</a>	<a href="#">Malignant neoplasm of nipple and areola, left male breast</a>
<a href="#">C50.029</a>	<a href="#">Malignant neoplasm of nipple and areola, unspecified male breast</a>
<a href="#">C50.1</a>	<a href="#">Malignant neoplasm of central portion of breast</a>
<a href="#">C50.11</a>	<a href="#">Malignant neoplasm of central portion of breast, female</a>
<a href="#">C50.111</a>	<a href="#">Malignant neoplasm of central portion of right female breast</a>
<a href="#">C50.112</a>	<a href="#">Malignant neoplasm of central portion of left female breast</a>
<a href="#">C50.119</a>	<a href="#">Malignant neoplasm of central portion of unspecified female breast</a>
<a href="#">C50.12</a>	<a href="#">Malignant neoplasm of central portion of breast, male</a>
<a href="#">C50.121</a>	<a href="#">Malignant neoplasm of central portion of right male breast</a>
<a href="#">C50.122</a>	<a href="#">Malignant neoplasm of central portion of left male breast</a>
<a href="#">C50.129</a>	<a href="#">Malignant neoplasm of central portion of unspecified male breast</a>
<a href="#">C50.2</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of breast</a>
<a href="#">C50.21</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of breast, female</a>
<a href="#">C50.211</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of right female breast</a>
<a href="#">C50.212</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of left female breast</a>
<a href="#">C50.219</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of unspecified female breast</a>
<a href="#">C50.22</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of breast, male</a>
<a href="#">C50.221</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of right male breast</a>
<a href="#">C50.222</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of left male breast</a>
<a href="#">C50.229</a>	<a href="#">Malignant neoplasm of upper-inner quadrant of unspecified male breast</a>
<a href="#">C50.3</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of breast</a>
<a href="#">C50.31</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of breast, female</a>



<a href="#">C50.311</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of right female breast</a>
<a href="#">C50.312</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of left female breast</a>
<a href="#">C50.319</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of unspecified female breast</a>
<a href="#">C50.32</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of breast, male</a>
<a href="#">C50.321</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of right male breast</a>
<a href="#">C50.322</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of left male breast</a>
<a href="#">C50.329</a>	<a href="#">Malignant neoplasm of lower-inner quadrant of unspecified male breast</a>
<a href="#">C50.4</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of breast</a>
<a href="#">C50.41</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of breast, female</a>
<a href="#">C50.411</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of right female breast</a>
<a href="#">C50.412</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of left female breast</a>
<a href="#">C50.419</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of unspecified female breast</a>
<a href="#">C50.42</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of breast, male</a>
<a href="#">C50.421</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of right male breast</a>
<a href="#">C50.422</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of left male breast</a>
<a href="#">C50.429</a>	<a href="#">Malignant neoplasm of upper-outer quadrant of unspecified male breast</a>
<a href="#">C50.5</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of breast</a>
<a href="#">C50.51</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of breast, female</a>
<a href="#">C50.511</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of right female breast</a>
<a href="#">C50.512</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of left female breast</a>
<a href="#">C50.519</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of unspecified female breast</a>
<a href="#">C50.52</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of breast, male</a>
<a href="#">C50.521</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of right male breast</a>
<a href="#">C50.522</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of left male breast</a>
<a href="#">C50.529</a>	<a href="#">Malignant neoplasm of lower-outer quadrant of unspecified male breast</a>
<a href="#">C50.6</a>	<a href="#">Malignant neoplasm of axillary tail of breast</a>
<a href="#">C50.61</a>	<a href="#">Malignant neoplasm of axillary tail of breast, female</a>
<a href="#">C50.611</a>	<a href="#">Malignant neoplasm of axillary tail of right female breast</a>
<a href="#">C50.612</a>	<a href="#">Malignant neoplasm of axillary tail of left female breast</a>
<a href="#">C50.619</a>	<a href="#">Malignant neoplasm of axillary tail of unspecified female breast</a>
<a href="#">C50.62</a>	<a href="#">Malignant neoplasm of axillary tail of breast, male</a>
<a href="#">C50.621</a>	<a href="#">Malignant neoplasm of axillary tail of right male breast</a>
<a href="#">C50.622</a>	<a href="#">Malignant neoplasm of axillary tail of left male breast</a>
<a href="#">C50.629</a>	<a href="#">Malignant neoplasm of axillary tail of unspecified male breast</a>
<a href="#">C50.8</a>	<a href="#">Malignant neoplasm of overlapping sites of breast</a>
<a href="#">C50.81</a>	<a href="#">Malignant neoplasm of overlapping sites of breast, female</a>
<a href="#">C50.811</a>	<a href="#">Malignant neoplasm of overlapping sites of right female breast</a>
<a href="#">C50.812</a>	<a href="#">Malignant neoplasm of overlapping sites of left female breast</a>
<a href="#">C50.819</a>	<a href="#">Malignant neoplasm of overlapping sites of unspecified female breast</a>
<a href="#">C50.82</a>	<a href="#">Malignant neoplasm of overlapping sites of breast, male</a>
<a href="#">C50.821</a>	<a href="#">Malignant neoplasm of overlapping sites of right male breast</a>

<a href="#">C50.822</a>	<a href="#">Malignant neoplasm of overlapping sites of left male breast</a>
<a href="#">C50.829</a>	<a href="#">Malignant neoplasm of overlapping sites of unspecified male breast</a>
<a href="#">C50.9</a>	<a href="#">Malignant neoplasm of breast of unspecified site</a>
<a href="#">C50.91</a>	<a href="#">Malignant neoplasm of breast of unspecified site, female</a>
<a href="#">C50.911</a>	<a href="#">Malignant neoplasm of unspecified site of right female breast</a>
<a href="#">C50.912</a>	<a href="#">Malignant neoplasm of unspecified site of left female breast</a>
<a href="#">C50.919</a>	<a href="#">Malignant neoplasm of unspecified site of unspecified female breast</a>
<a href="#">C50.92</a>	<a href="#">Malignant neoplasm of breast of unspecified site, male</a>
<a href="#">C50.921</a>	<a href="#">Malignant neoplasm of unspecified site of right male breast</a>
<a href="#">C50.922</a>	<a href="#">Malignant neoplasm of unspecified site of left male breast</a>
<a href="#">C50.929</a>	<a href="#">Malignant neoplasm of unspecified site of unspecified male breast</a>
<a href="#">C51</a>	<a href="#">Malignant neoplasm of vulva</a>
<a href="#">C51.0</a>	<a href="#">Malignant neoplasm of labium majus</a>
<a href="#">C51.1</a>	<a href="#">Malignant neoplasm of labium minus</a>
<a href="#">C51.2</a>	<a href="#">Malignant neoplasm of clitoris</a>
<a href="#">C51.8</a>	<a href="#">Malignant neoplasm of overlapping sites of vulva</a>
<a href="#">C51.9</a>	<a href="#">Malignant neoplasm of vulva, unspecified</a>
<a href="#">C52</a>	<a href="#">Malignant neoplasm of vagina</a>
<a href="#">C53</a>	<a href="#">Malignant neoplasm of cervix uteri</a>
<a href="#">C53.0</a>	<a href="#">Malignant neoplasm of endocervix</a>
<a href="#">C53.1</a>	<a href="#">Malignant neoplasm of exocervix</a>
<a href="#">C53.8</a>	<a href="#">Malignant neoplasm of overlapping sites of cervix uteri</a>
<a href="#">C53.9</a>	<a href="#">Malignant neoplasm of cervix uteri, unspecified</a>
<a href="#">C54</a>	<a href="#">Malignant neoplasm of corpus uteri</a>
<a href="#">C54.0</a>	<a href="#">Malignant neoplasm of isthmus uteri</a>
<a href="#">C54.1</a>	<a href="#">Malignant neoplasm of endometrium</a>
<a href="#">C54.2</a>	<a href="#">Malignant neoplasm of myometrium</a>
<a href="#">C54.3</a>	<a href="#">Malignant neoplasm of fundus uteri</a>
<a href="#">C54.8</a>	<a href="#">Malignant neoplasm of overlapping sites of corpus uteri</a>
<a href="#">C54.9</a>	<a href="#">Malignant neoplasm of corpus uteri, unspecified</a>
<a href="#">C55</a>	<a href="#">Malignant neoplasm of uterus, part unspecified</a>
<a href="#">C56</a>	<a href="#">Malignant neoplasm of ovary</a>
<a href="#">C56.1</a>	<a href="#">Malignant neoplasm of right ovary</a>
<a href="#">C56.2</a>	<a href="#">Malignant neoplasm of left ovary</a>
<a href="#">C56.9</a>	<a href="#">Malignant neoplasm of unspecified ovary</a>
<a href="#">C57</a>	<a href="#">Malignant neoplasm of other and unspecified female genital organs</a>
<a href="#">C57.0</a>	<a href="#">Malignant neoplasm of fallopian tube</a>
<a href="#">C57.00</a>	<a href="#">Malignant neoplasm of unspecified fallopian tube</a>
<a href="#">C57.01</a>	<a href="#">Malignant neoplasm of right fallopian tube</a>
<a href="#">C57.02</a>	<a href="#">Malignant neoplasm of left fallopian tube</a>
<a href="#">C57.1</a>	<a href="#">Malignant neoplasm of broad ligament</a>

<a href="#">C57.10</a>	<a href="#">Malignant neoplasm of unspecified broad ligament</a>
<a href="#">C57.11</a>	<a href="#">Malignant neoplasm of right broad ligament</a>
<a href="#">C57.12</a>	<a href="#">Malignant neoplasm of left broad ligament</a>
<a href="#">C57.2</a>	<a href="#">Malignant neoplasm of round ligament</a>
<a href="#">C57.20</a>	<a href="#">Malignant neoplasm of unspecified round ligament</a>
<a href="#">C57.21</a>	<a href="#">Malignant neoplasm of right round ligament</a>
<a href="#">C57.22</a>	<a href="#">Malignant neoplasm of left round ligament</a>
<a href="#">C57.3</a>	<a href="#">Malignant neoplasm of parametrium</a>
<a href="#">C57.4</a>	<a href="#">Malignant neoplasm of uterine adnexa, unspecified</a>
<a href="#">C57.7</a>	<a href="#">Malignant neoplasm of other specified female genital organs</a>
<a href="#">C57.8</a>	<a href="#">Malignant neoplasm of overlapping sites of female genital organs</a>
<a href="#">C57.9</a>	<a href="#">Malignant neoplasm of female genital organ, unspecified</a>
<a href="#">C58</a>	<a href="#">Malignant neoplasm of placenta</a>
<a href="#">C60</a>	<a href="#">Malignant neoplasm of penis</a>
<a href="#">C60.0</a>	<a href="#">Malignant neoplasm of prepuce</a>
<a href="#">C60.1</a>	<a href="#">Malignant neoplasm of glans penis</a>
<a href="#">C60.2</a>	<a href="#">Malignant neoplasm of body of penis</a>
<a href="#">C60.8</a>	<a href="#">Malignant neoplasm of overlapping sites of penis</a>
<a href="#">C60.9</a>	<a href="#">Malignant neoplasm of penis, unspecified</a>
<a href="#">C61</a>	<a href="#">Malignant neoplasm of prostate</a>
<a href="#">C62</a>	<a href="#">Malignant neoplasm of testis</a>
<a href="#">C62.0</a>	<a href="#">Malignant neoplasm of undescended testis</a>
<a href="#">C62.00</a>	<a href="#">Malignant neoplasm of unspecified undescended testis</a>
<a href="#">C62.01</a>	<a href="#">Malignant neoplasm of undescended right testis</a>
<a href="#">C62.02</a>	<a href="#">Malignant neoplasm of undescended left testis</a>
<a href="#">C62.1</a>	<a href="#">Malignant neoplasm of descended testis</a>
<a href="#">C62.10</a>	<a href="#">Malignant neoplasm of unspecified descended testis</a>
<a href="#">C62.11</a>	<a href="#">Malignant neoplasm of descended right testis</a>
<a href="#">C62.12</a>	<a href="#">Malignant neoplasm of descended left testis</a>
<a href="#">C62.9</a>	<a href="#">Malignant neoplasm of testis, unspecified whether descended or undescended</a>
<a href="#">C62.90</a>	<a href="#">Malignant neoplasm of unspecified testis, unspecified whether descended or undescended</a>
<a href="#">C62.91</a>	<a href="#">Malignant neoplasm of right testis, unspecified whether descended or undescended</a>
<a href="#">C62.92</a>	<a href="#">Malignant neoplasm of left testis, unspecified whether descended or undescended</a>
<a href="#">C63</a>	<a href="#">Malignant neoplasm of other and unspecified male genital organs</a>
<a href="#">C63.0</a>	<a href="#">Malignant neoplasm of epididymis</a>
<a href="#">C63.00</a>	<a href="#">Malignant neoplasm of unspecified epididymis</a>
<a href="#">C63.01</a>	<a href="#">Malignant neoplasm of right epididymis</a>
<a href="#">C63.02</a>	<a href="#">Malignant neoplasm of left epididymis</a>
<a href="#">C63.1</a>	<a href="#">Malignant neoplasm of spermatic cord</a>

<a href="#">C63.10</a>	<a href="#">Malignant neoplasm of unspecified spermatic cord</a>
<a href="#">C63.11</a>	<a href="#">Malignant neoplasm of right spermatic cord</a>
<a href="#">C63.12</a>	<a href="#">Malignant neoplasm of left spermatic cord</a>
<a href="#">C63.2</a>	<a href="#">Malignant neoplasm of scrotum</a>
<a href="#">C63.7</a>	<a href="#">Malignant neoplasm of other specified male genital organs</a>
<a href="#">C63.8</a>	<a href="#">Malignant neoplasm of overlapping sites of male genital organs</a>
<a href="#">C63.9</a>	<a href="#">Malignant neoplasm of male genital organ, unspecified</a>
<a href="#">C64</a>	<a href="#">Malignant neoplasm of kidney, except renal pelvis</a>
<a href="#">C64.1</a>	<a href="#">Malignant neoplasm of right kidney, except renal pelvis</a>
<a href="#">C64.2</a>	<a href="#">Malignant neoplasm of left kidney, except renal pelvis</a>
<a href="#">C64.9</a>	<a href="#">Malignant neoplasm of unspecified kidney, except renal pelvis</a>
<a href="#">C65</a>	<a href="#">Malignant neoplasm of renal pelvis</a>
<a href="#">C65.1</a>	<a href="#">Malignant neoplasm of right renal pelvis</a>
<a href="#">C65.2</a>	<a href="#">Malignant neoplasm of left renal pelvis</a>
<a href="#">C65.9</a>	<a href="#">Malignant neoplasm of unspecified renal pelvis</a>
<a href="#">C66</a>	<a href="#">Malignant neoplasm of ureter</a>
<a href="#">C66.1</a>	<a href="#">Malignant neoplasm of right ureter</a>
<a href="#">C66.2</a>	<a href="#">Malignant neoplasm of left ureter</a>
<a href="#">C66.9</a>	<a href="#">Malignant neoplasm of unspecified ureter</a>
<a href="#">C67</a>	<a href="#">Malignant neoplasm of bladder</a>
<a href="#">C67.0</a>	<a href="#">Malignant neoplasm of trigone of bladder</a>
<a href="#">C67.1</a>	<a href="#">Malignant neoplasm of dome of bladder</a>
<a href="#">C67.2</a>	<a href="#">Malignant neoplasm of lateral wall of bladder</a>
<a href="#">C67.3</a>	<a href="#">Malignant neoplasm of anterior wall of bladder</a>
<a href="#">C67.4</a>	<a href="#">Malignant neoplasm of posterior wall of bladder</a>
<a href="#">C67.5</a>	<a href="#">Malignant neoplasm of bladder neck</a>
<a href="#">C67.6</a>	<a href="#">Malignant neoplasm of ureteric orifice</a>
<a href="#">C67.7</a>	<a href="#">Malignant neoplasm of urachus</a>
<a href="#">C67.8</a>	<a href="#">Malignant neoplasm of overlapping sites of bladder</a>
<a href="#">C67.9</a>	<a href="#">Malignant neoplasm of bladder, unspecified</a>
<a href="#">C68</a>	<a href="#">Malignant neoplasm of other and unspecified urinary organs</a>
<a href="#">C68.0</a>	<a href="#">Malignant neoplasm of urethra</a>
<a href="#">C68.1</a>	<a href="#">Malignant neoplasm of paraurethral glands</a>
<a href="#">C68.8</a>	<a href="#">Malignant neoplasm of overlapping sites of urinary organs</a>
<a href="#">C68.9</a>	<a href="#">Malignant neoplasm of urinary organ, unspecified</a>
<a href="#">C69</a>	<a href="#">Malignant neoplasm of eye and adnexa</a>
<a href="#">C69.0</a>	<a href="#">Malignant neoplasm of conjunctiva</a>
<a href="#">C69.00</a>	<a href="#">Malignant neoplasm of unspecified conjunctiva</a>
<a href="#">C69.01</a>	<a href="#">Malignant neoplasm of right conjunctiva</a>
<a href="#">C69.02</a>	<a href="#">Malignant neoplasm of left conjunctiva</a>
<a href="#">C69.1</a>	<a href="#">Malignant neoplasm of cornea</a>

<a href="#">C69.10</a>	<a href="#">Malignant neoplasm of unspecified cornea</a>
<a href="#">C69.11</a>	<a href="#">Malignant neoplasm of right cornea</a>
<a href="#">C69.12</a>	<a href="#">Malignant neoplasm of left cornea</a>
<a href="#">C69.2</a>	<a href="#">Malignant neoplasm of retina</a>
<a href="#">C69.20</a>	<a href="#">Malignant neoplasm of unspecified retina</a>
<a href="#">C69.21</a>	<a href="#">Malignant neoplasm of right retina</a>
<a href="#">C69.22</a>	<a href="#">Malignant neoplasm of left retina</a>
<a href="#">C69.3</a>	<a href="#">Malignant neoplasm of choroid</a>
<a href="#">C69.30</a>	<a href="#">Malignant neoplasm of unspecified choroid</a>
<a href="#">C69.31</a>	<a href="#">Malignant neoplasm of right choroid</a>
<a href="#">C69.32</a>	<a href="#">Malignant neoplasm of left choroid</a>
<a href="#">C69.4</a>	<a href="#">Malignant neoplasm of ciliary body</a>
<a href="#">C69.40</a>	<a href="#">Malignant neoplasm of unspecified ciliary body</a>
<a href="#">C69.41</a>	<a href="#">Malignant neoplasm of right ciliary body</a>
<a href="#">C69.42</a>	<a href="#">Malignant neoplasm of left ciliary body</a>
<a href="#">C69.5</a>	<a href="#">Malignant neoplasm of lacrimal gland and duct</a>
<a href="#">C69.50</a>	<a href="#">Malignant neoplasm of unspecified lacrimal gland and duct</a>
<a href="#">C69.51</a>	<a href="#">Malignant neoplasm of right lacrimal gland and duct</a>
<a href="#">C69.52</a>	<a href="#">Malignant neoplasm of left lacrimal gland and duct</a>
<a href="#">C69.6</a>	<a href="#">Malignant neoplasm of orbit</a>
<a href="#">C69.60</a>	<a href="#">Malignant neoplasm of unspecified orbit</a>
<a href="#">C69.61</a>	<a href="#">Malignant neoplasm of right orbit</a>
<a href="#">C69.62</a>	<a href="#">Malignant neoplasm of left orbit</a>
<a href="#">C69.8</a>	<a href="#">Malignant neoplasm of overlapping sites of eye and adnexa</a>
<a href="#">C69.80</a>	<a href="#">Malignant neoplasm of overlapping sites of unspecified eye and adnexa</a>
<a href="#">C69.81</a>	<a href="#">Malignant neoplasm of overlapping sites of right eye and adnexa</a>
<a href="#">C69.82</a>	<a href="#">Malignant neoplasm of overlapping sites of left eye and adnexa</a>
<a href="#">C69.9</a>	<a href="#">Malignant neoplasm of unspecified site of eye</a>
<a href="#">C69.90</a>	<a href="#">Malignant neoplasm of unspecified site of unspecified eye</a>
<a href="#">C69.91</a>	<a href="#">Malignant neoplasm of unspecified site of right eye</a>
<a href="#">C69.92</a>	<a href="#">Malignant neoplasm of unspecified site of left eye</a>
<a href="#">C70</a>	<a href="#">Malignant neoplasm of meninges</a>
<a href="#">C70.0</a>	<a href="#">Malignant neoplasm of cerebral meninges</a>
<a href="#">C70.1</a>	<a href="#">Malignant neoplasm of spinal meninges</a>
<a href="#">C70.9</a>	<a href="#">Malignant neoplasm of meninges, unspecified</a>
<a href="#">C71</a>	<a href="#">Malignant neoplasm of brain</a>
<a href="#">C71.0</a>	<a href="#">Malignant neoplasm of cerebrum, except lobes and ventricles</a>
<a href="#">C71.1</a>	<a href="#">Malignant neoplasm of frontal lobe</a>
<a href="#">C71.2</a>	<a href="#">Malignant neoplasm of temporal lobe</a>
<a href="#">C71.3</a>	<a href="#">Malignant neoplasm of parietal lobe</a>
<a href="#">C71.4</a>	<a href="#">Malignant neoplasm of occipital lobe</a>

<a href="#"><u>C71.5</u></a>	<a href="#"><u>Malignant neoplasm of cerebral ventricle</u></a>
<a href="#"><u>C71.6</u></a>	<a href="#"><u>Malignant neoplasm of cerebellum</u></a>
<a href="#"><u>C71.7</u></a>	<a href="#"><u>Malignant neoplasm of brain stem</u></a>
<a href="#"><u>C71.8</u></a>	<a href="#"><u>Malignant neoplasm of overlapping sites of brain</u></a>
<a href="#"><u>C71.9</u></a>	<a href="#"><u>Malignant neoplasm of brain, unspecified</u></a>
<a href="#"><u>C72</u></a>	<a href="#"><u>Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system</u></a>
<a href="#"><u>C72.0</u></a>	<a href="#"><u>Malignant neoplasm of spinal cord</u></a>
<a href="#"><u>C72.1</u></a>	<a href="#"><u>Malignant neoplasm of cauda equina</u></a>
<a href="#"><u>C72.2</u></a>	<a href="#"><u>Malignant neoplasm of olfactory nerve</u></a>
<a href="#"><u>C72.20</u></a>	<a href="#"><u>Malignant neoplasm of unspecified olfactory nerve</u></a>
<a href="#"><u>C72.21</u></a>	<a href="#"><u>Malignant neoplasm of right olfactory nerve</u></a>
<a href="#"><u>C72.22</u></a>	<a href="#"><u>Malignant neoplasm of left olfactory nerve</u></a>
<a href="#"><u>C72.3</u></a>	<a href="#"><u>Malignant neoplasm of optic nerve</u></a>
<a href="#"><u>C72.30</u></a>	<a href="#"><u>Malignant neoplasm of unspecified optic nerve</u></a>
<a href="#"><u>C72.31</u></a>	<a href="#"><u>Malignant neoplasm of right optic nerve</u></a>
<a href="#"><u>C72.32</u></a>	<a href="#"><u>Malignant neoplasm of left optic nerve</u></a>
<a href="#"><u>C72.4</u></a>	<a href="#"><u>Malignant neoplasm of acoustic nerve</u></a>
<a href="#"><u>C72.40</u></a>	<a href="#"><u>Malignant neoplasm of unspecified acoustic nerve</u></a>
<a href="#"><u>C72.41</u></a>	<a href="#"><u>Malignant neoplasm of right acoustic nerve</u></a>
<a href="#"><u>C72.42</u></a>	<a href="#"><u>Malignant neoplasm of left acoustic nerve</u></a>
<a href="#"><u>C72.5</u></a>	<a href="#"><u>Malignant neoplasm of other and unspecified cranial nerves</u></a>
<a href="#"><u>C72.50</u></a>	<a href="#"><u>Malignant neoplasm of unspecified cranial nerve</u></a>
<a href="#"><u>C72.59</u></a>	<a href="#"><u>Malignant neoplasm of other cranial nerves</u></a>
<a href="#"><u>C72.9</u></a>	<a href="#"><u>Malignant neoplasm of central nervous system, unspecified</u></a>
<a href="#"><u>C73</u></a>	<a href="#"><u>Malignant neoplasm of thyroid gland</u></a>
<a href="#"><u>C74</u></a>	<a href="#"><u>Malignant neoplasm of adrenal gland</u></a>
<a href="#"><u>C74.0</u></a>	<a href="#"><u>Malignant neoplasm of cortex of adrenal gland</u></a>
<a href="#"><u>C74.00</u></a>	<a href="#"><u>Malignant neoplasm of cortex of unspecified adrenal gland</u></a>
<a href="#"><u>C74.01</u></a>	<a href="#"><u>Malignant neoplasm of cortex of right adrenal gland</u></a>
<a href="#"><u>C74.02</u></a>	<a href="#"><u>Malignant neoplasm of cortex of left adrenal gland</u></a>
<a href="#"><u>C74.1</u></a>	<a href="#"><u>Malignant neoplasm of medulla of adrenal gland</u></a>
<a href="#"><u>C74.10</u></a>	<a href="#"><u>Malignant neoplasm of medulla of unspecified adrenal gland</u></a>
<a href="#"><u>C74.11</u></a>	<a href="#"><u>Malignant neoplasm of medulla of right adrenal gland</u></a>
<a href="#"><u>C74.12</u></a>	<a href="#"><u>Malignant neoplasm of medulla of left adrenal gland</u></a>
<a href="#"><u>C74.9</u></a>	<a href="#"><u>Malignant neoplasm of unspecified part of adrenal gland</u></a>
<a href="#"><u>C74.90</u></a>	<a href="#"><u>Malignant neoplasm of unspecified part of unspecified adrenal gland</u></a>
<a href="#"><u>C74.91</u></a>	<a href="#"><u>Malignant neoplasm of unspecified part of right adrenal gland</u></a>
<a href="#"><u>C74.92</u></a>	<a href="#"><u>Malignant neoplasm of unspecified part of left adrenal gland</u></a>
<a href="#"><u>C75</u></a>	<a href="#"><u>Malignant neoplasm of other endocrine glands and related structures</u></a>
<a href="#"><u>C75.0</u></a>	<a href="#"><u>Malignant neoplasm of parathyroid gland</u></a>
<a href="#"><u>C75.1</u></a>	<a href="#"><u>Malignant neoplasm of pituitary gland</u></a>

<a href="#">C75.2</a>	<a href="#">Malignant neoplasm of craniopharyngeal duct</a>
<a href="#">C75.3</a>	<a href="#">Malignant neoplasm of pineal gland</a>
<a href="#">C75.4</a>	<a href="#">Malignant neoplasm of carotid body</a>
<a href="#">C75.5</a>	<a href="#">Malignant neoplasm of aortic body and other paraganglia</a>
<a href="#">C75.8</a>	<a href="#">Malignant neoplasm with pluriglandular involvement, unspecified</a>
<a href="#">C75.9</a>	<a href="#">Malignant neoplasm of endocrine gland, unspecified</a>
<a href="#">C76</a>	<a href="#">Malignant neoplasm of other and ill-defined sites</a>
<a href="#">C76.0</a>	<a href="#">Malignant neoplasm of head, face and neck</a>
<a href="#">C76.1</a>	<a href="#">Malignant neoplasm of thorax</a>
<a href="#">C76.2</a>	<a href="#">Malignant neoplasm of abdomen</a>
<a href="#">C76.3</a>	<a href="#">Malignant neoplasm of pelvis</a>
<a href="#">C76.4</a>	<a href="#">Malignant neoplasm of upper limb</a>
<a href="#">C76.40</a>	<a href="#">Malignant neoplasm of unspecified upper limb</a>
<a href="#">C76.41</a>	<a href="#">Malignant neoplasm of right upper limb</a>
<a href="#">C76.42</a>	<a href="#">Malignant neoplasm of left upper limb</a>
<a href="#">C76.5</a>	<a href="#">Malignant neoplasm of lower limb</a>
<a href="#">C76.50</a>	<a href="#">Malignant neoplasm of unspecified lower limb</a>
<a href="#">C76.51</a>	<a href="#">Malignant neoplasm of right lower limb</a>
<a href="#">C76.52</a>	<a href="#">Malignant neoplasm of left lower limb</a>
<a href="#">C76.8</a>	<a href="#">Malignant neoplasm of other specified ill-defined sites</a>
<a href="#">C77</a>	<a href="#">Secondary and unspecified malignant neoplasm of lymph nodes</a>
<a href="#">C77.0</a>	<a href="#">Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck</a>
<a href="#">C77.1</a>	<a href="#">Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes</a>
<a href="#">C77.2</a>	<a href="#">Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes</a>
<a href="#">C77.3</a>	<a href="#">Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes</a>
<a href="#">C77.4</a>	<a href="#">Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes</a>
<a href="#">C77.5</a>	<a href="#">Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes</a>
<a href="#">C77.8</a>	<a href="#">Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions</a>
<a href="#">C77.9</a>	<a href="#">Secondary and unspecified malignant neoplasm of lymph node, unspecified</a>
<a href="#">C78</a>	<a href="#">Secondary malignant neoplasm of respiratory and digestive organs</a>
<a href="#">C78.0</a>	<a href="#">Secondary malignant neoplasm of lung</a>
<a href="#">C78.00</a>	<a href="#">Secondary malignant neoplasm of unspecified lung</a>
<a href="#">C78.01</a>	<a href="#">Secondary malignant neoplasm of right lung</a>
<a href="#">C78.02</a>	<a href="#">Secondary malignant neoplasm of left lung</a>
<a href="#">C78.1</a>	<a href="#">Secondary malignant neoplasm of mediastinum</a>
<a href="#">C78.2</a>	<a href="#">Secondary malignant neoplasm of pleura</a>
<a href="#">C78.3</a>	<a href="#">Secondary malignant neoplasm of other and unspecified respiratory organs</a>

<a href="#"><u>C78.30</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified respiratory organ</u></a>
<a href="#"><u>C78.39</u></a>	<a href="#"><u>Secondary malignant neoplasm of other respiratory organs</u></a>
<a href="#"><u>C78.4</u></a>	<a href="#"><u>Secondary malignant neoplasm of small intestine</u></a>
<a href="#"><u>C78.5</u></a>	<a href="#"><u>Secondary malignant neoplasm of large intestine and rectum</u></a>
<a href="#"><u>C78.6</u></a>	<a href="#"><u>Secondary malignant neoplasm of retroperitoneum and peritoneum</u></a>
<a href="#"><u>C78.7</u></a>	<a href="#"><u>Secondary malignant neoplasm of liver and intrahepatic bile duct</u></a>
<a href="#"><u>C78.8</u></a>	<a href="#"><u>Secondary malignant neoplasm of other and unspecified digestive organs</u></a>
<a href="#"><u>C78.80</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified digestive organ</u></a>
<a href="#"><u>C78.89</u></a>	<a href="#"><u>Secondary malignant neoplasm of other digestive organs</u></a>
<a href="#"><u>C79</u></a>	<a href="#"><u>Secondary malignant neoplasm of other and unspecified sites</u></a>
<a href="#"><u>C79.0</u></a>	<a href="#"><u>Secondary malignant neoplasm of kidney and renal pelvis</u></a>
<a href="#"><u>C79.00</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified kidney and renal pelvis</u></a>
<a href="#"><u>C79.01</u></a>	<a href="#"><u>Secondary malignant neoplasm of right kidney and renal pelvis</u></a>
<a href="#"><u>C79.02</u></a>	<a href="#"><u>Secondary malignant neoplasm of left kidney and renal pelvis</u></a>
<a href="#"><u>C79.1</u></a>	<a href="#"><u>Secondary malignant neoplasm of bladder and other and unspecified urinary organs</u></a>
<a href="#"><u>C79.10</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified urinary organs</u></a>
<a href="#"><u>C79.11</u></a>	<a href="#"><u>Secondary malignant neoplasm of bladder</u></a>
<a href="#"><u>C79.19</u></a>	<a href="#"><u>Secondary malignant neoplasm of other urinary organs</u></a>
<a href="#"><u>C79.2</u></a>	<a href="#"><u>Secondary malignant neoplasm of skin</u></a>
<a href="#"><u>C79.3</u></a>	<a href="#"><u>Secondary malignant neoplasm of brain and cerebral meninges</u></a>
<a href="#"><u>C79.31</u></a>	<a href="#"><u>Secondary malignant neoplasm of brain</u></a>
<a href="#"><u>C79.32</u></a>	<a href="#"><u>Secondary malignant neoplasm of cerebral meninges</u></a>
<a href="#"><u>C79.4</u></a>	<a href="#"><u>Secondary malignant neoplasm of other and unspecified parts of nervous system</u></a>
<a href="#"><u>C79.40</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified part of nervous system</u></a>
<a href="#"><u>C79.49</u></a>	<a href="#"><u>Secondary malignant neoplasm of other parts of nervous system</u></a>
<a href="#"><u>C79.5</u></a>	<a href="#"><u>Secondary malignant neoplasm of bone and bone marrow</u></a>
<a href="#"><u>C79.51</u></a>	<a href="#"><u>Secondary malignant neoplasm of bone</u></a>
<a href="#"><u>C79.52</u></a>	<a href="#"><u>Secondary malignant neoplasm of bone marrow</u></a>
<a href="#"><u>C79.6</u></a>	<a href="#"><u>Secondary malignant neoplasm of ovary</u></a>
<a href="#"><u>C79.60</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified ovary</u></a>
<a href="#"><u>C79.61</u></a>	<a href="#"><u>Secondary malignant neoplasm of right ovary</u></a>
<a href="#"><u>C79.62</u></a>	<a href="#"><u>Secondary malignant neoplasm of left ovary</u></a>
<a href="#"><u>C79.7</u></a>	<a href="#"><u>Secondary malignant neoplasm of adrenal gland</u></a>
<a href="#"><u>C79.70</u></a>	<a href="#"><u>Secondary malignant neoplasm of unspecified adrenal gland</u></a>
<a href="#"><u>C79.71</u></a>	<a href="#"><u>Secondary malignant neoplasm of right adrenal gland</u></a>
<a href="#"><u>C79.72</u></a>	<a href="#"><u>Secondary malignant neoplasm of left adrenal gland</u></a>
<a href="#"><u>C79.8</u></a>	<a href="#"><u>Secondary malignant neoplasm of other specified sites</u></a>
<a href="#"><u>C79.81</u></a>	<a href="#"><u>Secondary malignant neoplasm of breast</u></a>
<a href="#"><u>C79.82</u></a>	<a href="#"><u>Secondary malignant neoplasm of genital organs</u></a>
<a href="#"><u>C79.89</u></a>	<a href="#"><u>Secondary malignant neoplasm of other specified sites</u></a>



<a href="#">C79.9</a>	<a href="#">Secondary malignant neoplasm of unspecified site</a>
<a href="#">C7A</a>	<a href="#">Malignant neuroendocrine tumors</a>
<a href="#">C7A.0</a>	<a href="#">Malignant carcinoid tumors</a>
<a href="#">C7A.00</a>	<a href="#">Malignant carcinoid tumor of unspecified site</a>
<a href="#">C7A.01</a>	<a href="#">Malignant carcinoid tumors of the small intestine</a>
<a href="#">C7A.010</a>	<a href="#">Malignant carcinoid tumor of the duodenum</a>
<a href="#">C7A.011</a>	<a href="#">Malignant carcinoid tumor of the jejunum</a>
<a href="#">C7A.012</a>	<a href="#">Malignant carcinoid tumor of the ileum</a>
<a href="#">C7A.019</a>	<a href="#">Malignant carcinoid tumor of the small intestine, unspecified portion</a>
<a href="#">C7A.02</a>	<a href="#">Malignant carcinoid tumors of the appendix, large intestine, and rectum</a>
<a href="#">C7A.020</a>	<a href="#">Malignant carcinoid tumor of the appendix</a>
<a href="#">C7A.021</a>	<a href="#">Malignant carcinoid tumor of the cecum</a>
<a href="#">C7A.022</a>	<a href="#">Malignant carcinoid tumor of the ascending colon</a>
<a href="#">C7A.023</a>	<a href="#">Malignant carcinoid tumor of the transverse colon</a>
<a href="#">C7A.024</a>	<a href="#">Malignant carcinoid tumor of the descending colon</a>
<a href="#">C7A.025</a>	<a href="#">Malignant carcinoid tumor of the sigmoid colon</a>
<a href="#">C7A.026</a>	<a href="#">Malignant carcinoid tumor of the rectum</a>
<a href="#">C7A.029</a>	<a href="#">Malignant carcinoid tumor of the large intestine, unspecified portion</a>
<a href="#">C7A.09</a>	<a href="#">Malignant carcinoid tumors of other sites</a>
<a href="#">C7A.090</a>	<a href="#">Malignant carcinoid tumor of the bronchus and lung</a>
<a href="#">C7A.091</a>	<a href="#">Malignant carcinoid tumor of the thymus</a>
<a href="#">C7A.092</a>	<a href="#">Malignant carcinoid tumor of the stomach</a>
<a href="#">C7A.093</a>	<a href="#">Malignant carcinoid tumor of the kidney</a>
<a href="#">C7A.094</a>	<a href="#">Malignant carcinoid tumor of the foregut, unspecified</a>
<a href="#">C7A.095</a>	<a href="#">Malignant carcinoid tumor of the midgut, unspecified</a>
<a href="#">C7A.096</a>	<a href="#">Malignant carcinoid tumor of the hindgut, unspecified</a>
<a href="#">C7A.098</a>	<a href="#">Malignant carcinoid tumors of other sites</a>
<a href="#">C7A.1</a>	<a href="#">Malignant poorly differentiated neuroendocrine tumors</a>
<a href="#">C7A.8</a>	<a href="#">Other malignant neuroendocrine tumors</a>
<a href="#">C7B</a>	<a href="#">Secondary neuroendocrine tumors</a>
<a href="#">C7B.0</a>	<a href="#">Secondary carcinoid tumors</a>
<a href="#">C7B.00</a>	<a href="#">Secondary carcinoid tumors unspecified site</a>
<a href="#">C7B.01</a>	<a href="#">Secondary carcinoid tumors of distant lymph nodes</a>
<a href="#">C7B.02</a>	<a href="#">Secondary carcinoid tumors of liver</a>
<a href="#">C7B.03</a>	<a href="#">Secondary carcinoid tumors of bone</a>
<a href="#">C7B.04</a>	<a href="#">Secondary carcinoid tumors of peritoneum</a>
<a href="#">C7B.09</a>	<a href="#">Secondary carcinoid tumors of other sites</a>
<a href="#">C7B.1</a>	<a href="#">Secondary Merkel cell carcinoma</a>
<a href="#">C7B.8</a>	<a href="#">Other secondary neuroendocrine tumors</a>
<a href="#">C80</a>	<a href="#">Malignant neoplasm without specification of site</a>
<a href="#">C80.0</a>	<a href="#">Disseminated malignant neoplasm, unspecified</a>

<a href="#">C80.1</a>	<a href="#">Malignant (primary) neoplasm, unspecified</a>
<a href="#">C80.2</a>	<a href="#">Malignant neoplasm associated with transplanted organ</a>
<a href="#">C81</a>	<a href="#">Hodgkin lymphoma</a>
<a href="#">C81.0</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma</a>
<a href="#">C81.00</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma unspecified site</a>
<a href="#">C81.01</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C81.02</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma intrathoracic lymph nodes</a>
<a href="#">C81.03</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma intra-abdominal lymph nodes</a>
<a href="#">C81.04</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C81.05</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.06</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma intrapelvic lymph nodes</a>
<a href="#">C81.07</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma spleen</a>
<a href="#">C81.08</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of multiple sites</a>
<a href="#">C81.09</a>	<a href="#">Nodular lymphocyte predominant Hodgkin lymphoma extranodal and solid organ sites</a>
<a href="#">C81.1</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma</a>
<a href="#">C81.10</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma unspecified site</a>
<a href="#">C81.11</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C81.12</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma intrathoracic lymph nodes</a>
<a href="#">C81.13</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma intra-abdominal lymph nodes</a>
<a href="#">C81.14</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C81.15</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.16</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma intrapelvic lymph nodes</a>
<a href="#">C81.17</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma spleen</a>
<a href="#">C81.18</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma lymph nodes of multiple sites</a>
<a href="#">C81.19</a>	<a href="#">Nodular sclerosis Hodgkin lymphoma extranodal and solid organ sites</a>
<a href="#">C81.2</a>	<a href="#">Mixed cellularity Hodgkin lymphoma</a>
<a href="#">C81.20</a>	<a href="#">Mixed cellularity Hodgkin lymphoma unspecified site</a>
<a href="#">C81.21</a>	<a href="#">Mixed cellularity Hodgkin lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C81.22</a>	<a href="#">Mixed cellularity Hodgkin lymphoma intrathoracic lymph nodes</a>
<a href="#">C81.23</a>	<a href="#">Mixed cellularity Hodgkin lymphoma intra-abdominal lymph nodes</a>
<a href="#">C81.24</a>	<a href="#">Mixed cellularity Hodgkin lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C81.25</a>	<a href="#">Mixed cellularity Hodgkin lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.26</a>	<a href="#">Mixed cellularity Hodgkin lymphoma intrapelvic lymph nodes</a>
<a href="#">C81.27</a>	<a href="#">Mixed cellularity Hodgkin lymphoma spleen</a>

<a href="#">C81.28</a>	<a href="#">Mixed cellularity Hodgkin lymphoma lymph nodes of multiple sites</a>
<a href="#">C81.29</a>	<a href="#">Mixed cellularity Hodgkin lymphoma extranodal and solid organ sites</a>
<a href="#">C81.3</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma</a>
<a href="#">C81.30</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma unspecified site</a>
<a href="#">C81.31</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C81.32</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma intrathoracic lymph nodes</a>
<a href="#">C81.33</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma intra-abdominal lymph nodes</a>
<a href="#">C81.34</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C81.35</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.36</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma intrapelvic lymph nodes</a>
<a href="#">C81.37</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma spleen</a>
<a href="#">C81.38</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma lymph nodes of multiple sites</a>
<a href="#">C81.39</a>	<a href="#">Lymphocyte depleted Hodgkin lymphoma extranodal and solid organ sites</a>
<a href="#">C81.4</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma</a>
<a href="#">C81.40</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma unspecified site</a>
<a href="#">C81.41</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C81.42</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma intrathoracic lymph nodes</a>
<a href="#">C81.43</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma intra-abdominal lymph nodes</a>
<a href="#">C81.44</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C81.45</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.46</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma intrapelvic lymph nodes</a>
<a href="#">C81.47</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma spleen</a>
<a href="#">C81.48</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma lymph nodes of multiple sites</a>
<a href="#">C81.49</a>	<a href="#">Lymphocyte-rich Hodgkin lymphoma extranodal and solid organ sites</a>
<a href="#">C81.7</a>	<a href="#">Other Hodgkin lymphoma</a>
<a href="#">C81.70</a>	<a href="#">Other Hodgkin lymphoma unspecified site</a>
<a href="#">C81.71</a>	<a href="#">Other Hodgkin lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C81.72</a>	<a href="#">Other Hodgkin lymphoma intrathoracic lymph nodes</a>
<a href="#">C81.73</a>	<a href="#">Other Hodgkin lymphoma intra-abdominal lymph nodes</a>
<a href="#">C81.74</a>	<a href="#">Other Hodgkin lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C81.75</a>	<a href="#">Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.76</a>	<a href="#">Other Hodgkin lymphoma intrapelvic lymph nodes</a>
<a href="#">C81.77</a>	<a href="#">Other Hodgkin lymphoma spleen</a>
<a href="#">C81.78</a>	<a href="#">Other Hodgkin lymphoma lymph nodes of multiple sites</a>
<a href="#">C81.79</a>	<a href="#">Other Hodgkin lymphoma extranodal and solid organ sites</a>
<a href="#">C81.9</a>	<a href="#">Hodgkin lymphoma, unspecified</a>
<a href="#">C81.90</a>	<a href="#">Hodgkin lymphoma, unspecified, unspecified site</a>
<a href="#">C81.91</a>	<a href="#">Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck</a>
<a href="#">C81.92</a>	<a href="#">Hodgkin lymphoma, unspecified, intrathoracic lymph nodes</a>
<a href="#">C81.93</a>	<a href="#">Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes</a>

<a href="#">C81.94</a>	<a href="#">Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb</a>
<a href="#">C81.95</a>	<a href="#">Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb</a>
<a href="#">C81.96</a>	<a href="#">Hodgkin lymphoma, unspecified, intrapelvic lymph nodes</a>
<a href="#">C81.97</a>	<a href="#">Hodgkin lymphoma, unspecified, spleen</a>
<a href="#">C81.98</a>	<a href="#">Hodgkin lymphoma, unspecified, lymph nodes of multiple sites</a>
<a href="#">C81.99</a>	<a href="#">Hodgkin lymphoma, unspecified, extranodal and solid organ sites</a>
<a href="#">C82</a>	<a href="#">Follicular lymphoma</a>
<a href="#">C82.0</a>	<a href="#">Follicular lymphoma grade I</a>
<a href="#">C82.00</a>	<a href="#">Follicular lymphoma grade I unspecified site</a>
<a href="#">C82.01</a>	<a href="#">Follicular lymphoma grade I lymph nodes of head, face, and neck</a>
<a href="#">C82.02</a>	<a href="#">Follicular lymphoma grade I intrathoracic lymph nodes</a>
<a href="#">C82.03</a>	<a href="#">Follicular lymphoma grade I intra-abdominal lymph nodes</a>
<a href="#">C82.04</a>	<a href="#">Follicular lymphoma grade I lymph nodes of axilla and upper limb</a>
<a href="#">C82.05</a>	<a href="#">Follicular lymphoma grade I lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.06</a>	<a href="#">Follicular lymphoma grade I intrapelvic lymph nodes</a>
<a href="#">C82.07</a>	<a href="#">Follicular lymphoma grade I spleen</a>
<a href="#">C82.08</a>	<a href="#">Follicular lymphoma grade I lymph nodes of multiple sites</a>
<a href="#">C82.09</a>	<a href="#">Follicular lymphoma grade I extranodal and solid organ sites</a>
<a href="#">C82.1</a>	<a href="#">Follicular lymphoma grade II</a>
<a href="#">C82.10</a>	<a href="#">Follicular lymphoma grade II unspecified site</a>
<a href="#">C82.11</a>	<a href="#">Follicular lymphoma grade II lymph nodes of head, face, and neck</a>
<a href="#">C82.12</a>	<a href="#">Follicular lymphoma grade II intrathoracic lymph nodes</a>
<a href="#">C82.13</a>	<a href="#">Follicular lymphoma grade II intra-abdominal lymph nodes</a>
<a href="#">C82.14</a>	<a href="#">Follicular lymphoma grade II lymph nodes of axilla and upper limb</a>
<a href="#">C82.15</a>	<a href="#">Follicular lymphoma grade II lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.16</a>	<a href="#">Follicular lymphoma grade II intrapelvic lymph nodes</a>
<a href="#">C82.17</a>	<a href="#">Follicular lymphoma grade II spleen</a>
<a href="#">C82.18</a>	<a href="#">Follicular lymphoma grade II lymph nodes of multiple sites</a>
<a href="#">C82.19</a>	<a href="#">Follicular lymphoma grade II extranodal and solid organ sites</a>
<a href="#">C82.2</a>	<a href="#">Follicular lymphoma grade III, unspecified</a>
<a href="#">C82.20</a>	<a href="#">Follicular lymphoma grade III, unspecified, unspecified site</a>
<a href="#">C82.21</a>	<a href="#">Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck</a>
<a href="#">C82.22</a>	<a href="#">Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes</a>
<a href="#">C82.23</a>	<a href="#">Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes</a>
<a href="#">C82.24</a>	<a href="#">Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb</a>
<a href="#">C82.25</a>	<a href="#">Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.26</a>	<a href="#">Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes</a>
<a href="#">C82.27</a>	<a href="#">Follicular lymphoma grade III, unspecified, spleen</a>
<a href="#">C82.28</a>	<a href="#">Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites</a>

<a href="#">C82.29</a>	<a href="#">Follicular lymphoma grade III, unspecified, extranodal and solid organ sites</a>
<a href="#">C82.3</a>	<a href="#">Follicular lymphoma grade IIIa</a>
<a href="#">C82.30</a>	<a href="#">Follicular lymphoma grade IIIa unspecified site</a>
<a href="#">C82.31</a>	<a href="#">Follicular lymphoma grade IIIa lymph nodes of head, face, and neck</a>
<a href="#">C82.32</a>	<a href="#">Follicular lymphoma grade IIIa intrathoracic lymph nodes</a>
<a href="#">C82.33</a>	<a href="#">Follicular lymphoma grade IIIa intra-abdominal lymph nodes</a>
<a href="#">C82.34</a>	<a href="#">Follicular lymphoma grade IIIa lymph nodes of axilla and upper limb</a>
<a href="#">C82.35</a>	<a href="#">Follicular lymphoma grade IIIa lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.36</a>	<a href="#">Follicular lymphoma grade IIIa intrapelvic lymph nodes</a>
<a href="#">C82.37</a>	<a href="#">Follicular lymphoma grade IIIa spleen</a>
<a href="#">C82.38</a>	<a href="#">Follicular lymphoma grade IIIa lymph nodes of multiple sites</a>
<a href="#">C82.39</a>	<a href="#">Follicular lymphoma grade IIIa extranodal and solid organ sites</a>
<a href="#">C82.4</a>	<a href="#">Follicular lymphoma grade IIIb</a>
<a href="#">C82.40</a>	<a href="#">Follicular lymphoma grade IIIb unspecified site</a>
<a href="#">C82.41</a>	<a href="#">Follicular lymphoma grade IIIb lymph nodes of head, face, and neck</a>
<a href="#">C82.42</a>	<a href="#">Follicular lymphoma grade IIIb intrathoracic lymph nodes</a>
<a href="#">C82.43</a>	<a href="#">Follicular lymphoma grade IIIb intra-abdominal lymph nodes</a>
<a href="#">C82.44</a>	<a href="#">Follicular lymphoma grade IIIb lymph nodes of axilla and upper limb</a>
<a href="#">C82.45</a>	<a href="#">Follicular lymphoma grade IIIb lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.46</a>	<a href="#">Follicular lymphoma grade IIIb intrapelvic lymph nodes</a>
<a href="#">C82.47</a>	<a href="#">Follicular lymphoma grade IIIb spleen</a>
<a href="#">C82.48</a>	<a href="#">Follicular lymphoma grade IIIb lymph nodes of multiple sites</a>
<a href="#">C82.49</a>	<a href="#">Follicular lymphoma grade IIIb extranodal and solid organ sites</a>
<a href="#">C82.5</a>	<a href="#">Diffuse follicle center lymphoma</a>
<a href="#">C82.50</a>	<a href="#">Diffuse follicle center lymphoma unspecified site</a>
<a href="#">C82.51</a>	<a href="#">Diffuse follicle center lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C82.52</a>	<a href="#">Diffuse follicle center lymphoma intrathoracic lymph nodes</a>
<a href="#">C82.53</a>	<a href="#">Diffuse follicle center lymphoma intra-abdominal lymph nodes</a>
<a href="#">C82.54</a>	<a href="#">Diffuse follicle center lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C82.55</a>	<a href="#">Diffuse follicle center lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.56</a>	<a href="#">Diffuse follicle center lymphoma intrapelvic lymph nodes</a>
<a href="#">C82.57</a>	<a href="#">Diffuse follicle center lymphoma spleen</a>
<a href="#">C82.58</a>	<a href="#">Diffuse follicle center lymphoma lymph nodes of multiple sites</a>
<a href="#">C82.59</a>	<a href="#">Diffuse follicle center lymphoma extranodal and solid organ sites</a>
<a href="#">C82.6</a>	<a href="#">Cutaneous follicle center lymphoma</a>
<a href="#">C82.60</a>	<a href="#">Cutaneous follicle center lymphoma unspecified site</a>
<a href="#">C82.61</a>	<a href="#">Cutaneous follicle center lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C82.62</a>	<a href="#">Cutaneous follicle center lymphoma intrathoracic lymph nodes</a>
<a href="#">C82.63</a>	<a href="#">Cutaneous follicle center lymphoma intra-abdominal lymph nodes</a>
<a href="#">C82.64</a>	<a href="#">Cutaneous follicle center lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C82.65</a>	<a href="#">Cutaneous follicle center lymphoma lymph nodes of inguinal region and lower limb</a>

<a href="#">C82.66</a>	<a href="#">Cutaneous follicle center lymphoma intrapelvic lymph nodes</a>
<a href="#">C82.67</a>	<a href="#">Cutaneous follicle center lymphoma spleen</a>
<a href="#">C82.68</a>	<a href="#">Cutaneous follicle center lymphoma lymph nodes of multiple sites</a>
<a href="#">C82.69</a>	<a href="#">Cutaneous follicle center lymphoma extranodal and solid organ sites</a>
<a href="#">C82.8</a>	<a href="#">Other types of follicular lymphoma</a>
<a href="#">C82.80</a>	<a href="#">Other types of follicular lymphoma unspecified site</a>
<a href="#">C82.81</a>	<a href="#">Other types of follicular lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C82.82</a>	<a href="#">Other types of follicular lymphoma intrathoracic lymph nodes</a>
<a href="#">C82.83</a>	<a href="#">Other types of follicular lymphoma intra-abdominal lymph nodes</a>
<a href="#">C82.84</a>	<a href="#">Other types of follicular lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C82.85</a>	<a href="#">Other types of follicular lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.86</a>	<a href="#">Other types of follicular lymphoma intrapelvic lymph nodes</a>
<a href="#">C82.87</a>	<a href="#">Other types of follicular lymphoma spleen</a>
<a href="#">C82.88</a>	<a href="#">Other types of follicular lymphoma lymph nodes of multiple sites</a>
<a href="#">C82.89</a>	<a href="#">Other types of follicular lymphoma extranodal and solid organ sites</a>
<a href="#">C82.9</a>	<a href="#">Follicular lymphoma, unspecified</a>
<a href="#">C82.90</a>	<a href="#">Follicular lymphoma, unspecified unspecified site</a>
<a href="#">C82.91</a>	<a href="#">Follicular lymphoma, unspecified lymph nodes of head, face, and neck</a>
<a href="#">C82.92</a>	<a href="#">Follicular lymphoma, unspecified intrathoracic lymph nodes</a>
<a href="#">C82.93</a>	<a href="#">Follicular lymphoma, unspecified intra-abdominal lymph nodes</a>
<a href="#">C82.94</a>	<a href="#">Follicular lymphoma, unspecified lymph nodes of axilla and upper limb</a>
<a href="#">C82.95</a>	<a href="#">Follicular lymphoma, unspecified lymph nodes of inguinal region and lower limb</a>
<a href="#">C82.96</a>	<a href="#">Follicular lymphoma, unspecified intrapelvic lymph nodes</a>
<a href="#">C82.97</a>	<a href="#">Follicular lymphoma, unspecified spleen</a>
<a href="#">C82.98</a>	<a href="#">Follicular lymphoma, unspecified lymph nodes of multiple sites</a>
<a href="#">C82.99</a>	<a href="#">Follicular lymphoma, unspecified extranodal and solid organ sites</a>
<a href="#">C83</a>	<a href="#">Non-follicular lymphoma</a>
<a href="#">C83.0</a>	<a href="#">Small cell B-cell lymphoma</a>
<a href="#">C83.00</a>	<a href="#">Small cell B-cell lymphoma unspecified site</a>
<a href="#">C83.01</a>	<a href="#">Small cell B-cell lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C83.02</a>	<a href="#">Small cell B-cell lymphoma intrathoracic lymph nodes</a>
<a href="#">C83.03</a>	<a href="#">Small cell B-cell lymphoma intra-abdominal lymph nodes</a>
<a href="#">C83.04</a>	<a href="#">Small cell B-cell lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C83.05</a>	<a href="#">Small cell B-cell lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.06</a>	<a href="#">Small cell B-cell lymphoma intrapelvic lymph nodes</a>
<a href="#">C83.07</a>	<a href="#">Small cell B-cell lymphoma spleen</a>
<a href="#">C83.08</a>	<a href="#">Small cell B-cell lymphoma lymph nodes of multiple sites</a>
<a href="#">C83.09</a>	<a href="#">Small cell B-cell lymphoma extranodal and solid organ sites</a>
<a href="#">C83.1</a>	<a href="#">Mantle cell lymphoma</a>
<a href="#">C83.10</a>	<a href="#">Mantle cell lymphoma unspecified site</a>

<a href="#">C83.11</a>	<a href="#">Mantle cell lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C83.12</a>	<a href="#">Mantle cell lymphoma intrathoracic lymph nodes</a>
<a href="#">C83.13</a>	<a href="#">Mantle cell lymphoma intra-abdominal lymph nodes</a>
<a href="#">C83.14</a>	<a href="#">Mantle cell lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C83.15</a>	<a href="#">Mantle cell lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.16</a>	<a href="#">Mantle cell lymphoma intrapelvic lymph nodes</a>
<a href="#">C83.17</a>	<a href="#">Mantle cell lymphoma spleen</a>
<a href="#">C83.18</a>	<a href="#">Mantle cell lymphoma lymph nodes of multiple sites</a>
<a href="#">C83.19</a>	<a href="#">Mantle cell lymphoma extranodal and solid organ sites</a>
<a href="#">C83.3</a>	<a href="#">Diffuse large B-cell lymphoma</a>
<a href="#">C83.30</a>	<a href="#">Diffuse large B-cell lymphoma unspecified site</a>
<a href="#">C83.31</a>	<a href="#">Diffuse large B-cell lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C83.32</a>	<a href="#">Diffuse large B-cell lymphoma intrathoracic lymph nodes</a>
<a href="#">C83.33</a>	<a href="#">Diffuse large B-cell lymphoma intra-abdominal lymph nodes</a>
<a href="#">C83.34</a>	<a href="#">Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C83.35</a>	<a href="#">Diffuse large B-cell lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.36</a>	<a href="#">Diffuse large B-cell lymphoma intrapelvic lymph nodes</a>
<a href="#">C83.37</a>	<a href="#">Diffuse large B-cell lymphoma spleen</a>
<a href="#">C83.38</a>	<a href="#">Diffuse large B-cell lymphoma lymph nodes of multiple sites</a>
<a href="#">C83.39</a>	<a href="#">Diffuse large B-cell lymphoma extranodal and solid organ sites</a>
<a href="#">C83.5</a>	<a href="#">Lymphoblastic (diffuse) lymphoma</a>
<a href="#">C83.50</a>	<a href="#">Lymphoblastic (diffuse) lymphoma unspecified site</a>
<a href="#">C83.51</a>	<a href="#">Lymphoblastic (diffuse) lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C83.52</a>	<a href="#">Lymphoblastic (diffuse) lymphoma intrathoracic lymph nodes</a>
<a href="#">C83.53</a>	<a href="#">Lymphoblastic (diffuse) lymphoma intra-abdominal lymph nodes</a>
<a href="#">C83.54</a>	<a href="#">Lymphoblastic (diffuse) lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C83.55</a>	<a href="#">Lymphoblastic (diffuse) lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.56</a>	<a href="#">Lymphoblastic (diffuse) lymphoma intrapelvic lymph nodes</a>
<a href="#">C83.57</a>	<a href="#">Lymphoblastic (diffuse) lymphoma spleen</a>
<a href="#">C83.58</a>	<a href="#">Lymphoblastic (diffuse) lymphoma lymph nodes of multiple sites</a>
<a href="#">C83.59</a>	<a href="#">Lymphoblastic (diffuse) lymphoma extranodal and solid organ sites</a>
<a href="#">C83.7</a>	<a href="#">Burkitt lymphoma</a>
<a href="#">C83.70</a>	<a href="#">Burkitt lymphoma unspecified site</a>
<a href="#">C83.71</a>	<a href="#">Burkitt lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C83.72</a>	<a href="#">Burkitt lymphoma intrathoracic lymph nodes</a>
<a href="#">C83.73</a>	<a href="#">Burkitt lymphoma intra-abdominal lymph nodes</a>
<a href="#">C83.74</a>	<a href="#">Burkitt lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C83.75</a>	<a href="#">Burkitt lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.76</a>	<a href="#">Burkitt lymphoma intrapelvic lymph nodes</a>
<a href="#">C83.77</a>	<a href="#">Burkitt lymphoma spleen</a>
<a href="#">C83.78</a>	<a href="#">Burkitt lymphoma lymph nodes of multiple sites</a>

<a href="#">C83.79</a>	<a href="#">Burkitt lymphoma extranodal and solid organ sites</a>
<a href="#">C83.8</a>	<a href="#">Other non-follicular lymphoma</a>
<a href="#">C83.80</a>	<a href="#">Other non-follicular lymphoma unspecified site</a>
<a href="#">C83.81</a>	<a href="#">Other non-follicular lymphoma lymph nodes of head, face, and neck</a>
<a href="#">C83.82</a>	<a href="#">Other non-follicular lymphoma intrathoracic lymph nodes</a>
<a href="#">C83.83</a>	<a href="#">Other non-follicular lymphoma intra-abdominal lymph nodes</a>
<a href="#">C83.84</a>	<a href="#">Other non-follicular lymphoma lymph nodes of axilla and upper limb</a>
<a href="#">C83.85</a>	<a href="#">Other non-follicular lymphoma lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.86</a>	<a href="#">Other non-follicular lymphoma intrapelvic lymph nodes</a>
<a href="#">C83.87</a>	<a href="#">Other non-follicular lymphoma spleen</a>
<a href="#">C83.88</a>	<a href="#">Other non-follicular lymphoma lymph nodes of multiple sites</a>
<a href="#">C83.89</a>	<a href="#">Other non-follicular lymphoma extranodal and solid organ sites</a>
<a href="#">C83.9</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified</a>
<a href="#">C83.90</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified unspecified site</a>
<a href="#">C83.91</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck</a>
<a href="#">C83.92</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes</a>
<a href="#">C83.93</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes</a>
<a href="#">C83.94</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb</a>
<a href="#">C83.95</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb</a>
<a href="#">C83.96</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes</a>
<a href="#">C83.97</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified spleen</a>
<a href="#">C83.98</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites</a>
<a href="#">C83.99</a>	<a href="#">Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites</a>
<a href="#">C84</a>	<a href="#">Mature T/NK-cell lymphomas</a>
<a href="#">C84.0</a>	<a href="#">Mycosis fungoides</a>
<a href="#">C84.00</a>	<a href="#">Mycosis fungoides unspecified site</a>
<a href="#">C84.01</a>	<a href="#">Mycosis fungoides lymph nodes of head, face, and neck</a>
<a href="#">C84.02</a>	<a href="#">Mycosis fungoides intrathoracic lymph nodes</a>
<a href="#">C84.03</a>	<a href="#">Mycosis fungoides intra-abdominal lymph nodes</a>
<a href="#">C84.04</a>	<a href="#">Mycosis fungoides lymph nodes of axilla and upper limb</a>
<a href="#">C84.05</a>	<a href="#">Mycosis fungoides lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.06</a>	<a href="#">Mycosis fungoides intrapelvic lymph nodes</a>
<a href="#">C84.07</a>	<a href="#">Mycosis fungoides spleen</a>
<a href="#">C84.08</a>	<a href="#">Mycosis fungoides lymph nodes of multiple sites</a>
<a href="#">C84.09</a>	<a href="#">Mycosis fungoides extranodal and solid organ sites</a>
<a href="#">C84.1</a>	<a href="#">Sézary disease</a>
<a href="#">C84.10</a>	<a href="#">Sézary disease unspecified site</a>
<a href="#">C84.11</a>	<a href="#">Sézary disease lymph nodes of head, face, and neck</a>
<a href="#">C84.12</a>	<a href="#">Sézary disease intrathoracic lymph nodes</a>



<a href="#">C84.13</a>	<a href="#">Sézary disease intra-abdominal lymph nodes</a>
<a href="#">C84.14</a>	<a href="#">Sézary disease lymph nodes of axilla and upper limb</a>
<a href="#">C84.15</a>	<a href="#">Sézary disease lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.16</a>	<a href="#">Sézary disease intrapelvic lymph nodes</a>
<a href="#">C84.17</a>	<a href="#">Sézary disease spleen</a>
<a href="#">C84.18</a>	<a href="#">Sézary disease lymph nodes of multiple sites</a>
<a href="#">C84.19</a>	<a href="#">Sézary disease extranodal and solid organ sites</a>
<a href="#">C84.4</a>	<a href="#">Peripheral T-cell lymphoma, not classified</a>
<a href="#">C84.40</a>	<a href="#">Peripheral T-cell lymphoma, not classified unspecified site</a>
<a href="#">C84.41</a>	<a href="#">Peripheral T-cell lymphoma, not classified lymph nodes of head, face, and neck</a>
<a href="#">C84.42</a>	<a href="#">Peripheral T-cell lymphoma, not classified intrathoracic lymph nodes</a>
<a href="#">C84.43</a>	<a href="#">Peripheral T-cell lymphoma, not classified intra-abdominal lymph nodes</a>
<a href="#">C84.44</a>	<a href="#">Peripheral T-cell lymphoma, not classified lymph nodes of axilla and upper limb</a>
<a href="#">C84.45</a>	<a href="#">Peripheral T-cell lymphoma, not classified lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.46</a>	<a href="#">Peripheral T-cell lymphoma, not classified intrapelvic lymph nodes</a>
<a href="#">C84.47</a>	<a href="#">Peripheral T-cell lymphoma, not classified spleen</a>
<a href="#">C84.48</a>	<a href="#">Peripheral T-cell lymphoma, not classified lymph nodes of multiple sites</a>
<a href="#">C84.49</a>	<a href="#">Peripheral T-cell lymphoma, not classified extranodal and solid organ sites</a>
<a href="#">C84.6</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive</a>
<a href="#">C84.60</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive unspecified site</a>
<a href="#">C84.61</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive lymph nodes of head, face, and neck</a>
<a href="#">C84.62</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive intrathoracic lymph nodes</a>
<a href="#">C84.63</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive intra-abdominal lymph nodes</a>
<a href="#">C84.64</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive lymph nodes of axilla and upper limb</a>
<a href="#">C84.65</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.66</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive intrapelvic lymph nodes</a>
<a href="#">C84.67</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive spleen</a>
<a href="#">C84.68</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive lymph nodes of multiple sites</a>
<a href="#">C84.69</a>	<a href="#">Anaplastic large cell lymphoma, ALK-positive extranodal and solid organ sites</a>
<a href="#">C84.7</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative</a>
<a href="#">C84.70</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative unspecified site</a>
<a href="#">C84.71</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative lymph nodes of head, face, and neck</a>
<a href="#">C84.72</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative intrathoracic lymph nodes</a>
<a href="#">C84.73</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative intra-abdominal lymph nodes</a>
<a href="#">C84.74</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative lymph nodes of axilla and upper limb</a>
<a href="#">C84.75</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative lymph nodes of inguinal region and lower limb</a>

<a href="#">C84.76</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative intrapelvic lymph nodes</a>
<a href="#">C84.77</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative spleen</a>
<a href="#">C84.78</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative lymph nodes of multiple sites</a>
<a href="#">C84.79</a>	<a href="#">Anaplastic large cell lymphoma, ALK-negative extranodal and solid organ sites</a>
<a href="#">C84.9</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified</a>
<a href="#">C84.90</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, unspecified site</a>
<a href="#">C84.91</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck</a>
<a href="#">C84.92</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes</a>
<a href="#">C84.93</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes</a>
<a href="#">C84.94</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb</a>
<a href="#">C84.95</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.96</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes</a>
<a href="#">C84.97</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, spleen</a>
<a href="#">C84.98</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites</a>
<a href="#">C84.99</a>	<a href="#">Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites</a>
<a href="#">C84.A</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified</a>
<a href="#">C84.A0</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, unspecified site</a>
<a href="#">C84.A1</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, lymph nodes of head, face, and neck</a>
<a href="#">C84.A2</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes</a>
<a href="#">C84.A3</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes</a>
<a href="#">C84.A4</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb</a>
<a href="#">C84.A5</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.A6</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes</a>
<a href="#">C84.A7</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, spleen</a>
<a href="#">C84.A8</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites</a>
<a href="#">C84.A9</a>	<a href="#">Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites</a>
<a href="#">C84.Z</a>	<a href="#">Other mature T/NK-cell lymphomas</a>
<a href="#">C84.Z0</a>	<a href="#">Other mature T/NK-cell lymphomas, unspecified site</a>
<a href="#">C84.Z1</a>	<a href="#">Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck</a>
<a href="#">C84.Z2</a>	<a href="#">Other mature T/NK-cell lymphomas, intrathoracic lymph nodes</a>
<a href="#">C84.Z3</a>	<a href="#">Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes</a>
<a href="#">C84.Z4</a>	<a href="#">Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb</a>
<a href="#">C84.Z5</a>	<a href="#">Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb</a>
<a href="#">C84.Z6</a>	<a href="#">Other mature T/NK-cell lymphomas, intrapelvic lymph nodes</a>
<a href="#">C84.Z7</a>	<a href="#">Other mature T/NK-cell lymphomas, spleen</a>
<a href="#">C84.Z8</a>	<a href="#">Other mature T/NK-cell lymphomas, lymph nodes of multiple sites</a>
<a href="#">C84.Z9</a>	<a href="#">Other mature T/NK-cell lymphomas, extranodal and solid organ sites</a>

<a href="#">C85</a>	<a href="#">Other specified and unspecified types of non-Hodgkin lymphoma</a>
<a href="#">C85.1</a>	<a href="#">Unspecified B-cell lymphoma</a>
<a href="#">C85.10</a>	<a href="#">Unspecified B-cell lymphoma, unspecified site</a>
<a href="#">C85.11</a>	<a href="#">Unspecified B-cell lymphoma, lymph nodes of head, face, and neck</a>
<a href="#">C85.12</a>	<a href="#">Unspecified B-cell lymphoma, intrathoracic lymph nodes</a>
<a href="#">C85.13</a>	<a href="#">Unspecified B-cell lymphoma, intra-abdominal lymph nodes</a>
<a href="#">C85.14</a>	<a href="#">Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb</a>
<a href="#">C85.15</a>	<a href="#">Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb</a>
<a href="#">C85.16</a>	<a href="#">Unspecified B-cell lymphoma, intrapelvic lymph nodes</a>
<a href="#">C85.17</a>	<a href="#">Unspecified B-cell lymphoma, spleen</a>
<a href="#">C85.18</a>	<a href="#">Unspecified B-cell lymphoma, lymph nodes of multiple sites</a>
<a href="#">C85.19</a>	<a href="#">Unspecified B-cell lymphoma, extranodal and solid organ sites</a>
<a href="#">C85.2</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma</a>
<a href="#">C85.20</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, unspecified site</a>
<a href="#">C85.21</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck</a>
<a href="#">C85.22</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes</a>
<a href="#">C85.23</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes</a>
<a href="#">C85.24</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb</a>
<a href="#">C85.25</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb</a>
<a href="#">C85.26</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes</a>
<a href="#">C85.27</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, spleen</a>
<a href="#">C85.28</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites</a>
<a href="#">C85.29</a>	<a href="#">Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites</a>
<a href="#">C85.8</a>	<a href="#">Other specified types of non-Hodgkin lymphoma</a>
<a href="#">C85.80</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, unspecified site</a>
<a href="#">C85.81</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck</a>
<a href="#">C85.82</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes</a>
<a href="#">C85.83</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes</a>
<a href="#">C85.84</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb</a>
<a href="#">C85.85</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb</a>
<a href="#">C85.86</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes</a>
<a href="#">C85.87</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, spleen</a>
<a href="#">C85.88</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites</a>
<a href="#">C85.89</a>	<a href="#">Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites</a>
<a href="#">C85.9</a>	<a href="#">Non-Hodgkin lymphoma, unspecified</a>
<a href="#">C85.90</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, unspecified site</a>

<a href="#">C85.91</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck</a>
<a href="#">C85.92</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes</a>
<a href="#">C85.93</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes</a>
<a href="#">C85.94</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb</a>
<a href="#">C85.95</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb</a>
<a href="#">C85.96</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes</a>
<a href="#">C85.97</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, spleen</a>
<a href="#">C85.98</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites</a>
<a href="#">C85.99</a>	<a href="#">Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites</a>
<a href="#">C86</a>	<a href="#">Other specified types of T/NK-cell lymphoma</a>
<a href="#">C86.0</a>	<a href="#">Extranodal NK/T-cell lymphoma, nasal type</a>
<a href="#">C86.1</a>	<a href="#">Hepatosplenic T-cell lymphoma</a>
<a href="#">C86.2</a>	<a href="#">Enteropathy-type (intestinal) T-cell lymphoma</a>
<a href="#">C86.3</a>	<a href="#">Subcutaneous panniculitis-like T-cell lymphoma</a>
<a href="#">C86.4</a>	<a href="#">Blastic NK-cell lymphoma</a>
<a href="#">C86.5</a>	<a href="#">Angioimmunoblastic T-cell lymphoma</a>
<a href="#">C86.6</a>	<a href="#">Primary cutaneous CD30-positive T-cell proliferations</a>
<a href="#">C88</a>	<a href="#">Malignant immunoproliferative diseases and certain other B-cell lymphomas</a>
<a href="#">C88.0</a>	<a href="#">Waldenström macroglobulinemia</a>
<a href="#">C88.2</a>	<a href="#">Heavy chain disease</a>
<a href="#">C88.3</a>	<a href="#">Immunoproliferative small intestinal disease</a>
<a href="#">C88.4</a>	<a href="#">Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]</a>
<a href="#">C88.8</a>	<a href="#">Other malignant immunoproliferative diseases</a>
<a href="#">C88.9</a>	<a href="#">Malignant immunoproliferative disease, unspecified</a>
<a href="#">C90</a>	<a href="#">Multiple myeloma and malignant plasma cell neoplasms</a>
<a href="#">C90.0</a>	<a href="#">Multiple myeloma</a>
<a href="#">C90.00</a>	<a href="#">Multiple myeloma, not having achieved remission</a>
<a href="#">C90.01</a>	<a href="#">Multiple myeloma, in remission</a>
<a href="#">C90.02</a>	<a href="#">Multiple myeloma, in relapse</a>
<a href="#">C90.1</a>	<a href="#">Plasma cell leukemia</a>
<a href="#">C90.10</a>	<a href="#">Plasma cell leukemia, not having achieved remission</a>
<a href="#">C90.11</a>	<a href="#">Plasma cell leukemia, in remission</a>
<a href="#">C90.12</a>	<a href="#">Plasma cell leukemia, in relapse</a>
<a href="#">C90.2</a>	<a href="#">Extramedullary plasmacytoma</a>
<a href="#">C90.20</a>	<a href="#">Extramedullary plasmacytoma not having achieved remission</a>
<a href="#">C90.21</a>	<a href="#">Extramedullary plasmacytoma in remission</a>
<a href="#">C90.22</a>	<a href="#">Extramedullary plasmacytoma in relapse</a>
<a href="#">C90.3</a>	<a href="#">Solitary plasmacytoma</a>
<a href="#">C90.30</a>	<a href="#">Solitary plasmacytoma, not having achieved remission</a>
<a href="#">C90.31</a>	<a href="#">Solitary plasmacytoma, in remission</a>

<a href="#">C90.32</a>	<a href="#">Solitary plasmacytoma, in relapse</a>
<a href="#">C91</a>	<a href="#">Lymphoid leukemia</a>
<a href="#">C91.0</a>	<a href="#">Acute lymphoblastic leukemia [ALL]</a>
<a href="#">C91.00</a>	<a href="#">Acute lymphoblastic leukemia not having achieved remission</a>
<a href="#">C91.01</a>	<a href="#">Acute lymphoblastic leukemia, in remission</a>
<a href="#">C91.02</a>	<a href="#">Acute lymphoblastic leukemia, in relapse</a>
<a href="#">C91.1</a>	<a href="#">Chronic lymphocytic leukemia of B-cell type</a>
<a href="#">C91.10</a>	<a href="#">Chronic lymphocytic leukemia of B-cell type, not having achieved remission</a>
<a href="#">C91.11</a>	<a href="#">Chronic lymphocytic leukemia of B-cell type, in remission</a>
<a href="#">C91.12</a>	<a href="#">Chronic lymphocytic leukemia of B-cell type, in relapse</a>
<a href="#">C91.3</a>	<a href="#">Prolymphocytic leukemia of B-cell type</a>
<a href="#">C91.30</a>	<a href="#">Prolymphocytic leukemia of B-cell type, not having achieved remission</a>
<a href="#">C91.31</a>	<a href="#">Prolymphocytic leukemia of B-cell type, in remission</a>
<a href="#">C91.32</a>	<a href="#">Prolymphocytic leukemia of B-cell type, in relapse</a>
<a href="#">C91.4</a>	<a href="#">Hairy cell leukemia</a>
<a href="#">C91.40</a>	<a href="#">Hairy cell leukemia, not having achieved remission</a>
<a href="#">C91.41</a>	<a href="#">Hairy cell leukemia, in remission</a>
<a href="#">C91.42</a>	<a href="#">Hairy cell leukemia, in relapse</a>
<a href="#">C91.5</a>	<a href="#">Adult T-cell lymphoma/leukemia (HTLV-1-associated)</a>
<a href="#">C91.50</a>	<a href="#">Adult T-cell lymphoma/leukemia (HTLV-1-associated), not having achieved remission</a>
<a href="#">C91.51</a>	<a href="#">Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission</a>
<a href="#">C91.52</a>	<a href="#">Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse</a>
<a href="#">C91.6</a>	<a href="#">Prolymphocytic leukemia of T-cell type</a>
<a href="#">C91.60</a>	<a href="#">Prolymphocytic leukemia of T-cell type, not having achieved remission</a>
<a href="#">C91.61</a>	<a href="#">Prolymphocytic leukemia of T-cell type, in remission</a>
<a href="#">C91.62</a>	<a href="#">Prolymphocytic leukemia of T-cell type, in relapse</a>
<a href="#">C91.9</a>	<a href="#">Lymphoid leukemia, unspecified</a>
<a href="#">C91.90</a>	<a href="#">Lymphoid leukemia, unspecified, not having achieved remission</a>
<a href="#">C91.91</a>	<a href="#">Lymphoid leukemia, unspecified, in remission</a>
<a href="#">C91.92</a>	<a href="#">Lymphoid leukemia, unspecified, in relapse</a>
<a href="#">C91.A</a>	<a href="#">Mature B-cell leukemia Burkitt-type</a>
<a href="#">C91.A0</a>	<a href="#">Mature B-cell leukemia Burkitt-type, not having achieved remission</a>
<a href="#">C91.A1</a>	<a href="#">Mature B-cell leukemia Burkitt-type, in remission</a>
<a href="#">C91.A2</a>	<a href="#">Mature B-cell leukemia Burkitt-type, in relapse</a>
<a href="#">C91.Z</a>	<a href="#">Other lymphoid leukemia</a>
<a href="#">C91.Z0</a>	<a href="#">Other lymphoid leukemia, not having achieved remission</a>
<a href="#">C91.Z1</a>	<a href="#">Other lymphoid leukemia, in remission</a>
<a href="#">C91.Z2</a>	<a href="#">Other lymphoid leukemia, in relapse</a>
<a href="#">C92</a>	<a href="#">Myeloid leukemia</a>
<a href="#">C92.0</a>	<a href="#">Acute myeloblastic leukemia</a>
<a href="#">C92.00</a>	<a href="#">Acute myeloblastic leukemia, not having achieved remission</a>

<a href="#">C92.01</a>	<a href="#">Acute myeloblastic leukemia, in remission</a>
<a href="#">C92.02</a>	<a href="#">Acute myeloblastic leukemia, in relapse</a>
<a href="#">C92.1</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-positive</a>
<a href="#">C92.10</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission</a>
<a href="#">C92.11</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-positive, in remission</a>
<a href="#">C92.12</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-positive, in relapse</a>
<a href="#">C92.2</a>	<a href="#">Atypical chronic myeloid leukemia, BCR/ABL-negative</a>
<a href="#">C92.20</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission</a>
<a href="#">C92.21</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-negative, in remission</a>
<a href="#">C92.22</a>	<a href="#">Chronic myeloid leukemia, BCR/ABL-negative, in relapse</a>
<a href="#">C92.3</a>	<a href="#">Myeloid sarcoma</a>
<a href="#">C92.30</a>	<a href="#">Myeloid sarcoma, not having achieved remission</a>
<a href="#">C92.31</a>	<a href="#">Myeloid sarcoma, in remission</a>
<a href="#">C92.32</a>	<a href="#">Myeloid sarcoma, in relapse</a>
<a href="#">C92.4</a>	<a href="#">Acute promyelocytic leukemia</a>
<a href="#">C92.40</a>	<a href="#">Acute promyelocytic leukemia, not having achieved remission</a>
<a href="#">C92.41</a>	<a href="#">Acute promyelocytic leukemia, in remission</a>
<a href="#">C92.42</a>	<a href="#">Acute promyelocytic leukemia, in relapse</a>
<a href="#">C92.5</a>	<a href="#">Acute myelomonocytic leukemia</a>
<a href="#">C92.50</a>	<a href="#">Acute myelomonocytic leukemia, not having achieved remission</a>
<a href="#">C92.51</a>	<a href="#">Acute myelomonocytic leukemia, in remission</a>
<a href="#">C92.52</a>	<a href="#">Acute myelomonocytic leukemia, in relapse</a>
<a href="#">C92.6</a>	<a href="#">Acute myeloid leukemia with 11q23-abnormality</a>
<a href="#">C92.60</a>	<a href="#">Acute myeloid leukemia with 11q23-abnormality, not having achieved remission</a>
<a href="#">C92.61</a>	<a href="#">Acute myeloid leukemia with 11q23-abnormality, in remission</a>
<a href="#">C92.62</a>	<a href="#">Acute myeloid leukemia with 11q23-abnormality, in relapse</a>
<a href="#">C92.9</a>	<a href="#">Myeloid leukemia, unspecified</a>
<a href="#">C92.90</a>	<a href="#">Myeloid leukemia, unspecified, not having achieved remission</a>
<a href="#">C92.91</a>	<a href="#">Myeloid leukemia, unspecified, in remission</a>
<a href="#">C92.92</a>	<a href="#">Myeloid leukemia, unspecified, in relapse</a>
<a href="#">C92.A</a>	<a href="#">Acute myeloid leukemia with multilineage dysplasia</a>
<a href="#">C92.A0</a>	<a href="#">Acute myeloid leukemia with multilineage dysplasia, not having achieved remission</a>
<a href="#">C92.A1</a>	<a href="#">Acute myeloid leukemia with multilineage dysplasia, in remission</a>
<a href="#">C92.A2</a>	<a href="#">Acute myeloid leukemia with multilineage dysplasia, in relapse</a>
<a href="#">C92.Z</a>	<a href="#">Other myeloid leukemia</a>
<a href="#">C92.Z0</a>	<a href="#">Other myeloid leukemia, not having achieved remission</a>
<a href="#">C92.Z1</a>	<a href="#">Other myeloid leukemia, in remission</a>
<a href="#">C92.Z2</a>	<a href="#">Other myeloid leukemia, in relapse</a>
<a href="#">C93</a>	<a href="#">Monocytic leukemia</a>
<a href="#">C93.0</a>	<a href="#">Acute monoblastic/monocytic leukemia</a>

<a href="#">C93.00</a>	<a href="#">Acute monoblastic/monocytic leukemia, not having achieved remission</a>
<a href="#">C93.01</a>	<a href="#">Acute monoblastic/monocytic leukemia, in remission</a>
<a href="#">C93.02</a>	<a href="#">Acute monoblastic/monocytic leukemia, in relapse</a>
<a href="#">C93.1</a>	<a href="#">Chronic myelomonocytic leukemia</a>
<a href="#">C93.10</a>	<a href="#">Chronic myelomonocytic leukemia, not having achieved remission</a>
<a href="#">C93.11</a>	<a href="#">Chronic myelomonocytic leukemia, in remission</a>
<a href="#">C93.12</a>	<a href="#">Chronic myelomonocytic leukemia, in relapse</a>
<a href="#">C93.3</a>	<a href="#">Juvenile myelomonocytic leukemia</a>
<a href="#">C93.30</a>	<a href="#">Juvenile myelomonocytic leukemia, not having achieved remission</a>
<a href="#">C93.31</a>	<a href="#">Juvenile myelomonocytic leukemia, in remission</a>
<a href="#">C93.32</a>	<a href="#">Juvenile myelomonocytic leukemia, in relapse</a>
<a href="#">C93.9</a>	<a href="#">Monocytic leukemia, unspecified</a>
<a href="#">C93.90</a>	<a href="#">Monocytic leukemia, unspecified, not having achieved remission</a>
<a href="#">C93.91</a>	<a href="#">Monocytic leukemia, unspecified, in remission</a>
<a href="#">C93.92</a>	<a href="#">Monocytic leukemia, unspecified, in relapse</a>
<a href="#">C93.Z</a>	<a href="#">Other monocytic leukemia</a>
<a href="#">C93.Z0</a>	<a href="#">Other monocytic leukemia, not having achieved remission</a>
<a href="#">C93.Z1</a>	<a href="#">Other monocytic leukemia, in remission</a>
<a href="#">C93.Z2</a>	<a href="#">Other monocytic leukemia, in relapse</a>
<a href="#">C94</a>	<a href="#">Other leukemias of specified cell type</a>
<a href="#">C94.0</a>	<a href="#">Acute erythroid leukemia</a>
<a href="#">C94.00</a>	<a href="#">Acute erythroid leukemia, not having achieved remission</a>
<a href="#">C94.01</a>	<a href="#">Acute erythroid leukemia, in remission</a>
<a href="#">C94.02</a>	<a href="#">Acute erythroid leukemia, in relapse</a>
<a href="#">C94.2</a>	<a href="#">Acute megakaryoblastic leukemia</a>
<a href="#">C94.20</a>	<a href="#">Acute megakaryoblastic leukemia, not having achieved remission</a>
<a href="#">C94.21</a>	<a href="#">Acute megakaryoblastic leukemia, in remission</a>
<a href="#">C94.22</a>	<a href="#">Acute megakaryoblastic leukemia, in relapse</a>
<a href="#">C94.3</a>	<a href="#">Mast cell leukemia</a>
<a href="#">C94.30</a>	<a href="#">Mast cell leukemia, not having achieved remission</a>
<a href="#">C94.31</a>	<a href="#">Mast cell leukemia, in remission</a>
<a href="#">C94.32</a>	<a href="#">Mast cell leukemia, in relapse</a>
<a href="#">C94.4</a>	<a href="#">Acute panmyelosis with myelofibrosis</a>
<a href="#">C94.40</a>	<a href="#">Acute panmyelosis with myelofibrosis, not having achieved remission</a>
<a href="#">C94.41</a>	<a href="#">Acute panmyelosis with myelofibrosis, in remission</a>
<a href="#">C94.42</a>	<a href="#">Acute panmyelosis with myelofibrosis, in relapse</a>
<a href="#">C94.6</a>	<a href="#">Myelodysplastic disease, not classified</a>
<a href="#">C94.8</a>	<a href="#">Other specified leukemias</a>
<a href="#">C94.80</a>	<a href="#">Other specified leukemias, not having achieved remission</a>
<a href="#">C94.81</a>	<a href="#">Other specified leukemias, in remission</a>
<a href="#">C94.82</a>	<a href="#">Other specified leukemias, in relapse</a>

<a href="#">C95</a>	<a href="#">Leukemia of unspecified cell type</a>
<a href="#">C95.0</a>	<a href="#">Acute leukemia of unspecified cell type</a>
<a href="#">C95.00</a>	<a href="#">Acute leukemia of unspecified cell type, not having achieved remission</a>
<a href="#">C95.01</a>	<a href="#">Acute leukemia of unspecified cell type, in remission</a>
<a href="#">C95.02</a>	<a href="#">Acute leukemia of unspecified cell type, in relapse</a>
<a href="#">C95.1</a>	<a href="#">Chronic leukemia of unspecified cell type</a>
<a href="#">C95.10</a>	<a href="#">Chronic leukemia of unspecified cell type, not having achieved remission</a>
<a href="#">C95.11</a>	<a href="#">Chronic leukemia of unspecified cell type, in remission</a>
<a href="#">C95.12</a>	<a href="#">Chronic leukemia of unspecified cell type, in relapse</a>
<a href="#">C95.9</a>	<a href="#">Leukemia, unspecified</a>
<a href="#">C95.90</a>	<a href="#">Leukemia, unspecified, not having achieved remission</a>
<a href="#">C95.91</a>	<a href="#">Leukemia, unspecified, in remission</a>
<a href="#">C95.92</a>	<a href="#">Leukemia, unspecified, in relapse</a>
<a href="#">C96</a>	<a href="#">Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue</a>
<a href="#">C96.0</a>	<a href="#">Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis</a>
<a href="#">C96.2</a>	<a href="#">Malignant mast cell neoplasm</a>
<a href="#">C96.20</a>	<a href="#">Malignant mast cell neoplasm, unspecified</a>
<a href="#">C96.21</a>	<a href="#">Aggressive systemic mastocytosis</a>
<a href="#">C96.22</a>	<a href="#">Mast cell sarcoma</a>
<a href="#">C96.29</a>	<a href="#">Other malignant mast cell neoplasm</a>
<a href="#">C96.4</a>	<a href="#">Sarcoma of dendritic cells (accessory cells)</a>
<a href="#">C96.5</a>	<a href="#">Multifocal and unisystemic Langerhans-cell histiocytosis</a>
<a href="#">C96.6</a>	<a href="#">Unifocal Langerhans-cell histiocytosis</a>
<a href="#">C96.9</a>	<a href="#">Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified</a>
<a href="#">C96.A</a>	<a href="#">Secondary carcinoid tumors Histiocytic sarcoma</a>
<a href="#">C96.Z</a>	<a href="#">Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue</a>
<a href="#">D00</a>	<a href="#">Carcinoma in situ of oral cavity, esophagus and stomach</a>
<a href="#">D00.0</a>	<a href="#">Carcinoma in situ of lip, oral cavity and pharynx</a>
<a href="#">D00.00</a>	<a href="#">Carcinoma in situ of oral cavity, unspecified site</a>
<a href="#">D00.01</a>	<a href="#">Carcinoma in situ of labial mucosa and vermilion border</a>
<a href="#">D00.02</a>	<a href="#">Carcinoma in situ of buccal mucosa</a>
<a href="#">D00.03</a>	<a href="#">Carcinoma in situ of gingiva and edentulous alveolar ridge</a>
<a href="#">D00.04</a>	<a href="#">Carcinoma in situ of soft palate</a>
<a href="#">D00.05</a>	<a href="#">Carcinoma in situ of hard palate</a>
<a href="#">D00.06</a>	<a href="#">Carcinoma in situ of floor of mouth</a>
<a href="#">D00.07</a>	<a href="#">Carcinoma in situ of tongue</a>
<a href="#">D00.08</a>	<a href="#">Carcinoma in situ of pharynx</a>
<a href="#">D00.1</a>	<a href="#">Carcinoma in situ of esophagus</a>
<a href="#">D00.2</a>	<a href="#">Carcinoma in situ of stomach</a>



<a href="#"><u>D01</u></a>	<a href="#"><u>Carcinoma in situ of other and unspecified digestive organs</u></a>
<a href="#"><u>D01.0</u></a>	<a href="#"><u>Carcinoma in situ of colon</u></a>
<a href="#"><u>D01.1</u></a>	<a href="#"><u>Carcinoma in situ of rectosigmoid junction</u></a>
<a href="#"><u>D01.2</u></a>	<a href="#"><u>Carcinoma in situ of rectum</u></a>
<a href="#"><u>D01.3</u></a>	<a href="#"><u>Carcinoma in situ of anus and anal canal</u></a>
<a href="#"><u>D01.4</u></a>	<a href="#"><u>Carcinoma in situ of other and unspecified parts of intestine</u></a>
<a href="#"><u>D01.40</u></a>	<a href="#"><u>Carcinoma in situ of unspecified part of intestine</u></a>
<a href="#"><u>D01.49</u></a>	<a href="#"><u>Carcinoma in situ of other parts of intestine</u></a>
<a href="#"><u>D01.5</u></a>	<a href="#"><u>Carcinoma in situ of liver, gallbladder and bile ducts</u></a>
<a href="#"><u>D01.7</u></a>	<a href="#"><u>Carcinoma in situ of other specified digestive organs</u></a>
<a href="#"><u>D01.9</u></a>	<a href="#"><u>Carcinoma in situ of digestive organ, unspecified</u></a>
<a href="#"><u>D02</u></a>	<a href="#"><u>Carcinoma in situ of middle ear and respiratory system</u></a>
<a href="#"><u>D02.0</u></a>	<a href="#"><u>Carcinoma in situ of larynx</u></a>
<a href="#"><u>D02.1</u></a>	<a href="#"><u>Carcinoma in situ of trachea</u></a>
<a href="#"><u>D02.2</u></a>	<a href="#"><u>Carcinoma in situ of bronchus and lung</u></a>
<a href="#"><u>D02.20</u></a>	<a href="#"><u>Carcinoma in situ of unspecified bronchus and lung</u></a>
<a href="#"><u>D02.21</u></a>	<a href="#"><u>Carcinoma in situ of right bronchus and lung</u></a>
<a href="#"><u>D02.22</u></a>	<a href="#"><u>Carcinoma in situ of left bronchus and lung</u></a>
<a href="#"><u>D02.3</u></a>	<a href="#"><u>Carcinoma in situ of other parts of respiratory system</u></a>
<a href="#"><u>D02.4</u></a>	<a href="#"><u>Carcinoma in situ of respiratory system, unspecified</u></a>
<a href="#"><u>D03</u></a>	<a href="#"><u>Melanoma in situ</u></a>
<a href="#"><u>D03.0</u></a>	<a href="#"><u>Melanoma in situ of lip</u></a>
<a href="#"><u>D03.1</u></a>	<a href="#"><u>Melanoma in situ of eyelid, including canthus</u></a>
<a href="#"><u>D03.10</u></a>	<a href="#"><u>Melanoma in situ of unspecified eyelid, including canthus</u></a>
<a href="#"><u>D03.11</u></a>	<a href="#"><u>Melanoma in situ of right eyelid, including canthus</u></a>
<a href="#"><u>D03.111</u></a>	<a href="#"><u>Melanoma in situ of right upper eyelid, including canthus</u></a>
<a href="#"><u>D03.112</u></a>	<a href="#"><u>Melanoma in situ of right lower eyelid, including canthus</u></a>
<a href="#"><u>D03.12</u></a>	<a href="#"><u>Melanoma in situ of left eyelid, including canthus</u></a>
<a href="#"><u>D03.121</u></a>	<a href="#"><u>Melanoma in situ of left upper eyelid, including canthus</u></a>
<a href="#"><u>D03.122</u></a>	<a href="#"><u>Melanoma in situ of left lower eyelid, including canthus</u></a>
<a href="#"><u>D03.2</u></a>	<a href="#"><u>Melanoma in situ of ear and external auricular canal</u></a>
<a href="#"><u>D03.20</u></a>	<a href="#"><u>Melanoma in situ of unspecified ear and external auricular canal</u></a>
<a href="#"><u>D03.21</u></a>	<a href="#"><u>Melanoma in situ of right ear and external auricular canal</u></a>
<a href="#"><u>D03.22</u></a>	<a href="#"><u>Melanoma in situ of left ear and external auricular canal</u></a>
<a href="#"><u>D03.3</u></a>	<a href="#"><u>Melanoma in situ of other and unspecified parts of face</u></a>
<a href="#"><u>D03.30</u></a>	<a href="#"><u>Melanoma in situ of unspecified part of face</u></a>
<a href="#"><u>D03.39</u></a>	<a href="#"><u>Melanoma in situ of other parts of face</u></a>
<a href="#"><u>D03.4</u></a>	<a href="#"><u>Melanoma in situ of scalp and neck</u></a>
<a href="#"><u>D03.5</u></a>	<a href="#"><u>Melanoma in situ of trunk</u></a>
<a href="#"><u>D03.51</u></a>	<a href="#"><u>Melanoma in situ of anal skin</u></a>
<a href="#"><u>D03.52</u></a>	<a href="#"><u>Melanoma in situ of breast (skin) (soft tissue)</u></a>

<a href="#">D03.59</a>	<a href="#">Melanoma in situ of other part of trunk</a>
<a href="#">D03.6</a>	<a href="#">Melanoma in situ of upper limb, including shoulder</a>
<a href="#">D03.60</a>	<a href="#">Melanoma in situ of unspecified upper limb, including shoulder</a>
<a href="#">D03.61</a>	<a href="#">Melanoma in situ of right upper limb, including shoulder</a>
<a href="#">D03.62</a>	<a href="#">Melanoma in situ of left upper limb, including shoulder</a>
<a href="#">D03.7</a>	<a href="#">Melanoma in situ of lower limb, including hip</a>
<a href="#">D03.70</a>	<a href="#">Melanoma in situ of unspecified lower limb, including hip</a>
<a href="#">D03.71</a>	<a href="#">Melanoma in situ of right lower limb, including hip</a>
<a href="#">D03.72</a>	<a href="#">Melanoma in situ of left lower limb, including hip</a>
<a href="#">D03.8</a>	<a href="#">Melanoma in situ of other sites</a>
<a href="#">D03.9</a>	<a href="#">Melanoma in situ, unspecified</a>
<a href="#">D04</a>	<a href="#">Carcinoma in situ of skin</a>
<a href="#">D04.0</a>	<a href="#">Carcinoma in situ of skin of lip</a>
<a href="#">D04.1</a>	<a href="#">Carcinoma in situ of skin of eyelid, including canthus</a>
<a href="#">D04.10</a>	<a href="#">Carcinoma in situ of skin of unspecified eyelid, including canthus</a>
<a href="#">D04.11</a>	<a href="#">Carcinoma in situ of skin of right eyelid, including canthus</a>
<a href="#">D04.111</a>	<a href="#">Carcinoma in situ of skin of right upper eyelid, including canthus</a>
<a href="#">D04.112</a>	<a href="#">Carcinoma in situ of skin of right lower eyelid, including canthus</a>
<a href="#">D04.12</a>	<a href="#">Carcinoma in situ of skin of left eyelid, including canthus</a>
<a href="#">D04.121</a>	<a href="#">Carcinoma in situ of skin of left upper eyelid, including canthus</a>
<a href="#">D04.122</a>	<a href="#">Carcinoma in situ of skin of left lower eyelid, including canthus</a>
<a href="#">D04.2</a>	<a href="#">Carcinoma in situ of skin of ear and external auricular canal</a>
<a href="#">D04.20</a>	<a href="#">Carcinoma in situ of skin of unspecified ear and external auricular canal</a>
<a href="#">D04.21</a>	<a href="#">Carcinoma in situ of skin of right ear and external auricular canal</a>
<a href="#">D04.22</a>	<a href="#">Carcinoma in situ of skin of left ear and external auricular canal</a>
<a href="#">D04.3</a>	<a href="#">Carcinoma in situ of skin of other and unspecified parts of face</a>
<a href="#">D04.30</a>	<a href="#">Carcinoma in situ of skin of unspecified part of face</a>
<a href="#">D04.39</a>	<a href="#">Carcinoma in situ of skin of other parts of face</a>
<a href="#">D04.4</a>	<a href="#">Carcinoma in situ of skin of scalp and neck</a>
<a href="#">D04.5</a>	<a href="#">Carcinoma in situ of skin of trunk</a>
<a href="#">D04.6</a>	<a href="#">Carcinoma in situ of skin of upper limb, including shoulder</a>
<a href="#">D04.60</a>	<a href="#">Carcinoma in situ of skin of unspecified upper limb, including shoulder</a>
<a href="#">D04.61</a>	<a href="#">Carcinoma in situ of skin of right upper limb, including shoulder</a>
<a href="#">D04.62</a>	<a href="#">Carcinoma in situ of skin of left upper limb, including shoulder</a>
<a href="#">D04.7</a>	<a href="#">Carcinoma in situ of skin of lower limb, including hip</a>
<a href="#">D04.70</a>	<a href="#">Carcinoma in situ of skin of unspecified lower limb, including hip</a>
<a href="#">D04.71</a>	<a href="#">Carcinoma in situ of skin of right lower limb, including hip</a>
<a href="#">D04.72</a>	<a href="#">Carcinoma in situ of skin of left lower limb, including hip</a>
<a href="#">D04.8</a>	<a href="#">Carcinoma in situ of skin of other sites</a>
<a href="#">D04.9</a>	<a href="#">Carcinoma in situ of skin, unspecified</a>
<a href="#">D05</a>	<a href="#">Carcinoma in situ of breast</a>

<a href="#">D05.0</a>	<a href="#">Lobular carcinoma in situ of breast</a>
<a href="#">D05.00</a>	<a href="#">Lobular carcinoma in situ of unspecified breast</a>
<a href="#">D05.01</a>	<a href="#">Lobular carcinoma in situ of right breast</a>
<a href="#">D05.02</a>	<a href="#">Lobular carcinoma in situ of left breast</a>
<a href="#">D05.1</a>	<a href="#">Intraductal carcinoma in situ of breast</a>
<a href="#">D05.10</a>	<a href="#">Intraductal carcinoma in situ of unspecified breast</a>
<a href="#">D05.11</a>	<a href="#">Intraductal carcinoma in situ of right breast</a>
<a href="#">D05.12</a>	<a href="#">Intraductal carcinoma in situ of left breast</a>
<a href="#">D05.8</a>	<a href="#">Other specified type of carcinoma in situ of breast</a>
<a href="#">D05.80</a>	<a href="#">Other specified type of carcinoma in situ of unspecified breast</a>
<a href="#">D05.81</a>	<a href="#">Other specified type of carcinoma in situ of right breast</a>
<a href="#">D05.82</a>	<a href="#">Other specified type of carcinoma in situ of left breast</a>
<a href="#">D05.9</a>	<a href="#">Unspecified type of carcinoma in situ of breast</a>
<a href="#">D05.90</a>	<a href="#">Unspecified type of carcinoma in situ of unspecified breast</a>
<a href="#">D05.91</a>	<a href="#">Unspecified type of carcinoma in situ of right breast</a>
<a href="#">D05.92</a>	<a href="#">Unspecified type of carcinoma in situ of left breast</a>
<a href="#">D06</a>	<a href="#">Carcinoma in situ of cervix uteri</a>
<a href="#">D06.0</a>	<a href="#">Carcinoma in situ of endocervix</a>
<a href="#">D06.1</a>	<a href="#">Carcinoma in situ of exocervix</a>
<a href="#">D06.7</a>	<a href="#">Carcinoma in situ of other parts of cervix</a>
<a href="#">D06.9</a>	<a href="#">Carcinoma in situ of cervix, unspecified</a>
<a href="#">D07</a>	<a href="#">Carcinoma in situ of other and unspecified genital organs</a>
<a href="#">D07.0</a>	<a href="#">Carcinoma in situ of endometrium</a>
<a href="#">D07.1</a>	<a href="#">Carcinoma in situ of vulva</a>
<a href="#">D07.2</a>	<a href="#">Carcinoma in situ of vagina</a>
<a href="#">D07.3</a>	<a href="#">Carcinoma in situ of other and unspecified female genital organs</a>
<a href="#">D07.30</a>	<a href="#">Carcinoma in situ of unspecified female genital organs</a>
<a href="#">D07.39</a>	<a href="#">Carcinoma in situ of other female genital organs</a>
<a href="#">D07.4</a>	<a href="#">Carcinoma in situ of penis</a>
<a href="#">D07.5</a>	<a href="#">Carcinoma in situ of prostate</a>
<a href="#">D07.6</a>	<a href="#">Carcinoma in situ of other and unspecified male genital organs</a>
<a href="#">D07.60</a>	<a href="#">Carcinoma in situ of unspecified male genital organs</a>
<a href="#">D07.61</a>	<a href="#">Carcinoma in situ of scrotum</a>
<a href="#">D07.69</a>	<a href="#">Carcinoma in situ of other male genital organs</a>
<a href="#">D09</a>	<a href="#">Carcinoma in situ of other and unspecified sites</a>
<a href="#">D09.0</a>	<a href="#">Carcinoma in situ of bladder</a>
<a href="#">D09.1</a>	<a href="#">Carcinoma in situ of other and unspecified urinary organs</a>
<a href="#">D09.10</a>	<a href="#">Carcinoma in situ of unspecified urinary organ</a>
<a href="#">D09.19</a>	<a href="#">Carcinoma in situ of other urinary organs</a>
<a href="#">D09.2</a>	<a href="#">Carcinoma in situ of eye</a>
<a href="#">D09.20</a>	<a href="#">Carcinoma in situ of unspecified eye</a>

<a href="#">D09.21</a>	<a href="#">Carcinoma in situ of right eye</a>
<a href="#">D09.22</a>	<a href="#">Carcinoma in situ of left eye</a>
<a href="#">D09.3</a>	<a href="#">Carcinoma in situ of thyroid and other endocrine glands</a>
<a href="#">D09.8</a>	<a href="#">Carcinoma in situ of other specified sites</a>
<a href="#">D09.9</a>	<a href="#">Carcinoma in situ, unspecified</a>
<a href="#">D18.02</a>	<a href="#">Hemangioma of intracranial structures</a>
<a href="#">D32</a>	<a href="#">Benign neoplasm of meninges</a>
<a href="#">D32.0</a>	<a href="#">Benign neoplasm of cerebral meninges</a>
<a href="#">D32.1</a>	<a href="#">Benign neoplasm of spinal meninges</a>
<a href="#">D32.9</a>	<a href="#">Benign neoplasm of meninges, unspecified</a>
<a href="#">D33.-</a>	<a href="#">Benign neoplasm of brain and other parts of central nervous system</a>
<a href="#">D33.0</a>	<a href="#">Benign neoplasm of brain, supratentorial</a>
<a href="#">D33.1</a>	<a href="#">Benign neoplasm of brain, infratentorial</a>
<a href="#">D33.2</a>	<a href="#">Benign neoplasm of brain, unspecified</a>
<a href="#">D33.3</a>	<a href="#">Benign neoplasm of cranial nerves</a>
<a href="#">D33.4</a>	<a href="#">Benign neoplasm of spinal cord</a>
<a href="#">D33.7</a>	<a href="#">Benign neoplasm of other specified parts of central nervous system</a>
<a href="#">D33.9</a>	<a href="#">Benign neoplasm of central nervous system, unspecified</a>
<a href="#">D35.2</a>	<a href="#">Benign neoplasm of pituitary gland</a>
<a href="#">D35.3</a>	<a href="#">Benign neoplasm of craniopharyngeal duct</a>
<a href="#">D35.4</a>	<a href="#">Benign neoplasm of pineal gland</a>
<a href="#">D42</a>	<a href="#">Neoplasm of uncertain behavior of meninges</a>
<a href="#">D42.0</a>	<a href="#">Neoplasm of uncertain behavior of cerebral meninges</a>
<a href="#">D42.1</a>	<a href="#">Neoplasm of uncertain behavior of spinal meninges</a>
<a href="#">D42.9</a>	<a href="#">Neoplasm of uncertain behavior of meninges, unspecified</a>
<a href="#">D43</a>	<a href="#">Neoplasm of uncertain behavior of brain and central nervous system</a>
<a href="#">D43.0</a>	<a href="#">Neoplasm of uncertain behavior of brain, supratentorial</a>
<a href="#">D43.1</a>	<a href="#">Neoplasm of uncertain behavior of brain, infratentorial</a>
<a href="#">D43.2</a>	<a href="#">Neoplasm of uncertain behavior of brain, unspecified</a>
<a href="#">D43.3</a>	<a href="#">Neoplasm of uncertain behavior of cranial nerves</a>
<a href="#">D43.4</a>	<a href="#">Neoplasm of uncertain behavior of spinal cord</a>
<a href="#">D43.8</a>	<a href="#">Neoplasm of uncertain behavior of other specified parts of central nervous system</a>
<a href="#">D43.9</a>	<a href="#">Neoplasm of uncertain behavior of central nervous system, unspecified</a>
<a href="#">D44.3</a>	<a href="#">Neoplasm of uncertain behavior of pituitary gland</a>
<a href="#">D44.4</a>	<a href="#">Neoplasm of uncertain behavior of craniopharyngeal duct</a>
<a href="#">D44.5</a>	<a href="#">Neoplasm of uncertain behavior of pineal gland</a>
<a href="#">D45</a>	<a href="#">Polycythemia vera</a>
<a href="#">D46</a>	<a href="#">Myelodysplastic syndromes</a>
<a href="#">D46.0</a>	<a href="#">Refractory anemia without ring sideroblasts, so stated</a>
<a href="#">D46.1</a>	<a href="#">Refractory anemia with ring sideroblasts</a>
<a href="#">D46.2</a>	<a href="#">Refractory anemia with excess of blasts [RAEB]</a>

<a href="#">D46.20</a>	<a href="#">Refractory anemia with excess of blasts, unspecified</a>
<a href="#">D46.21</a>	<a href="#">Refractory anemia with excess of blasts 1</a>
<a href="#">D46.22</a>	<a href="#">Refractory anemia with excess of blasts 2</a>
<a href="#">D46.4</a>	<a href="#">Refractory anemia, unspecified</a>
<a href="#">D46.9</a>	<a href="#">Myelodysplastic syndrome, unspecified</a>
<a href="#">D46.A</a>	<a href="#">Refractory cytopenia with multilineage dysplasia</a>
<a href="#">D46.B</a>	<a href="#">Refractory cytopenia with multilineage dysplasia and ring sideroblasts</a>
<a href="#">D46.C</a>	<a href="#">Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality</a>
<a href="#">D46.Z</a>	<a href="#">Other myelodysplastic syndromes</a>
<a href="#">D47.02</a>	<a href="#">Systemic mastocytosis</a>
<a href="#">D47.1</a>	<a href="#">Chronic myeloproliferative disease</a>
<a href="#">D47.3</a>	<a href="#">Essential (hemorrhagic) thrombocythemia</a>
<a href="#">D47.4</a>	<a href="#">Osteomyelofibrosis</a>
<a href="#">D47.9</a>	<a href="#">Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified</a>
<a href="#">D47.Z</a>	<a href="#">Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue</a>
<a href="#">D47.Z1</a>	<a href="#">Post-transplant lymphoproliferative disorder (PTLD)</a>
<a href="#">D47.Z9</a>	<a href="#">Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue</a>
<a href="#">D49.6</a>	<a href="#">Neoplasm of unspecified behavior of brain</a>
<a href="#">D49.7</a>	<a href="#">Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system</a>
<a href="#">R85.614</a>	<a href="#">Cytologic evidence of malignancy on smear of anus</a>
<a href="#">R87.614</a>	<a href="#">Cytologic evidence of malignancy on smear of cervix</a>
<a href="#">R87.624</a>	<a href="#">Cytologic evidence of malignancy on smear of vagina</a>
<a href="#">ICD-10-CM-Code Specific</a>	<a href="#">ICD-10-CM-Code Definition</a>
<a href="#">C00</a>	<a href="#">Malignant neoplasm of lip</a>
<a href="#">C00.0</a>	<a href="#">Malignant neoplasm of external upper lip</a>
<a href="#">C00.1</a>	<a href="#">Malignant neoplasm of external lower lip</a>
<a href="#">C00.2</a>	<a href="#">Malignant neoplasm of external lip, unspecified</a>
<a href="#">C00.3</a>	<a href="#">Malignant neoplasm of upper lip, inner aspect</a>
<a href="#">C00.4</a>	<a href="#">Malignant neoplasm of lower lip, inner aspect</a>
<a href="#">C00.5</a>	<a href="#">Malignant neoplasm of lip, unspecified, inner aspect</a>
<a href="#">C00.6</a>	<a href="#">Malignant neoplasm of commissure of lip, unspecified</a>
<a href="#">C00.8</a>	<a href="#">Malignant neoplasm of overlapping sites of lip</a>
<a href="#">C00.9</a>	<a href="#">Malignant neoplasm of lip, unspecified</a>
<a href="#">C01</a>	<a href="#">Malignant neoplasm of base of tongue</a>
<a href="#">C02</a>	<a href="#">Malignant neoplasm of other and unspecified parts of tongue</a>
<a href="#">C02.0</a>	<a href="#">Malignant neoplasm of dorsal surface of tongue</a>
<a href="#">C02.1</a>	<a href="#">Malignant neoplasm of border of tongue</a>

C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified
C03	Malignant neoplasm of gum
C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C04	Malignant neoplasm of floor of mouth
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified
C05	Malignant neoplasm of palate
C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.2	Malignant neoplasm of uvula
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06	Malignant neoplasm of other and unspecified parts of mouth
C06.0	Malignant neoplasm of cheek mucosa
C06.1	Malignant neoplasm of vestibule of mouth
C06.2	Malignant neoplasm of retromolar area
C06.8	Malignant neoplasm of overlapping sites of other and unspecified parts of mouth
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
C06.9	Malignant neoplasm of mouth, unspecified
C07	Malignant neoplasm of parotid gland
C08	Malignant neoplasm of other and unspecified major salivary glands
C08.0	Malignant neoplasm of submandibular gland
C08.1	Malignant neoplasm of sublingual gland
C08.9	Malignant neoplasm of major salivary gland, unspecified
C09	Malignant neoplasm of tonsil
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C10	Malignant neoplasm of oropharynx
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis

C10.2	Malignant neoplasm of lateral wall of oropharynx
C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified
C11	Malignant neoplasm of nasopharynx
C11.0	Malignant neoplasm of superior wall of nasopharynx
C11.1	Malignant neoplasm of posterior wall of nasopharynx
C11.2	Malignant neoplasm of lateral wall of nasopharynx
C11.3	Malignant neoplasm of anterior wall of nasopharynx
C11.8	Malignant neoplasm of overlapping sites of nasopharynx
C11.9	Malignant neoplasm of nasopharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13	Malignant neoplasm of hypopharynx
C13.0	Malignant neoplasm of postericoid region
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2	Malignant neoplasm of posterior wall of hypopharynx
C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C15	Malignant neoplasm of esophagus
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16	Malignant neoplasm of stomach
C16.0	Malignant neoplasm of cardia
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17	Malignant neoplasm of small intestine
C17.0	Malignant neoplasm of duodenum

C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18	Malignant neoplasm of colon
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21	Malignant neoplasm of anus and anal canal
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C22	Malignant neoplasm of liver and intrahepatic bile ducts
C22.0	Liver cell carcinoma
C22.1	Intrahepatic bile duct carcinoma
C22.2	Hepatoblastoma
C22.3	Angiosarcoma of liver
C22.4	Other sarcomas of liver
C22.7	Other specified carcinomas of liver
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C23	Malignant neoplasm of gallbladder
C24	Malignant neoplasm of other and unspecified parts of biliary tract
C24.0	Malignant neoplasm of extrahepatic bile duct
C24.1	Malignant neoplasm of ampulla of Vater
C24.8	Malignant neoplasm of overlapping sites of biliary tract
C24.9	Malignant neoplasm of biliary tract, unspecified
C25	Malignant neoplasm of pancreas
C25.0	Malignant neoplasm of head of pancreas
C25.1	Malignant neoplasm of body of pancreas



C25.2	Malignant neoplasm of tail of pancreas
C25.3	Malignant neoplasm of pancreatic duct
C25.4	Malignant neoplasm of endocrine pancreas
C25.7	Malignant neoplasm of other parts of pancreas
C25.8	Malignant neoplasm of overlapping sites of pancreas
C25.9	Malignant neoplasm of pancreas, unspecified
C26	Malignant neoplasm of other and ill-defined digestive organs
C26.0	Malignant neoplasm of intestinal tract, part unspecified
C26.1	Malignant neoplasm of spleen
C26.9	Malignant neoplasm of ill-defined sites within the digestive system
C30	Malignant neoplasm of nasal cavity and middle ear
C30.0	Malignant neoplasm of nasal cavity
C30.1	Malignant neoplasm of middle ear
C31	Malignant neoplasm of accessory sinuses
C31.0	Malignant neoplasm of maxillary sinus
C31.1	Malignant neoplasm of ethmoidal sinus
C31.2	Malignant neoplasm of frontal sinus
C31.3	Malignant neoplasm of sphenoid sinus
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses
C31.9	Malignant neoplasm of accessory sinus, unspecified
C32	Malignant neoplasm of larynx
C32.0	Malignant neoplasm of glottis
C32.1	Malignant neoplasm of supraglottis
C32.2	Malignant neoplasm of subglottis
C32.3	Malignant neoplasm of laryngeal cartilage
C32.8	Malignant neoplasm of overlapping sites of larynx
C32.9	Malignant neoplasm of larynx, unspecified
C33	Malignant neoplasm of trachea
C34	Malignant neoplasm of bronchus and lung
C34.0	Malignant neoplasm of main bronchus
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.1	Malignant neoplasm of upper lobe, bronchus or lung
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.3	Malignant neoplasm of lower lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung

C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.8	Malignant neoplasm of overlapping sites of bronchus and lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.9	Malignant neoplasm of unspecified part of bronchus or lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C37	Malignant neoplasm of thymus
C38	Malignant neoplasm of heart, mediastinum and pleura
C38.0	Malignant neoplasm of heart
C38.1	Malignant neoplasm of anterior mediastinum
C38.2	Malignant neoplasm of posterior mediastinum
C38.3	Malignant neoplasm of mediastinum, part unspecified
C38.4	Malignant neoplasm of pleura
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
C39	Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified
C40	Malignant neoplasm of bone and articular cartilage of limbs
C40.0	Malignant neoplasm of scapula and long bones of upper limb
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb
C40.01	Malignant neoplasm of scapula and long bones of right upper limb
C40.02	Malignant neoplasm of scapula and long bones of left upper limb
C40.1	Malignant neoplasm of short bones of upper limb
C40.10	Malignant neoplasm of short bones of unspecified upper limb
C40.11	Malignant neoplasm of short bones of right upper limb
C40.12	Malignant neoplasm of short bones of left upper limb
C40.2	Malignant neoplasm of long bones of lower limb
C40.20	Malignant neoplasm of long bones of unspecified lower limb
C40.21	Malignant neoplasm of long bones of right lower limb
C40.22	Malignant neoplasm of long bones of left lower limb
C40.3	Malignant neoplasm of short bones of lower limb
C40.30	Malignant neoplasm of short bones of unspecified lower limb
C40.31	Malignant neoplasm of short bones of right lower limb
C40.32	Malignant neoplasm of short bones of left lower limb
C40.8	Malignant neoplasm of overlapping sites of bone and articular cartilage of
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb

C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb
C40.9	Malignant neoplasm of unspecified bones and articular cartilage of limb
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb
C41	Malignant neoplasm of bone and articular cartilage of other and unspecified sites
C41.0	Malignant neoplasm of bones of skull and face
C41.1	Malignant neoplasm of mandible
C41.2	Malignant neoplasm of vertebral column
C41.3	Malignant neoplasm of ribs, sternum and clavicle
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified
C43	Malignant melanoma of skin
C43.0	Malignant melanoma of lip
C43.1	Malignant melanoma of eyelid, including canthus
C43.10	Malignant melanoma of unspecified eyelid, including canthus
C43.11	Malignant melanoma of right eyelid, including canthus
C43.111	Malignant melanoma of right upper eyelid, including canthus
C43.112	Malignant melanoma of right lower eyelid, including canthus
C43.12	Malignant melanoma of left eyelid, including canthus
C43.121	Malignant melanoma of left upper eyelid, including canthus
C43.122	Malignant melanoma of left lower eyelid, including canthus
C43.2	Malignant melanoma of ear and external auricular canal
C43.20	Malignant melanoma of unspecified ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.22	Malignant melanoma of left ear and external auricular canal
C43.3	Malignant melanoma of other and unspecified parts of face
C43.30	Malignant melanoma of unspecified part of face
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.4	Malignant melanoma of scalp and neck
C43.5	Malignant melanoma of trunk
C43.51	Malignant melanoma of anal skin
C43.52	Malignant melanoma of skin of breast
C43.59	Malignant melanoma of other part of trunk
C43.6	Malignant melanoma of upper limb, including shoulder
C43.60	Malignant melanoma of unspecified upper limb, including shoulder

C43.61	Malignant melanoma of right upper limb, including shoulder
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.7	Malignant melanoma of lower limb, including hip
C43.70	Malignant melanoma of unspecified lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.72	Malignant melanoma of left lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
C43.9	Malignant melanoma of skin, unspecified
C44.00	Unspecified malignant neoplasm of skin of lip
C44.09	Other specified malignant neoplasm of skin of lip
C44.10	Unspecified malignant neoplasm of skin of eyelid, including canthus
C44.101	Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus
C44.102	Unspecified malignant neoplasm of skin of right eyelid, including canthus
C44.1021	Unspecified malignant neoplasm of skin of right upper eyelid, including canthus
C44.1022	Unspecified malignant neoplasm of skin of right lower eyelid, including canthus
C44.109	Unspecified malignant neoplasm of skin of left eyelid, including canthus
C44.1091	Unspecified malignant neoplasm of skin of left upper eyelid, including canthus
C44.1092	Unspecified malignant neoplasm of skin of left lower eyelid, including canthus
C44.13	Sebaceous cell carcinoma of skin of eyelid, including canthus
C44.131	Sebaceous cell carcinoma of skin of unspecified eyelid, including canthus
C44.132	Sebaceous cell carcinoma of skin of right eyelid, including canthus
C44.1321	Sebaceous cell carcinoma of skin of right upper eyelid, including canthus
C44.1322	Sebaceous cell carcinoma of skin of right lower eyelid, including canthus
C44.139	Sebaceous cell carcinoma of skin of left eyelid, including canthus
C44.1391	Sebaceous cell carcinoma of skin of left upper eyelid, including canthus
C44.1392	Sebaceous cell carcinoma of skin of left lower eyelid, including canthus
C44.19	Other specified malignant neoplasm of skin of eyelid, including canthus
C44.191	Other specified malignant neoplasm of skin of unspecified eyelid, including canthus
C44.192	Other specified malignant neoplasm of skin of right eyelid, including canthus
C44.1921	Other specified malignant neoplasm of skin of right upper eyelid, including canthus
C44.1922	Other specified malignant neoplasm of skin of right lower eyelid, including canthus
C44.199	Other specified malignant neoplasm of skin of left eyelid, including canthus
C44.1991	Other specified malignant neoplasm of skin of left upper eyelid, including canthus
C44.1992	Other specified malignant neoplasm of skin of left lower eyelid, including canthus
C44.20	Unspecified malignant neoplasm of skin of ear and external auricular canal
C44.201	Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal

C44.202	Unspecified malignant neoplasm of skin of right ear and external auricular canal
C44.209	Unspecified malignant neoplasm of skin of left ear and external auricular canal
C44.29	Other specified malignant neoplasm of skin of ear and external auricular canal
C44.291	Other specified malignant neoplasm of skin of unspecified ear and external auricular canal
C44.292	Other specified malignant neoplasm of skin of right ear and external auricular canal
C44.299	Other specified malignant neoplasm of skin of left ear and external auricular canal
C44.30	Unspecified malignant neoplasm of skin of other and unspecified parts of face
C44.300	Unspecified malignant neoplasm of skin of unspecified part of face
C44.301	Unspecified malignant neoplasm of skin of nose
C44.309	Unspecified malignant neoplasm of skin of other parts of face
C44.39	Other specified malignant neoplasm of skin of other and unspecified parts of face
C44.390	Other specified malignant neoplasm of skin of unspecified parts of face
C44.391	Other specified malignant neoplasm of skin of nose
C44.399	Other specified malignant neoplasm of skin of other parts of face
C44.40	Unspecified malignant neoplasm of skin of scalp and neck
C44.49	Other specified malignant neoplasm of skin of scalp and neck
C44.50	Unspecified malignant neoplasm of skin of trunk
C44.500	Unspecified malignant neoplasm of anal skin
C44.501	Unspecified malignant neoplasm of skin of breast
C44.509	Unspecified malignant neoplasm of skin of other part of trunk
C44.59	Other specified malignant neoplasm of skin of trunk
C44.590	Other specified malignant neoplasm of anal skin
C44.591	Other specified malignant neoplasm of skin of breast
C44.599	Other specified malignant neoplasm of skin of other part of trunk
C44.60	Unspecified malignant neoplasm of skin of upper limb, including shoulder
C44.601	Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder
C44.602	Unspecified malignant neoplasm of skin of right upper limb, including shoulder
C44.609	Unspecified malignant neoplasm of skin of left upper limb, including shoulder
C44.69	Other specified malignant neoplasm of skin of upper limb, including shoulder
C44.691	Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder
C44.692	Other specified malignant neoplasm of skin of right upper limb, including shoulder
C44.699	Other specified malignant neoplasm of skin of left upper limb, including shoulder
C44.70	Unspecified malignant neoplasm of skin of lower limb, including hip
C44.701	Unspecified malignant neoplasm of skin of unspecified lower limb, including hip

C44.702	Unspecified malignant neoplasm of skin of right lower limb, including hip
C44.709	Unspecified malignant neoplasm of skin of left lower limb, including hip
C44.79	Other specified malignant neoplasm of skin of lower limb, including hip
C44.791	Other specified malignant neoplasm of skin of unspecified lower limb, including hip
C44.792	Other specified malignant neoplasm of skin of right lower limb, including hip
C44.799	Other specified malignant neoplasm of skin of left lower limb, including hip
C44.80	Unspecified malignant neoplasm of overlapping sites of skin
C44.89	Other specified malignant neoplasm of overlapping sites of skin
C44.90	Unspecified malignant neoplasm of skin, unspecified
C44.99	Other specified malignant neoplasm of skin, unspecified
C45	Mesothelioma
C45.0	Mesothelioma of pleura
C45.1	Mesothelioma of peritoneum
C45.2	Mesothelioma of pericardium
C45.7	Mesothelioma of other sites
C45.9	Mesothelioma, unspecified
C46	Kaposi's sarcoma
C46.0	Kaposi's sarcoma of skin
C46.1	Kaposi's sarcoma of soft tissue
C46.2	Kaposi's sarcoma of palate
C46.3	Kaposi's sarcoma of lymph nodes
C46.4	Kaposi's sarcoma of gastrointestinal sites
C46.5	Kaposi's sarcoma of lung
C46.50	Kaposi's sarcoma of unspecified lung
C46.51	Kaposi's sarcoma of right lung
C46.52	Kaposi's sarcoma of left lung
C46.7	Kaposi's sarcoma of other sites
C46.9	Kaposi's sarcoma, unspecified
C47	Malignant neoplasm of peripheral nerves and autonomic nervous system
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C47.1	Malignant neoplasm of peripheral nerves of upper limb, including shoulder
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.2	Malignant neoplasm of peripheral nerves of lower limb, including hip
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip

C47.3	Malignant neoplasm of peripheral nerves of thorax
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48	Malignant neoplasm of retroperitoneum and peritoneum
C48.0	Malignant neoplasm of retroperitoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49	Malignant neoplasm of other connective and soft tissue
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.1	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.2	Malignant neoplasm of connective and soft tissue of lower limb, including hip
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C49.A	Gastrointestinal stromal tumor
C49.A0	Gastrointestinal stromal tumor, unspecified site
C49.A1	Gastrointestinal stromal tumor, of esophagus
C49.A2	Gastrointestinal stromal tumor, of stomach
C49.A3	Gastrointestinal stromal tumor, of small intestine
C49.A4	Gastrointestinal stromal tumor, of large intestine
C49.A5	Gastrointestinal stromal tumor, of rectum

C49.A9	Gastrointestinal stromal tumor, of other sites
C4A	Merkel cell carcinoma
C4A.0	Merkel cell carcinoma of lip
C4A.1	Merkel cell carcinoma of eyelid, including canthus
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus
C4A.11	Merkel cell carcinoma of right eyelid, including canthus
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus
C4A.12	Merkel cell carcinoma of left eyelid, including canthus
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus
C4A.2	Merkel cell carcinoma of ear and external auricular canal
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal
C4A.21	Merkel cell carcinoma of right ear and external auricular canal
C4A.22	Merkel cell carcinoma of left ear and external auricular canal
C4A.3	Merkel cell carcinoma of other and unspecified parts of face
C4A.30	Merkel cell carcinoma of unspecified part of face
C4A.31	Merkel cell carcinoma of nose
C4A.39	Merkel cell carcinoma of other parts of face
C4A.4	Merkel cell carcinoma of scalp and neck
C4A.5	Merkel cell carcinoma of trunk
C4A.51	Merkel cell carcinoma of anal skin
C4A.52	Merkel cell carcinoma of skin of breast
C4A.59	Merkel cell carcinoma of other part of trunk
C4A.6	Merkel cell carcinoma of upper limb, including shoulder
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder
C4A.7	Merkel cell carcinoma of lower limb, including hip
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip
C4A.71	Merkel cell carcinoma of right lower limb, including hip
C4A.72	Merkel cell carcinoma of left lower limb, including hip
C4A.8	Merkel cell carcinoma of overlapping sites
C4A.9	Merkel cell carcinoma, unspecified
C50	Malignant neoplasm of breast
C50.0	Malignant neoplasm of nipple and areola
C50.01	Malignant neoplasm of nipple and areola, female
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.02	Malignant neoplasm of nipple and areola, male



C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.1	Malignant neoplasm of central portion of breast
C50.11	Malignant neoplasm of central portion of breast, female
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.12	Malignant neoplasm of central portion of breast, male
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.2	Malignant neoplasm of upper-inner quadrant of breast
C50.21	Malignant neoplasm of upper-inner quadrant of breast, female
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.22	Malignant neoplasm of upper-inner quadrant of breast, male
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.3	Malignant neoplasm of lower-inner quadrant of breast
C50.31	Malignant neoplasm of lower-inner quadrant of breast, female
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.32	Malignant neoplasm of lower-inner quadrant of breast, male
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.4	Malignant neoplasm of upper-outer quadrant of breast
C50.41	Malignant neoplasm of upper-outer quadrant of breast, female
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.42	Malignant neoplasm of upper-outer quadrant of breast, male
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
C50.5	Malignant neoplasm of lower-outer quadrant of breast
C50.51	Malignant neoplasm of lower-outer quadrant of breast, female

C50.511	Malignant neoplasm of lower outer quadrant of right female breast
C50.512	Malignant neoplasm of lower outer quadrant of left female breast
C50.519	Malignant neoplasm of lower outer quadrant of unspecified female breast
C50.52	Malignant neoplasm of lower outer quadrant of breast, male
C50.521	Malignant neoplasm of lower outer quadrant of right male breast
C50.522	Malignant neoplasm of lower outer quadrant of left male breast
C50.529	Malignant neoplasm of lower outer quadrant of unspecified male breast
C50.6	Malignant neoplasm of axillary tail of breast
C50.61	Malignant neoplasm of axillary tail of breast, female
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.62	Malignant neoplasm of axillary tail of breast, male
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.8	Malignant neoplasm of overlapping sites of breast
C50.81	Malignant neoplasm of overlapping sites of breast, female
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.82	Malignant neoplasm of overlapping sites of breast, male
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.9	Malignant neoplasm of breast of unspecified site
C50.91	Malignant neoplasm of breast of unspecified site, female
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.92	Malignant neoplasm of breast of unspecified site, male
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C51	Malignant neoplasm of vulva
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C51.9	Malignant neoplasm of vulva, unspecified
C52	Malignant neoplasm of vagina

C53	Malignant neoplasm of cervix uteri
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri
C53.9	Malignant neoplasm of cervix uteri, unspecified
C54	Malignant neoplasm of corpus uteri
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C56	Malignant neoplasm of ovary
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.9	Malignant neoplasm of unspecified ovary
C57	Malignant neoplasm of other and unspecified female genital organs
C57.0	Malignant neoplasm of fallopian tube
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.02	Malignant neoplasm of left fallopian tube
C57.1	Malignant neoplasm of broad ligament
C57.10	Malignant neoplasm of unspecified broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.12	Malignant neoplasm of left broad ligament
C57.2	Malignant neoplasm of round ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.21	Malignant neoplasm of right round ligament
C57.22	Malignant neoplasm of left round ligament
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C57.9	Malignant neoplasm of female genital organ, unspecified
C58	Malignant neoplasm of placenta
C60	Malignant neoplasm of penis
C60.0	Malignant neoplasm of prepuce
C60.1	Malignant neoplasm of glans penis
C60.2	Malignant neoplasm of body of penis
C60.8	Malignant neoplasm of overlapping sites of penis

C60.9	Malignant neoplasm of penis, unspecified
C61	Malignant neoplasm of prostate
C62	Malignant neoplasm of testis
C62.0	Malignant neoplasm of undescended testis
C62.00	Malignant neoplasm of unspecified undescended testis
C62.01	Malignant neoplasm of undescended right testis
C62.02	Malignant neoplasm of undescended left testis
C62.1	Malignant neoplasm of descended testis
C62.10	Malignant neoplasm of unspecified descended testis
C62.11	Malignant neoplasm of descended right testis
C62.12	Malignant neoplasm of descended left testis
C62.9	Malignant neoplasm of testis, unspecified whether descended or undescended
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended
C63	Malignant neoplasm of other and unspecified male genital organs
C63.0	Malignant neoplasm of epididymis
C63.00	Malignant neoplasm of unspecified epididymis
C63.01	Malignant neoplasm of right epididymis
C63.02	Malignant neoplasm of left epididymis
C63.1	Malignant neoplasm of spermatic cord
C63.10	Malignant neoplasm of unspecified spermatic cord
C63.11	Malignant neoplasm of right spermatic cord
C63.12	Malignant neoplasm of left spermatic cord
C63.2	Malignant neoplasm of scrotum
C63.7	Malignant neoplasm of other specified male genital organs
C63.8	Malignant neoplasm of overlapping sites of male genital organs
C63.9	Malignant neoplasm of male genital organ, unspecified
C64	Malignant neoplasm of kidney, except renal pelvis
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65	Malignant neoplasm of renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66	Malignant neoplasm of ureter
C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter

C66.9	Malignant neoplasm of unspecified ureter
C67	Malignant neoplasm of bladder
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C68	Malignant neoplasm of other and unspecified urinary organs
C68.0	Malignant neoplasm of urethra
C68.1	Malignant neoplasm of paraurethral glands
C68.8	Malignant neoplasm of overlapping sites of urinary organs
C68.9	Malignant neoplasm of urinary organ, unspecified
C69	Malignant neoplasm of eye and adnexa
C69.0	Malignant neoplasm of conjunctiva
C69.00	Malignant neoplasm of unspecified conjunctiva
C69.01	Malignant neoplasm of right conjunctiva
C69.02	Malignant neoplasm of left conjunctiva
C69.1	Malignant neoplasm of cornea
C69.10	Malignant neoplasm of unspecified cornea
C69.11	Malignant neoplasm of right cornea
C69.12	Malignant neoplasm of left cornea
C69.2	Malignant neoplasm of retina
C69.20	Malignant neoplasm of unspecified retina
C69.21	Malignant neoplasm of right retina
C69.22	Malignant neoplasm of left retina
C69.3	Malignant neoplasm of choroid
C69.30	Malignant neoplasm of unspecified choroid
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid
C69.4	Malignant neoplasm of ciliary body
C69.40	Malignant neoplasm of unspecified ciliary body
C69.41	Malignant neoplasm of right ciliary body
C69.42	Malignant neoplasm of left ciliary body
C69.5	Malignant neoplasm of lacrimal gland and duct
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct
C69.51	Malignant neoplasm of right lacrimal gland and duct

C69.52	Malignant neoplasm of left lacrimal gland and duct
C69.6	Malignant neoplasm of orbit
C69.60	Malignant neoplasm of unspecified orbit
C69.61	Malignant neoplasm of right orbit
C69.62	Malignant neoplasm of left orbit
C69.8	Malignant neoplasm of overlapping sites of eye and adnexa
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa
C69.9	Malignant neoplasm of unspecified site of eye
C69.90	Malignant neoplasm of unspecified site of unspecified eye
C69.91	Malignant neoplasm of unspecified site of right eye
C69.92	Malignant neoplasm of unspecified site of left eye
C70	Malignant neoplasm of meninges
C70.0	Malignant neoplasm of cerebral meninges
C70.1	Malignant neoplasm of spinal meninges
C70.9	Malignant neoplasm of meninges, unspecified
C71	Malignant neoplasm of brain
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified
C72	Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system
C72.0	Malignant neoplasm of spinal cord
C72.1	Malignant neoplasm of cauda equina
C72.2	Malignant neoplasm of olfactory nerve
C72.20	Malignant neoplasm of unspecified olfactory nerve
C72.21	Malignant neoplasm of right olfactory nerve
C72.22	Malignant neoplasm of left olfactory nerve
C72.3	Malignant neoplasm of optic nerve
C72.30	Malignant neoplasm of unspecified optic nerve
C72.31	Malignant neoplasm of right optic nerve
C72.32	Malignant neoplasm of left optic nerve
C72.4	Malignant neoplasm of acoustic nerve
C72.40	Malignant neoplasm of unspecified acoustic nerve

C72.41	Malignant neoplasm of right acoustic nerve
C72.42	Malignant neoplasm of left acoustic nerve
C72.5	Malignant neoplasm of other and unspecified cranial nerves
C72.50	Malignant neoplasm of unspecified cranial nerve
C72.59	Malignant neoplasm of other cranial nerves
C72.9	Malignant neoplasm of central nervous system, unspecified
C73	Malignant neoplasm of thyroid gland
C74	Malignant neoplasm of adrenal gland
C74.0	Malignant neoplasm of cortex of adrenal gland
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland
C74.01	Malignant neoplasm of cortex of right adrenal gland
C74.02	Malignant neoplasm of cortex of left adrenal gland
C74.1	Malignant neoplasm of medulla of adrenal gland
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland
C74.11	Malignant neoplasm of medulla of right adrenal gland
C74.12	Malignant neoplasm of medulla of left adrenal gland
C74.9	Malignant neoplasm of unspecified part of adrenal gland
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland
C74.91	Malignant neoplasm of unspecified part of right adrenal gland
C74.92	Malignant neoplasm of unspecified part of left adrenal gland
C75	Malignant neoplasm of other endocrine glands and related structures
C75.0	Malignant neoplasm of parathyroid gland
C75.1	Malignant neoplasm of pituitary gland
C75.2	Malignant neoplasm of craniopharyngeal duct
C75.3	Malignant neoplasm of pineal gland
C75.4	Malignant neoplasm of carotid body
C75.5	Malignant neoplasm of aortic body and other paraganglia
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified
C75.9	Malignant neoplasm of endocrine gland, unspecified
C76	Malignant neoplasm of other and ill-defined sites
C76.0	Malignant neoplasm of head, face and neck
C76.1	Malignant neoplasm of thorax
C76.2	Malignant neoplasm of abdomen
C76.3	Malignant neoplasm of pelvis
C76.4	Malignant neoplasm of upper limb
C76.40	Malignant neoplasm of unspecified upper limb
C76.41	Malignant neoplasm of right upper limb
C76.42	Malignant neoplasm of left upper limb
C76.5	Malignant neoplasm of lower limb
C76.50	Malignant neoplasm of unspecified lower limb
C76.51	Malignant neoplasm of right lower limb

C76.52	Malignant neoplasm of left lower limb
C76.8	Malignant neoplasm of other specified ill-defined sites
C77	Secondary and unspecified malignant neoplasm of lymph nodes
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78	Secondary malignant neoplasm of respiratory and digestive organs
C78.0	Secondary malignant neoplasm of lung
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura
C78.3	Secondary malignant neoplasm of other and unspecified respiratory organs
C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C78.39	Secondary malignant neoplasm of other respiratory organs
C78.4	Secondary malignant neoplasm of small intestine
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.8	Secondary malignant neoplasm of other and unspecified digestive organs
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C78.89	Secondary malignant neoplasm of other digestive organs
C79	Secondary malignant neoplasm of other and unspecified sites
C79.0	Secondary malignant neoplasm of kidney and renal pelvis
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
C79.1	Secondary malignant neoplasm of bladder and other and unspecified urinary organs
C79.10	Secondary malignant neoplasm of unspecified urinary organs
C79.11	Secondary malignant neoplasm of bladder
C79.19	Secondary malignant neoplasm of other urinary organs



C79.2	Secondary malignant neoplasm of skin
C79.3	Secondary malignant neoplasm of brain and cerebral meninges
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of cerebral meninges
C79.4	Secondary malignant neoplasm of other and unspecified parts of nervous system
C79.40	Secondary malignant neoplasm of unspecified part of nervous system
C79.49	Secondary malignant neoplasm of other parts of nervous system
C79.5	Secondary malignant neoplasm of bone and bone marrow
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C79.6	Secondary malignant neoplasm of ovary
C79.60	Secondary malignant neoplasm of unspecified ovary
C79.61	Secondary malignant neoplasm of right ovary
C79.62	Secondary malignant neoplasm of left ovary
C79.7	Secondary malignant neoplasm of adrenal gland
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C79.71	Secondary malignant neoplasm of right adrenal gland
C79.72	Secondary malignant neoplasm of left adrenal gland
C79.8	Secondary malignant neoplasm of other specified sites
C79.81	Secondary malignant neoplasm of breast
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site
C7A	Malignant neuroendocrine tumors
C7A.0	Malignant carcinoid tumors
C7A.00	Malignant carcinoid tumor of unspecified site
C7A.01	Malignant carcinoid tumors of the small intestine
C7A.010	Malignant carcinoid tumor of the duodenum
C7A.011	Malignant carcinoid tumor of the jejunum
C7A.012	Malignant carcinoid tumor of the ileum
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.02	Malignant carcinoid tumors of the appendix, large intestine, and rectum
C7A.020	Malignant carcinoid tumor of the appendix
C7A.021	Malignant carcinoid tumor of the cecum
C7A.022	Malignant carcinoid tumor of the ascending colon
C7A.023	Malignant carcinoid tumor of the transverse colon
C7A.024	Malignant carcinoid tumor of the descending colon
C7A.025	Malignant carcinoid tumor of the sigmoid colon
C7A.026	Malignant carcinoid tumor of the rectum
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.09	Malignant carcinoid tumors of other sites

C7A.090	Malignant carcinoid tumor of the bronchus and lung
C7A.091	Malignant carcinoid tumor of the thymus
C7A.092	Malignant carcinoid tumor of the stomach
C7A.093	Malignant carcinoid tumor of the kidney
C7A.094	Malignant carcinoid tumor of the foregut, unspecified
C7A.095	Malignant carcinoid tumor of the midgut, unspecified
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified
C7A.098	Malignant carcinoid tumors of other sites
C7A.1	Malignant poorly differentiated neuroendocrine tumors
C7A.8	Other malignant neuroendocrine tumors
C7B	Secondary neuroendocrine tumors
C7B.0	Secondary carcinoid tumors
C7B.00	Secondary carcinoid tumors unspecified site
C7B.01	Secondary carcinoid tumors of distant lymph nodes
C7B.02	Secondary carcinoid tumors of liver
C7B.03	Secondary carcinoid tumors of bone
C7B.04	Secondary carcinoid tumors of peritoneum
C7B.09	Secondary carcinoid tumors of other sites
C7B.1	Secondary Merkel cell carcinoma
C7B.8	Other secondary neuroendocrine tumors
C80	Malignant neoplasm without specification of site
C80.0	Disseminated malignant neoplasm, unspecified
C80.1	Malignant (primary) neoplasm, unspecified
C80.2	Malignant neoplasm associated with transplanted organ
C81	Hodgkin lymphoma
C81.0	Nodular lymphocyte predominant Hodgkin lymphoma
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma unspecified site
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of head, face, and neck
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma intrathoracic lymph nodes
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma intra-abdominal lymph nodes
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of axilla and upper limb
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma intrapelvic lymph nodes
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma spleen
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma lymph nodes of multiple sites
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma extranodal and solid organ sites

C81.1	Nodular sclerosis Hodgkin lymphoma
C81.10	Nodular sclerosis Hodgkin lymphoma unspecified site
C81.11	Nodular sclerosis Hodgkin lymphoma lymph nodes of head, face, and neck
C81.12	Nodular sclerosis Hodgkin lymphoma intrathoracic lymph nodes
C81.13	Nodular sclerosis Hodgkin lymphoma intra-abdominal lymph nodes
C81.14	Nodular sclerosis Hodgkin lymphoma lymph nodes of axilla and upper limb
C81.15	Nodular sclerosis Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis Hodgkin lymphoma intrapelvic lymph nodes
C81.17	Nodular sclerosis Hodgkin lymphoma spleen
C81.18	Nodular sclerosis Hodgkin lymphoma lymph nodes of multiple sites
C81.19	Nodular sclerosis Hodgkin lymphoma extranodal and solid organ sites
C81.2	Mixed-cellularity Hodgkin lymphoma
C81.20	Mixed-cellularity Hodgkin lymphoma unspecified site
C81.21	Mixed-cellularity Hodgkin lymphoma lymph nodes of head, face, and neck
C81.22	Mixed-cellularity Hodgkin lymphoma intrathoracic lymph nodes
C81.23	Mixed-cellularity Hodgkin lymphoma intra-abdominal lymph nodes
C81.24	Mixed-cellularity Hodgkin lymphoma lymph nodes of axilla and upper limb
C81.25	Mixed-cellularity Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.26	Mixed-cellularity Hodgkin lymphoma intrapelvic lymph nodes
C81.27	Mixed-cellularity Hodgkin lymphoma spleen
C81.28	Mixed-cellularity Hodgkin lymphoma lymph nodes of multiple sites
C81.29	Mixed-cellularity Hodgkin lymphoma extranodal and solid organ sites
C81.3	Lymphocyte depleted Hodgkin lymphoma
C81.30	Lymphocyte depleted Hodgkin lymphoma unspecified site
C81.31	Lymphocyte depleted Hodgkin lymphoma lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted Hodgkin lymphoma intrathoracic lymph nodes
C81.33	Lymphocyte depleted Hodgkin lymphoma intra-abdominal lymph nodes
C81.34	Lymphocyte depleted Hodgkin lymphoma lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted Hodgkin lymphoma intrapelvic lymph nodes
C81.37	Lymphocyte depleted Hodgkin lymphoma spleen
C81.38	Lymphocyte depleted Hodgkin lymphoma lymph nodes of multiple sites
C81.39	Lymphocyte depleted Hodgkin lymphoma extranodal and solid organ sites
C81.4	Lymphocyte rich Hodgkin lymphoma
C81.40	Lymphocyte rich Hodgkin lymphoma unspecified site
C81.41	Lymphocyte rich Hodgkin lymphoma lymph nodes of head, face, and neck
C81.42	Lymphocyte rich Hodgkin lymphoma intrathoracic lymph nodes
C81.43	Lymphocyte rich Hodgkin lymphoma intra-abdominal lymph nodes
C81.44	Lymphocyte rich Hodgkin lymphoma lymph nodes of axilla and upper limb

C81.45	Lymphocyte-rich Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich Hodgkin lymphoma intrapelvic lymph nodes
C81.47	Lymphocyte-rich Hodgkin lymphoma spleen
C81.48	Lymphocyte-rich Hodgkin lymphoma lymph nodes of multiple sites
C81.49	Lymphocyte-rich Hodgkin lymphoma extranodal and solid organ sites
C81.7	Other Hodgkin lymphoma
C81.70	Other Hodgkin lymphoma unspecified site
C81.71	Other Hodgkin lymphoma lymph nodes of head, face, and neck
C81.72	Other Hodgkin lymphoma intrathoracic lymph nodes
C81.73	Other Hodgkin lymphoma intra-abdominal lymph nodes
C81.74	Other Hodgkin lymphoma lymph nodes of axilla and upper limb
C81.75	Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.76	Other Hodgkin lymphoma intrapelvic lymph nodes
C81.77	Other Hodgkin lymphoma spleen
C81.78	Other Hodgkin lymphoma lymph nodes of multiple sites
C81.79	Other Hodgkin lymphoma extranodal and solid organ sites
C81.9	Hodgkin lymphoma, unspecified
C81.90	Hodgkin lymphoma, unspecified, unspecified site
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C81.97	Hodgkin lymphoma, unspecified, spleen
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C82	Follicular lymphoma
C82.0	Follicular lymphoma grade I
C82.00	Follicular lymphoma grade I unspecified site
C82.01	Follicular lymphoma grade I lymph nodes of head, face, and neck
C82.02	Follicular lymphoma grade I intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I lymph nodes of inguinal region and lower limb
C82.06	Follicular lymphoma grade I intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I spleen
C82.08	Follicular lymphoma grade I lymph nodes of multiple sites
C82.09	Follicular lymphoma grade I extranodal and solid organ sites
C82.1	Follicular lymphoma grade II

C82.10	Follicular lymphoma grade II unspecified site
C82.11	Follicular lymphoma grade II lymph nodes of head, face, and neck
C82.12	Follicular lymphoma grade II intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II lymph nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade II intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II spleen
C82.18	Follicular lymphoma grade II lymph nodes of multiple sites
C82.19	Follicular lymphoma grade II extranodal and solid organ sites
C82.2	Follicular lymphoma grade III, unspecified
C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
C82.3	Follicular lymphoma grade IIIa
C82.30	Follicular lymphoma grade IIIa unspecified site
C82.31	Follicular lymphoma grade IIIa lymph nodes of head, face, and neck
C82.32	Follicular lymphoma grade IIIa intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa spleen
C82.38	Follicular lymphoma grade IIIa lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIIa extranodal and solid organ sites
C82.4	Follicular lymphoma grade IIIb
C82.40	Follicular lymphoma grade IIIb unspecified site
C82.41	Follicular lymphoma grade IIIb lymph nodes of head, face, and neck
C82.42	Follicular lymphoma grade IIIb intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb intrapelvic lymph nodes

C82.47	Follicular lymphoma-grade IIIb-spleen
C82.48	Follicular lymphoma-grade IIIb-lymph nodes of multiple sites
C82.49	Follicular lymphoma-grade IIIb-extranodal and solid organ sites
C82.5	Diffuse follicle center lymphoma
C82.50	Diffuse follicle center lymphoma-unspecified site
C82.51	Diffuse follicle center lymphoma-lymph nodes of head, face, and neck
C82.52	Diffuse follicle center lymphoma-intrathoracic lymph nodes
C82.53	Diffuse follicle center lymphoma-intra-abdominal lymph nodes
C82.54	Diffuse follicle center lymphoma-lymph nodes of axilla and upper limb
C82.55	Diffuse follicle center lymphoma-lymph nodes of inguinal region and lower limb
C82.56	Diffuse follicle center lymphoma-intrapelvic lymph nodes
C82.57	Diffuse follicle center lymphoma-spleen
C82.58	Diffuse follicle center lymphoma-lymph nodes of multiple sites
C82.59	Diffuse follicle center lymphoma-extranodal and solid organ sites
C82.6	Cutaneous follicle center lymphoma
C82.60	Cutaneous follicle center lymphoma-unspecified site
C82.61	Cutaneous follicle center lymphoma-lymph nodes of head, face, and neck
C82.62	Cutaneous follicle center lymphoma-intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma-intra-abdominal lymph nodes
C82.64	Cutaneous follicle center lymphoma-lymph nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma-lymph nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma-intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma-spleen
C82.68	Cutaneous follicle center lymphoma-lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma-extranodal and solid organ sites
C82.8	Other types of follicular lymphoma
C82.80	Other types of follicular lymphoma-unspecified site
C82.81	Other types of follicular lymphoma-lymph nodes of head, face, and neck
C82.82	Other types of follicular lymphoma-intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma-intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma-lymph nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma-lymph nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma-intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma-spleen
C82.88	Other types of follicular lymphoma-lymph nodes of multiple sites
C82.89	Other types of follicular lymphoma-extranodal and solid organ sites
C82.9	Follicular lymphoma, unspecified
C82.90	Follicular lymphoma, unspecified unspecified site
C82.91	Follicular lymphoma, unspecified lymph nodes of head, face, and neck
C82.92	Follicular lymphoma, unspecified intrathoracic lymph nodes

C82.93	Follicular lymphoma, unspecified intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified lymph nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified lymph nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified intrapelvic lymph nodes
C82.97	Follicular lymphoma, unspecified spleen
C82.98	Follicular lymphoma, unspecified lymph nodes of multiple sites
C82.99	Follicular lymphoma, unspecified extranodal and solid organ sites
C83	Non-follicular lymphoma
C83.0	Small cell B-cell lymphoma
C83.00	Small cell B-cell lymphoma unspecified site
C83.01	Small cell B-cell lymphoma lymph nodes of head, face, and neck
C83.02	Small cell B-cell lymphoma intrathoracic lymph nodes
C83.03	Small cell B-cell lymphoma intra-abdominal lymph nodes
C83.04	Small cell B-cell lymphoma lymph nodes of axilla and upper limb
C83.05	Small cell B-cell lymphoma lymph nodes of inguinal region and lower limb
C83.06	Small cell B-cell lymphoma intrapelvic lymph nodes
C83.07	Small cell B-cell lymphoma spleen
C83.08	Small cell B-cell lymphoma lymph nodes of multiple sites
C83.09	Small cell B-cell lymphoma extranodal and solid organ sites
C83.1	Mantle cell lymphoma
C83.10	Mantle cell lymphoma unspecified site
C83.11	Mantle cell lymphoma lymph nodes of head, face, and neck
C83.12	Mantle cell lymphoma intrathoracic lymph nodes
C83.13	Mantle cell lymphoma intra-abdominal lymph nodes
C83.14	Mantle cell lymphoma lymph nodes of axilla and upper limb
C83.15	Mantle cell lymphoma lymph nodes of inguinal region and lower limb
C83.16	Mantle cell lymphoma intrapelvic lymph nodes
C83.17	Mantle cell lymphoma spleen
C83.18	Mantle cell lymphoma lymph nodes of multiple sites
C83.19	Mantle cell lymphoma extranodal and solid organ sites
C83.3	Diffuse large B-cell lymphoma
C83.30	Diffuse large B-cell lymphoma unspecified site
C83.31	Diffuse large B-cell lymphoma lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma spleen
C83.38	Diffuse large B-cell lymphoma lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma extranodal and solid organ sites

C83.5	Lymphoblastic (diffuse) lymphoma
C83.50	Lymphoblastic (diffuse) lymphoma unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma intra-abdominal lymph nodes
C83.54	Lymphoblastic (diffuse) lymphoma lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma spleen
C83.58	Lymphoblastic (diffuse) lymphoma lymph nodes of multiple sites
C83.59	Lymphoblastic (diffuse) lymphoma extranodal and solid organ sites
C83.7	Burkitt lymphoma
C83.70	Burkitt lymphoma unspecified site
C83.71	Burkitt lymphoma lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma intrathoracic lymph nodes
C83.73	Burkitt lymphoma intra-abdominal lymph nodes
C83.74	Burkitt lymphoma lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma lymph nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma intrapelvic lymph nodes
C83.77	Burkitt lymphoma spleen
C83.78	Burkitt lymphoma lymph nodes of multiple sites
C83.79	Burkitt lymphoma extranodal and solid organ sites
C83.8	Other non-follicular lymphoma
C83.80	Other non-follicular lymphoma unspecified site
C83.81	Other non-follicular lymphoma lymph nodes of head, face, and neck
C83.82	Other non-follicular lymphoma intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma lymph nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma lymph nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma spleen
C83.88	Other non-follicular lymphoma lymph nodes of multiple sites
C83.89	Other non-follicular lymphoma extranodal and solid organ sites
C83.9	Non-follicular (diffuse) lymphoma, unspecified
C83.90	Non-follicular (diffuse) lymphoma, unspecified unspecified site
C83.91	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck
C83.92	Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes
C83.93	Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes
C83.94	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb



C83.95	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb
C83.96	Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes
C83.97	Non-follicular (diffuse) lymphoma, unspecified spleen
C83.98	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites
C83.99	Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites
C84	Mature T/NK-cell lymphomas
C84.0	Mycosis fungoides
C84.00	Mycosis fungoides unspecified site
C84.01	Mycosis fungoides lymph nodes of head, face, and neck
C84.02	Mycosis fungoides intrathoracic lymph nodes
C84.03	Mycosis fungoides intra-abdominal lymph nodes
C84.04	Mycosis fungoides lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides intrapelvic lymph nodes
C84.07	Mycosis fungoides spleen
C84.08	Mycosis fungoides lymph nodes of multiple sites
C84.09	Mycosis fungoides extranodal and solid organ sites
C84.1	Sézary disease
C84.10	Sézary disease unspecified site
C84.11	Sézary disease lymph nodes of head, face, and neck
C84.12	Sézary disease intrathoracic lymph nodes
C84.13	Sézary disease intra-abdominal lymph nodes
C84.14	Sézary disease lymph nodes of axilla and upper limb
C84.15	Sézary disease lymph nodes of inguinal region and lower limb
C84.16	Sézary disease intrapelvic lymph nodes
C84.17	Sézary disease spleen
C84.18	Sézary disease lymph nodes of multiple sites
C84.19	Sézary disease extranodal and solid organ sites
C84.4	Peripheral T-cell lymphoma, not classified
C84.40	Peripheral T-cell lymphoma, not classified unspecified site
C84.41	Peripheral T-cell lymphoma, not classified lymph nodes of head, face, and neck
C84.42	Peripheral T-cell lymphoma, not classified intrathoracic lymph nodes
C84.43	Peripheral T-cell lymphoma, not classified intra-abdominal lymph nodes
C84.44	Peripheral T-cell lymphoma, not classified lymph nodes of axilla and upper limb
C84.45	Peripheral T-cell lymphoma, not classified lymph nodes of inguinal region and lower limb
C84.46	Peripheral T-cell lymphoma, not classified intrapelvic lymph nodes
C84.47	Peripheral T-cell lymphoma, not classified spleen
C84.48	Peripheral T-cell lymphoma, not classified lymph nodes of multiple sites
C84.49	Peripheral T-cell lymphoma, not classified extranodal and solid organ sites
C84.6	Anaplastic large cell lymphoma, ALK-positive

C84.60	Anaplastic large cell lymphoma, ALK-positive unspecified site
C84.61	Anaplastic large cell lymphoma, ALK-positive lymph nodes of head, face, and neck
C84.62	Anaplastic large cell lymphoma, ALK-positive intrathoracic lymph nodes
C84.63	Anaplastic large cell lymphoma, ALK-positive intra-abdominal lymph nodes
C84.64	Anaplastic large cell lymphoma, ALK-positive lymph nodes of axilla and upper limb
C84.65	Anaplastic large cell lymphoma, ALK-positive lymph nodes of inguinal region and lower limb
C84.66	Anaplastic large cell lymphoma, ALK-positive intrapelvic lymph nodes
C84.67	Anaplastic large cell lymphoma, ALK-positive spleen
C84.68	Anaplastic large cell lymphoma, ALK-positive lymph nodes of multiple sites
C84.69	Anaplastic large cell lymphoma, ALK-positive extranodal and solid organ sites
C84.7	Anaplastic large cell lymphoma, ALK-negative
C84.70	Anaplastic large cell lymphoma, ALK-negative unspecified site
C84.71	Anaplastic large cell lymphoma, ALK-negative lymph nodes of head, face, and neck
C84.72	Anaplastic large cell lymphoma, ALK-negative intrathoracic lymph nodes
C84.73	Anaplastic large cell lymphoma, ALK-negative intra-abdominal lymph nodes
C84.74	Anaplastic large cell lymphoma, ALK-negative lymph nodes of axilla and upper limb
C84.75	Anaplastic large cell lymphoma, ALK-negative lymph nodes of inguinal region and lower limb
C84.76	Anaplastic large cell lymphoma, ALK-negative intrapelvic lymph nodes
C84.77	Anaplastic large cell lymphoma, ALK-negative spleen
C84.78	Anaplastic large cell lymphoma, ALK-negative lymph nodes of multiple sites
C84.79	Anaplastic large cell lymphoma, ALK-negative extranodal and solid organ sites
C84.9	Mature T/NK cell lymphomas, unspecified
C84.90	Mature T/NK cell lymphomas, unspecified, unspecified site
C84.91	Mature T/NK cell lymphomas, unspecified, lymph nodes of head, face, and neck
C84.92	Mature T/NK cell lymphomas, unspecified, intrathoracic lymph nodes
C84.93	Mature T/NK cell lymphomas, unspecified, intra-abdominal lymph nodes
C84.94	Mature T/NK cell lymphomas, unspecified, lymph nodes of axilla and upper limb
C84.95	Mature T/NK cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb
C84.96	Mature T/NK cell lymphomas, unspecified, intrapelvic lymph nodes
C84.97	Mature T/NK cell lymphomas, unspecified, spleen
C84.98	Mature T/NK cell lymphomas, unspecified, lymph nodes of multiple sites
C84.99	Mature T/NK cell lymphomas, unspecified, extranodal and solid organ sites
C84.A	Cutaneous T-cell lymphoma, unspecified
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site

C84.A1	Cutaneous T-cell lymphoma, unspecified, lymph nodes of head, face, and neck
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites
C84.Z	Other mature T/NK-cell lymphomas
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84.Z7	Other mature T/NK-cell lymphomas, spleen
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C85	Other specified and unspecified types of non-Hodgkin lymphoma
C85.1	Unspecified B-cell lymphoma
C85.10	Unspecified B-cell lymphoma, unspecified site
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes
C85.17	Unspecified B-cell lymphoma, spleen
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites
C85.2	Mediastinal (thymic) large B-cell lymphoma
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb

C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.8	Other specified types of non-Hodgkin lymphoma
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C85.9	Non-Hodgkin lymphoma, unspecified
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C85.97	Non-Hodgkin lymphoma, unspecified, spleen
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C86	Other specified types of T/NK-cell lymphoma
C86.0	Extranodal NK/T-cell lymphoma, nasal type
C86.1	Hepatosplenic T-cell lymphoma
C86.2	Enteropathy type (intestinal) T-cell lymphoma
C86.3	Subcutaneous panniculitis-like T-cell lymphoma
C86.4	Blastic NK-cell lymphoma
C86.5	Angioimmunoblastic T-cell lymphoma
C86.6	Primary cutaneous CD30-positive T-cell proliferations
C88	Malignant immunoproliferative diseases and certain other B-cell lymphomas
C88.0	Waldenström macroglobulinemia

C88.2	Heavy-chain disease
C88.3	Immunoproliferative small-intestinal disease
C88.4	Extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT lymphoma]
C88.8	Other malignant immunoproliferative diseases
C88.9	Malignant immunoproliferative disease, unspecified
C90	Multiple myeloma and malignant plasma-cell neoplasms
C90.0	Multiple myeloma
C90.00	Multiple myeloma, not having achieved remission
C90.01	Multiple myeloma, in remission
C90.02	Multiple myeloma, in relapse
C90.1	Plasma-cell leukemia
C90.10	Plasma-cell leukemia, not having achieved remission
C90.11	Plasma-cell leukemia, in remission
C90.12	Plasma-cell leukemia, in relapse
C90.2	Extramedullary plasmacytoma
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.21	Extramedullary plasmacytoma in remission
C90.22	Extramedullary plasmacytoma in relapse
C90.3	Solitary plasmacytoma
C90.30	Solitary plasmacytoma, not having achieved remission
C90.31	Solitary plasmacytoma, in remission
C90.32	Solitary plasmacytoma, in relapse
C91	Lymphoid leukemia
C91.0	Acute lymphoblastic leukemia [ALL]
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse
C91.1	Chronic lymphocytic leukemia of B-cell type
C91.10	Chronic lymphocytic leukemia of B-cell type, not having achieved remission
C91.11	Chronic lymphocytic leukemia of B-cell type, in remission
C91.12	Chronic lymphocytic leukemia of B-cell type, in relapse
C91.3	Prolymphocytic leukemia of B-cell type
C91.30	Prolymphocytic leukemia of B-cell type, not having achieved remission
C91.31	Prolymphocytic leukemia of B-cell type, in remission
C91.32	Prolymphocytic leukemia of B-cell type, in relapse
C91.4	Hairy-cell leukemia
C91.40	Hairy-cell leukemia, not having achieved remission
C91.41	Hairy-cell leukemia, in remission
C91.42	Hairy-cell leukemia, in relapse
C91.5	Adult T-cell lymphoma/leukemia (HTLV-1-associated)

C91.50	Adult T-cell lymphoma/leukemia (HTLV-1 associated), not having achieved remission
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1 associated), in remission
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1 associated), in relapse
C91.6	Prolymphocytic leukemia of T-cell type
C91.60	Prolymphocytic leukemia of T-cell type, not having achieved remission
C91.61	Prolymphocytic leukemia of T-cell type, in remission
C91.62	Prolymphocytic leukemia of T-cell type, in relapse
C91.9	Lymphoid leukemia, unspecified
C91.90	Lymphoid leukemia, unspecified, not having achieved remission
C91.91	Lymphoid leukemia, unspecified, in remission
C91.92	Lymphoid leukemia, unspecified, in relapse
C91.A	Mature B-cell leukemia Burkitt type
C91.A0	Mature B-cell leukemia Burkitt type, not having achieved remission
C91.A1	Mature B-cell leukemia Burkitt type, in remission
C91.A2	Mature B-cell leukemia Burkitt type, in relapse
C91.Z	Other lymphoid leukemia
C91.Z0	Other lymphoid leukemia, not having achieved remission
C91.Z1	Other lymphoid leukemia, in remission
C91.Z2	Other lymphoid leukemia, in relapse
C92	Myeloid leukemia
C92.0	Acute myeloblastic leukemia
C92.00	Acute myeloblastic leukemia, not having achieved remission
C92.01	Acute myeloblastic leukemia, in remission
C92.02	Acute myeloblastic leukemia, in relapse
C92.1	Chronic myeloid leukemia, BCR/ABL positive
C92.10	Chronic myeloid leukemia, BCR/ABL positive, not having achieved remission
C92.11	Chronic myeloid leukemia, BCR/ABL positive, in remission
C92.12	Chronic myeloid leukemia, BCR/ABL positive, in relapse
C92.2	Atypical chronic myeloid leukemia, BCR/ABL negative
C92.20	Chronic myeloid leukemia, BCR/ABL negative, not having achieved remission
C92.21	Chronic myeloid leukemia, BCR/ABL negative, in remission
C92.22	Chronic myeloid leukemia, BCR/ABL negative, in relapse
C92.3	Myeloid sarcoma
C92.30	Myeloid sarcoma, not having achieved remission
C92.31	Myeloid sarcoma, in remission
C92.32	Myeloid sarcoma, in relapse
C92.4	Acute promyelocytic leukemia
C92.40	Acute promyelocytic leukemia, not having achieved remission
C92.41	Acute promyelocytic leukemia, in remission
C92.42	Acute promyelocytic leukemia, in relapse
C92.5	Acute myelomonocytic leukemia

C92.50	Acute myelomonocytic leukemia, not having achieved remission
C92.51	Acute myelomonocytic leukemia, in remission
C92.52	Acute myelomonocytic leukemia, in relapse
C92.6	Acute myeloid leukemia with 11q23 abnormality
C92.60	Acute myeloid leukemia with 11q23 abnormality, not having achieved remission
C92.61	Acute myeloid leukemia with 11q23 abnormality, in remission
C92.62	Acute myeloid leukemia with 11q23 abnormality, in relapse
C92.9	Myeloid leukemia, unspecified
C92.90	Myeloid leukemia, unspecified, not having achieved remission
C92.91	Myeloid leukemia, unspecified, in remission
C92.92	Myeloid leukemia, unspecified, in relapse
C92.A	Acute myeloid leukemia with multilineage dysplasia
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse
C92.Z	Other myeloid leukemia
C92.Z0	Other myeloid leukemia, not having achieved remission
C92.Z1	Other myeloid leukemia, in remission
C92.Z2	Other myeloid leukemia, in relapse
C93	Monocytic leukemia
C93.0	Acute monoblastic/monocytic leukemia
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission
C93.01	Acute monoblastic/monocytic leukemia, in remission
C93.02	Acute monoblastic/monocytic leukemia, in relapse
C93.1	Chronic myelomonocytic leukemia
C93.10	Chronic myelomonocytic leukemia, not having achieved remission
C93.11	Chronic myelomonocytic leukemia, in remission
C93.12	Chronic myelomonocytic leukemia, in relapse
C93.3	Juvenile myelomonocytic leukemia
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission
C93.31	Juvenile myelomonocytic leukemia, in remission
C93.32	Juvenile myelomonocytic leukemia, in relapse
C93.9	Monocytic leukemia, unspecified
C93.90	Monocytic leukemia, unspecified, not having achieved remission
C93.91	Monocytic leukemia, unspecified, in remission
C93.92	Monocytic leukemia, unspecified, in relapse
C93.Z	Other monocytic leukemia
C93.Z0	Other monocytic leukemia, not having achieved remission
C93.Z1	Other monocytic leukemia, in remission
C93.Z2	Other monocytic leukemia, in relapse

C94	Other leukemias of specified cell type
C94.0	Acute erythroid leukemia
C94.00	Acute erythroid leukemia, not having achieved remission
C94.01	Acute erythroid leukemia, in remission
C94.02	Acute erythroid leukemia, in relapse
C94.2	Acute megakaryoblastic leukemia
C94.20	Acute megakaryoblastic leukemia, not having achieved remission
C94.21	Acute megakaryoblastic leukemia, in remission
C94.22	Acute megakaryoblastic leukemia, in relapse
C94.3	Mast cell leukemia
C94.30	Mast cell leukemia, not having achieved remission
C94.31	Mast cell leukemia, in remission
C94.32	Mast cell leukemia, in relapse
C94.4	Acute panmyelosis with myelofibrosis
C94.40	Acute panmyelosis with myelofibrosis, not having achieved remission
C94.41	Acute panmyelosis with myelofibrosis, in remission
C94.42	Acute panmyelosis with myelofibrosis, in relapse
C94.6	Myelodysplastic disease, not classified
C94.8	Other specified leukemias
C94.80	Other specified leukemias, not having achieved remission
C94.81	Other specified leukemias, in remission
C94.82	Other specified leukemias, in relapse
C95	Leukemia of unspecified cell type
C95.0	Acute leukemia of unspecified cell type
C95.00	Acute leukemia of unspecified cell type, not having achieved remission
C95.01	Acute leukemia of unspecified cell type, in remission
C95.02	Acute leukemia of unspecified cell type, in relapse
C95.1	Chronic leukemia of unspecified cell type
C95.10	Chronic leukemia of unspecified cell type, not having achieved remission
C95.11	Chronic leukemia of unspecified cell type, in remission
C95.12	Chronic leukemia of unspecified cell type, in relapse
C95.9	Leukemia, unspecified
C95.90	Leukemia, unspecified, not having achieved remission
C95.91	Leukemia, unspecified, in remission
C95.92	Leukemia, unspecified, in relapse
C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.0	Multifocal and multisystemic (disseminated) Langerhans cell histiocytosis
C96.2	Malignant mast cell neoplasm
C96.20	Malignant mast cell neoplasm, unspecified
C96.21	Aggressive systemic mastocytosis
C96.22	Mast cell sarcoma



C96.29	Other malignant mast-cell neoplasm
C96.4	Sarcoma of dendritic cells (accessory cells)
C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis
C96.6	Unifocal Langerhans-cell histiocytosis
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.A	Secondary carcinoid tumors Histiocytic sarcoma
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
D00	Carcinoma in situ of oral cavity, esophagus and stomach
D00.0	Carcinoma in situ of lip, oral cavity and pharynx
D00.00	Carcinoma in situ of oral cavity, unspecified site
D00.01	Carcinoma in situ of labial mucosa and vermillion border
D00.02	Carcinoma in situ of buccal mucosa
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge
D00.04	Carcinoma in situ of soft palate
D00.05	Carcinoma in situ of hard palate
D00.06	Carcinoma in situ of floor of mouth
D00.07	Carcinoma in situ of tongue
D00.08	Carcinoma in situ of pharynx
D00.1	Carcinoma in situ of esophagus
D00.2	Carcinoma in situ of stomach
D01	Carcinoma in situ of other and unspecified digestive organs
D01.0	Carcinoma in situ of colon
D01.1	Carcinoma in situ of rectosigmoid junction
D01.2	Carcinoma in situ of rectum
D01.3	Carcinoma in situ of anus and anal canal
D01.4	Carcinoma in situ of other and unspecified parts of intestine
D01.40	Carcinoma in situ of unspecified part of intestine
D01.49	Carcinoma in situ of other parts of intestine
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts
D01.7	Carcinoma in situ of other specified digestive organs
D01.9	Carcinoma in situ of digestive organ, unspecified
D02	Carcinoma in situ of middle ear and respiratory system
D02.0	Carcinoma in situ of larynx
D02.1	Carcinoma in situ of trachea
D02.2	Carcinoma in situ of bronchus and lung
D02.20	Carcinoma in situ of unspecified bronchus and lung
D02.21	Carcinoma in situ of right bronchus and lung
D02.22	Carcinoma in situ of left bronchus and lung
D02.3	Carcinoma in situ of other parts of respiratory system
D02.4	Carcinoma in situ of respiratory system, unspecified

D03	Melanoma in situ
D03.0	Melanoma in situ of lip
D03.1	Melanoma in situ of eyelid, including canthus
D03.10	Melanoma in situ of unspecified eyelid, including canthus
D03.11	Melanoma in situ of right eyelid, including canthus
D03.111	Melanoma in situ of right upper eyelid, including canthus
D03.112	Melanoma in situ of right lower eyelid, including canthus
D03.12	Melanoma in situ of left eyelid, including canthus
D03.121	Melanoma in situ of left upper eyelid, including canthus
D03.122	Melanoma in situ of left lower eyelid, including canthus
D03.2	Melanoma in situ of ear and external auricular canal
D03.20	Melanoma in situ of unspecified ear and external auricular canal
D03.21	Melanoma in situ of right ear and external auricular canal
D03.22	Melanoma in situ of left ear and external auricular canal
D03.3	Melanoma in situ of other and unspecified parts of face
D03.30	Melanoma in situ of unspecified part of face
D03.39	Melanoma in situ of other parts of face
D03.4	Melanoma in situ of scalp and neck
D03.5	Melanoma in situ of trunk
D03.51	Melanoma in situ of anal skin
D03.52	Melanoma in situ of breast (skin) (soft tissue)
D03.59	Melanoma in situ of other part of trunk
D03.6	Melanoma in situ of upper limb, including shoulder
D03.60	Melanoma in situ of unspecified upper limb, including shoulder
D03.61	Melanoma in situ of right upper limb, including shoulder
D03.62	Melanoma in situ of left upper limb, including shoulder
D03.7	Melanoma in situ of lower limb, including hip
D03.70	Melanoma in situ of unspecified lower limb, including hip
D03.71	Melanoma in situ of right lower limb, including hip
D03.72	Melanoma in situ of left lower limb, including hip
D03.8	Melanoma in situ of other sites
D03.9	Melanoma in situ, unspecified
D04	Carcinoma in situ of skin
D04.0	Carcinoma in situ of skin of lip
D04.1	Carcinoma in situ of skin of eyelid, including canthus
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus
D04.11	Carcinoma in situ of skin of right eyelid, including canthus
D04.111	Carcinoma in situ of skin of right upper eyelid, including canthus
D04.112	Carcinoma in situ of skin of right lower eyelid, including canthus
D04.12	Carcinoma in situ of skin of left eyelid, including canthus
D04.121	Carcinoma in situ of skin of left upper eyelid, including canthus

D04.122	Carcinoma in situ of skin of left lower eyelid, including canthus
D04.2	Carcinoma in situ of skin of ear and external auricular canal
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal
D04.21	Carcinoma in situ of skin of right ear and external auricular canal
D04.22	Carcinoma in situ of skin of left ear and external auricular canal
D04.3	Carcinoma in situ of skin of other and unspecified parts of face
D04.30	Carcinoma in situ of skin of unspecified part of face
D04.39	Carcinoma in situ of skin of other parts of face
D04.4	Carcinoma in situ of skin of scalp and neck
D04.5	Carcinoma in situ of skin of trunk
D04.6	Carcinoma in situ of skin of upper limb, including shoulder
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder
D04.61	Carcinoma in situ of skin of right upper limb, including shoulder
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder
D04.7	Carcinoma in situ of skin of lower limb, including hip
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip
D04.71	Carcinoma in situ of skin of right lower limb, including hip
D04.72	Carcinoma in situ of skin of left lower limb, including hip
D04.8	Carcinoma in situ of skin of other sites
D04.9	Carcinoma in situ of skin, unspecified
D05	Carcinoma in situ of breast
D05.0	Lobular carcinoma in situ of breast
D05.00	Lobular carcinoma in situ of unspecified breast
D05.01	Lobular carcinoma in situ of right breast
D05.02	Lobular carcinoma in situ of left breast
D05.1	Intraductal carcinoma in situ of breast
D05.10	Intraductal carcinoma in situ of unspecified breast
D05.11	Intraductal carcinoma in situ of right breast
D05.12	Intraductal carcinoma in situ of left breast
D05.8	Other specified type of carcinoma in situ of breast
D05.80	Other specified type of carcinoma in situ of unspecified breast
D05.81	Other specified type of carcinoma in situ of right breast
D05.82	Other specified type of carcinoma in situ of left breast
D05.9	Unspecified type of carcinoma in situ of breast
D05.90	Unspecified type of carcinoma in situ of unspecified breast
D05.91	Unspecified type of carcinoma in situ of right breast
D05.92	Unspecified type of carcinoma in situ of left breast
D06	Carcinoma in situ of cervix uteri
D06.0	Carcinoma in situ of endocervix
D06.1	Carcinoma in situ of exocervix
D06.7	Carcinoma in situ of other parts of cervix

D06.9	Carcinoma in situ of cervix, unspecified
D07	Carcinoma in situ of other and unspecified genital organs
D07.0	Carcinoma in situ of endometrium
D07.1	Carcinoma in situ of vulva
D07.2	Carcinoma in situ of vagina
D07.3	Carcinoma in situ of other and unspecified female genital organs
D07.30	Carcinoma in situ of unspecified female genital organs
D07.39	Carcinoma in situ of other female genital organs
D07.4	Carcinoma in situ of penis
D07.5	Carcinoma in situ of prostate
D07.6	Carcinoma in situ of other and unspecified male genital organs
D07.60	Carcinoma in situ of unspecified male genital organs
D07.61	Carcinoma in situ of scrotum
D07.69	Carcinoma in situ of other male genital organs
D09	Carcinoma in situ of other and unspecified sites
D09.0	Carcinoma in situ of bladder
D09.1	Carcinoma in situ of other and unspecified urinary organs
D09.10	Carcinoma in situ of unspecified urinary organ
D09.19	Carcinoma in situ of other urinary organs
D09.2	Carcinoma in situ of eye
D09.20	Carcinoma in situ of unspecified eye
D09.21	Carcinoma in situ of right eye
D09.22	Carcinoma in situ of left eye
D09.3	Carcinoma in situ of thyroid and other endocrine glands
D09.8	Carcinoma in situ of other specified sites
D09.9	Carcinoma in situ, unspecified
D18.02	Hemangioma of intracranial structures
D32	Benign neoplasm of meninges
D32.0	Benign neoplasm of cerebral meninges
D32.1	Benign neoplasm of spinal meninges
D32.9	Benign neoplasm of meninges, unspecified
D33.-	Benign neoplasm of brain and other parts of central nervous system
D33.0	Benign neoplasm of brain, supratentorial
D33.1	Benign neoplasm of brain, infratentorial
D33.2	Benign neoplasm of brain, unspecified
D33.3	Benign neoplasm of cranial nerves
D33.4	Benign neoplasm of spinal cord
D33.7	Benign neoplasm of other specified parts of central nervous system
D33.9	Benign neoplasm of central nervous system, unspecified
D35.2	Benign neoplasm of pituitary gland
D35.3	Benign neoplasm of craniopharyngeal duct

D35.4	Benign neoplasm of pineal gland
D42	Neoplasm of uncertain behavior of meninges
D42.0	Neoplasm of uncertain behavior of cerebral meninges
D42.1	Neoplasm of uncertain behavior of spinal meninges
D42.9	Neoplasm of uncertain behavior of meninges, unspecified
D43	Neoplasm of uncertain behavior of brain and central nervous system
D43.0	Neoplasm of uncertain behavior of brain, supratentorial
D43.1	Neoplasm of uncertain behavior of brain, infratentorial
D43.2	Neoplasm of uncertain behavior of brain, unspecified
D43.3	Neoplasm of uncertain behavior of cranial nerves
D43.4	Neoplasm of uncertain behavior of spinal cord
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified
D44.3	Neoplasm of uncertain behavior of pituitary gland
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct
D44.5	Neoplasm of uncertain behavior of pineal gland
D45	Polycythemia vera
D46	Myelodysplastic syndromes
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.2	Refractory anemia with excess of blasts [RAEB]
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.22	Refractory anemia with excess of blasts 2
D46.4	Refractory anemia, unspecified
D46.9	Myelodysplastic syndrome, unspecified
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.Z	Other myelodysplastic syndromes
D47.02	Systemic mastocytosis
D47.1	Chronic myeloproliferative disease
D47.3	Essential (hemorrhagic) thrombocythemia
D47.4	Osteomyelofibrosis
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
D47.Z	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue

D49.6	Neoplasm of unspecified behavior of brain
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system
D72.110	Idiopathic hypereosinophilic syndrome [HES]
D72.111	Lymphocytic Variant Hypereosinophilic Syndrome [LHES]
D72.118	Other hypereosinophilic syndrome
D72.119	Hypereosinophilic syndrome [HES], unspecified
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

\*This list can also be viewed on the SEER Program website under Reporting Guidelines:

<https://seer.cancer.gov/tools/casefinding/>

## Appendix E: RICR Standard for Inclusion and Reportability/RICR Reportable List

**Table 2. NAACCR Version 21: Comparison of Reportable Cancers: CoC, SEER, NPCR and CCCR.**

	CoC	SEER	NPCR	CCCR
<b>Reportable Diagnoses</b>	<p>1. Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the <i>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</i> (2008)<sup>39</sup>.</p> <p>2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in Table 3.</p> <p>3. Carcinoid, NOS of the appendix C181 (as of 1/1/2015).</p>	<p>1. Behavior code of 2 or 3 in ICD-O-3.2; or, for 2010 and later diagnoses, behavior code 3 according to the <i>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</i> (2008)<sup>39</sup>.</p> <p>2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in Table 3.</p> <p>3. As of 01/01/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.</p> <p>4. Carcinoid, NOS of the appendix C181 (as of</p>	<p>1. Behavior code of 2 or 3 in ICD-O-3 (includes VIN III, VAIN III, AIN III); or, for 2010 and later diagnoses, behavior code 3 according to the <i>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</i> (2008)<sup>39</sup>.</p> <p>2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in Table 3.</p> <p>3. As of 01/01/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.</p> <p>4. Carcinoid, NOS</p>	<p>1. Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the <i>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</i> (2008)<sup>39</sup>.</p> <p>2. Benign (behaviour code of 0 in ICD-O-3) intracranial and central nervous system tumors (ICD-O-3 topography codes C70-C72) (1/1/1992).</p> <p>3. Benign (behaviour code of 0 in ICD-O-3) endocrine glands and related structures (ICD-O-3 Topography codes C75.1-C75.3) (1/1/2007).</p> <p>4. Borderline (behavior code 1) malignancies (all</p>

	CoC	SEER	NPCR	CCCR
		<p>1/1/2015).</p> <p>5. All GIST tumors are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2.</p> <p>6. Nearly all thymomas are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. The exceptions are microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0).</p> <p>7. Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (as of 1/1/2016).</p> <p>8. Pancreatic intraepithelial neoplasia (PanIN III) (as of 1/1/2016).</p>	<p>of the appendix C181 (as of 1/1/2015).</p> <p>5. All GIST tumors are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2.</p> <p>6. Nearly all thymomas are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. The exceptions are microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0).</p> <p><b>**Please note: CIS of the cervix and CIN III are reportable to RICR for cases diagnosed 1/1/2018 and forward</b></p>	<p>topographies in ICD-O-3) (1/1/1992).</p> <p>5. Carcinoid, NOS of the appendix C181 (as of 1/1/2012).</p> <p>6. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features, NIFTP (1/1/2017).</p> <p>7. Non-invasive EFVPTC C739 (1/1/2017).</p> <p>8. Non-invasive encapsulated follicular variant of papillary thyroid carcinoma EFVPTC C739 (1/1/2017).</p> <p>9. Non-invasive FTP C739 (1/1/2017).</p>



	CoC	SEER	NPCR	CCCR
		9. Penile intraepithelial neoplasia III (PeIN III) (as of 1/1/2016).		
Exceptions (not reportable)	<p>1. Skin cancers (C44._) with histology 8000-8110 (after 1/1/2003); prior to that date, AJCC stage groups 2-4 in this group were reportable.</p> <p>2. CIS of the cervix and CIN III or SIN III (after 1/1/96).</p> <p>3. PIN III (after 1/1/96).</p> <p>4. VIN III (after 1/1/96).</p> <p>5. VAIN III (after 1/1/96).</p> <p>6. AIN (after 1/1/96).</p>	<p>1. Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110.</p> <p>2. CIS of the cervix and CIN III or SIN III of cervix (after 1/1/96).</p> <p>3. PIN III (after 1/1/2001).</p>	<p>1. Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110.</p> <p>2. CIS of the cervix and CIN III or SIN III- (prior to 1/1/2018).</p> <p>3. PIN III (after 1/1/2001).</p>	<p>1. Skin cancers (C44._) with histologies 8050-8084, 8090-8110 (1/1/1992).</p> <p>2. Skin cancers (C44._) with histologies 8000-8005, 8010-8046 (1/1/2007).</p> <p>3. In situ (behaviour code of 2 in ICD-O-3) of the cervix including CIN III (1/1/2007).</p> <p>4. In situ (behaviour code of 2 in ICD-O-3) including PIN III of the prostate (1/1/2007).</p> <p>5. In situ (behaviour code of 2 in ICD-O-3) of the colon and rectum with histology 8148 (1/1/2019).</p>

\* Juvenile astrocytomas should be reported as 9421/3.

**Table 3. Primary Site Codes for Non-Malignant Primary Intracranial and Central Nervous System Tumors (non-malignant primary intracranial and central nervous system tumors with a behavior code of 0 or 1 [benign/borderline] are reportable regardless of histologic type for these topography codes).**

Topography	
Codes	Description
C70.0	Meninges
C70.1	Cerebral Meninges
C70.9	Spinal meninges
C70.9	Meninges, NOS
C71.0	Brain Cerebrum
C71.1	Frontal lobe
C71.2	Temporal lobe
C71.3	Parietal lobe
C71.4	Occipital lobe
C71.5	Ventricle, NOS
C71.6	Cerebellum, NOS
C71.7	Brain stem
C71.8	Overlapping lesion of brain
C71.9	Brain, NOS
C72.0	Spinal Cord, Cranial Nerves, and Other Parts of the Central Nervous System
C72.1	Spinal cord
C72.2	Cauda equina
C72.3	Olfactory nerve
C72.3	Optic nerve
C72.4	Acoustic nerve
C72.5	Cranial nerve, NOS
C72.8	Overlapping lesion of brain and central nervous system
C72.9	Nervous system, NOS
C75.1	Other Endocrine Glands and Related Structures
C75.2	Pituitary gland
C75.3	Craniopharyngeal duct
C75.3	Pineal gland

\*This list can be found in the NAACCR Data Dictionary, Chapter 3: <http://datadictionary.naaccr.org/?c=3>

**IMPORTANT NOTE:** This list is not intended to be an exhaustive list of all reportable conditions. Please refer to the General Rules for Reportability and to the ICD-O-3 Manual.

#### General Rules for Reportability

All cases meeting the following criteria must be reported to the RICR:

- (a) Any in situ or invasive neoplasm with a behavior code of “/2” or “/3” in the International Classification of Diseases for Oncology (ICD-O) Third Edition
- (b) All solid tumors of the brain and central nervous system, including meninges and intracranial endocrine structures, listed in the ICD-O-3 with behavior codes of “/0”, “/1”, “/2”, or “/3.”
- (c) Any diagnosis including any of the following words:

- Cancer
- Carcinoma
- Adenocarcinoma
- Carcinoid tumor
- Leukemia
- Lymphoma
- Malignant
- Sarcoma

- (d) Any reportable diagnosis which contains any of the following ambiguous terms in the final diagnosis:

Apparent(ly)	Most likely
Appears	Presumed
Comparable with	Probable
Compatible with	Suspect(ed)
Consistent with	Suspicious (for)
Favors	Typical (of)
Malignant appearing	

Exceptions:

Cases meeting the following criteria are not reportable to the RICR:

- (a) Diagnoses based on cytology specimens containing any ambiguous term listed in (d) above.
- (b) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable

If any uncertainty regarding the reporting of a particular case exists, the reporting facility or independent clinical laboratory shall contact the RICR for guidance at (401) 443-2803 ext. 516 or view information on the following website <http://www.hari.org/ricr.html>.

Please use the current ICD-O-3 manual for determination of site and histology:  
<https://www.naaccr.org/icdo3/>

## CHAPTER VIII:

### REQUIRED STATUS TABLE (ITEM # ORDER)

The following table presents Version 21 of the RICR required status summarizing the requirements and recommendations for collection of each item by standard-setting groups. Differences from Version 18 are marked “Revised” in the “Note” column of the table. Item’s marked in the “Reporting Facility Required” column are items that are required to be submitted to the RICR by all reporting facilities in their monthly data submissions.

**NPCR** Refers to requirements and recommendations of NPCR regarding data items that should be collected or computed by NPCR state registries.

**CoC** Refers to requirements of CoC. Facilities should refer to the CoC STORE manual for further clarification of required fields.

**NAACCR** Refers to requirements and recommendations of NAACCR regarding data items that should be collected or computed by NAACCR state registries.

Formatted: Font: 12 pt

Rhode Island Cancer Registry Reporting Facility - Required Data Items Cases diagnosed 2020 - Forward						
Item #	Item Name	NPCR	CoC	Reporting Facility - Required	Source of Standard	Note
10	Record Type	R	.	X	NAACCR	
20	Patient ID Number	R	.		Reporting Registry	
21	Patient System ID-Hosp	.	.		NAACCR	
30	Registry Type	.	.		NAACCR	
35	FIN Coding System					Retired
37	Reserved 00					Retired
40	Registry ID	R	.	X	NAACCR	
45	NPI--Registry ID	.	.	X	CMS	
50	NAACCR Record Version	R	.	X	NAACCR	
60	Tumor Record Number	.	.		NAACCR	
70	Addr at DX--City	R	R	X	CoC	
80	Addr at DX--State	R	R	X	CoC	
81	State at DX Geocode 1970/80/90	D	.		NAACCR	

Formatted Table

82	State at DX Geocode 2000	D	.		NAACCR	
83	State at DX Geocode 2010	D	.		NAACCR	
84	State at DX Geocode 2020	D	.		NAACCR	
89	County at DX Analysis	D	.		NAACCR	
90	County at DX Reported	R	R	X	FIPS/SEER	
94	County at DX Geocode 1970/80/90	D	.		NAACCR	
95	County at DX Geocode2000	D	.		NAACCR	
96	County at DX Geocode2010	D	.		NAACCR	
97	County at DX Geocode2020	D	.		NAACCR	
100	Addr at DX--Postal Code	R	R	X	CoC	
102	Addr at DX--Country	.	R	X	NAACCR	
110	Census Tract 1970/80/90	RH*	.	X	SEER	
120	Census Cod Sys 1970/80/90	RH*	.	X	SEER	
125	Census Tract 2020	D	.	X	NAACCR	
130	Census Tract 2000	RH	.	X	NAACCR	
135	Census Tract 2010	R	.	X	NAACCR	
140	Census Tract Cod Sys--Alt					Retired
145	Census Tr Poverty Indictr	D	.		NAACCR	Revised
150	Marital Status at DX	.	.	X	SEER	
160	Race 1	R	R	X	SEER/CoC	
161	Race 2	R	.	X	SEER	Revised
162	Race 3	R	.	X	SEER	Revised
163	Race 4	R	.	X	SEER	Revised
164	Race 5	R	.	X	SEER	Revised
170	Race Coding Sys--Current	.	.		NAACCR	Revised
180	Race Coding Sys--Original	.	.		NAACCR	Revised

190	Spanish/Hispanic Origin	R	R	X	SEER/CoC	Revised
191	NHIA Derived Hisp Origin	D	.		NAACCR	
192	IHS Link	R*	.		NPCR	
193	Race--NAPIA(derived API)	R	.		NAACCR	Revised
200	Computed Ethnicity	R	.		SEER	
210	Computed Ethnicity Source	R	.		SEER	
220	Sex	R	R	X	SEER/CoC	
230	Age at Diagnosis	R	R	X	SEER/CoC	
240	Date of Birth	R	R	X	SEER/CoC	
241	Date of Birth Flag	R	.	X	NAACCR	Revised
250	Birthplace	RH*	.	X	SEER/CoC	
252	Birthplace--State	R*	R	X	NAACCR	
254	Birthplace--Country	R*	R	X	NAACCR	
260	Religion					Retired
270	Census Occ Code 1970-2000	R*	.		Census/NPCR	
272	Census Ind Code 2010 CDC	R*	.		Census/NPCR	
280	Census Ind Code 1970-2000	R*	.		Census/NPCR	
282	Census Occ Code 2010 CDC	R*	.		Census/NPCR	
290	Occupation Source	R*	.		NPCR	
300	Industry Source	R*	.		NPCR	
310	Text--Usual Occupation	R*	.	X	NPCR	
320	Text--Usual Industry	R*	.	X	NPCR	
330	Census Occ/Ind Sys 70-00	R*	.		NPCR	
339	RUCA 2000	D	.		NAACCR	
340	Tobacco History					Retired
341	RUCA 2010	D	.		NAACCR	
345	URIC 2000	D	.		NAACCR	
346	URIC 2010	D	.		NAACCR	

350	Alcohol History					Retired
351	GeoLocationID - 1970/80/90	D	.		NAACCR	
352	GeoLocationID - 2000	D	.		NAACCR	
353	GeoLocationID - 2010	D	.		NAACCR	
354	GeoLocationID - 2020	D	.		NAACCR	
360	Family History of Cancer					Retired
361	Census Block Group 2020	.	.		Census	
362	Census Block Group 2000	.	.		Census	
363	Census Block Group 2010	.	.		Census	
364	Census Tr Cert 1970/80/90	RH*	.	X	SEER	
365	Census Tr Certainty 2000	RH	.	X	NAACCR	
366	GIS Coordinate Quality	R*	.		NAACCR	
367	Census Tr Certainty 2010	R	.	X	NAACCR	
368	Census Block Grp 1970/80/90	.	.		Census	
369	Census Tract Certainty 2020	D	.	X	NAACCR	
370	Reserved 01					Retired
380	Sequence Number-- Central	R	.		SEER	
390	Date of Diagnosis	R	R	X	SEER/CoC	
391	Date of Diagnosis Flag	R	.	X	NAACCR	
400	Primary Site	R	R	X	SEER/CoC	
410	Laterality	R	R	X	SEER/CoC	
419	Morph--Type&Behav ICD-O-2	.	.			
420	Histology (92-00) ICD-O-2	RH	RH	X	SEER/CoC	
430	Behavior (92-00) ICD-O-2	RH	RH	X	SEER/CoC	
439	Date of Mult Tumors Flag	.	RH		NAACCR	

440	Grade	RH	RH	X	SEER/CoC	
441	Grade Path Value	RH*	RH	X	AJCC	Revised
442	Ambiguous Terminology DX	.	RH		SEER	
443	Date Conclusive DX	.	RH		SEER	
444	Mult Tum Rpt as One Prim	.	RH		SEER	
445	Date of Mult Tumors	.	RH		SEER	
446	Multiplicity Counter	.	RH		SEER	
447	Number of Tumors/Hist					Retired
448	Date Conclusive DX Flag	.	RH		NAACCR	
449	Grade Path System	RH*	RH	X	AJCC	Revised
450	Site Coding Sys--Current	R	.	X	NAACCR	Revised
460	Site Coding Sys--Original	.	.		NAACCR	Revised
470	Morph Coding Sys--Current	R	.	X	NAACCR	Revised
480	Morph Coding Sys--Originl	.	.		NAACCR	Revised
490	Diagnostic Confirmation	R	R	X	SEER/CoC	
500	Type of Reporting Source	R	.	X	SEER	
501	Casefinding Source	R*	.	X	NAACCR	
510	Screening Date					Retired
520	Screening Result					Retired
521	Morph--Type&Behav ICD-O-3	.	.			
522	Histologic Type ICD-O-3	R	R	X	SEER/CoC	
523	Behavior Code ICD-O-3	R	R	X	SEER/CoC	
530	Reserved 02					Retired
538	Reporting Hospital FAN					Retired
540	Reporting Facility	R	R	X	CoC	
545	NPI--Reporting Facility	R*	R	X	CMS	
550	Accession Number--Hosp	.	R	X	CoC	
560	Sequence Number--Hospital	.	R	X	CoC	



570	Abstracted By	.	R	X	CoC	
580	Date of 1st Contact	R	R	X	CoC	
581	Date of 1st Contact Flag	R	R	X	NAACCR	
590	Date of Inpt Adm	.	.		NAACCR	
591	Date of Inpt Adm Flag	.	.		NAACCR	
600	Date of Inpt Disch	.	.		NAACCR	
601	Date of Inpt Disch Flag	.	.		NAACCR	
605	Inpatient Status	.	.		NAACCR	
610	Class of Case	R	R	X	CoC	
620	Year First Seen This CA					Retired
630	Primary Payer at DX	R*	R	X	CoC	
640	Inpatient/Outpt Status					Retired
650	Presentation at CA Conf					Retired
660	Date of CA Conference					Retired
665	RX Hosp--ASA Class					Retired
668	RX Hosp--Surg App 2010	.	R		CoC	
670	RX Hosp--Surg Prim Site	.	R		CoC	
672	RX Hosp--Scope Reg LN Sur	.	R		CoC	
674	RX Hosp--Surg Oth Reg/Dis	.	R		CoC	
676	RX Hosp--Reg LN Removed	.	RH		CoC	
678	RX Hosp--Surg Timing					Retired
680	Reserved 03					Retired
682	Date Regional Lymph Node Dissection	.	R		NAACCR	
683	Date Regional Lymph Node Dissection Flag	.	.		NAACCR	Revised
690	RX Hosp--Radiation	.	.		SEER	
700	RX Hosp--Chemo	.	R		CoC	
710	RX Hosp--Hormone	.	R		CoC	
720	RX Hosp--BRM	.	R		CoC	
730	RX Hosp--Other	.	R		CoC	
740	RX Hosp--DX/Stg Proc	.	R		CoC	
742	RX Hosp--Screen/BX Proc1					Retired
743	RX Hosp--Screen/BX Proc2					Retired

744	RX Hosp--Screen/BX Proc3					Retired
745	RX Hosp--Screen/BX Proc4					Retired
746	RX Hosp--Surg Site 98-02	.	RH		CoC	
747	RX Hosp--Scope Reg 98-02	.	RH		CoC	
748	RX Hosp--Surg Oth 98-02	.	RH		CoC	
750	Reserved 04					Retired
752	Tumor Size Clinical	.	.		SEER	
754	Tumor Size Pathologic	.	.		SEER	
756	Tumor Size Summary	R	R	X	NPCR/CoC	
759	SEER Summary Stage 2000	RH	RH	X	SEER	
760	SEER Summary Stage 1977	RH	RH	X	SEER	
762	Derived Summary Stage 2018	.	.		SEER	
764	Summary Stage 2018	R	.	X	SEER	Revised
770	Loc/Reg/Distant Stage					Retired
772	EOD Primary Tumor	.	.		SEER	
774	EOD Regional Nodes	.	.		SEER	
776	EOD Mets	.	.		SEER	
779	Extent of Disease 10-Dig	.	.			
780	EOD--Tumor Size	.	RH		SEER/CoC	
785	Derived EOD 2018 T	.	.		SEER	
790	EOD--Extension	.	.		SEER	
795	Derived EOD 2018 M	.	.		SEER	
800	EOD--Extension Prost Path	.	.		SEER	
810	EOD--Lymph Node Involv	.	.		SEER	
815	Derived EOD 2018 N	.	.		SEER	
818	Derived EOD 2018 Stage Group	.	.		SEER	
820	Regional Nodes Positive	R	R	X	SEER/CoC	

830	Regional Nodes Examined	R	R	X	SEER/CoC	
832	Date of Sentinel Lymph Node Biopsy	.	RS		CoC	
833	Date of Sentinel Lymph Node Biopsy Flag	.	.		SEER	Revised
834	Sentinel Lymph Nodes Examined	.	RS	X	CoC	
835	Sentinel Lymph Nodes Positive	.	RS	X	CoC	
840	EOD--Old 13 Digit	.	.		SEER	
850	EOD--Old 2 Digit	.	.		SEER	
860	EOD--Old 4 Digit	.	.		SEER	
870	Coding System for EOD	.	.		SEER	
880	TNM Path T	.	RH		AJCC	Revised
890	TNM Path N	.	RH		AJCC	Revised
900	TNM Path M	.	RH		AJCC	Revised
910	TNM Path Stage Group	.	RH		AJCC	Revised
920	TNM Path Descriptor	.	RH		CoC	Revised
930	TNM Path Staged By	.	RH	X	CoC	
940	TNM Clin T	.	RH		AJCC	Revised
950	TNM Clin N	.	RH		AJCC	Revised
960	TNM Clin M	.	RH		AJCC	Revised
970	TNM Clin Stage Group	.	RH		AJCC	Revised
980	TNM Clin Descriptor	.	RH		CoC	Revised
990	TNM Clin Staged By	.	RH	X	CoC	
995	AJCC ID	D	D	X	NAACCR	
1000	TNM Other T					Retired
1001	AJCC TNM Clin T	.	R	X	AJCC	
1002	AJCC TNM Clin N	.	R	X	AJCC	
1003	AJCC TNM Clin M	.	R	X	AJCC	
1004	AJCC TNM Clin Stage Group	.	R	X	AJCC	
1010	TNM Other N					Retired
1011	AJCC TNM Path T	.	R	X	AJCC	
1012	AJCC TNM Path N	.	R	X	AJCC	
1013	AJCC TNM Path M	.	R	X	AJCC	
1014	AJCC TNM Path Stage Group	.	R	X	AJCC	
1020	TNM Other M					Retired

1021	AJCC TNM Post Therapy Path (yp) T	.	R	X	AJCC	Revised
1022	AJCC TNM Post Therapy Path (yp) N	.	R	X	AJCC	Revised
1023	AJCC TNM Post Therapy Path (yp) M	.	R	X	AJCC	Revised
1024	AJCC TNM Post Therapy Path (yp) Stage Group	.	R	X	AJCC	Revised
1030	TNM Other Stage Group					Retired
1031	AJCC TNM Clin T Suffix	.	R	X	AJCC	
1032	AJCC TNM Path T Suffix	.	R	X	AJCC	
1033	AJCC TNM Post Therapy Path (yp) T Suffix	.	R	X	AJCC	Revised
1034	AJCC TNM Clin N Suffix	.	R	X	AJCC	
1035	AJCC TNM Path N Suffix	.	R	X	AJCC	
1036	AJCC TNM Post Therapy Path (yp) N Suffix	.	R	X	AJCC	Revised
1040	TNM Other Staged By					Retired
1050	TNM Other Descriptor					Retired
1060	TNM Edition Number	.	R	X	CoC	Revised
1062	AJCC TNM Post Therapy Clin (yc) T	.	R	X	AJCC	New
1063	AJCC TNM Post Therapy Clin (yc) T Suffix	.	R	X	AJCC	New
1064	AJCC TNM Post Therapy Clin (yc) N	.	R	X	AJCC	New
1065	AJCC TNM Post Therapy Clin (yc) N Suffix	.	R	X	AJCC	New
1066	AJCC TNM Post Therapy Clin (yc) M	.	R	X	AJCC	New
1067	AJCC TNM Post Therapy Clin (yc) Stage Group	.	.	X	AJCC	New
1068	Grade Post Therapy Clin (yc)	R*	R	X	NAACCR	New
1070	Other Staging System					Retired
1080	Date of 1st Positive BX					Retired
1090	Site of Distant Met 1					Retired
1100	Site of Distant Met 2					Retired
1110	Site of Distant Met 3					Retired
1112	Mets at DX-Bone	.	R		SEER	
1113	Mets at DX-Brain	.	R		SEER	
1114	Mets at Dx-Distant LN	.	R		SEER	

1115	Mets at DX-Liver	.	R		SEER	
1116	Mets at DX-Lung	.	R		SEER	
1117	Mets at DX-Other	.	R		SEER	
1120	Pediatric Stage	.	.		CoC	
1130	Pediatric Staging System	.	.		CoC	
1140	Pediatric Staged By	.	.		CoC	
1150	Tumor Marker 1	.	RH		SEER	
1160	Tumor Marker 2	.	RH		SEER	
1170	Tumor Marker 3	.	RH		SEER	
1180	Reserved 05					Retired
1182	Lymphovascular Invasion	R*	R	X	AJCC	
1190	Reserved 06					Retired
1200	RX Date Surgery	R	R	X	CoC	
1201	RX Date Surgery Flag	R	R	X	NAACCR	
1210	RX Date Radiation	R	R	X	CoC	
1211	RX Date Radiation Flag	R	.	X	NAACCR	Revised
1220	RX Date Chemo	R	R	X	CoC	
1221	RX Date Chemo Flag	R	.	X	NAACCR	Revised
1230	RX Date Hormone	R	R	X	CoC	
1231	RX Date Hormone Flag	R	R	X	NAACCR	
1240	RX Date BRM	R	R	X	CoC	
1241	RX Date BRM Flag	R	R	X	NAACCR	
1250	RX Date Other	R	R	X	CoC	
1251	RX Date Other Flag	R	.	X	NAACCR	Revised
1260	Date Initial RX SEER	R#	.	X	SEER	
1261	Date Initial RX SEER Flag	R#	.	X	NAACCR	
1270	Date 1st Crs RX CoC	R#	R	X	CoC	
1271	Date 1st Crs RX CoC Flag	R#	.	X	NAACCR	Revised
1280	RX Date DX/Stg Proc	.	R	X	CoC	
1281	RX Date DX/Stg Proc Flag	.	R	X	NAACCR	
1285	RX Summ--Treatment Status	R#	R	X	SEER/CoC	
1290	RX Summ--Surg Prim Site	R	R	X	SEER/CoC	

1292	RX Summ--Scope Reg LN Sur	R	R	X	SEER/CoC	
1294	RX Summ--Surg Oth Reg/Dis	R	R	X	SEER/CoC	
1296	RX Summ--Reg LN Examined	.	RH	X	SEER/CoC	
1300	Reserved 07					Retired
1310	RX Summ--Surgical Approch	.	RH		CoC	
1320	RX Summ--Surgical Margins	.	R		CoC	
1330	RX Summ--Reconstruct 1st	.	RH		SEER	Revised
1340	Reason for No Surgery	R	R	X	SEER/CoC	
1350	RX Summ--DX/Stg Proc	.	R	X	CoC	
1360	RX Summ--Radiation	RH	.	X	SEER	
1370	RX Summ--Rad to CNS	.	.		SEER/CoC	
1380	RX Summ--Surg/Rad Seq	R	R	X	SEER/CoC	
1390	RX Summ--Chemo	R	R	X	SEER/CoC	
1400	RX Summ--Hormone	R	R	X	SEER/CoC	
1410	RX Summ--BRM	R	R	X	SEER/CoC	
1420	RX Summ--Other	R	R	X	SEER/CoC	
1430	Reason for No Radiation	R	R	X	CoC	
1440	Reason for No Chemo					Retired
1450	Reason for No Hormone					Retired
1460	RX Coding System-- Current	R	.	X	NAACCR	Revised
1470	Protocol Eligibility Stat					Retired
1480	Protocol Participation					Retired
1490	Referral to Support Serv					Retired
1500	First Course Calc Method					Retired

1501	Phase I Dose per Fraction	.	R	X	CoC	
1502	Phase I Radiation External Beam Planning Tech	.	R	X	CoC	
1503	Phase I Number of Fractions	.	R	X	CoC	
1504	Phase I Radiation Primary Treatment Volume	.	R	X	CoC	
1505	Phase I Radiation to Draining Lymph Nodes	.	R	X	CoC	
1506	Phase I Radiation Treatment Modality	R	R	X	CoC	
1507	Phase I Total Dose	.	R	X	CoC	
1510	Rad--Regional Dose: cGy	.	.		CoC	
1511	Phase II Dose per Fraction	.	R	X	CoC	
1512	Phase II Radiation External Beam Planning Tech	.	R	X	CoC	
1513	Phase II Number of Fractions	.	R	X	CoC	
1514	Phase II Radiation Primary Treatment Volume	.	R	X	CoC	
1515	Phase II Radiation to Draining Lymph Nodes	.	R	X	CoC	
1516	Phase II Radiation Treatment Modality	.	R	X	CoC	
1517	Phase II Total Dose	.	R	X	CoC	
1520	Rad--No of Treatment Vol	.	.		CoC	
1521	Phase III Dose per Fraction	.	R	X	CoC	
1522	Phase III Radiation External Beam Planning Tech	.	R	X	CoC	
1523	Phase III Number of Fractions	.	R	X	CoC	
1524	Phase III Radiation Primary Treatment Volume	.	R	X	CoC	
1525	Phase III Radiation to Draining Lymph Nodes	.	R	X	CoC	

1526	Phase III Radiation Treatment Modality	.	R	X	CoC	
1527	Phase III Total Dose	.	R	X	CoC	
1530	Rad--Elapsed RX Days					Retired
1531	Radiation Treatment Discontinued Early	.	R	X	CoC	
1532	Number of Phases of Rad Treatment to this Volume	.	R	X	CoC	
1533	Total Dose	.	R	X	CoC	
1540	Rad--Treatment Volume	.	.		CoC	
1550	Rad--Location of RX	.	R	X	CoC	
1560	Rad--Intent of Treatment					Retired
1570	Rad--Regional RX Modality	RH	.	X	CoC	
1580	Rad--RX Completion Status					Retired
1590	Rad--Local Control Status					Retired
1600	Chemotherapy Field 1					Retired
1610	Chemotherapy Field 2					Retired
1620	Chemotherapy Field 3					Retired
1630	Chemotherapy Field 4					Retired
1632	Neoadjuvant Therapy	.	.		SEER	New
1633	Neoadjuvant Therapy-Clinical Response	.	.		SEER	New
1634	Neoadjuvant Therapy-Treatment Effect	.	.		SEER	New
1639	RX Summ--Systemic/Sur Seq	R	R	X	CoC	
1640	RX Summ--Surgery Type	.	.		SEER	
1642	RX Summ--Screen/BX Proc1					Retired
1643	RX Summ--Screen/BX Proc2					Retired
1644	RX Summ--Screen/BX Proc3					Retired
1645	RX Summ--Screen/BX Proc4					Retired
1646	RX Summ--Surg Site 98-02	.	RH		SEER/CoC	Revised



1647	RX Summ--Scope Reg 98-02	.	RH		SEER/CoC	
1648	RX Summ--Surg Oth 98-02	.	RH		SEER/CoC	
1650	Reserved 08					Retired
1660	Subsq RX 2nd Course Date	.	.		CoC	
1661	Subsq RX 2ndCrS Date Flag	.	.		NAACCR	
1670	Subsq RX 2nd Course Codes	.	.			
1671	Subsq RX 2nd Course Surg	.	.		CoC	
1672	Subsq RX 2nd Course Rad	.	.		CoC	
1673	Subsq RX 2nd Course Chemo	.	.		CoC	
1674	Subsq RX 2nd Course Horm	.	.		CoC	
1675	Subsq RX 2nd Course BRM	.	.		CoC	
1676	Subsq RX 2nd Course Oth	.	.		CoC	
1677	Subsq RX 2nd--Scope LN SU	.	.		CoC	
1678	Subsq RX 2nd--Surg Oth	.	.		CoC	
1679	Subsq RX 2nd--Reg LN Rem	.	.		CoC	
1680	Subsq RX 3rd Course Date	.	.		CoC	
1681	Subsq RX 3rdCrS Date Flag	.	.		NAACCR	
1690	Subsq RX 3rd Course Codes	.	.			
1691	Subsq RX 3rd Course Surg	.	.		CoC	
1692	Subsq RX 3rd Course Rad	.	.		CoC	
1693	Subsq RX 3rd Course Chemo	.	.		CoC	
1694	Subsq RX 3rd Course Horm	.	.		CoC	
1695	Subsq RX 3rd Course BRM	.	.		CoC	

1696	Subsq RX 3rd Course Oth	.	.		CoC	
1697	Subsq RX 3rd--Scope LN Su	.	.		CoC	
1698	Subsq RX 3rd--Surg Oth	.	.		CoC	
1699	Subsq RX 3rd--Reg LN Rem	.	.		CoC	
1700	Subsq RX 4th Course Date	.	.		CoC	
1701	Subsq RX 4thCrS Date Flag	.	.		NAACCR	
1710	Subsq RX 4th Course Codes	.	.			
1711	Subsq RX 4th Course Surg	.	.		CoC	
1712	Subsq RX 4th Course Rad	.	.		CoC	
1713	Subsq RX 4th Course Chemo	.	.		CoC	
1714	Subsq RX 4th Course Horm	.	.		CoC	
1715	Subsq RX 4th Course BRM	.	.		CoC	
1716	Subsq RX 4th Course Oth	.	.		CoC	
1717	Subsq RX 4th--Scope LN Su	.	.		CoC	
1718	Subsq RX 4th--Surg Oth	.	.		CoC	
1719	Subsq RX 4th--Reg LN Rem	.	.		CoC	
1720	Subsq RX 5th Course Date					Retired
1730	Subsq RX 5th Course Codes					Retired
1731	Subsq RX 5th Course Surg					Retired
1732	Subsq RX 5th Course Rad					Retired
1733	Subsq RX 5th Course Chemo					Retired
1734	Subsq RX 5th Course Horm					Retired
1735	Subsq RX 5th Course BRM					Retired

1736	Subsq RX 5th Course Oth					Retired
1737	Subsq RX 5th--Scope LN Su					Retired
1738	Subsq RX 5th--Surg Oth					Retired
1739	Subsq RX 5th--Reg LN Rem					Retired
1740	Reserved 09					Retired
1741	Subsq RX--Reconstruct Del	.	.		CoC	
1750	Date of Last Contact	R	R	X	SEER/CoC	
1751	Date of Last Contact Flag	R	.	X	NAACCR	Revised
1755	Date of Death--Canada	.	.		CCCR	
1756	Date of Death--CanadaFlag	.	.		NAACCR	
1760	Vital Status	R	R	X	SEER/CoC	
1762	Vital Status Recode	D	.		NAACCR	
1770	Cancer Status	.	R	X	CoC	
1772	Date of Last Cancer (tumor) Status	.	R		CoC	
1773	Date of Last Cancer (tumor) Status Flag		.		NAACCR	Revised
1775	Record Number Recode	D	.		NAACCR	Revised
1780	Quality of Survival	.	.		CoC	
1782	Surv-Date Active Followup	D	.		NAACCR	Revised
1783	Surv-Flag Active Followup	D	.		NAACCR	Revised
1784	Surv-Mos Active Followup	D	.		NAACCR	Revised
1785	Surv-Date Presumed Alive	D	.		NAACCR	
1786	Surv-Flag Presumed Alive	D	.		NAACCR	
1787	Surv-Mos Presumed Alive	D	.		NAACCR	
1788	Surv-Date DX Recode	D	.		NAACCR	
1790	Follow-Up Source	R*	R	X	CoC	

1791	Follow-up Source Central	R	.	X	NAACCR	Reporting Facilities: Please code to "00" only
1800	Next Follow-Up Source	.	R		CoC	
1810	Addr Current--City	.	.	X	SEER	Revised
1820	Addr Current--State	.	.	X	SEER	Revised
1830	Addr Current--Postal Code	.	.	X	SEER	Revised
1832	Addr Current--Country	.	.	X	NAACCR	Revised
1835	Reserved 10					Retired
1840	County--Current	.	.		NAACCR	
1842	Follow-Up Contact--City	.	.		SEER	
1844	Follow-Up Contact--State	.	.		SEER	
1846	Follow-Up Contact--Postal	.	.		SEER	
1847	FollowUp Contact--Country	.	.		NAACCR	
1850	Unusual Follow-Up Method	.	.		NAACCR	
1860	Recurrence Date--1st	.	R		CoC	
1861	Recurrence Date--1st Flag	.	.		NAACCR	Revised
1870	Recurrence Distant Sites					Retired
1871	Recurrence Distant Site 1					Retired
1872	Recurrence Distant Site 2					Retired
1873	Recurrence Distant Site 3					Retired
1880	Recurrence Type--1st	.	R		CoC	
1890	Recurrence Type--1st--Oth					Retired
1900	Reserved 11					Retired
1910	Cause of Death	R	.	X	SEER	
1914	SEER Cause Specific COD	D	.		SEER	
1915	SEER Other COD	D	.		SEER	
1920	ICD Revision Number	R	.	X	SEER	
1930	Autopsy	.	.		NAACCR	

1940	Place of Death	RH	.	X	NPCR	
1942	Place of Death--State	R	.	X	NAACCR	
1944	Place of Death--Country	R*	.	X	NAACCR	
1960	Site (73-91) ICD-O-1	.	.		SEER	
1970	Morph (73-91) ICD-O-1	.	.			
1971	Histology (73-91) ICD-O-1	.	.		SEER	
1972	Behavior (73-91) ICD-O-1	.	.		SEER	
1973	Grade (73-91) ICD-O-1	.	.		SEER	
1980	ICD-O-2 Conversion Flag	.	.		SEER	Revised
1981	Over-ride SS/NodesPos	.	.		NAACCR	
1982	Over-ride SS/TNM-N	.	.		NAACCR	
1983	Over-ride SS/TNM-M	.	.		NAACCR	
1984	Over-ride SS/DisMet1	.	.			Retired
1985	Over-ride Acsn/Class/Seq	.	.		NAACCR	Revised
1986	Over-ride HospSeq/DxConf	.	.		NAACCR	Revised
1987	Over-ride CoC-Site/Type	.	.		NAACCR	Revised
1988	Over-ride HospSeq/Site	.	.		NAACCR	Revised
1989	Over-ride Site/TNM-StgGrp	.	.		NAACCR	Revised
1990	Over-ride Age/Site/Morph	R	.	X	SEER	Revised
1992	Over-ride TNM Stage	.	.		NAACCR	Revised
1993	Over-ride TNM Tis	.	.		NAACCR	Revised
1994	Over-ride TNM 3	.	.		NAACCR	
2000	Over-ride SeqNo/DxConf	R	.	X	SEER	
2010	Over-ride Site/Lat/SeqNo	R	.	X	SEER	
2020	Over-ride Surg/DxConf	R	.	X	SEER	Revised
2030	Over-ride Site/Type	R	.	X	SEER	Revised
2040	Over-ride Histology	R	.	X	SEER	Revised
2050	Over-ride Report Source	R	.	X	SEER	
2060	Over-ride Ill-define Site	R	.	X	SEER	
2070	Over-ride Leuk, Lymphoma	R	.	X	SEER	Revised

2071	Over-ride Site/Behavior	R	.	X	SEER	Revised
2072	Over-ride Site/EOD/DX Dt	.	.		SEER	
2073	Over-ride Site/Lat/EOD	.	.		SEER	
2074	Over-ride Site/Lat/Morph	R	.	X	SEER	Revised
2078	Over-ride Name/Sex	R	.	X	NAACCR	
2080	Reserved 13					Retired
2081	CRC CHECKSUM	.	.		NAACCR	
2085	Date Case Initiated	.	.		NAACCR	
2090	Date Case Completed	.	.		NAACCR	
2092	Date Case Completed--CoC	.	D	X	CoC	
2100	Date Case Last Changed	.	D	X	NAACCR	
2110	Date Case Report Exported	R	.	X	NPCR	
2111	Date Case Report Received	R	.		NPCR	
2112	Date Case Report Loaded	R	.		NPCR	
2113	Date Tumor Record Availbl	R	.	X	NPCR	
2114	Future Use Timeliness 1					Retired
2115	Future Use Timeliness 2					Retired
2116	ICD-O-3 Conversion Flag	R	.	X	SEER	Revised
2117	Schema ID Version Current	D	D	X	SEER	New
2118	Schema ID Version Original	D	D	X	SEER	New
2120	SEER Coding Sys--Current	.	.		NAACCR	
2130	SEER Coding Sys--Original	.	.		NAACCR	
2140	CoC Coding Sys--Current	.	.		CoC	Revised
2150	CoC Coding Sys--Original	.	.		CoC	Revised
2152	CoC Accredited Flag	R	.	X	NPCR	
2155	RQRS NCDB Submission Flag	.	.		CoC	Revised
2156	AJCC API Version Current	.	D		AJCC	New

2157	AJCC API Version Original	.	D		AJCC	New
2158	AJCC Cancer Surveillance API Version Current	D	D	X	AJCC	New
2159	AJCC Cancer Surveillance API Version Original	D	D	X	AJCC	New
2160	Subsq Report for Primary					Retired
2161	Reserved 18					Retired
2162	Reserved 19					Retired
2163	Reserved 20					Retired
2170	Vendor Name	.	R	X	NAACCR	
2180	SEER Type of Follow-Up	.	.		SEER	Revised
2190	SEER Record Number	.	.		SEER	
2200	Diagnostic Proc 73-87	.	.		SEER	Revised
2210	Reserved 14					Retired
2220	State/Requestor Items	.	.		Varies	
2230	Name--Last	R	.	X	SEER	Revised
2232	Name--Birth Surname	R	.	X	NAACCR	New
2240	Name--First	R	.	X	SEER	Revised
2250	Name--Middle	R	.	X	SEER	Revised
2260	Name--Prefix	.	.		NAACCR	
2270	Name--Suffix	.	.	X	NAACCR	
2280	Name--Alias	R	.	X	NAACCR	
2290	Name--Spouse/Parent	.	.	X	NAACCR	
2300	Medical Record Number	R	.	X	NAACCR	Revised
2310	Military Record No Suffix	.	.		CoC	
2315	Medicare Beneficiary Identifier	R*	.	X	NAACCR	Revised
2320	Social Security Number	R	.	X	SEER	Revised
2330	Addr at DX--No & Street	R	.	X	SEER	Revised
2335	Addr at DX--Supplementl	R	.	X	SEER	Revised
2350	Addr Current--No & Street	.	.	X	SEER	Revised
2352	Latitude	R*	.		NAACCR	
2354	Longitude	R*	.		NAACCR	

2355	Addr Current-- Supplementl	.	.	X	SEER	Revised
2360	Telephone	.	.	X	SEER	Revised
2370	DC State					Retired
2380	DC State File Number	R	.		State	
2390	Name--Maiden	.	.	X	NAACCR	Revised
2392	Follow-Up Contact-- No&St	.	.		SEER	
2393	Follow-Up Contact-- Suppl	.	.		SEER	
2394	Follow-Up Contact-- Name	.	.		SEER	
2400	Reserved 15					Retired
2410	Institution Referred From	.	.		CoC	
2415	NPI--Inst Referred From	.	R		CMS	
2420	Institution Referred To	.	.		CoC	
2425	NPI--Inst Referred To	.	R		CMS	
2430	Last Follow-Up Hospital					Retired
2440	Following Registry	.	.		CoC	
2445	NPI--Following Registry	.	.		CMS	
2450	Reserved 16					Retired
2460	Physician--Managing	.	.		NAACCR	
2465	NPI--Physician-- Managing	.	.	X	CMS	Revised
2470	Physician--Follow-Up	.	.		CoC	
2475	NPI--Physician--Follow- Up	.	.	X	CMS	Revised
2480	Physician--Primary Surg	.	.		CoC	
2485	NPI--Physician--Primary Surg	.	R	X	CMS	
2490	Physician 3	.	.		CoC	
2495	NPI--Physician 3	.	R		CMS	
2500	Physician 4	.	.		CoC	
2505	NPI--Physician 4	.	R		CMS	
2508	EHR Reporting	.	.		NAACCR	
2510	Reserved 12					Retired
2520	Text--DX Proc--PE	R^	.	X	NPCR	
2530	Text--DX Proc--X- ray/Scan	R^	.	X	NPCR	
2540	Text--DX Proc--Scopes	R^	.	X	NPCR	



2550	Text--DX Proc--Lab Tests	R^	.	X	NPCR	
2560	Text--DX Proc--Op	R^	.	X	NPCR	
2570	Text--DX Proc--Path	R^	.	X	NPCR	
2580	Text--Primary Site Title	R^	.	X	NPCR	
2590	Text--Histology Title	R^	.	X	NPCR	
2600	Text--Staging	R^	.	X	NPCR	
2610	RX Text--Surgery	R^	.	X	NPCR	
2620	RX Text--Radiation (Beam)	R^	.	X	NPCR	
2630	RX Text--Radiation Other	R^	.	X	NPCR	
2640	RX Text--Chemo	R^	.	X	NPCR	
2650	RX Text--Hormone	R^	.	X	NPCR	
2660	RX Text--BRM	R^	.	X	NPCR	
2670	RX Text--Other	R^	.	X	NPCR	
2680	Text--Remarks	.	.	X	NPCR	
2690	Text--Place of Diagnosis	.	.	X	NPCR	
2700	Reserved 17					Retired
2730	CS PreRx Tumor Size					Retired
2735	CS PreRx Extension					Retired
2740	CS PreRx Tum Sz/Ext Eval					Retired
2750	CS PreRx Lymph Nodes					Retired
2755	CS PreRx Reg Nodes Eval					Retired
2760	CS PreRx Mets at DX					Retired
2765	CS PreRx Mets Eval					Retired
2770	CS PostRx Tumor Size					Retired
2775	CS PostRx Extension					Retired
2780	CS PostRx Lymph Nodes					Retired
2785	CS PostRx Mets at DX					Retired
2800	CS Tumor Size	RH*	RH	X	AJCC	
2810	CS Extension	RH*	RH	X	AJCC	
2820	CS Tumor Size/Ext Eval	RH*	RH	X	AJCC	
2830	CS Lymph Nodes	RH*	RH	X	AJCC	
2840	CS Lymph Nodes Eval	RH*	RH	X	AJCC	
2850	CS Mets at DX	RH*	RH	X	AJCC	
2851	CS Mets at Dx-Bone	.	RH	X	AJCC	
2852	CS Mets at Dx-Brain	.	RH	X	AJCC	

2853	CS Mets at Dx-Liver	.	RH	X	AJCC	
2854	CS Mets at Dx-Lung	.	RH	X	AJCC	
2860	CS Mets Eval	RH*	RH	X	AJCC	
2861	CS Site-Specific Factor 7	RH*	RH	X	AJCC	
2862	CS Site-Specific Factor 8	RH*	RH	X	AJCC	
2863	CS Site-Specific Factor 9	RH*	RH	X	AJCC	
2864	CS Site-Specific Factor10	RH*	RH	X	AJCC	
2865	CS Site-Specific Factor11	RH*	RH	X	AJCC	
2866	CS Site-Specific Factor12	RH*	RH	X	AJCC	
2867	CS Site-Specific Factor13	RH*	RH	X	AJCC	
2868	CS Site-Specific Factor14	RH*	RH	X	AJCC	
2869	CS Site-Specific Factor15	RH*	RH	X	AJCC	
2870	CS Site-Specific Factor16	RH*	RH	X	AJCC	
2871	CS Site-Specific Factor17	RH*	RH	X	AJCC	
2872	CS Site-Specific Factor18	.	RH	X	AJCC	
2873	CS Site-Specific Factor19	.	RH	X	AJCC	
2874	CS Site-Specific Factor20	.	RH	X	AJCC	
2875	CS Site-Specific Factor21	.	RH	X	AJCC	
2876	CS Site-Specific Factor22	.	RH	X	AJCC	
2877	CS Site-Specific Factor23	.	RH	X	AJCC	
2878	CS Site-Specific Factor24	.	RH	X	AJCC	
2879	CS Site-Specific Factor25	RH*	RH	X	AJCC	
2880	CS Site-Specific Factor 1	RH*	RH	X	AJCC	
2890	CS Site-Specific Factor 2	RH*	RH	X	AJCC	
2900	CS Site-Specific Factor 3	RH*	RH	X	AJCC	
2910	CS Site-Specific Factor 4	RH*	RH	X	AJCC	
2920	CS Site-Specific Factor 5	RH*	RH	X	AJCC	

2930	CS Site-Specific Factor 6	RH*	RH	X	AJCC	
2935	CS Version Input Original	R*	RH	X	AJCC	
2936	CS Version Derived	RH*	DH	X	AJCC	
2937	CS Version Input Current	R*	RH	X	AJCC	
2940	Derived AJCC-6 T	.	DH		AJCC	
2950	Derived AJCC-6 T Descript	.	DH		AJCC	
2960	Derived AJCC-6 N	.	DH		AJCC	
2970	Derived AJCC-6 N Descript	.	DH		AJCC	
2980	Derived AJCC-6 M	.	DH		AJCC	
2990	Derived AJCC-6 M Descript	.	DH		AJCC	
3000	Derived AJCC-6 Stage Grp	.	DH		AJCC	
3010	Derived SS1977	.	DH		AJCC	
3020	Derived SS2000	RH*	DH	X	AJCC	
3030	Derived AJCC--Flag	.	DH	X	AJCC	
3040	Derived SS1977--Flag	.	DH		AJCC	
3050	Derived SS2000--Flag	RH*	DH	X	AJCC	
3100	Archive FIN	.	R	X	CoC	
3105	NPI--Archive FIN	.	R	X	CMS	
3110	Comorbid/Complication 1	.	RH		CoC	
3120	Comorbid/Complication 2	.	RH		CoC	
3130	Comorbid/Complication 3	.	RH		CoC	
3140	Comorbid/Complication 4	.	RH		CoC	
3150	Comorbid/Complication 5	.	RH		CoC	
3160	Comorbid/Complication 6	.	RH		CoC	
3161	Comorbid/Complication 7	.	RH		CoC	
3162	Comorbid/Complication 8	.	RH		CoC	
3163	Comorbid/Complication 9	.	RH		CoC	

3164	Comorbid/Complication 10	.	RH		CoC	
3165	ICD Revision Comorbid	.	.		CoC	
3170	RX Date Mst Defn Srg	R	R	X	CoC	
3171	RX Date Mst Defn Srg Flag	R	.	X	NAACCR	Revised
3180	RX Date Surg Disch	.	R		CoC	
3181	RX Date Surg Disch Flag	.	.		NAACCR	Revised
3190	Readm Same Hosp 30 Days	.	R		CoC	
3200	Rad--Boost RX Modality	.	.		CoC	
3210	Rad--Boost Dose cGy	.	.		CoC	
3220	RX Date Rad Ended	.	R	X	CoC	
3221	RX Date Rad Ended Flag	.	.	X	NAACCR	Revised
3230	RX Date Systemic	.	R	X	CoC	
3231	RX Date Systemic Flag	.	.	X	NAACCR	Revised
3250	RX Summ--Transplnt/Endocr	R	R	X	CoC	
3260	Pain Assessment					Retired
3270	RX Summ--Palliative Proc	.	R		CoC	
3280	RX Hosp--Palliative Proc	.	R		CoC	
3300	RuralUrban Continuum 1993	D	.		NAACCR	
3310	RuralUrban Continuum 2003	D	.		NAACCR	
3312	RuralUrban Continuum 2013	D	.		NAACCR	
3400	Derived AJCC-7 T	RH*	DH	X	AJCC	
3402	Derived AJCC-7 T Descript	RH*	DH	X	AJCC	
3410	Derived AJCC-7 N	RH*	DH	X	AJCC	
3412	Derived AJCC-7 N Descript	RH*	DH	X	AJCC	
3420	Derived AJCC-7 M	RH*	DH	X	AJCC	
3422	Derived AJCC-7 M Descript	RH*	DH	X	AJCC	
3430	Derived AJCC-7 Stage Grp	RH*	DH	X	AJCC	
3440	Derived PreRx-7 T	.	.		AJCC	
3442	Derived PreRx-7 T Descrip	.	.		AJCC	

3450	Derived PreRx-7 N	.	.		AJCC	
3452	Derived PreRx-7 N Descrip	.	.		AJCC	
3460	Derived PreRx-7 M	.	.		AJCC	
3462	Derived PreRx-7 M Descrip	.	.		AJCC	
3470	Derived PreRx-7 Stage Grp	.	.		AJCC	
3480	Derived PostRx-7 T	.	.		AJCC	
3482	Derived PostRx-7 N	.	.		AJCC	
3490	Derived PostRx-7 M	.	.		AJCC	
3492	Derived PostRx-7 Stge Grp	.	.		AJCC	
3600	Derived Neoadjuv Rx Flag	.	.		AJCC	
3605	Derived SEER Path Stg Grp	.	.		SEER	
3610	Derived SEER Clin Stg Grp	.	.		SEER	
3614	Derived SEER Cmb Stg Grp	.	.		SEER	
3616	Derived SEER Combined T	.	.		SEER	
3618	Derived SEER Combined N	.	.		SEER	
3620	Derived SEER Combined M	.	.		SEER	
3622	Derived SEER Cmb T Src	.	.		SEER	
3624	Derived SEER Cmb N Src	.	.		SEER	
3626	Derived SEER Cmb M Src	.	.		SEER	
3645	NPCR Derived AJCC 8 TNM Clin Stg Grp	.	.		NPCR	
3646	NPCR Derived AJCC 8 TNM Path Stg Grp	.	.		NPCR	
3647	NPCR Derived AJCC 8 TNM Post Therapy Stg Grp	.	.		NPCR	
3650	NPCR Derived Clin Stg Grp	.	.		NPCR	Revised
3655	NPCR Derived Path Stg Grp	.	.		NPCR	Revised

3700	SEER Site-Specific Fact 1	.	.		SEER	
3702	SEER Site-Specific Fact 2	.	.		SEER	
3704	SEER Site-Specific Fact 3	.	.		SEER	
3706	SEER Site-Specific Fact 4	.	.		SEER	
3708	SEER Site-Specific Fact 5	.	.		SEER	
3710	SEER Site-Specific Fact 6	.	.		SEER	
3720	NPCR Specific Field	R	.		NPCR	
3750	Over-ride CS 1	.	RH		AJCC	
3751	Over-ride CS 2	.	RH		AJCC	
3752	Over-ride CS 3	.	RH		AJCC	
3753	Over-ride CS 4	.	RH		AJCC	
3754	Over-ride CS 5	.	RH		AJCC	
3755	Over-ride CS 6	.	RH		AJCC	
3756	Over-ride CS 7	.	RH		AJCC	
3757	Over-ride CS 8	.	RH		AJCC	
3758	Over-ride CS 9	.	RH		AJCC	
3759	Over-ride CS 10	.	RH		AJCC	
3760	Over-ride CS 11	.	RH		AJCC	
3761	Over-ride CS 12	.	RH		AJCC	
3762	Over-ride CS 13	.	RH		AJCC	
3763	Over-ride CS 14	.	RH		AJCC	
3764	Over-ride CS 15	.	RH		AJCC	
3765	Over-ride CS 16	.	RH		AJCC	
3766	Over-ride CS 17	.	RH		AJCC	
3767	Over-ride CS 18	.	RH		AJCC	
3768	Over-ride CS 19	.	RH		AJCC	
3769	Over-ride CS 20	.	RH		AJCC/NPCR	Revised
3780	Secondary Diagnosis 1	.	R		CoC	
3782	Secondary Diagnosis 2	.	R		CoC	
3784	Secondary Diagnosis 3	.	R		CoC	
3786	Secondary Diagnosis 4	.	R		CoC	
3788	Secondary Diagnosis 5	.	R		CoC	
3790	Secondary Diagnosis 6	.	R		CoC	

3792	Secondary Diagnosis 7	.	R		CoC	
3794	Secondary Diagnosis 8	.	R		CoC	
3796	Secondary Diagnosis 9	.	R		CoC	
3798	Secondary Diagnosis 10	.	R		CoC	
3800	Schema ID	D	D	X	NAACCR	
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	.	RS	X	NAACCR	
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	.	RS	X	NAACCR	
3803	Adenoid Cystic Basaloid Pattern	.	RS	X	NAACCR	
3804	Adenopathy	.	RS	X	NAACCR	Revised
3805	AFP Post-Orchiectomy Lab Value	.	RS	X	NAACCR	
3806	AFP Post-Orchiectomy Range	.	RS	X	NAACCR	
3807	AFP Pre-Orchiectomy Lab Value	.	RS	X	NAACCR	
3808	AFP Pre-Orchiectomy Range	.	RS	X	NAACCR	
3809	AFP Pretreatment Interpretation	.	RS	X	NAACCR	Revised
3810	AFP Pretreatment Lab Value	.	RS	X	NAACCR	
3811	Anemia	.	RS	X	NAACCR	Revised
3812	B symptoms	.	RS	X	NAACCR	Revised
3813	Bilirubin Pretreatment Total Lab Value	.	RS	X	NAACCR	
3814	Bilirubin Pretreatment Unit of Measure	.	RS	X	NAACCR	
3815	Bone Invasion	.	RS	X	NAACCR	
3816	Brain Molecular Markers	R	.	X	NAACCR	
3817	Breslow Tumor Thickness	R	RS	X	NAACCR	Revised
3818	CA-125 Pretreatment Interpretation	.	RS	X	NAACCR	Revised
3819	CEA Pretreatment Interpretation	.	RS	X	NAACCR	Revised
3820	CEA Pretreatment Lab Value	.	RS	X	NAACCR	
3821	Chromosome 3 Status	.	RS	X	NAACCR	
3822	Chromosome 8q Status	.	RS	X	NAACCR	

3823	Circumferential Resection Margin (CRM)	.	RS	X	NAACCR	Revised
3824	Creatinine Pretreatment Lab Value	.	RS	X	NAACCR	
3825	Creatinine Pretreatment Unit of Measure	.	RS	X	NAACCR	
3826	Estrogen Receptor Percent Positive or Range	.	RS	X	NAACCR	
3827	Estrogen Receptor Summary	R	RS	X	NAACCR	Revised
3828	Estrogen Receptor Total Allred Score	.	RS	X	NAACCR	
3829	Esophagus and EGJ Tumor Epicenter	.	RS	X	NAACCR	Revised
3830	Extranodal Extension Clin (non-Head and Neck)	.	RS	X	NAACCR	
3831	Extranodal Extension Head and Neck Clinical	.	RS	X	NAACCR	
3832	Extranodal Extension Head and Neck Pathological	.	RS	X	NAACCR	Revised
3833	Extranodal Extension Path (non-Head and Neck)	.	RS	X	NAACCR	
3834	Extravascular Matrix Patterns	.	RS	X	NAACCR	
3835	Fibrosis Score	R	RS	X	NAACCR	
3836	FIGO Stage	.	RS	X	NAACCR	
3837	Gestational Trophoblastic Prognostic Scoring Index	.	RS	X	NAACCR	Revised
3838	Gleason Patterns Clinical	R	RS	X	NAACCR	Revised
3839	Gleason Patterns Pathological	R	RS	X	NAACCR	Revised
3840	Gleason Score Clinical	R	RS	X	NAACCR	Revised
3841	Gleason Score Pathological	R	RS	X	NAACCR	Revised
3842	Gleason Tertiary Pattern	RS*	RS	X	NAACCR	Revised
3843	Grade Clinical	R	R	X	NAACCR	



3844	Grade Pathological	R	R	X	NAACCR	Revised
3845	Grade Post Therapy Path (yp)	R*	R	X	NAACCR	Revised
3846	hCG Post-Orchiectomy Lab Value	.	RS	X	NAACCR	
3847	hCG Post-Orchiectomy Range	.	RS	X	NAACCR	
3848	hCG Pre-Orchiectomy Lab Value	.	RS	X	NAACCR	
3849	hCG Pre-Orchiectomy Range	.	RS	X	NAACCR	
3850	HER2 IHC Summary	.	.	X	NAACCR	Revised
3851	HER2 ISH Dual Probe Copy Number	.	.	X	NAACCR	Revised
3852	HER2 ISH Dual Probe Ratio	.	.	X	NAACCR	Revised
3853	HER2 ISH Single Probe Copy Number	.	.	X	NAACCR	Revised
3854	HER2 ISH Summary	.	.	X	NAACCR	Revised
3855	HER2 Overall Summary	RS	RS	X	NAACCR	Revised
3856	Heritable Trait	.	RS	X	NAACCR	Revised
3857	High Risk Cytogenetics	.	RS	X	NAACCR	Revised
3858	High Risk Histologic Features	.	RS	X	NAACCR	
3859	HIV Status	.	.		NAACCR	Revised
3860	International Normalized Ratio Prothrombin Time	.	RS	X	NAACCR	
3861	Ipsilateral Adrenal Gland Involvement	.	RS	X	NAACCR	
3862	JAK2	.	RS	X	NAACCR	
3863	Ki-67	.	RS	X	NAACCR	
3864	Invasion Beyond Capsule	.	RS	X	NAACCR	
3865	KIT Gene Immunohistochemistry	.	RS	X	NAACCR	Revised
3866	KRAS	.	RS	X	NAACCR	
3867	LDH Post-Orchiectomy Range	.	RS	X	NAACCR	
3868	LDH Pre-Orchiectomy Range	.	RS	X	NAACCR	
3869	LDH Level	.	RS	X	NAACCR	Revised

3870	LDH Upper Limits of Normal	.	RS	X	NAACCR	
3871	LN Assessment Method Femoral-Inguinal	.	RS	X	NAACCR	
3872	LN Assessment Method Para-Aortic	.	RS	X	NAACCR	
3873	LN Assessment Method Pelvic	.	RS	X	NAACCR	
3874	LN Distant Assessment Method	.	RS	X	NAACCR	
3875	LN Distant: Mediastinal, Scalene	.	RS	X	NAACCR	
3876	LN Head and Neck Levels I-III	.	RS	X	NAACCR	
3877	LN Head and Neck Levels IV-V	.	RS	X	NAACCR	
3878	LN Head and Neck Levels VI-VII	.	RS	X	NAACCR	
3879	LN Head and Neck Other	.	RS	X	NAACCR	
3880	LN Isolated Tumor Cells (ITC)	.	RS	X	NAACCR	
3881	LN Laterality	.	RS	X	NAACCR	
3882	LN Positive Axillary Level I-II	.	RS	X	NAACCR	
3883	LN Size	.	RS	X	NAACCR	Revised
3884	LN Status Femoral-Inguinal, Para-Aortic, Pelvic	.	RS	X	NAACCR	
3885	Lymphocytosis	.	RS	X	NAACCR	Revised
3886	Major Vein Involvement	.	RS	X	NAACCR	
3887	Measured Basal Diameter	.	RS	X	NAACCR	
3888	Measured Thickness	.	RS	X	NAACCR	
3889	Methylation of O6-Methylguanine-Methyltransferase	.	RS	X	NAACCR	
3890	Microsatellite Instability (MSI)	RS*	RS	X	NAACCR	Revised
3891	Microvascular Density	.	RS	X	NAACCR	
3892	Mitotic Count Uveal Melanoma	.	RS	X	NAACCR	
3893	Mitotic Rate Melanoma	.	RS	X	NAACCR	Revised

3894	Multigene Signature Method	.	RS	X	NAACCR	
3895	Multigene Signature Results	.	RS	X	NAACCR	
3896	NCCN International Prognostic Index (IPI)	.	RS	X	NAACCR	
3897	Number of Cores Examined	.	RS	X	NAACCR	Revised
3898	Number of Cores Positive	.	RS	X	NAACCR	Revised
3899	Number of Examined Para-Aortic Nodes	.	RS	X	NAACCR	
3900	Number of Examined Pelvic Nodes	.	RS	X	NAACCR	
3901	Number of Positive Para-Aortic Nodes	.	RS	X	NAACCR	
3902	Number of Positive Pelvic Nodes	.	RS	X	NAACCR	
3903	Oncotype Dx Recurrence Score-DCIS	.	RS	X	NAACCR	
3904	Oncotype Dx Recurrence Score-Invasive	.	RS	X	NAACCR	Revised
3905	Oncotype Dx Risk Level-DCIS	.	RS	X	NAACCR	
3906	Oncotype Dx Risk Level-Invasive	.	RS	X	NAACCR	
3907	Organomegaly	.	RS	X	NAACCR	Revised
3908	Percent Necrosis Post Neoadjuvant	.	RS	X	NAACCR	Revised
3909	Perineural Invasion	.	RS	X	NAACCR	
3910	Peripheral Blood Involvement	.	RS	X	NAACCR	Revised
3911	Peritoneal Cytology	.	RS	X	NAACCR	
3913	Pleural Effusion	.	RS	X	NAACCR	
3914	Progesterone Receptor Percent Positive or Range	.	RS	X	NAACCR	
3915	Progesterone Receptor Summary	R	RS	X	NAACCR	Revised
3916	Progesterone Receptor Total Allred Score	.	RS	X	NAACCR	
3917	Primary Sclerosing Cholangitis	.	RS	X	NAACCR	

3918	Profound Immune Suppression	.	RS	X	NAACCR	
3919	EOD Prostate Pathologic Extension	.	.		SEER	Revised
3920	PSA (Prostatic Specific Antigen) Lab Value	R	RS	X	NAACCR	Revised
3921	Residual Tumor Volume Post Cytoreduction	.	RS	X	NAACCR	
3922	Response to Neoadjuvant Therapy	.	RS	X	NAACCR	
3923	S Category Clinical	.	RS	X	NAACCR	Revised
3924	S Category Pathological	.	RS	X	NAACCR	Revised
3925	Sarcomatoid Features	.	RS	X	NAACCR	
3926	Schema Discriminator 1	R	RS	X	NAACCR	Revised
3927	Schema Discriminator 2	R	RS	X	NAACCR	Revised
3928	Schema Discriminator 3	.	RS		NAACCR	Revised
3929	Separate Tumor Nodules	.	RS	X	NAACCR	
3930	Serum Albumin Pretreatment Level	.	RS	X	NAACCR	Revised
3931	Serum Beta-2 Microglobulin Pretreatment Level	.	RS	X	NAACCR	Revised
3932	LDH Lab Value	R	RS	X	NAACCR	Revised
3933	Thrombocytopenia	.	RS	X	NAACCR	Revised
3934	Tumor Deposits	.	RS	X	NAACCR	
3935	Tumor Growth Pattern	.	RS	X	NAACCR	
3936	Ulceration	.	RS	X	NAACCR	Revised
3937	Visceral and Parietal Pleural Invasion	.	RS	X	NAACCR	
3938	ALK Rearrangement	.	RS	X	NAACCR	New
3939	EGFR Mutational Analysis	.	RS	X	NAACCR	New
3940	BRAF Mutational Analysis	.	RS	X	NAACCR	New
3941	NRAS Mutational Analysis	.	RS	X	NAACCR	New
3942	CA 19-9 PreTX Lab Value	.	RS	X	NAACCR	New
3943	NCDB--SARSCoV2--Test	.	R*	X	CoC	New
3944	NCDB--SARSCoV2--Pos	.	R*	X	CoC	New
3945	NCDB--SARSCoV2--Pos Date	.	R*	X	CoC	New

3946	NCDB--COVID19--Tx Impact	.	R*	X	CoC	New
7010	Path Reporting Fac ID 1	.	.		HL7	
7011	Path Reporting Fac ID 2	.	.		HL7	
7012	Path Reporting Fac ID 3	.	.		HL7	
7013	Path Reporting Fac ID 4	.	.		HL7	
7014	Path Reporting Fac ID 5	.	.		HL7	
7090	Path Report Number 1	.	.		HL7	
7091	Path Report Number 2	.	.		HL7	
7092	Path Report Number 3	.	.		HL7	
7093	Path Report Number 4	.	.		HL7	
7094	Path Report Number 5	.	.		HL7	
7100	Path Order Phys Lic No 1	.	.		HL7	
7101	Path Order Phys Lic No 2	.	.		HL7	
7102	Path Order Phys Lic No 3	.	.		HL7	
7103	Path Order Phys Lic No 4	.	.		HL7	
7104	Path Order Phys Lic No 5	.	.		HL7	
7190	Path Ordering Fac No 1	.	.		HL7	
7191	Path Ordering Fac No 2	.	.		HL7	
7192	Path Ordering Fac No 3	.	.		HL7	
7193	Path Ordering Fac No 4	.	.		HL7	
7194	Path Ordering Fac No 5	.	.		HL7	
7320	Path Date Spec Collect 1	.	.		HL7	
7321	Path Date Spec Collect 2	.	.		HL7	
7322	Path Date Spec Collect 3	.	.		HL7	
7323	Path Date Spec Collect 4	.	.		HL7	
7324	Path Date Spec Collect 5	.	.		HL7	
7480	Path Report Type 1	.	.		HL7	
7481	Path Report Type 2	.	.		HL7	
7482	Path Report Type 3	.	.		HL7	
7483	Path Report Type 4	.	.		HL7	
7484	Path Report Type 5	.	.		HL7	

9960	Height	R	.	X	NPCR	
9961	Weight	R	.	X	NPCR	
9965	Tobacco Use Cigarette	R	.	X	NPCR	
9966	Tobacco Use Other Smoke	R	.	X	NPCR	
9967	Tobacco Use Smokeless	R	.	X	NPCR	
9968	Tobacco Use NOS	R	.	X	NPCR	
9980	EDP MDE Link	R	.		NPCR	
9981	EDP MDE Link Date	R	.		NPCR	
9990	HIS Purchased/Referred Care Delivery Area	R	.		NPCR	
9991	Urban Indian Health Organization	R	.		NPCR	
9992	Urban Indian health Organization (UIHO) Facility	R	.		NPCR	
12010	ECC Flag					

**Codes for Recommendation:**

. No recommendation  
D Derived  
D\* Derived, when available  
R Required  
R# Required; central registries may code available data using either SEER or CoC data items and associated rules  
R\* Required, when available  
R^ Required, these text requirements may be met with one or several text block fields  
RC Collected by SEER from CoC-accredited hospitals  
RH Historically collected and currently transmitted  
RH\* Historically collected and currently transmitted when available  
RS Required, site specific  
RS\* Required, site specific; when available  
S Supplementary/recommended

## Appendix G: NAACCR Approved Abstract Abbreviation List

Formatted: Font: 16 pt, Font color: Accent 1

### NAACCR RECOMMENDED ABBREVIATION LIST ORDERED BY WORD/TERM(S)

WORD/TERM(S)	ABBREVIATION/SYMBOL
<b>A</b>	
Abdomen (abdominal)	ABD
Abdomen/Pelvis	A/P
Abdominal perineal	AP
Abnormal	ABN or ABNL
Above	^
Above knee (amputation)	AK(A)
Absent/Absence	ABS
Abstract/Abstracted	ABST
Achilles tendon reflex	ATR
Acid phosphatase	ACID PHOS
Acquired Immune Deficiency Syndrome	AIDS
Activities of daily living	ADL
Acute granulocytic leukemia	AGL
Acute lymphocytic leukemia	ALL
Acute myelogenous leukemia	AML
Acute myocardial infarction	AMI
Acute renal failure	ARF
Acute Respiratory Distress (Disease) Syndrome	ARDS
Acute tubular necrosis	ATN
Adenocarcinoma	ADENOCA
Adenopathy	ADENOP
Adenosine triphosphate	ATP
Adjacent	ADJ
Admission/Admit	ADM
Adrenal cortex	AC
Adrenal cortical hormone	ACH
Adrenocorticotrophic hormone	ACTH
Adult-onset Diabetes Mellitus	AODM
Adverse drug reaction	ADR
Affirmative	AFF
African American	AA
Against medical advice	AMA
AIDS-related condition (complex)	ARC

WORD/TERM(S)	ABBREVIATION/SYMBOL
AIDS-related disease	ARD
Air contrast barium enema	ACBE
Albumin	ALB
Alcohol	ETOH
Alkaline phosphatase	ALK PHOS
Alpha-fetoprotein	AFP
Also known as	AKA
Ambulatory	AMB
Amount	AMT
Amputation	AMP
Amyotrophic lateral sclerosis	ALS
Anal intraepithelial neoplasia, grade III	AIN III or AIN 3
Anaplastic	ANAP
And	&
Angiography/Angiogram	ANGIO
Anterior	ANT
Anteroposterior	A-P
Antibiotics	ABX
Antibody	AB
Antidiuretic hormone	ADH
Antigen	AG
Aortic stenosis	A-STEN
Apparently	APPL'Y
Appendix	APP
Approximately	≈
Aromatase inhibitor	AI
Arrhythmia	ARRHY
Arterial blood gases	ABG
Arteriosclerotic cardiovascular disease	ASCVD
Arteriosclerotic heart disease	ASHD
Arteriosclerotic Peripheral Vascular Disease	ASPVD
Arteriosclerosis/Arteriosclerotic	AS
Arteriovenous	AV
Arteriovenous malformation	AVM
Artery (ial)	ART
As soon as possible	ASAP
Ascending colon	A-COLON
Aspiration	ASP
Aspirin, Acetylsalicylic acid	ASA



WORD/TERM(S)	ABBREVIATION/SYMBOL
Associated	ASSOC
At	@
Atrial fibrillation	A FIB
Atrial flutter	A FLUTTER
Atrial premature complexes	APC
Atrial stenosis/insufficiency/incompetence	AI
Auscultation & percussion	A&P
Autoimmune hemolytic anemia	AIHA
Autonomic nervous system	ANS
Autopsy	AUT
Average	AVG
Axilla(ry)	AX
Axillary lymph node dissection	AXLND or ALND
<b>B</b>	
Bacillus Calmette-Guerin	BCG
Barium	BA
Barium enema	BE
Bartholin's, Urethral & Skene's	BUS
Basal cell carcinoma	BCC
Base of tongue	BOT
Before noon	AM
Below knee (amputation)	BK(A)
Benign prostatic hypertrophy/hyperplasia	BPH
Bilateral	BIL or B/L
Bilateral salpingo-oophorectomy	BSO
Bile duct	BD
Biological response modifier	BRM
Biopsy	BX
Bipolar affective disorder	BAD
Black female	B/F or BF
Black male	B/M or BM
Bladder tumor	BT
Blood pressure	BP
Blood urea nitrogen	BUN
Blood volume	BV
Bloom-Richardson	BR
Body mass index	BMI
Body surface area	BSA
Bone marrow	BM

WORD/TERM(S)	ABBREVIATION/SYMBOL
Bone marrow biopsy	BMBX
Bone marrow transplant	BMT
Bone scan	BSC
Bowel movement	BM
Brachytherapy	BRACHY
Brain tumor	BT
Breast cancer susceptibility gene	BRCA 1 and BRCA 2
Bright red blood per rectum	BRBPR
Brother	BRO
<b>C</b>	
Calcification(s)	CA++ or CALC(S)
Calcium	CA
Cancer	Spell out; do not abbreviate
Cancer Antigen 125	CA 125
Capsule(s)	CAP(S)
Carbohydrate Antigen 19-9	CA 19-9
Carcinoembryonic antigen	CEA
Carcinoma	CA
Carcinoma <i>in situ</i>	CIS
Cardiovascular disease	CVD
CAT/CT scan/Computerized axial tomography	CT
Centigray	CGY
Centimeter	CM
Centimeters from nipple	CFN
Central nervous system	CNS
Cerebrospinal fluid	CSF
Cerebrovascular accident	CVA
Cervical intraepithelial neoplasia	CIN
Cervical intraepithelial neoplasia, grade III	CIN III or CIN 3
Cervical spine	C-SPINE
Cervical vertebrae	C1-C7
Change	CHG
Chemotherapy	CHEMO
Chest, abdomen, pelvis	C/A/P
Chest X-ray	CXR
Chief complaint	CC
Chromogenic in situ hybridization	CISH
Chronic	CHR
Chronic granulocytic leukemia	CGL

WORD/TERM(S)	ABBREVIATION/SYMBOL
Chronic lymphocytic leukemia	CLL
Chronic myeloid (myelocytic) leukemia	CML
Chronic obstructive lung disease	COLD
Chronic obstructive pulmonary disease	COPD
Chronic renal failure	CRF
Chronic ulcerative colitis	CUC
Cigarettes	CIG
Circulating tumor cells	CTC
Circumferential resection margin	CRM
Clear	CLR
Cobalt 60	CO60
Collaborative stage	CS
Colon, Ascending	A-COLON
Colon, Descending	D-COLON
Colon, Sigmoid	SIG COLON or S-COLON
Colon, Transverse	TRANS-COLON or T-COLON
Colony-stimulating factor	C-SF
Complaint (-ning) of	C/O
Complete blood count	CBC
Congenital heart disease	CHD
Congestive heart failure	CHF
Consistent with	C/W
Continue/continuous	CONT
Contralateral	CONTRA
Coronary artery bypass graft	CABG
Coronary artery disease	CAD
Coronary care unit	CCU
Cubic centimeter	CC
Cystic fibrosis	CF
Cystoscopy	CYSTO
Cytology	CYTO
<b>D</b>	
Date of birth	DOB
Date of death	DOD
Dead on arrival	DOA
Decrease(d)	DECR
Deep tendon reflex	DTR
Deep vein thrombosis	DVT
Degenerative joint disease	DJD

WORD/TERM(S)	ABBREVIATION/SYMBOL
Deoxyribonucleic acid	DNA
Dermatology	DERM
Descending colon	D-COLON
Diabetes mellitus	DM
Diagnosis	DX
Diameter	DIAM
Diethylstilbestrol	DES
Differentiated/differential	DIFF
Differential diagnosis	DDX
Digital rectal examination	DRE
Dilatation and curettage	D&C
Discharge	DISCH or D/C
Discontinue(d)	DC
Disease	DZ
Disseminated intravascular coagulopathy	DIC
Disseminated tumor cells	DTC
Don't /Doesn't know	DK
Ductal carcinoma <i>in situ</i>	DCIS
Due to	D/T
Dyspnea on exertion	DOE
<b>E</b>	
Ears, nose, and throat	ENT
Electrocardiogram	ECG/EKG
Electroencephalogram	EEG
Electromyogram	EMG
Electron volt	EV
Elevated	ELEV or ^
Emergency department	ED
Emergency room	ER
End stage renal disease	ESRD
Endoscopic retrograde cholangiopancreatography	ERCP
Enlarged	ENLGD or ENL
Epidermal growth factor receptor	EGFR
Equal(s)	=
Esophagogastro-duodenoscopy	EGD
Estrogen receptor (assay)	ER(A)
Evaluation	EVAL
Every	Q
Every day	QD

WORD/TERM(S)	ABBREVIATION/SYMBOL
Evidence of	E/O
Exam under anesthesia	EUA
Examination	EXAM
Excision/excised	EXC(D)
Expired	EXP
Exploratory	EXPL
Exploratory laparotomy	EXPL LAP or EXP LAP
Extend/extension	EXT
External beam radiotherapy	EBRT
External radiation therapy	XRT
Eye, ear, nose, throat	EENT
<b>F</b>	
Familial adenomatous polyposis	FAP
Family History	FHX
Fever of unknown origin	FUO
Fine needle aspiration	FNA
Fine needle aspiration biopsy	FNAB
First course of treatment	FCOT
Floor of mouth	FOM
Flow cytometry	FLOW CYTO
Fluid	FL
Fluorescence in situ hybridization	FISH
Fluoroscopy	FLURO
Follicular lymphoma international prognostic index	FLIPI
Follow-up	FU
For example	E.G.
Fraction(s)	FX(S)
Fracture	FX
Frequent/Frequency	FREQ
Frozen section	FS
Full thickness skin graft	FTSG
<b>G</b>	
Gallbladder	GB
Gastroesophageal	GE
Gastroesophageal reflux disease	GERD
Gastrointestinal	GI
Gastrointestinal stromal tumors	GIST
General/Generalized	GEN
Genitourinary	GU

WORD/TERM(S)	ABBREVIATION/SYMBOL
Grade	GR
Gray	GY
Greater/Greater than	>
Gynecology	GYN
<b>H</b>	
Hematocrit	HCT
Hematology/Oncology (ist)	HEM/ONC
Hematoxylin and Eosin	H&E
Hemoglobin	HGB
Hemoglobin and hematocrit	H/H
Hepatitis A (virus)	HAV or HEP A
Hepatitis B (virus)	HBV or HEP B
Hepatitis C (virus)	HCV or HEP C
Hepatitis D (virus)	HDV or HEP D
Hepatosplenomegaly	HSM
High dose rate	HDR
High grade squamous intraepithelial lesion	HGSIL
Hispanic female	HF
Hispanic male	HM
History	HX
History and physical	H&P
History of	H/O
History of present illness	HPI
Hormone	HORM
Hormone replacement therapy	HRT
Hospital	HOSP
Hour(s)	HR(S)
Human chorionic gonadotropin	HCG
Human epidermal growth factor receptor 2	HER2
Human Immunodeficiency Virus	HIV
Human Papilloma Virus	HPV
Human T-Lymphotropic Virus, (Type III)	HTLV
Hypertension	HTN
Hypertensive cardiovascular disease	HCVD
Hypertensive vascular disease	HVD
Hysterectomy	HYST
<b>I</b>	
Idiopathic hypertrophic subaortic stenosis	IHSS
Idiopathic thrombocytopenia	ITP

WORD/TERM(S)	ABBREVIATION/SYMBOL
Immunoglobulin	IG
Immunohistochemical	IHC
Impression	IMP
Incision & drainage	I&D
Includes/Including	INCL
Increase(d)	INCR
Inferior	INF
Inferior vena cava	IVC
Infiltrating	INFILT or INFIL
Infiltrating/invasive ductal carcinoma	IDC
Inflammatory bowel disease	IBD
Inpatient	IP or INPT
Insulin-dependent diabetes mellitus	IDDM
Intensity modulated radiation therapy	IMRT
Intensive care unit	ICU
Intercostal margin	ICM
Intercostal space	ICS
Intermittent positive pressure breathing	IPPB
Internal	INT
International prognostic index (for lymphoma)	IPI
International prognostic score	IPS
Interstitial lung disease	ILD
Intracavitary brachytherapy	ICB
Intramuscular	IM
Intraperitoneal	IP
Intrathecal	IT
Intravenous	IV
Intravenous cholangiogram	IVCA
Intravenous pyelogram	IVP
Invade(s)/invading/invasion	INV
Involve(s)/involvement/involving	INVL
Iodine 131	I-131
Ipsilateral	IPSI
Irregular	IRREG
Isolated tumor cells	ITC
<b>J</b>	
Janus kinase 2	JAK2
Jugular venous distention	JVD
Juvenile rheumatic arthritis	JRA

WORD/TERM(S)	ABBREVIATION/SYMBOL
<b>K</b>	
Kaposi sarcoma	KS
Kidneys, ureters, bladder	KUB
Kilogram	KG
Kilovolt	KV
<b>L</b>	
Laboratory	LAB
Lactic dehydrogenase	LDH
Laparotomy	LAP
Large	LRG
Laryngeal intraepithelial neoplasia	LIN
Last menstrual period	LMP
Lateral	LAT
Left	LT
Left bundle branch block	LBBS
Left costal margin	LCM
Left lower extremity	LLE
Left lower lobe	LLL
Left lower quadrant	LLQ
Left salpingo-oophorectomy	LSO
Left upper extremity	LUE
Left upper lobe	LUL
Left upper outer quadrant	LUOQ
Left upper quadrant	LUQ
Less/Less than	<
Licensed practical nurse	LPN
Linear accelerator	LINAC
Liver function test	LFT
Liver/spleen scan	LS SCAN
Lobular carcinoma in situ	LCIS
Low dose rate	LDR
Lower extremity	LE
Lower inner quadrant	LIQ
Lower outer quadrant	LOQ
Lumbar spine	L-SPINE
Lumbar vertebra	L1-L5
Lumbosacral	LS
Lupus erythematosus	SLE
Lymph node(s)	LN(S)



WORD/TERM(S)	ABBREVIATION/SYMBOL
Lymph node dissection	LND
Lymphadenopathy	LAD or LAN
Lymphadenopathy-associated virus	LAV
Lymph/vascular invasion / Lymphovascular invasion	LVI
<b>M</b>	
Macrophage colony-stimulating factor	M-CSF
Magnetic resonance cholangiopancreatography	MRCP
Magnetic resonance imaging	MRI
Main stem bronchus	MSB
Malignant/malignancy	MALIG or MAL
Malignant melanoma	Spell out; do not abbreviate
Mammogram	MMG or MAMMO
Mandible/mandibular	MAND
Maternal grandfather	MGF
Maternal grandmother	MGM
Maximum	MAX
Medical center	MC
Medical Oncology (ist)	MED ONC
Medication	MED
Megavolt	MV
Melanoma in situ	MIS
Metastatic/Metastasis	METS
Methicillin Resistant Staphylococcus Aureus	MRSA
Microgram	MCG
Microsatellite instability	MSI
Microscopic	MICRO
Middle lobe	ML
Millicurie (hours)	MC(H)
Milligram (hours)	MG(H)
Milliliter	ML
Millimeter	MM
Million electron volts	MEV
Minimally invasive breast biopsy	MIBB
Minimum	MIN
Minus	-
Minute	MIN
Mitral valve prolapse	MVP
Mixed combined immunodeficiency	MCID
Mixed connective tissue disease	MCTD

WORD/TERM(S)	ABBREVIATION/SYMBOL
Moderate(ly)	MOD
Moderately differentiated	MD, MOD DIFF or M/DIFF
Modified radical mastectomy	MRM
Monoclonal gammaopathy of uncertain significance	MGUS
Month(s)	MO(S)
More/More than	>
Mucinous cystic neoplasm	MCN
Multifocal atrial tachycardia	MAT
Multifocal premature ventricular contraction	MPVC
Multiple	MULT
Multiple sclerosis	MS
Multiple myeloma	Spell out; do not abbreviate
Myasthenia gravis	MG
Myelodysplastic syndrome	MDS
Myocardial infarction	MI
<b>N</b>	
Nausea and vomiting, nausea/vomiting	N&V or N/V
Neck vein distention	NVD
Negative	NEG or -
Neoplasm	NEOPL
Neuroendocrine tumor	NET
Neurology	NEURO
No evidence	NE
No evidence of disease	NED
No significant findings	NSF
Non-Hodgkin lymphoma	NHL
Non insulin dependent diabetes mellitus	NIDDM
Non small cell carcinoma	NSCCA
Non small cell lung carcinoma	NSCLC
Normal	NL or NML or NORM
Not applicable	NA or N/A
Not elsewhere classified	NEC
Not otherwise specified	NOS
Not recorded	NR
Not reportable	NR
Number	#
Nursing home	NH
<b>O</b>	
Obstetrics	OB

WORD/TERM(S)	ABBREVIATION/SYMBOL
Obstructed (-ing, -ion)	OBST
Oncology (ist)	ONC
Operating room	OR
Operative report	OP RPT
Organic brain syndrome	OBS
Orthopedics	ORTHO
Otology	OTO
Ounce	OZ
Outpatient	OP or OUTPT
<b>P</b>	
Pack years	PY
Packs per day	PPD
Palpated (-able)	PALP
Papanicolaou smear	PAP
Papillary	PAP
Papillary transitional cell carcinoma	PTCC
Past/personal (medical) history	PMH
Paternal grandfather	PGF
Paternal grandmother	PGM
Pathology	PATH
Patient	PT
Pediatrics	PEDS
Pelvic inflammatory disease	PID
Peptic ulcer disease	PUD
Per rectum	PR
Percutaneous	PERC
Percutaneous transhepatic cholecystogram	PTC
Performance status	PS
Peripheral blood stem cell transplant	PBSCT
Peripheral nervous system	PNS
Peripheral vascular disease	PVD
Phosphorus 32	P32
Physical examination	PE
Physiotherapy/Physical therapy	PT
Platelets	PLT
Plus	+
Polycythemia vera	P VERA or PCV
Poorly differentiated	PD, POOR DIFF or P/DIFF
Positive	POS or +

WORD/TERM(S)	ABBREVIATION/SYMBOL
Positron emission tomography	PET
Possible	POSS
Posterior	POST
Postoperative(-ly)	POST OP
Pound(s)	LB(S) or #
Premature atrial contraction	PAC
Preoperative(-ly)	PRE OP
Prescription	RX
Previous	PREV
Primary care physician	PCP
Primary medical physician	PMP
Prior to admission	PTA
Probable (-ly)	PROB
Proctoscopy	PROCTO
Progesterone receptor (assay)	PR(A)
Prostatic intraepithelial neoplasia, grade III	PIN III or PIN 3
Prostatic specific antigen	PSA
Pulmonary	PULM
<b>Q</b>	
Quadrant	QUAD
<b>R</b>	
Radiation absorbed dose	RAD
Radiation Oncology	RAD ONC or RONC
Radiation therapy	RT or RXT
Radical retropubic prostatectomy	RRP
Radioactive iodine	RAI
Radioactive iodine uptake	RAIU
Radioimmunoassay	RIA
Received	REC'D
Recommend	REC
Red blood cells (count)	RBC
Refractory anemia	REFRACT ANEM
Refractory anemia with excess blasts	RAEB
Regarding	RE
Regional	REG
Regional medical center	RMC
Regular	REG
Regular sinus rhythm	RSR
Renal cell carcinoma	RCC

WORD/TERM(S)	ABBREVIATION/SYMBOL
Resection (ed)	RESEC
Reticulum cell sarcoma	RCS
Review of outside films	ROF
Review of outside slides	ROS
Rheumatic heart disease	RHD
Rheumatoid arthritis	RA
Right	RT
Right bundle branch block	RBBB
Right costal margin	RCM
Right inner quadrant	RIQ
Right lower extremity	RLE
Right lower lobe	RLL
Right lower quadrant	RLQ
Right middle lobe	RML
Right outer quadrant	ROQ
Right salpingo-oophorectomy	RSO
Right upper extremity	RUE
Right upper lobe	RUL
Right upper quadrant	RUQ
Robotic assisted laparoscopy	RAL
Robotic assisted radical prostatectomy	RARP
Rule out	R/O
<b>S</b>	
Sacral spine	S-SPINE
Sacral vertebra	S1-S5
Salpingo-oophorectomy	SO
Satisfactory	SATIS
Sentinel lymph node	SLN
Sentinel lymph node biopsy	SLNBX
Serum Chromogranin A	CGA
Serum glutamic oxaloacetic transaminase	SGOT
Serum glutamic pyruvic transaminase	SGPT
Serum protein electrophoresis	SPEP
Severe combined immunodeficiency syndrome	SCID
Short(ness) of breath	SOB
Sick sinus syndrome	SSS
Sigmoid colon	SIG COLON or S-COLON
Small	SM
Small bowel	SB

WORD/TERM(S)	ABBREVIATION/SYMBOL
Small cell carcinoma	SmCC
Small lymphocytic lymphoma	SLL
Social history	SH or SHX
Specimen	SPEC
Spine, Cervical	C-SPINE
Spine, Lumbar	L-SPINE
Spine, Sacral	S-SPINE
Spine, Thoracic	T-SPINE
Split thickness skin graft	STSG
Squamous	SQ
Squamous cell carcinoma	SCC or SQCC
Squamous intraepithelial neoplasia	SIN III or SIN 3
Status post	S/P
Stem cell transplant	SCT
Subcutaneous	SUBCU or SUBQ
Suggestive	SUGG
Summary stage	SS
Superior vena cava	SVC
Supraclavicular	SCV
Supraclavicular fossa	SCF
Surgery/Surgical	SURG
Suspicious/suspected	SUSP
Symptoms	SX
Syndrome of inappropriate ADH	SIADH
Systemic lupus erythematosus	SLE
<b>T</b>	
Thoracic spine	T-SPINE
Thoracic vertebra	T1-T12
Thrombotic thrombocytopenia purpura	TTP
Times	X
Tobacco	TOB
Total abdominal hysterectomy	TAH
Total abdominal hysterectomy- bilateral salpingo-oophorectomy	TAH-BSO
Total vaginal hysterectomy	TVH
Transient ischemic attack	TIA
Transitional cell carcinoma	TCC
Transrectal ultrasound	TRUS
Transurethral resection	TUR
Transurethral resection bladder	TURB

WORD/TERM(S)	ABBREVIATION/SYMBOL
Transurethral resection prostate	TURP
Transverse colon	TRANS-COLON or T-COLON
Treatment	TX
True vocal cord	TVC
Tuberculosis	TB
Tumor board	TB
Tumor, node, metastasis	TNM
Tumor size	TS
Twice a day (daily)	BID
<b>U</b>	
Ultrasound	US
Undifferentiated	UNDIFF
Unknown	UNK
Upper extremity	UE
Upper gastrointestinal (series)	UGI
Upper inner quadrant	UIQ
Upper outer quadrant	UOQ
Upper respiratory infection	URI
Urinary tract infection	UTI
<b>V</b>	
Vagina/Vaginal	VAG
Vaginal hysterectomy	VAG HYST
Vaginal intraepithelial neoplasia (grade III)	VAIN III or VAIN 3
Vertical growth phase	VGP
Vertical growth rate	VGR
Vital signs	VS
Vulvar intraepithelial neoplasia (grade III)	VIN III or VIN 3
<b>W</b>	
Weeks(s)	WK(S)
Weight	WT
Weight loss	WL
Well differentiated	WD, WELL DIF or W/DIFF
White blood cells (count)	WBC
White female	W/F or WF
White male	W/M or WM
With	W/
Within normal limits	WNL
Without	W/O
Wolff-Parkinson-White syndrome	WPW

WORD/TERM(S)	ABBREVIATION/SYMBOL
Work-up	W/U
<b>X</b>	
Xray	XR
<b>Y</b>	
Year(s)	YR(S)
Year old	YO or Y/O

**NAACCR RECOMMENDED ABBREVIATION LIST  
ORDERED BY ABBREVIATION/SYMBOL**

ABBREVIATION/SYMBOL	WORD/TERM(S)
^	Above or elevated
&	And
≈	Approximately
@	At
=	Equals
>	Greater than, more, or more than
<	Less or less than
-	Negative or minus
#	Number or pound(s)
+	Plus or positive
X	Times
<b>A</b>	
A FIB	Atrial fibrillation
A FLUTTER	Atrial flutter
A&P	Auscultation & percussion
A/P	Abdomen/Pelvis
AA	African American
AB	Antibody
ABD	Abdomen (abdominal)
ABG	Arterial blood gases
ABN	Abnormal
ABNL	Abnormal
ABS	Absent/Absence
ABST	Abstract/Abstracted
ABX	Antibiotics
AC	Adrenal cortex
ACBE	Air contrast barium enema
ACH	Adrenal cortical hormone



ABBREVIATION/SYMBOL	WORD/TERM(S)
ACID PHOS	Acid phosphatase
A-COLON	Ascending Colon
ACTH	Adrenocorticotrophic hormone
ADENOCA	Adenocarcinoma
ADENOP	Adenopathy
ADH	Antidiuretic hormone
ADJ	Adjacent
ADL	Activities of daily living
ADM	Admission/Admit
ADR	Adverse drug reaction
AFF	Affirmative
AFP	Alpha-fetoprotein
AG	Antigen
AGL	Acute granulocytic leukemia
AI	Aromatase inhibitor
AI	Atrial stenosis/insufficiency/incompetence
AIDS	Acquired Immune Deficiency Syndrome
AIHA	Autoimmune hemolytic anemia
AIN III or AIN 3	Anal intraepithelial neoplasia, grade III
AK(A)	Above knee (amputation)
AKA	Also known as
ALB	Albumin
ALK PHOS	Alkaline phosphatase
ALL	Acute lymphocytic leukemia
ALND	Axillary Lymph node dissection
ALS	Amyotrophic lateral sclerosis
AM	Before noon
AMA	Against medical advice
AMB	Ambulatory
AMI	Acute myocardial infarction
AML	Acute myelogenous leukemia
AMP	Amputation
AMT	Amount
ANAP	Anaplastic
ANGIO	Angiography/Angiogram
ANS	Autonomic nervous system
ANT	Anterior
AODM	Adult-onset Diabetes Mellitus
AP	Abdominal perineal

ABBREVIATION/SYMBOL	WORD/TERM(S)
A-P	Anteroposterior
APC	Atrial premature complexes
APP	Appendix
APPL'Y	Apparently
ARC	AIDS-related condition (complex)
ARD	AIDS-related disease
ARDS	Acute Respiratory Distress (Disease) Syndrome
ARF	Acute renal failure
ARRHY	Arrhythmia
ART	Artery (ial)
AS	Arteriosclerosis/Arteriosclerotic
ASA	Aspirin, Acetylsalicylic acid
ASAP	As soon as possible
ASCVD	Arteriosclerotic cardiovascular disease
ASHD	Arteriosclerotic heart disease
ASP	Aspiration
ASPVD	Arteriosclerotic Peripheral Vascular Disease
ASSOC	Associated
A-STEN	Aortic stenosis
ATN	Acute tubular necrosis
ATP	Adenosine triphosphate
ATR	Achilles tendon reflex
AUT	Autopsy
AV	Arteriovenous
AVG	Average
AVM	Arteriovenous malformation
AX	Axilla(ry)
AXLND	Axillary Lymph node dissection
<b>B</b>	
B/F	Black female
B/L	Bilateral
B/M	Black male
BA	Barium
BAD	Bipolar affective disorder
BCC	Basal cell carcinoma
BCG	Bacillus Calmette-Guerin
BD	Bile duct
BE	Barium enema
BF	Black female

ABBREVIATION/SYMBOL	WORD/TERM(S)
BID	Twice a day (daily)
BIL	Bilateral
BK(A)	Below knee (amputation)
B/L	Bilateral
BM	Black Male
BM	Bone marrow
BM	Bowel movement
BMBX	Bone marrow biopsy
BMI	Body mass index
BMT	Bone marrow transplant
BOT	Base of tongue
BP	Blood pressure
BPH	Benign prostatic hypertrophy/hyperplasia
BR	Bloom-Richardson
BRACHY	Brachytherapy
BRBPR	Bright red blood per rectum
BRCA 1 and BRCA 2	Breast cancer susceptibility gene
BRM	Biological response modifier
BRO	Brother
BSA	Body surface area
BSC	Bone scan
BSO	Bilateral salpingo-oophorectomy
BT	Bladder tumor or Brain tumor
BUN	Blood urea nitrogen
BUS	Bartholin's, Urethral & Skene's
BV	Blood volume
BX	Biopsy
<b>C</b>	
C/A/P	Chest, abdomen, pelvis
C/O	Complaint (-ing) of
C/W	Consistent with
C1-C7	Cervical vertebrae
CA	Calcium
CA	Carcinoma
CA 125	Cancer antigen 125
CA 19-9	Carbohydrate antigen 19-9
CA++	Calcification(s)
CABG	Coronary artery bypass graft
CAD	Coronary artery disease

ABBREVIATION/SYMBOL	WORD/TERM(S)
CALC(S)	Calcification(s)
CAP(S)	Capsule(s)
CBC	Complete blood count
CC	Chief complaint or Cubic centimeter
CCU	Coronary care unit
CEA	Carcinoembryonic antigen
CF	Cystic fibrosis
CFN	Centimeters from nipple
CGA	Serum chromogranin A
CGL	Chronic granulocytic leukemia
CGY	Centigray
CHD	Congenital heart disease
CHEMO	Chemotherapy
CHF	Congestive heart failure
CHG	Change
CHR	Chronic
CIG	Cigarettes
CIN	Cervical intraepithelial neoplasia
CIN III or CIN 3	Cervical intraepithelial neoplasia, grade III
CIS	Carcinoma <i>in situ</i>
CISH	Chromogenic in situ hybridization
CLL	Chronic lymphocytic leukemia
CLR	Clear
CM	Centimeter
CML	Chronic myeloid (myelocytic) leukemia
CNS	Central nervous system
CO60	Cobalt 60
COLD	Chronic obstructive lung disease
CONT	Continue/continuous
CONTRA	Contralateral
COPD	Chronic obstructive pulmonary disease
CRF	Chronic renal failure
CRM	Circumferential resection margin
CS	Collaborative stage
CSF	Cerebrospinal fluid
C-SF	Colony stimulating factor
C-SPINE	Cervical spine
CT	CAT/CT scan/Computerized axial tomography
CTC	Circulating tumor cells

ABBREVIATION/SYMBOL	WORD/TERM(S)
CUC	Chronic ulcerative colitis
CVA	Cerebrovascular accident
CVD	Cardiovascular disease
CXR	Chest X-ray
CYSTO	Cystoscopy
CYTO	Cytology
<b>D</b>	
D&C	Dilatation and curettage
D/C	Discharge
D/T	Due to
DC	Discontinue(d)
DCIS	Ductal carcinoma in situ
D-COLON	Descending colon
DDX	Differential diagnosis
DECR	Decrease(d)
DERM	Dermatology
DES	Diethylstilbestrol
DIAM	Diameter
DIC	Disseminated intravascular coagulopathy
DIFF	Differentiated/differential
DISCH	Discharge
DJD	Degenerative joint disease
DK	Don't/Doesn't know
DM	Diabetes mellitus
DNA	Deoxyribonucleic acid
DOA	Dead on arrival
DOB	Date of birth
DOD	Date of death
DOE	Dyspnea on exertion
DRE	Digital rectal examination
DTC	Disseminated tumor cells
DTR	Deep tendon reflex
DVT	Deep vein thrombosis
DX	Diagnosis
DZ	Disease
<b>E</b>	
E.G.	For example
E/O	Evidence of
EBRT	External beam radiotherapy

ABBREVIATION/SYMBOL	WORD/TERM(S)
ECG/EKG	Electrocardiogram
ED	Emergency department
EEG	Electroencephalogram
EENT	Eye, ear, nose, throat
EGD	Esophagogastro-duodenoscopy
EGFR	Epidermal growth factor receptor
ELEV	Elevated
EMG	Electromyogram
ENL	Enlarged
ENLGD	Enlarged
ENT	Ears, nose, and throat
ER	Emergency room
ER(A)	Estrogen receptor (assay)
ERCP	Endoscopic retrograde cholangiopancreatography
ESRD	End stage renal disease
ETOH	Alcohol
EUA	Exam under anesthesia
EV	Electron volt
EVAL	Evaluation
EXAM	Examination
EXC(D)	Excision/excised
EXP	Expired
EXP LAP	Exploratory laparotomy
EXPL	Exploratory
EXPL LAP	Exploratory laparotomy
EXT	Extend/extension
<b>F</b>	
FAP	Familial adenomatous polyposis
FCOT	First course of treatment
FHX	Family History
FISH	Fluorescence in situ hybridization
FL	Fluid
FLIPI	Follicular lymphoma international prognostic index
FLOW CYTO	Flow cytometry
FLURO	Fluoroscopy
FNA	Fine needle aspiration
FNAB	Fine needle aspiration biopsy
FOM	Floor of mouth
FREQ	Frequent/Frequency

ABBREVIATION/SYMBOL	WORD/TERM(S)
FS	Frozen section
FTSG	Full thickness skin graft
FU	Follow-up
FUO	Fever of unknown origin
FX	Fracture
FX(S)	Fractions(s)
<b>G</b>	
GB	Gallbladder
GE	Gastroesophageal
GEN	General/Generalized
GERD	Gastroesophageal reflux disease
GI	Gastrointestinal
GIST	Gastrointestinal stromal tumors
GR	Grade
GU	Genitourinary
GY	Gray
GYN	Gynecology
<b>H</b>	
H&E	Hematoxylin and Eosin
H&P	History and physical
H/H	Hemoglobin and hematocrit
H/O	History of
HAV	Hepatitis A (virus)
HBV	Hepatitis B (virus)
HCG	Human chorionic gonadotropin
HCT	Hematocrit
HCV	Hepatitis C (virus)
HCVD	Hypertensive cardiovascular disease
HDR	High dose rate
HDV	Hepatitis D (virus)
HEM/ONC	Hematology/Oncology (ist)
HEP A	Hepatitis A (virus)
HEP B	Hepatitis B (virus)
HEP C	Hepatitis C (virus)
HEP D	Hepatitis D (virus)
HER2	Human epidermal growth factor receptor 2
HF	Hispanic female
HGB	Hemoglobin
HGSIL	High grade squamous intraepithelial lesion

ABBREVIATION/SYMBOL	WORD/TERM(S)
HIV	Human Immunodeficiency Virus
HM	Hispanic male
HORM	Hormone
HOSP	Hospital
HPI	History of present illness
HPV	Human Papilloma Virus
HR(S)	Hour/Hours
HRT	Hormone replacement therapy
HSM	Hepatosplenomegaly
HTLV	Human T-Lymphotropic Virus, (Type III)
HTN	Hypertension
HVD	Hypertensive vascular disease
HX	History
HYST	Hysterectomy
<b>I</b>	
I&D	Incision & drainage
I-131	Iodine 131
IBD	Inflammatory bowel disease
ICB	Intracavitary brachytherapy
ICM	Intercostal margin
ICS	Intercostal space
ICU	Intensive care unit
IDC	Infiltrating/invasive ductal carcinoma
IDDM	Insulin-dependent diabetes mellitus
IG	Immunoglobulin
IHC	Immunohistochemical
IHSS	Idiopathic hypertrophic subaortic stenosis
ILD	Interstitial lung disease
IM	Intramuscular
IMP	Impression
IMRT	Intensity modulated radiation therapy
INCL	Includes/Including
INCR	Increase(d)
INF	Inferior
INFIL	Infiltrating
INFILT	Infiltrating
INPT	Inpatient
INT	Internal
INV	Invade(s)/invading/invasion



ABBREVIATION/SYMBOL	WORD/TERM(S)
INVL	Involve(s)/involvement/involving
IP	Inpatient
IPI	International prognostic index (for lymphoma)
IPPB	Intermittent positive pressure breathing
IPS	International prognostic score
IPSI	Ipsilateral
IRREG	Irregular
IT	Intrathecal
ITC	Isolated tumor cells
ITP	Idiopathic thrombocytopenia
IV	Intravenous
IVC	Inferior vena cava
IVCA	Intravenous cholangiogram
IVP	Intravenous pyelogram
<b>J</b>	
JAK2	Janus kinase 2
JRA	Juvenile rheumatic arthritis
JVD	Jugular venous distention
<b>K</b>	
KG	Kilogram
KS	Kaposi sarcoma
KUB	Kidneys, ureters, bladder
KV	Kilovolt
<b>L</b>	
L1-L5	Lumbar vertebra
LAB	Laboratory
LAD	Lymphadenopathy
LAN	Lymphadenopathy
LAP	Laparotomy
LAT	Lateral
LAV	Lymphadenopathy-associated virus
LB(S)	Pound(s)
LBBB	Left bundle branch block
LCIS	Lobular carcinoma in situ
LCM	Left costal margin
LDH	Lactic dehydrogenase
LDR	Low dose rate
LE	Lower extremity
LFT	Liver function test

ABBREVIATION/SYMBOL	WORD/TERM(S)
LIN	Laryngeal intraepithelial neoplasia
LINAC	Linear accelerator
LIQ	Lower inner quadrant
LLE	Left lower extremity
LLL	Left lower lobe
LLQ	Left lower quadrant
LMP	Last menstrual period
LN(S)	Lymph node(s)
LND	Lymph node dissection
LOQ	Lower outer quadrant
LPN	Licensed practical nurse
LRG	Large
LS	Lumbosacral
LSO	Left salpingo-oophorectomy
L-SPINE	Lumbar spine
LS SCAN	Liver/spleen scan
LT	Left
LUE	Left upper extremity
LUL	Left upper lobe
LUOQ	Left upper outer quadrant
LUQ	Left upper quadrant
LVI	Lymph/vascular invasion / Lymphovascular invasion
<b>M</b>	
M/DIFF	Moderately differentiated
MAL	Malignant
MALIG	Malignant
MAMMO	Mammogram
MAND	Mandible/mandibular
MAT	Multifocal atrial tachycardia
MAX	Maximum
MC	Medical center
MC(H)	Millicurie (hours)
MCG	Microgram
MCID	Mixed combined immunodeficiency
M-CSF	Macrophage colony-stimulating factor
MCN	Mucinous cystic neoplasm
MCTD	Mixed connective tissue disease
MD	Moderately differentiated
MDS	Myelodysplastic syndrome

ABBREVIATION/SYMBOL	WORD/TERM(S)
MED	Medication
MED ONC	Medical oncology (ist)
METS	Metastatic/Metastasis
MEV	Million electron volts
MG	Myasthenia gravis
MG(H)	Milligram (hours)
MGF	Maternal grandfather
MGM	Maternal grandmother
MGUS	Monoclonal gammaopathy of uncertain significance
MI	Myocardial infarction
MIBB	Minimally invasive breast biopsy
MICRO	Microscopic
MIN	Minimum
MIN	Minute
MIS	Melanoma in situ
ML	Middle lobe
ML	Milliliter
MM	Millimeter
MMG	Mammogram
MO(S)	Months
MOD	Moderate(ly)
MOD DIFF	Moderately differentiated
MPVC	Multifocal premature ventricular contraction
MRCP	Magnetic resonance cholangiopancreatography
MRI	Magnetic resonance imaging
MRM	Modified radical mastectomy
MRSA	Methicillin Resistant Staphylococcus Aureus
MS	Multiple sclerosis
MSB	Main stem bronchus
MSI	Microsatellite instability
MULT	Multiple
MV	Megavolt
MVP	Mitral valve prolapse
N	
N&V	Nausea and vomiting
N/A	Not applicable
N/V	Nausea and vomiting
NA	Not applicable
NE	No evidence

ABBREVIATION/SYMBOL	WORD/TERM(S)
NEC	Not elsewhere classified
NED	No evidence of disease
NEG	Negative
NEOPL	Neoplasm
NET	Neuroendocrine tumor
NEURO	Neurology
NH	Nursing home
NHL	Non-Hodgkin lymphoma
NIDDM	Non insulin dependent diabetes mellitus
NL	Normal
NML	Normal
NORM	Normal
NOS	Not otherwise specified
NR	Not recorded
NR	Not reportable
NSCCA	Non small cell carcinoma
NSCLC	Non small cell lung carcinoma
NSF	No significant findings
NVD	Neck vein distention
<b>O</b>	
OB	Obstetrics
OBS	Organic brain syndrome
OBST	Obstructed (-ing, -ion)
ONC	Oncology (ist)
OP	Outpatient
OP RPT	Operative report
OR	Operating room
ORTHO	Orthopedics
OTO	Otology
OUTPT	Outpatient
OZ	Ounce
<b>P</b>	
P/DIFF	Poorly differentiated
P32	Phosphorus 32
PAC	Premature atrial contraction
PALP	Palpated (-able)
PAP	Papanicolaou smear
PAP	Papillary
PATH	Pathology

ABBREVIATION/SYMBOL	WORD/TERM(S)
PBSCT	Peripheral blood stem cell transplant
PCP	Primary care physician
PCV	Polycythemia vera
PD	Poorly differentiated
PE	Physical examination
PEDS	Pediatrics
PERC	Percutaneous
PET	Positron emission tomography
PGF	Paternal grandfather
PGM	Paternal grandmother
PID	Pelvic inflammatory disease
PIN III or PIN 3	Prostatic intraepithelial neoplasia, grade III
PLT	Platelets
PMH	Past/personal (medical) history
PMP	Primary medical physician
PNS	Peripheral nervous system
POOR DIFF	Poorly differentiated
POS	Positive
POSS	Possible
POST	Posterior
POST OP	Postoperative(-ly)
PPD	Packs per day
PR	Per rectum
PR(A)	Progesterone receptor (assay)
PRE OP	Preoperative(-ly)
PREV	Previous
PROB	Probable (-ly)
PROCTO	Proctoscopy
PS	Performance status
PSA	Prostatic specific antigen
PT	Patient
PT	Physiotherapy/Physical therapy
PTA	Prior to admission
PTC	Percutaneous transhepatic cholecystogram
PTCC	Papillary transitional cell carcinoma
PUD	Peptic ulcer disease
PULM	Pulmonary
PVD	Peripheral vascular disease
P VERA	Polycythemia vera

ABBREVIATION/SYMBOL	WORD/TERM(S)
PY	Pack years
<b>Q</b>	
Q	Every
QD	Every day
QUAD	Quadrant
<b>R</b>	
R/O	Rule out
RA	Rheumatoid arthritis
RAD	Radiation absorbed dose
RAD ONC	Radiation Oncology
RAEB	Refractory anemia with excess blasts
RAI	Radioactive iodine
RAIU	Radioactive iodine uptake
RAL	Robotic assisted laparoscopy
RARP	Robotic assisted radical prostatectomy
RBBB	Right bundle branch block
RBC	Red blood cells (count)
RCC	Renal cell carcinoma
RCM	Right costal margin
RCS	Reticulum cell sarcoma
RE	Regarding
REC	Recommend
REC'D	Received
REFRACT ANEM	Refractory anemia
REG	Regional
REG	Regular
RESEC	Resection (ed)
RHD	Rheumatic heart disease
RIA	Radioimmunoassay
RIQ	Right inner quadrant
RLE	Right lower extremity
RLL	Right lower lobe
RLQ	Right lower quadrant
RMC	Regional medical center
RML	Right middle lobe
ROF	Review of outside films
RONC	Radiation Oncology
ROQ	Right outer quadrant
ROS	Review of outside slides

ABBREVIATION/SYMBOL	WORD/TERM(S)
RRP	Radical retropubic prostatectomy
RSO	Right salpingo-oophorectomy
RSR	Regular sinus rhythm
RT	Radiation therapy
RT	Right
RUE	Right upper extremity
RUL	Right upper lobe
RUQ	Right upper quadrant
RX	Prescription
RXT	Radiation therapy
<b>S</b>	
S/P	Status post
S1-S5	Sacral vertebra
SATIS	Satisfactory
SB	Small bowel
SCC	Squamous cell carcinoma
SCF	Supraclavicular fossa
SCID	Severe combined immunodeficiency syndrome
S-COLON	Sigmoid colon
SCT	Stem cell transplant
SCV	Supraclavicular
SGOT	Serum glutamic oxaloacetic transaminase
SGPT	Serum glutamic pyruvic transaminase
SH	Social history
SHX	Social history
SIADH	Syndrome of inappropriate ADH
SIG COLON	Sigmoid colon
SIN III or SIN 3	Squamous intraepithelial neoplasia
SLE	Systemic lupus erythematosus
SLL	Small lymphocytic lymphoma
SLN	Sentinel lymph node
SLNBX	Sentinel lymph node biopsy
SM	Small
SmCC	Small cell carcinoma
SO	Salpingo-oophorectomy
SOB	Short(ness) of breath
SPEC	Specimen
SPEP	Serum protein electrophoresis
SQ	Squamous

ABBREVIATION/SYMBOL	WORD/TERM(S)
SS	Summary stage
S-SPINE	Sacral spine
SSS	Sick sinus syndrome
STSG	Split thickness skin graft
SQCC	Squamous cell carcinoma
SUBCU	Subcutaneous
SUBQ	Subcutaneous
SUGG	Suggestive
SURG	Surgery/Surgical
SUSP	Suspicious/suspected
SVC	Superior vena cava
SX	Symptoms
<b>T</b>	
T1-T12	Thoracic vertebra
TAH	Total abdominal hysterectomy
TAH-BSO	Total abdominal hysterectomy- bilateral salpingo-oophorectomy
TB	Tuberculosis
TB	Tumor board
TCC	Transitional cell carcinoma
T-COLON	Transverse colon
TIA	Transient ischemic attack
TNM	Tumor, node, metastasis
TOB	Tobacco
TRANS-COLON	Transverse colon
TRUS	Transrectal ultrasound
TS	Tumor size
T-SPINE	Thoracic spine
TTP	Thrombotic thrombocytopenia purpura
TUR	Transurethral resection
TURB	Transurethral resection bladder
TURP	Transurethral resection prostate
TVC	True vocal cord
TVH	Total vaginal hysterectomy
TX	Treatment
<b>U</b>	
UE	Upper extremity
UGI	Upper gastrointestinal (series)
UIQ	Upper inner quadrant
UNDIFF	Undifferentiated



ABBREVIATION/SYMBOL	WORD/TERM(S)
UNK	Unknown
UOQ	Upper outer quadrant
URI	Upper respiratory infection
US	Ultrasound
UTI	Urinary tract infection
<b>V</b>	
VAG	Vagina/Vaginal
VAG HYST	Vaginal hysterectomy
VAIN III or VAIN 3	Vaginal intraepithelial neoplasia (grade III)
VIN III or VIN 3	Vulvar intraepithelial neoplasia (grade III)
VGP	Vertical growth phase
VGR	Vertical growth rate
VS	Vital signs
<b>W</b>	
W/	With
W/DIFF	Well differentiated
W/F	White female
W/M	White male
W/O	Without
W/U	Work-up
WBC	White blood cells (count)
WD	Well differentiated
WELL DIFF	Well differentiated
WF	White female
WK(S)	Week(s)
WL	Weight loss
WM	White male
WNL	Within normal limits
WPW	Wolff-Parkinson-White syndrome
WT	Weight
<b>X</b>	
XR	Xray
XRT	External radiation therapy
<b>Y</b>	
Y/O	Year old
YO	Year old
YR(S)	Year(s)

**NAACCR RECOMMENDED ABBREVIATION LIST  
CONTEXT-SENSITIVE ABBREVIATIONS**

ABBREVIATION/SYMBOL	WORD/TERM(S)
AI	Aromatase inhibitor
AI	Atrial stenosis/insufficiency/incompetence
AP	Abdominal perineal
AP	Anteroposterior
BM	Black male
BM	Bone marrow
BM	Bowel movement
BT	Bladder tumor
BT	Brain tumor
CA	Calcium
CA	Carcinoma
CC	Chief complaint
CC	Cubic centimeter
ER	Emergency room
ER	Estrogen receptor
FX	Fraction
FX	Fracture
MIN	Minimum
MIN	Minute
ML	Middle lobe
ML	Milliliter
NR	Not recorded
NR	Not reportable
PAP	Papanicolaou smear
PAP	Papillary
PT	Patient
PT	Physiotherapy/Physical therapy
REG	Regional
REG	Regular
RT	Radiation therapy
RT	Right
TB	Tuberculosis
TB	Tumor board

**NAACCR RECOMMENDED ABBREVIATION LIST  
CONTEXT-SENSITIVE ABBREVIATIONS**

ABBREVIATION/SYMBOL	WORD/TERM(S)
AP	Anteroposterior
AP	Abdominal perineal
BM	Bone marrow
BM	Bowel movement
CA	Calcium
CA	Carcinoma
MIN	Minimum
MIN	Minute
ML	Milliliter
ML	Middle lobe
MM	Millimeter
MM	Multiple myeloma
PAP	Papillary
PAP	Papanicolaou smear
PT	Patient
PT	Physiotherapy/Physical therapy
RT	Right
RT	Radiation therapy

\*This list can be found on the NAACCR Website, Appendix G:

<http://datadictionary.naacccr.org/default.aspx?c=17&Version=21>

## Appendix H: Effective Dates for Cancer Registry Standard References

### Effective Dates\* for Cancer Registry Standard References

Updated February 19, 2021

These are the official dates of implementation for various coding references. Remember that your registry may have varied from these dates.

#### STAGING AND CODING

##### International Classification of Diseases for Oncology

First edition	1976 – 1991
Second edition <sup>U</sup>	1992 – 2000
Third edition <sup>U</sup>	2001 –
Third edition-additional terms approved by NAACCR	2014 –
Third edition-carcinoid of appendix made reportable	2015 –
Third edition-additional terms approved by NAACCR	2018 –
ICD-O-3.2 Update	2021 –

##### American Joint Committee on Cancer TNM Staging System

First edition	1978 – 1982
Second edition	1983 (breast only**) – 1988
Third edition	1989 – 1992 (all sites***)
Fourth edition	1993 – 1997
Fifth edition <sup>U</sup>	1998 – 2002
Sixth edition <sup>U</sup>	2003 – 2009
Seventh edition <sup>U</sup>	2010 – 2016
Eighth edition	2018 –
Chapter Revisions	2021 –

##### Summary Staging

<u>Summary Staging Guide</u>	1977 – 2000
<u>SEER Summary Staging Manual 2000</u> <sup>U</sup>	2001 – 2017
<u>SEER Summary Staging Manual 2018</u> (September 2019)	2018 –

##### Collaborative Stage Data Collection System <sup>U</sup>

	2004 –
Version 1.00	2004 –
Version 1.01 issued 8-12-04	2004 –
Version 1.02 issued 4-25-2005	2005 –
Version 1.03 issued 9-8-2006	2007 –
Version 1.04 issued 10-31-2007	2008 –
Version 2.00 issued 1-13-2010	2010 –
Version 2.03.00 issued 12-10-2010	2011 –
Version 2.04.00 issued 12-5-2011	2012 –
Version 2.05.50 issued 8-15-2013	2014 – 2015
Version 2.05.50 Required Site-Specific Factors ONLY	2016 – 2017

**SEER Extent of Disease Manual**

First edition	1988 – 1991
Second edition	1992 – 1997
Third edition <sup>U</sup>	1998 – 2003
Collected through Collaborative Stage	2004 – 2017
EOD 2018	2018 –

**DATA COLLECTION**

<b><u>Standards for Oncology Registry Entry (STORE)</u></b>	2018 – 2020
<b><u>STORE Revised for 2021</u></b>	2021 –

<b><u>Facility Oncology Registry Data Standards (FORDS) <sup>U</sup></u></b>	2003 - 2017
<b><u>FORDS Revised <sup>U</sup></u></b>	2004 – 2006
<b><u>FORDS Revised for 2007 <sup>U</sup></u></b>	2007 – 2008
<b><u>FORDS Revised for 2009</u></b>	2009 – 2009
<b><u>FORDS Revised for 2010 <sup>U</sup></u></b>	2010 – 2010
<b><u>FORDS Revised for 2011 (12-21-2010)</u></b>	2011 – 2011
<b><u>FORDS Revised for 2012 (4-9-2012)</u></b>	2012 – 2012
<b><u>FORDS Revised for 2013 (12-18-12)</u></b>	2013 – 2014
<b><u>FORDS Revised for 2015 (11-26-2014)</u></b>	2014 – 2015
<b><u>FORDS Revised for 2016 (01-01-2016)</u></b>	2016 – 2017

<b><u>Data Acquisition Manual</u></b>	1988 – 1994
1st revision 10/89	
2nd revision 10/90	

<b><u>Data Acquisition Manual, revised</u></b>	1994 – 1995
--	-------------

<b><u>Registry Operations and Data Standards (ROADS Manual)</u></b>	1996 – 2002
2-digit surgery codes	1988 – 1997
“new” surgery codes <sup>U</sup>	1998 – 2002

**SEER Program Code Manual**

First edition	1988 – 1991
Second edition	1992 – 1997
Third edition <sup>U</sup>	1998 – 2003H
Third edition revision 1 (treatment codes only) <sup>U</sup>	2003 – 2004

<b><u>SEER Program Coding and Staging Manual 2004 <sup>U</sup></u></b>	2004 – 2006
--	-------------

<b><u>SEER Program Coding and Staging Manual 2007 <sup>U</sup></u></b>	2007 – 2009
Updated Manual (December 22, 2008)	2007 – 2009

<b><u>SEER Program Coding and Staging Manual 2010 (11-2-2010)</u></b>	2010 – 2010
---	-------------

<b><u>SEER Program Coding and Staging Manual 2011 (9-27-2011)</u></b>	2011 – 2011
---	-------------

<b><u>SEER Program Coding and Staging Manual 2012</u></b>	2012 – 2012
---	-------------

<b><u>SEER Program Coding and Staging Manual 2013 (2-28-2013)</u></b>	2013 – 2013
---	-------------

<b><u>SEER Program Coding and Staging Manual 2014 (May 2014)</u></b>	2014 – 2014
--	-------------

<b><u>SEER Program Coding and Staging Manual 2015 (3-4-2015)</u></b>	2015 – 2015
--	-------------

<u>SEER Program Coding and Staging Manual 2016</u>	2016 – 2017
<u>SEER Program Coding and Staging Manual 2018</u>	2018 –
<b>Benign and Borderline Central Nervous System reporting</b>	2004 –
<b>Solid Tumor Rules</b>	2018 –
Update: Cutaneous Melanoma 2021+	2021 –
<b>Multiple Primaries and Histology Coding Rules <sup>U</sup></b>	2007 – 2017
<b>Hematopoietic Project</b>	
Hematopoietic Database <sup>U</sup> version 1.0-1.6	2010 – 2011
Hematopoietic Database, version 2.0-2.2 (2-25-2013)	2012 – 2013
Hematopoietic Database (released January 2014)	2010 –
Hematopoietic Database (released January 2015)	2010 –
Hematopoietic Database (release May 2018)	2010 –
Hematopoietic Database (release January 2019)	2010 –
Hematopoietic Database (release September 2020)	2010 –
<b>Grade Coding Manual (August 2019)</b>	2018 –
Version 1.7	
<b>Grade Coding Instructions 2014+ (11-21-2013)</b>	2014 – 2017
<b>CODING SYSTEMIC THERAPY</b>	
<b>SEER Self-instructional Manuals for Cancer Registrars,</b>	
Book 8: Antineoplastic Agents, third edition <sup>U</sup>	1993 – 2004
<b>SEER*Rx Interactive Antineoplastic Database</b>	
Version 1.0.0 (7-1-2005)	2005 – 2006
Update version 1.1.0 (8-15-2006)	2006 –
Update version 1.2.0 (9-14-2007)	2007 –
Update version 1.3.0 (5-1-2009)	2008 –
Update version 1.4.1 (1-11-2010)	2010 –
Update version 1.5.0 (9-24-2010)	2010 –
Version 2.0	2012 – 2012
Version 2.1.0 (1-23-2013)	2013 –
Version 2.2.0 (8-6-2013)	2013 –
Version 3.0.1 (September 2014)	2014 –
<b>CANCER PROGRAM STANDARDS</b>	
Cancer Program Manual 1986	1986 – 1990
Cancer Program Manual 1991	1991 – 1995
Cancer Program Standards (Volume I)	1996 – 2003
Cancer Program Standards revised for 2004 (Volume I) <sup>U</sup>	2004 – 2008
Cancer Program Standards 2009 Revised Edition (Volume I)	2009 – 2011
Cancer Program Standards 2012: Ensuring Patient-Centered Care	2012 – 2012
Cancer Program Standards 2012 Version 1.1: Ensuring Patient	2013 – 2013

<u><i>Centered Care</i> (released September 2012)</u>	
<u><i>Cancer Program Standards 2012 Version 1.2: Ensuring Patient</i></u>	<u>2013 – 2013</u>
<u><i>Centered Care</i> (released)</u>	
<u><i>Cancer Program Standards 2012 Version 1.2.1: Ensuring Patient</i></u>	<u>2014 – 2015</u>
<u><i>Centered Care</i> (released January 2014)</u>	
<u><i>Cancer Program Standards: Ensuring Patient-Centered Care</i></u>	<u>2016 – 2019</u>
<u>(2016 Edition)</u>	
<u><i>Cancer Program Standards: Optimal Resources for Cancer Care</i></u>	<u>2020 –</u>
<u>(2020 Standards)</u>	

\* Effective with cases diagnosed on or after January 1 of the initial stated year and ending with cases diagnosed on December 31 of the closing year

\*\* TNM staging of breast cancer was required as of 1982, prior to the second edition

\*\*\* The Commission on Cancer urged implementation of TNM staging of all sites as of 1989 but did not require it until 1991.

U Updated pages/errata were released after publication. See the following list for internet sources for these documents or contact the publishing organization's web site for a copy.

## Appendix I: References for Tumor Registrars or Tumor Reporting Personnel

### WHERE TO GET ERRATA/CLARIFICATIONS/ADDENDA/UPDATES/REVISIONS

STAGING AND CODING	Implementation Date*
<b>International Classification of Diseases for Oncology, third edition</b>	2001 –
ICD-O-3 Implementation Guideline (cases diagnosed on/after 1/1/2018)	2018 – 2020
<a href="https://www.naaccr.org/implementation-guidelines/#ICDO3">https://www.naaccr.org/implementation-guidelines/#ICDO3</a>	
ICD-O-3.2 Implementation Guideline (cases diagnosed on/after 1/1/2021)	2021 –
<a href="https://www.naaccr.org/icdo3/">https://www.naaccr.org/icdo3/</a>	
<b>AJCC Cancer Staging Manual, Eighth Edition</b>	2018 –
Summary of Changes; Updated Breast Chapter; Kindle Version	
<a href="https://cancerstaging.org/Pages/default.aspx">https://cancerstaging.org/Pages/default.aspx</a>	
AJCC 9 <sup>th</sup> version: Cervix update only	2021 –
<b>SEER Summary Staging Manual 2018</b>	2018 –
General Coding Instructions (September 2019)	
<a href="https://seer.cancer.gov/tools/ssm/">https://seer.cancer.gov/tools/ssm/</a>	
<b>Standards for Oncology Registry Entry (STORE)</b>	2018 – 2020
<a href="https://www.facs.org/~media/files/quality%20programs/cancer/ncdb/store_manual_2018.ashx">https://www.facs.org/~media/files/quality%20programs/cancer/ncdb/store_manual_2018.ashx</a>	
	2021 –
<a href="https://www.facs.org/~media/files/quality-programs/cancer/ncdb/store_manual_2021.ashx">https://www.facs.org/~media/files/quality-programs/cancer/ncdb/store_manual_2021.ashx</a>	
<b>Hematopoietic and Lymphoid Neoplasm Coding Manual &amp; Database</b>	2010 –
Published January 2019	
<a href="https://seer.cancer.gov/tools/heme/">https://seer.cancer.gov/tools/heme/</a>	
<b>SEER* Rx</b>	2005 –
<a href="https://seer.cancer.gov/tools/seerrx/">https://seer.cancer.gov/tools/seerrx/</a>	
<b>Extent of Disease (EOD)</b>	2018 –
<a href="https://seer.cancer.gov/tools/staging/">https://seer.cancer.gov/tools/staging/</a>	
<b>Site Specific Data Items (SSDIs)</b>	2018 –
<a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a>	
<b>2018 Grade</b>	2018 –
<a href="https://apps.naaccr.org/ssdi/list/">https://apps.naaccr.org/ssdi/list/</a>	



<b>2018 Solid Tumor Coding Rules</b>	2018 –
<a href="https://seer.cancer.gov/tools/solidtumor/">https://seer.cancer.gov/tools/solidtumor/</a>	
Cutaneous Melanoma update	2021 –
<b>CTR Guide to Coding Radiation Therapy Treatment in STORE</b>	2018 –
Version 2.0 (February 2020)	
<a href="https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/case_studies_coding_radiation_treatment.ashx">https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/case_studies_coding_radiation_treatment.ashx</a>	

Information gathered from different sources. Please see list below:

- Manual Reference Guide (revised March 8, 2019):  
<https://seer.cancer.gov/registrars/references.html>
- Effective Dates\* for Cancer Registry Standard References (Updated April 15, 2012):  
[http://sph.lsuhsu.edu/wp-content/uploads/2016/08/manuals\\_effective\\_dates.pdf](http://sph.lsuhsu.edu/wp-content/uploads/2016/08/manuals_effective_dates.pdf)
- The Ultimate List of Cancer Registry Resources for 2019: <https://www.mrahis.com/ultimate-list-cancer-registry-resources/>
- NAACCR 2021 Implementation Information: [https://www.naacr.org/wp-content/uploads/2020/10/2021-Implementation-Guidelines\\_20201009.pdf](https://www.naacr.org/wp-content/uploads/2020/10/2021-Implementation-Guidelines_20201009.pdf)

## Appendix J: Acronyms of Cancer Organizations for the United States

### ABBREVIATIONS AND ACRONYMS USED

<b>AACCR</b>	American Association of Central Cancer Registries
<b>ACoS</b>	American College of Surgeons
<b>ACS</b>	American Cancer Society
<b>AJCC</b>	American Joint Committee on Cancer
<b>BNA</b>	Block Numbering Area
<b>CCCR</b>	Canadian Council of Cancer Registries
<b>CDC</b>	Centers for Disease Control and Prevention
<b>CIN</b>	Cervical intraepithelial neoplasia
<b>CIS</b>	Carcinoma in situ
<b>CLIA</b>	Clinical Laboratory Improvement Act
<b>CoC</b>	Commission on Cancer (of ACoS)
<b>CPT</b>	Current Procedural Terminology (codes)
<b>CRC</b>	Cyclic redundancy code
<b>CS</b>	Collaborative Staging
<b>CTR</b>	Certified Tumor Registrar
<b>DAM</b>	Data Acquisition Manual (of ACoS)
<b>DCO</b>	Death Certificate Only
<b>EOD</b>	Extent of Disease
<b>FIPS</b>	Federal Information Processing Standards
<b>FORDS</b>	Facility Oncology Registry Data Standards (manual of ACoS)
<b>FTRO</b>	Fundamental Tumor Registry Operations Program (of ACoS)
<b>GenEDITS</b>	Generic EDITS Drive Program
<b>GIS</b>	Geographic Information System
<b>HCFA</b>	Health Care Finance Administration
<b>HIM</b>	Health Information Management
<b>IACR</b>	International Association of Cancer Registrars
<b>IARC</b>	International Agency for Research on Cancer
<b>ICD</b>	International Classification of Diseases
<b>ICD-O</b>	International Classification of Diseases for Oncology
<b>ICD-O-1</b>	International Classification of Diseases for Oncology, First Edition
<b>ICD-O-2</b>	International Classification of Diseases for Oncology, Second Edition
<b>ICD-O-3</b>	International Classification of Diseases for Oncology, Third Edition
<b>N.d.</b>	No date (bibliographic term: no ascertainable place of publication)
<b>NAACCR</b>	North American Association of Central Cancer Registries
<b>NAPIIA</b>	NAACCR Asian/Pacific Islander Identification Algorithm
<b>NCCCS</b>	National Coordinating Council for Cancer Surveillance
<b>NCDB</b>	National Cancer Data Base
<b>NCI</b>	National Cancer Institute
<b>NCRA</b>	National Cancer Registrars Association
<b>NHIA</b>	NAACCR Hispanic Identification Algorithm
<b>NPCR</b>	National Program of Cancer Registries

<b>NPI</b>	National Provider Identifier
<b>PIN</b>	Prostatic intraepithelial neoplasia
<b>ROADS</b>	Registry Operations and Data Standards (manual of ACoS)
<b>RX</b>	Treatment
<b>SEER</b>	Surveillance, Epidemiology, and End Results Program of NCI
<b>SIL</b>	Squamous intraepithelial lesion
<b>SS</b>	Summary Stage
<b>SSF</b>	Site Specific Factor
<b>TNM</b>	Tumor, Nodes and Metastasis: staging system of AJCC and UICC
<b>UDSWG</b>	Uniform Data Standards Work Group of NAACCR
<b>UICC</b>	Union Internationale Contre le Cancer (in English, International Union Against Cancer)
<b>USPS</b>	United States Postal Service
<b>WHO</b>	World Health Organization

\*This list can be found on the NAACCR website, Appendix C: <http://datadictionary.naacr.org/?c=13>